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Research summary: 
 
Breast cancer is the third most common cancer and the fourth highest cause of 
cancer death in Australia (1). Whilst in dogs, mammary tumours are the most 
common tumours in intact females (2), with approximately half being malignant 
(3). There is a strong degree of conservation and similarity in the pathobiology of 
mammary tumours between humans and dogs.  These tumours are similar in 
respects to age of onset (4, 5), morphology (4, 6) heterogeneity and 
tumourigenetic pathways (7). These tumourigenetic pathways demonstrate 
similar functional roles of key molecular targets (2, 8-10). 
 
An essential element of breast cancer research is the availability of samples for 
research studies. To help provide samples researchers have established 
biobanks that help collect and store samples. These sample sets can be used in 
many different fields but they are of particular use in oncology (11, 12). 
 
To help provide a long term comparative oncology resource this study established 
Australia’s first canine mammary tumour biobank; the Australian Veterinary 
Cancer Biobank. This biobank created a novel structure that utilized remote 
biobanking from a network of 56 veterinary clinics and three veterinary pathology 
services across Victoria, Australia. After developing a novel sample collection kit, 
the Dog Mammary Tissue Collection (DogMATIC) kit, the biobank collected 2 
samples per month. Samples collected produced similar RNA concentrations 
between tumour and normal samples. Overall, using a sample weight of 30 mg 
for each sample RNA isolation and a total volume of 50µL the average 5mm 
tumour punch biopsy from the DogMATIC kit would yield a total of 165.11µg for 
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downstream experiments. Additionally, 308 fixed canine mammary tumour 
samples were also biobanked for comparative oncology research. The overall 
prevalence of malignant tumours in collected samples was 39.6% and the 
specificity of collection by the biobank for malignant mammary tumours was 76%. 
 
Before this project there was no data on the survival of different breeds in 
Australia with mammary tumours. In addition, contemporary international studies 
lack representation of popular Australian breeds such as Jack Russell Terriers, 
Australian Cattle Dogs and Kelpies (13-17). Using the samples and follow-up data 
collected through the biobank this research demonstrated that nearly 40% of 
Canine Mammary Tumours (CMTs) in Australian dogs are malignant and occur 
in intact bitches. Additionally, Jack Russell Terriers, Kelpies, Pomeranians and 
Shih Tzus may be at higher risk of developing CMTs; whilst Gun dogs were more 
likely to develop a benign tumour.  CMTs were significantly more common in older 
dogs with peak onset at 10.5 years. Recurrence occurs in nearly 10% of dogs 
with a malignant mammary tumour. Malignant mammary tumours significantly 
impacted animal survival with most likely to die from their tumour or its  
metastasis. The lung was the most common site of metastasis and survival of 
animals was not affected by being pure breed or mixed breed, their geographical 
location or their breed group.  
 
Clinically breast cancer in women is a heterogeneous disease where tumours 
with the same histopathological classification and/or staging can diverge greatly 
in their outcomes for patients (18-22). To date, two studies have attempted to 
demonstrate the same breast cancer subtypes in dogs using IHC (3, 23). The 
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results of which have had conflicting associations with survival. To investigate the 
distribution and survival of these subtypes in Australian dogs’ malignant tumour 
samples were also subtyped. The basal-like subtype was the most common and 
was more likely to be found in pure bred dogs. Most importantly this subtype was 
significantly associated with death. The subtypes were not related to age, de-
sexing or histological type of the tumour.  
 
This study investigated three potential prognostic markers. The first of which, the 
parathyroid hormone-related protein (PTHrP) gene family has been implicated in 
both breast cancer (24) and osteosarcoma (OS) (25). This study investigated the 
role of PHTrP in both CMTs and a mouse model of OS. In CMTs, PTHrP does 
not provide any prognostic value. Whereas, in OS the loss of the receptor for 
PTHrP, PTHR1, produced a more differentiated tumour phenotype with increased 
mineralized osteoid and significantly diminished proliferation  
 
As veterinary pathologists are more frequently being asked to provide an opinion 
on the prognosis of cases (26) this study also evaluated the potential of three 
new prognostic markers. Runx2 had the most potential as a prognostic marker. 
Runx2 over-expressing tumours were associated with an aggressive phenotype 
and poorer survival. Animals with Runx2 over-expressing tumours were at higher 
risk of tumour progression and a poor outcome. 
 
Together the findings of this research support the development of biobanking for 
comparative oncology research in Australia and the use of canine mammary 
tumours as a model for human breast cancer. Finally, that both the molecular 
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subtypes of human breast cancer and the over-expression of Runx2 can be used 
in veterinary pathology to provide information on the prognosis of animals with 
malignant canine mammary tumours. 
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 Introduction: 
 Breast cancer 
There are over 12,000 new cases of breast cancer recorded in Australia each 
year; this represents over a quarter of all cancers seen in Australian women.  
Consequently, it is responsible for nearly 16% of cancer related deaths (27). One 
in nine women will be diagnosed with breast cancer before the age of 85 (27).  
In Australia the five-year relative survival of patients with breast cancer with no 
lymph node involvement is 96.5% and 80.2% for women with positive nodal 
status (20). Despite these high survival rates approximately 30% of patients with 
early stage breast cancer will develop metastases (28, 29).  Metastatic breast 
cancer is generally considered incurable (30). Two essential elements in 
improving patient outcomes and survival rates for patients who develop 
metastases are to define the most accurate method of classifying breast cancer 
as well as improving our understanding of the mechanisms involved in 
metastasis.  
Classifying breast cancer may improve determination of available treatment 
modalities and the prognosis of the patient. Better understanding of the 
mechanisms of metastasis would potentially provide therapeutic options to 
improve the survival rate of patients with advanced breast cancer. The ability to 
improve patient outcomes through better classification and understanding of 
metastasis hinges on the development of better animal models. Consequently, 
the following review will address the link between different breast cancer 
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classification methods in particular the molecular subtyping of breast cancer and 
how this can be aligned with the metastatic potential of a tumour and a patient’s 
prognosis. In addition, how the research methods used to establish novel 
prognostic markers and molecular subtypes can be improved using canine 
mammary tumours (CMTs) from domestic dogs as a spontaneous breast cancer 
model. 
  Molecular subtypes of breast cancer 
1.2.1 Breast cancer and its classification 
Breast cancer can be staged, diagnosed, classified and subtyped (20, 31, 32). 
Essentially, there is a clinical classification made by the treating clinician and a 
histopathological classification made by a pathologist. Breast cancer is graded 
into one of three grades by the treating physician using the tumour, node, 
metastasis system (TNM) (32). This system is based on the size of the tumour, 
the presence of malignant cells in adjacent lymph nodes and whether any distant 
metastases have been detected.  
Breast cancer is the malignant transformation of epithelial cells in the glandular 
lobules or ducts of the breast. Diagnosis and staging encompasses both the 
histopathological classification and stratification to determine the prognosis, likely 
survival time, and treatment options for the patient (32-34). The initial diagnosis 
can be made using a tissue section from a core biopsy of the tumour or from the 
tumour as a whole if it has been resected, and is based on its morphology. It is 
classified by the Nottingham modification of the Scarff-Bloom-Richardson method 
(20, 35). This method is a modification of the original Bloom and Richardson (36) 
classification method which uses three morphological features of the tumour for 
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grading. The three features being analysed and graded are: degree of tubule 
formation, mitotic activity and degree of nuclear pleomorphism (20, 36). The 
histopathological diagnosis is associated with the prognosis of a patient through 
the accumulated knowledge of the clinical features of each specific type of tumour  
(20, 35).  
 
The heterogeneity of breast cancer creates problems for physicians when 
staging, as patients at the same stage can have greatly different treatment 
responses and overall outcomes (19). This is why the histopathological 
classification of the cancer is very important. There are three levels in the grading 
system. Grade one cancers are predominantly papillary or tubular pattern with 
more nuclear size and shape (37). Specific clinical features are associated with 
different types of tumour and these are in turn linked to the prognosis (20-22). 
The histological grade conveys the most predictive power in earlier smaller 
tumours where it can accurately predict tumour behaviour (35). The prognostic 
strength of the Nottingham modification is not as strong across the spectrum of 
tumour grades (35). A strong predictive link between characterisation and/or 
classification systems is the goal in refining these characterization or 
classification systems is to create a method that allows an individualised 
approach to treatment that will result in the most successful therapy for a patient.  
 
1.2.2 Molecular subtyping of human breast cancer 
Clinically, tumours with the same histopathological classification can diverge 
greatly in relation to the clinical outcomes seen in different patients (35, 38). This 
wide spectrum of clinical behaviour makes it important to attempt to resolve this 
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heterogeneity seen in breast cancer in relation to its biological activity and 
pathogenesis. In an attempt to explain this heterogeneity, Perou and co-workers 
demonstrated the molecular portraits of human breast cancers. They found 
initially in cell lines (39) and then in solid tumours of human patients (31) that 
breast cancers could be stratified in to different molecular subtypes based on the 
expression of an ‘intrinsic’ set of 534 genes. The subtypes that were distinguished 
have been shown to hold true across multiple gene microarray platforms (40). 
From the initial research, these results have been refined in to five subtypes, the 
luminal subtype which is further divided into luminal A and luminal B tumours, 
human epidermal growth factor receptor 2 (HER2) positive tumours, basal-like 
and normal-like tumours. Basal-like tumours are more commonly known as triple 
negative tumours as they lack both estrogen (ER) and progesterone (PR) 
receptors, as well as not demonstrating genetic amplification of HER2. The 
normal-like subtype is not commonly used as it is believed to be due to a high 
number of contaminating normal cells during microarray analysis (41, 42).  
 
These five molecular subtypes from Perou and co-workers are claimed to not 
only help resolve the heterogeneity seen with breast cancer but may also have a 
stronger association with specific clinical factors, known to affect the prognosis 
of a patient, than the conventional classification methods (18, 43). These 
variables include histological grade and type (43-45), necrosis (46), lymph node 
involvement (43, 47), and overall survival (18). In addition, the presenting features 
of breast cancer such as age and tumour size have been shown to differ by 
molecular subtypes (48).  
 
Chapter 1 - Introduction 
13 
 
Some subtypes are also more strongly associated with other genetic factors 
known to affect the observed biological behaviour of the tumour. For instance, 
basal-like tumours are more frequently found in patients with breast cancer 1 
(BRCA1) mutations (49) or tumour protein 53 (TP53), a tumour suppressor gene, 
mutations (18). 
 
From the initial interpretation of these subtypes through microarray analysis, 
immunohistochemistry (IHC) was used as a simpler and more cost-effective 
identification technique (43, 45, 50, 51). The subtypes have been identified using 
different panels of antibodies (Table 1.1). All panels use antibodies which are 
targeted against ER and HER1 or HER2. The main panel variation comes from 
the selection of basal cell markers. Some studies have also used a basal cell 
marker in combination with a luminal cell marker such as cytokeratin 8/18 
(CK8/18) (45). This allows a more confident differentiation of luminal tumours 
from basal-like tumours. Though CK8/18 is described as a luminal cell marker it 
has been shown to be present in over 80% of basal-like tumours (45). Thus, its 
ability to help discriminate between luminal and basal types is severely limited. 
The number of antibodies and their targets often varies between research groups. 
One of the main contentious aspects of IHC identification of molecular subtypes 
is how to best define the basal-like subtype. Nielsen and co-workers suggest a 
panel of only four antibodies consisting of ER, HER1, HER2 and CK5/6 is all that 
is required to accurately identify basal tumours (50). Subsequent studies suggest 
an increased number of antibodies are required to more confidently predict the 
basal-like phenotype using IHC (45). Vimentin is an intermediate filament that 
can help differentiate mesenchymal cells from epithelial cells (52). From their 
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research Livasy and co-workers demonstrated that 17 of 18 basal-like tumours 
had positive vimentin localisation whilst none of the luminal or HER2 positive 
subtypes showed any positivity. Consequently, vimentin may be more useful than 
other basal cell markers such as p63, CK5, CK5/6 in identifying basal-like 
tumours (45, 53, 54).  
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Table 1.1 Comparison of antibodies used in immunohistochemistry to determine 
the subtype of breast cancer.  
Researcher Year Antibody panel 
Wiechmann(48) 2009 ER, PR, HER2 
Onitilo(47) 2009 ER, PR, HER2 
Del Casar(44) 2008 ER, PR, HER1, HER2 
Carey(43) 2006 ER, PR, HER1, CK5/6 
Matos(55) 2005 ER, HER2, p-cadherin, p63, CK5 
Nielsen(50) 2004 ER, PR, HER1, HER2, CK5/6 
Bertolo(56) 2008 ER, PR, HER1, HER2, CK5/6 
Bhargava(53) 2008 ER, PR, HER2, CK5, CK5/6 
Kusinska(54) 2009 ER, PR, HER2, CK5/6, CK14, CK17, cyclin-E, p-
cadherin, vimentin 
Livasy(45) 2005 ER, HER2, EGFR, SMA, CD10, p63, CK8/18, 
CK5/6, vimentin 
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Using IHC with tissue microarrays to subtype breast cancer is a more economical 
technique using tumour gene microarrays, potentially allowing for the routine 
subtyping of all new breast cancers diagnosed. To date, this technique has been 
used to stratify patients in a number of countries including the United States of 
America (43, 47), Japan (57), Tunisia (58), India (59), Norway (31) and Sweden 
(60). 
 
These five subtypes continue to be further defined and refined. An example of 
this, is the recent addition of a claudin-low subtype, though further research is 
required before this possible new subtype is adopted within mainstream breast 
cancer research (61).  
 
1.2.3 Mechanism of metastasis 
Up to 40% of patients with breast cancer develop metastatic disease (29). The 
location of where these metastases occur affects the prognosis of a patient (29). 
Of patients with metastatic breast cancer over 75% will develop skeletal 
metastases (62).  The impact for patients with breast cancer who have bone 
metastases is profound as these secondary tumours are essentially incurable 
(63). Up to 90% of lesions which form in the bone are osteolytic (63). The 
resorption and degradation of the bone surrounding the tumour leads to severe 
bone pain, spinal cord compression, and an increased risk of pathological 
fractures. These complications all lead to reduced quality of life and are a 
significant cause of morbidity (64). Currently, there are very few treatments which 
are successful for bone metastases (63). Consequently, a better understanding 
of the mechanisms behind metastasis and in particular the predilection of breast 
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cancer to metastasise to bone could identify therapeutic targets preventing the 
establishment of these distant metastases. Ultimately, this could improve 
patients’ quality of life and potentially their long-term survival. 
 
The proposed mechanism by which tumour cells from a primary breast cancer 
metastasises to bone has four main stages: 1) Proliferation and surrounding 
stromal invasion; 2) Intravasation, penetrating vasculature and entering the 
circulation; 3) Arrival in marrow, subsequent arrest and attachment to bony 
surfaces; finally 4) colonization of bone and subsequent destruction of 
surrounding tissue at distant metastatic sites (65). The most crucial aspect of the 
initial stage is the ability of tumour cells to invade the surrounding stroma. In order 
to do this the cells must penetrate the basement membrane of the capsule 
surrounding the epithelium of the ducts. A newly proposed mechanism for this is 
tumour cell budding around focally disrupted areas of the tumour capsule (66). 
Man and co-workers suggest that regardless of a breast tumour’s molecular 
subtype or histopathological presentation the mechanism by which it initially 
invades into the surrounding breast stroma is the same (66). This does not mean 
that once a tumour has begun invading the stroma that tumours with different 
subtypes follow the same course of disease progression. In fact, tumours with 
different subtypes can diverge significantly in relation to the patient ’s age (44), 
local vs. distant relapse (67), where they metastasise (68), and nodal involvement 
(48, 67). The variable factors which influence the metastatic potential of a tumour 
create a highly complex pathway which makes successfully characterizing the 
specific metastatic properties of tumour subtypes difficult. The molecular profile 
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of breast cancer is influenced by heredity (49, 69), somatic (70), chromosomal 
(71), and epigenetic mutations (72, 73).  
 
1.2.4 Molecular subtypes of breast cancer and 
metastasis 
Each individual molecular subtype of breast cancer may be associated with 
factors known to be significantly linked to metastasis such as invasion, nodal 
involvement and histological grade (43, 44, 48, 67). Does this mean that the 
molecular signature of these subtypes can be used to predict if a tumour will 
metastasise and do specific subtypes show preferential sites of relapse? If so, 
stratifying these cancers using this system may also shed light onto which gene 
pathways play a role in metastasis and whether the mechanism is common to all 
breast cancers, or do specific subtypes have unique relapse pathways? Using a 
very small sample set (n=7) in 2005 the molecular portrait of a metastatic breast 
cancer has been shown to mirror that of the primary lesion (74).  
 
Using the intrinsic gene set outlined by Sorlie (31), Smid and co-workers (68) 
were able to ascertain that the underlying tumour biology of each molecular 
subtype does vary depending on the site of relapse. This was established using 
significance analysis of microarrays (SAM) of differentially expressed genes 
which revealed that active WNT/β-catenin signalling contributed to metastasis to 
the brain of basal subtypes, whilst compromised or absent wingless-type MMTV 
integration site (Wnt) Wnt/β-catenin signalling facilitated metastasis to bone of 
luminal-B subtypes (68). In addition, another noteworthy finding was that the 
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genes up-regulated in metastatic HER2 positive tumours in the bone were entirely 
different from those that were up-regulated in metastatic luminal subtype 
tumours.  Furthermore, the expression patterns of the primary tumour subtype 
were shared with metastatic tumour at the preferred metastatic site (68).  
 
A 70-gene profile signature has been created which can delineate patients whose 
tumours have either a ‘poor prognosis’ or a ‘good prognosis’ signature (19). This 
profile signature predicted the prognosis of the patient better than other more 
frequently used prognostic indicators such as histological grade, stage, and 
lymph node involvement  (75). Consequently, this gene signature has been used 
as the basis of a clinical trial (76). Other researchers have also outlined gene 
signatures which have a strong link to the prognosis of a patient (77-79). 
Interestingly, these gene signatures only demonstrate limited over-lap of target 
genes yet demonstrate similar degrees of prognostic strength. 
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  Comparative oncology: Animal 
models for breast cancer 
The complexity of human diseases requires the use of animal models (80). The 
rationale for animal models includes their shorter lifespans, the opportunity for 
greater sample numbers and the ability to manipulate the system to knock out or 
alter a single gene to investigate its function and role in disease (80-82). While 
an ideal animal model for breast cancer would be spontaneous for practical 
reasons more frequently transgenic mouse models are used. These induced or 
transplanted tumours may vary significantly from the spontaneous tumours seen 
in the human (83). A drawback of using spontaneous animal tumours as a model 
is that researchers must wait for the tumours to develop, which may take years. 
In addition, they also must wait until a large enough sample pool can be collected. 
A method of negating this drawback is the establishment of a biobank – a large 
repository of samples available for research use.  For example, the Canine 
Comparative Oncology and Genetics Consortium (CCOGC) is a tissue bank for 
domestic animals including dogs for cancers such as: lymphoma, melanoma and 
osteosarcoma (OS) was established by the National Cancer Institute (NCI) in the 
USA. To date, there is no such similar organisation in Australia. The creation of 
a similar biobank in Australia would greatly enhance research opportunities for 
basic and translational research using domestic animals.  
 
Focusing on animal model use in breast cancer research, a gap analysis by over 
fifty of the UK’s most prominent breast cancer researchers identified that current 
critical gaps in knowledge are focused in areas of breast cancer initiation, 
disruption of signalling pathways initiating tumour formation, breast cancer 
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progression, and regulators of early progression and metastasis (84). Two 
recurring themes underpinning why research in these areas was not progressing 
were the lack of both clinical samples and appropriate animal models (84). 
Increased use of spontaneous animal models could assist in closing these 
knowledge gaps.  Further to this the authors also suggested that greater 
knowledge in these areas could lead to translational outcomes, these include the 
potential for patient-tailored approaches through identifying pre-invasive 
changes, determining which patients are at increased risk of tumour 
dissemination as well as identifying new therapeutic cellular targets (84).  
 
Traditional breast cancer research uses reliable animal models to allow in vivo 
studies of targets of interest (85). Rodent disease models, mainly murine, have 
been widely used to elucidate the aetiology, pathogenesis and therapeutic drug 
responses to human breast cancer (4). Over the last 25 years, over 100 different 
types of genetically engineered mice have been created which demonstrate the 
influence of specific genetic elements of the initiation and development of 
tumours in the mammary gland (85). 
 
The principle advantage of rodent models is that they provide a system that can 
be genetically manipulated. This provides researchers control over the system to 
allow the isolation of the physiological morphology and genetic regulation of the 
stages of tumour initiation, promotion and progression. This control provides an 
opportunity to breakdown the inherent complexity of tumourigenesis (86).  
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Thus, rodent models allow individual attributes of a tumour to be investigated 
despite not representing the heterogeneity seen with human breast cancer. Any 
given mouse model only reflects a small subset of the types of breast cancer 
seen in humans (87). As such, research which aims to explore a variable common 
to all human breast cancers or more than one subtype of human breast cancer 
requires multiple transgenic models to adequately represent the heterogeneity of 
breast cancers in humans.  
 
Another method for further characterising molecular subtypes is to use a mouse 
xenograft model. This is accomplished by transplanting human primary breast 
cancers into immunodeficient mice. The method aims to retain the tumour 
heterogeneity that can be lost in breast cancer cell lines that have been long 
established (88). The success rate of maintaining the xenografts in these models 
is only around 10% further demonstrating the difficulty of creating useful realistic 
animal models of human breast cancer (88).  
 
The greater similarity between the genomes of dogs and humans compared to 
that between rodents and humans (89-91), along with the spontaneous nature of 
canine tumours (92), allows stronger translational inferences to be made 
regarding the results of both in-vitro and ex-vivo studies than can be done with 
rodent models (89, 90). Dogs are one of the most susceptible species for 
developing spontaneous cancer (26). In addition, dogs are currently already used 
for dose response rates, side effects and toxicology research for new cancer 
therapeutics (92). The canine breast cancer model can also be used for in-vitro 
studies using cancer cell lines (93).   
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Additional advantages of CMTs over murine models relate to two areas firstly in 
terms of sample collection. Dog owners want to improve their dog’s health. This 
relates to the increasing prominence of companion animal welfare in many 
industrial nations, the ethical concerns of the public over using laboratory animals 
and finally the increasing demand in veterinary pathology for disciplines such as 
oncology (94). Secondly, unique breeding history resulting in, genomic, 
population bottlenecks provide an improved basis for identifying polygenetic traits 
of cancers and results in the need for smaller sample cohorts and controls (89, 
94). Many of the almost 400 different breeds of the modern dog show distinct 
prevalence of specific diseases (89).  
 
In this regard the use of these breeds with a predilection for CMTs as model for 
human breast cancer could be extremely useful. If CMTs can be shown to be 
similar to human breast cancer some of the current limitations in breast cancer 
research highlighted by Thompson (84) and his colleagues could be resolved 
using canine mammary tumours as a model for human breast cancer.   
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  Canine mammary tumours 
1.4.1 Classification and grading of CMTs 
Approaches to diagnosis, staging and classification of CMTs mirrors those used 
in human breast cancer (95). CMTs are diagnosed using a histopathological 
classification system by Misdorp et al. (96). This was first published in 1974 and 
then revised in 1999 (96). The categories used in this system were based on 
human classification (95). A further revision of CMT classification was proposed 
by Goldschmidt et al. in 2011 (97). The 1999 classification system included four 
classification categories whilst the system proposed by Goldschmidt et al. 
included eight categories with improved sub-category classification. These 
categories are (97):  
1) malignant epithelial neoplasms 
2) malignant epithelial neoplasms – special types 
3) malignant mesenchymal neoplasms 
4) carcinosarcoma,  
5) benign neoplasms 
6) hyperplasia/dysplasia 
7) neoplasms of the nipple  
8) hyperplasia/dysplasia of the nipple 
 
The differentiation between benign and malignant CMTs can be difficult with an 
estimated 10% of malignant cases being misdiagnosed as benign CMTs (95). 
Similarly to humans, the heterogeneity seen within a single tumour can make 
grading difficult (98). Consequently, the 2010 system also proposed a more 
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standardised grading system based on current evidence. Previously, multiple 
systems with different criteria had been proposed to grade malignant CMTs (99-
101). These were again based on human grading systems such as Elston and 
Ellis (Nottingham) (20) and Bloom and Richardson (36). 
 
Overall the benefit of the system proposed by Goldschmidt et al. is that it could 
help provide easier comparison between studies both retrospective and 
prospective (97).  
 
1.4.2 Similarity of canine mammary tumours to human 
breast cancer 
Mammary tumours are the most common tumours in intact female dogs (2), with 
approximately half of these tumours being malignant (3). Between half and three 
quarters of these malignant tumours will reoccur or metastasise within two years 
(6). The incidence of these tumours has been difficult to quantify. Reports indicate 
frequencies from 154 per 10,000 (12) to 205 per 100,000 (15).  Despite the wide 
variance in incidence, CMTs are more common than their human counterparts. 
The age standardized incidence of human breast is 85 per 100,000 as a world-
wide estimate (38).  
 
There is a strong degree of conservation and similarity in the pathobiology of 
mammary tumours between humans and dogs.  At a molecular level, up to ten 
percentage of human breast cancers are attributed to mutations in BRCA1. 
Mutations found in both species occur at highly conserved domains (2). BRCA1 
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shows a stronger association with malignant mammary tumours in dogs than 
BRCA2 (102). A high degree of homology is also found in the p53 tumour 
suppressor gene (103). P53 mutations are the most common genetic abnormality 
found in human breast cancers (104). P53 mutations are an independent marker 
for poor prognosis in CMTs too (105).  
 
Initial sequencing of the canine genome has predicted approximately 19,300 
genes nearly all of which are homologues of known human genes. The genome 
in its entirety is important for comparative studies with the human genome (89). 
Benign and malignant CMTs have been accepted as appropriate animal models 
for their human counterparts for decades (4, 6). In addition to the molecular level, 
CMTs have been shown to remarkably similar to human breast cancer in other 
regards. These tumours are similar in respects to onset age (4, 5), morphology 
(4, 6) heterogeneity and tumourigenetic pathways (7). These tumourigenetic 
pathways demonstrate similar functional roles of key molecular targets (2, 8-10).   
 
Figure 1.1 demonstrates the key pathological features seen in increasing grades 
of ductal carcinoma in situ (DCIS) in the mammary gland. The low-grade lesions 
in dog (A) and human (B) have similar morphology. The canine mammary 
specimen of moderate DCIS (C) demonstrates a similar papillary pattern to the 
human tissue (D). The high-grade DCIS of dog (E) also demonstrates the same 
solid pattern with a core of comedo necrosis as in the human tissue (F). These 
images clearly demonstrate the histological parallels in morphology between 
mammary tumours in these two species (6). 
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In addition, both women and bitches with a history of a benign atypical 
hyperplasic or carcinoma in-situ have an increased risk of a new primary 
mammary cancer (6, 106, 107). 
 
 
Figure 1.1 The similarity in pathological features of canine and human DCIS. 
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The biological markers used to characterize human breast cancers also convey 
similar clinical and prognostic information in dogs.  Many different classes of 
markers have been advocated as potentially diagnostically useful in breast 
cancer (108-110). These same markers have also been demonstrated in CMTs. 
They include markers for proliferation (8, 111), hormone receptors (3, 112, 113), 
adhesion molecules (114), growth factors (3, 23) and mucins(115). It has been 
suggested that most, if not all, genetic alterations that are associated with the 
progression of cancer in humans have also been identified in many different types 
of canine cancer (7). 
 
Companion dogs have been used in trialling new cancer therapeutics for over 40 
years (92). The release of the canine genome in 2005 (89) and the foundation of 
the CCOGC in 2006 (92) has created momentum for the increased use of dogs 
in human cancer research. The similarity between breast cancer in humans and 
mammary tumours in dogs has prompted an increased interest in particular in 
using the canine model for testing new potential therapeutics (7, 66). To further 
this area of research, the NCI has established the Comparative Oncology Trials 
Consortium (COTC) (92). The purpose of this consortium is to test pre-clinically 
new human therapeutics. The COTC has finished eight separate therapeutics 
trials using dogs, including evaluation of the mTOR inhibitor rapamycin in dogs 
with metastatic osteosarcoma (116). These dogs were actively recruited from the 
public population and were not laboratory animals (116). Dogs have the benefit 
of not being constricted traditional Phase I, Phase II, Phase III drug trials; they 
are able to be offered novel agents before conventional therapies (117). The 
results of these trials aid in designing human clinical trial structures (92). Some 
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research has been conducted in dogs concurrently with human trials (118).  The 
clear potential benefits of using the naturally occurring tumours in dogs for clinical 
trials is that experimental outcomes will allow “optimum design of human clinical 
trials, early identification of liabilities that are related to drug asset,  reduced late 
attrition or failure of cancer drugs in human patients and improved care of future 
human and canine cancer patients” (92). 
 
1.4.3 Factors influencing normal mammary tissue and 
CMT  
The most important risk factors associated with the development of CMTs are 
age, breed, akin to genetic predisposition, hormones and diet (95). Of these, 
hormone exposure and increasing age are the two most important risk factors 
(119). The association between exposure to endogenous sex hormones early in 
life and mammary tumour development was first established in 1969 (95, 119, 
120). The risk of a bitch developing a mammary tumour drops to 0.05% when 
spayed prior to their first oestrus (120, 121).  The prevalence of CMTs is 
decreasing in countries which operate preventive sterilisation programs (95). This 
includes countries such as the USA and parts of Western Europe (12, 13). 
Despite this, CMTs are still an important disease in veterinary medicine (122, 
123). The second risk factor increasing age peaks with the median age of tumour 
development in bitches between eight and ten years old (5). Additionally, 
malignant tumours are more likely to develop in older dogs compared to benign 
tumours (124).  
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There is a difference in the range of breeds at higher risk of developing a 
mammary tumour (12-15). In particular, the geographic location of studies 
appears to affect the association of risk to specific breeds. The risk of CMT 
development by breed varies by study and location. Results between different 
studies is also contradictory. Commonly, miniature and toy breeds have 
frequently been over-represented in epidemiological studies of CMTs (125). 
Though there is some data to suggest that small dog breeds in fact have a lower 
CMT incidence and better survival (126).  Larger breeds such as the German 
shepherd (16, 127) and Boxer (128, 129) are also commonly over-represented.  
Data in both small breed dogs and the Boxer are contradictory. For example, 
North American (130) data suggest Boxers are under-represented whereas the 
converse is true in European studies (13, 17, 128).  Other breeds at an increased 
risk include the English Springer Spaniel (12), Cocker Spaniel and Pointer (125).  
 
The canine mammary gland is made of three different epithelial cell types.  The 
lobules of the breast are lined by alveolar cells whilst the ducts, which ferry milk 
from the lobules to the nipple during lactation, are lined by ductal epithelial cells. 
Deeper to this, myoepithelial cells form a basal layer that is in contact with the 
basement membrane of the ducts. All three cell types stem from a common 
progenitor cell (131). Two important proteins in mammopoiesis are GATA binding 
protein 3 (GATA-3) and parathyroid hormone-related protein (PTHrP). GATA-3 is 
transcription factor that is a key regulator of mammopoiesis and the differential of 
cells into luminal epithelial cells (132). Parathyroid hormone related protein is 
required for normal mammary gland development (133, 134). They have also 
Chapter 1 - Introduction 
31 
 
been suggested as important genes in the development of breast cancer (135, 
136). 
 
  Biobanking for breast cancer 
research 
Collecting and storing biological samples and related data has a long history in 
many institutions such as public hospitals or laboratories, forensic laboratories 
and research laboratories for the purposes of scientific research. But it has not 
been until more recently, that the idea of collecting and storing these samples 
without an immediate purpose solely for potential future research by any research 
group has developed (137, 138). From this idea, the term ‘biobank’ has sprung. 
This term was first used in scientific literature in 1996 (139, 140). Biobanks are 
collections of many different types of biological material that has been collected 
and stored using rigorous protocols that ensure the long-term quality of 
biospecimens and their data for research.  
 
It has not been until more recently that policy and review processes have been 
developed to enforce and ensure the integrity of the biospecimens and data they 
collect (141, 142).  
 
An important part of the wider research community acknowledging the biobank 
as a significant research resource, more than just storing samples, was the 
recognition of the need for their professional management (139). The product 
long-term of stakeholder consultation and review are two key documents for the 
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establishment and maintenance of biobanks (141, 143). The first used by 
European biobanks is the International Society for Biological and Environment 
Repositories guidelines for best practice (141). Secondly, in the USA, the 
National Cancer Institute (NCI) Best Practices for Biospecimen Resources was 
produced by the NCI at the National Institutes of Health through the National 
Center for Biotechnology Information (NCBI) (144). These guidelines provide 
details on the technical and operational best practices of a biobank including: 
resource management, biospecimen collection, processing, storage and 
retrieval, quality management, collection and management of clinical data. In 
addition, they also define the scope, principles and considerations involved in the 
ethical and legal best practices of biobanks (141, 143).  
 
Currently, there is no equivalent best practice document in Australia. As such 
there is no resource for creating or maintaining a biobank that is nuanced for 
Australian legislation or policy. In 2012, the National Health and Medical 
Research Council (NHMRC) did publish the National Biobanking Strategy to help 
facilitate development as well as strengthen and improve collaboration between 
researchers and biobanks (145). This paper recognized that in Australia biobanks 
are mainly operated autonomously which has resulted in different processes and 
quality assurance measures for collecting/storing/annotating biospecimens. In 
addition, the depth and consistency of the clinical data associated specimens 
also varies between biobanks (145).  
  
Currently, numerous single institution biobanks exist both in Australia and 
worldwide as sample repositories in specific research clusters for diseases such 
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as autism (146), gynaecological tumours (147), cardiovascular disease (148),  
and paediatric tumours (149). In addition, there are also many well established 
single institution generic biobanks that collect variable tumour types and normal 
samples for medical research. Rutgers University Cell and DNA Repository is the 
world’s largest university based biobank (150).  More recently, large multi-
institutional biobanks have been set up to maximise the collection of valuable 
patient samples to create high volume research cohorts. In Australia, this 
includes, the Victorian Cancer Biobank (VCBB) which started in 2006 and now 
has over 33,000 samples (151). Internationally, the ‘String of Pearls’ biobanking 
initiative was established in 2007 and includes all eight university medical centres 
in the Netherlands. This biobank was established for cerebrovascular accident, 
type 2 diabetes mellitus, hereditary colorectal cancer, inflammatory bowel 
diseases, leukaemia, neurodegenerative diseases, renal failure, rheumatoid 
arthritis and arthrosis research (152). The Guangzhou Biobank, a collaboration 
between the University of Birmingham, the University of Hong Kong and the 
Guangzhou Occupational Diseases Prevention and Treatment Centre in China 
has over 30,000 participants and has been in existence for over a decade (153). 
Finally, possibly the world’s largest biobank – UK Biobank has collected DNA 
from over half a million participants (154).   
 
Biobanks are resources not only for disease research but also for genomics and 
are an important foundation for the rapidly growing field of personalized medicine 
(155, 156). Increasingly, biobanks have been established to study areas outside 
of the traditional mould of human disease research. Currently, biobanks also exist 
to support research in important aquaculture species (157) and endangered 
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species conservation (158). A novel use of biobank material has been to minimise 
costs of training guide dogs by identifying polymorphisms in genes which are 
related to their abilities (159).  A part of this extension in the notion of what 
biobanks can be used for has been their establishment for comparative oncology 
and therapeutics models. These include animals such as domesticated dogs and 
cats that are good natural models for human cancers. In particular, cancers such 
as lymphoma, osteosarcoma, prostate carcinoma and breast carcinoma (66).  
One of the largest examples of comparative oncology biobanking is the Pfizer- 
Canine Comparative Oncology Genomincs Centre (CCOGC) Biospecimen 
Repository run through the National Cancer Institute in the United States.  The 
CCOGC has collected over 1600 patient samples that represent tumours such as 
lymphoma, melanoma, hemangiosarcoma and osteosarcoma (160).  CMTs 
similarly to other tumour types such as lymphoma and osteosarcoma are a good 
natural model for its human disease counterpart (92, 161). Consequently, a 
foundation aim of this thesis was to establish a comparative oncology biobank in 
Australia for CMTs.  
 
Human biobanks are often localised in established tertiary or medical institutions 
with pathology departments. The guidelines for specimen collection within these 
biobanks, though under refinement, are well established (141). There is very little 
published data on creating a biobank using samples that are wholly collected 
outside a medical or research institution.   
 
Veterinary medicine differs from human medicine in that veterinarians ‘wear many 
caps’. They often assume the role of not only general practitioner, but surgeon 
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and oncologist as well. Consequently, many of the tissue samples a traditional 
biobank collects within a hospital are, in veterinary pathology, removed at the 
local veterinary clinic and not in a specialist or tertiary facility. Veterinary samples 
collected by a tertiary hospital are more likely to be cases of increased complexity 
or simply patients whose owners are able to pay for more rigorous treatment.  
 
  Potential prognostic markers for 
CMT 
An additional tangible advantage of using CMTs as a model for human breast 
cancer is the direct benefit to canine patient’s diagnosis and treatment. The 
heterogeneity of CMTs, in particular their variable biological behaviour, has made 
predicting patient prognosis and outcome solely on their histological 
characteristics unreliable (162). In clinical practice the histological type  (99), 
grade (99)  and lymph node status (113)  are used as prognostic predictors.  
 
Unlike, in routine pathological diagnosis of human breast cancer the biomarkers 
ER, PR and HER2 are not routinely used in CMT diagnosis. Currently, the use of 
IHC is limited in Australian veterinary pathology services. This is due, in part, to 
the additional cost that would be applied to the owner. In addition, for new 
prognostic markers, there are very few prospective survival studies (162).   
 
Consequently, there is a lack of significant validated prognostic markers for 
CMTs. As the identification of prognostic markers is not yet routine in veterinary 
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diagnostic pathology the validation of a robust biomarker with predictive value is 
still required to help identify animals in need of adjuvant therapies (162).  
 
This knowledge gap could be exploited to investigate new potential prognostic 
markers for the molecular subtypes of human breast cancer using the CMTs as 
a model. Results of this research would not only benefit humans but potentially 
also identify predictive prognostic markers for CMTs by providing larger 
prospective data with survival analysis. 
 
A novel group of biomarkers with prognostic potential include those traditionally 
associated with bone and cartilage formation including runt related transcription 
factor 2 (Runx2) (163), osteopontin (164) and PTHrP (165, 166). These genes 
which have been traditionally pigeon-holed as having a more restricted function 
have been shown to play wider roles in more tissues, including the mammary 
gland (133, 134, 164, 167).  These genes have been implicated in the 
development and progression of breast cancer (163, 168-171). The role of these 
genes in breast cancer is particularly interesting as the result of their expression 
in a primary or metastatic tumour may result in different functions based on the 
site. For example, PTHrP expression in primary breast cancers is associated with 
reduced metastasis to distant sites including bone (136, 172). Unlike these 
markers which have mainly been associated with ER negative breast cancers, 
GATA-3 has been associated in ER positive breast cancers (173, 174). Up to 
58% (3, 23) of CMTs are ER positive therefore it is important to have prognostic 
marker associated with this hormone receptor. 
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1.6.1 Runx-2 
Runx2 is a transcription factor that is considered a master-regulator in bone 
development and is essential for osteoblast differentiation (175). Runx2 is 
expressed in virgin, early pregnant and involuting glands (169). Runx2 is known 
to be oncogenic in lymphomas, where it has been shown to promote tumour 
development (176). There are significant gaps in our understanding about the 
role of Runx2 in epithelial cancers most data are limited to its role in breast and 
prostate cancer (169). This data suggests that Runx2 overexpression is 
associated with ER, PR and HER2 negative tumours. The luminal A subtype was 
associated with worse survival (169). 
 
In terms of metastasis Runx2 is believed to facilitate osteolytic activity around the 
tumour. When the expression of Runx2 is disrupted in breast cancer cell lines, 
MDA-MB/231, which are injected into SCID mice, the amount of detectable 
osteolytic lesions drops from 80% to 5% (177). In vitro studies show this effect 
was due to a reduction in osteoclast formation by Runx2 expression promoting 
the production of pro-osteoclastogenic cytokines including tumour necrosis factor 
beta (TNF-β), receptor activator of nuclear factor kappa-b ligand (RANKL) and 
interleukin-6 (IL-6) (177).  
 
Runx2 has been suggested as an important factor for initiation of epithelial-
mesenchymal transition (EMT) as demonstrated in thyroid carcinomas (178). 
EMT is where epithelial cells lose their epithelial characteristics and acquire 
mesenchymal cell properties. In the context of cancer, this includes increased 
potential for motility, increased invasion, metastasis and resistance to 
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chemotherapy (179) (180). The gene signature of cells which have undergone 
EMT significantly overlaps with metaplastic breast cancer subtypes in human 
breast cancers (181). The link between EMT and metaplastic cancer is very 
interesting as in women it is extremely rare accounting for 0.2-0.5% of all invasive 
breast cancers (182) but represents 50-66% of benign CMT(96) and between 10-
40% of carcinomas in CMTs (183). The clear predominance of the benign type in 
dogs is iteresting as they potentially are also the result of EMT but lack the 
aggressive features in malignant neoplastic cells associated with EMT. EMT in 
breast cancers is associated with invasion, migration and stem cell characteristics 
which are key features of cells with the potential to metastasise (181).  
 
1.6.2 Parathyroid hormone-related protein in breast 
cancer 
The PTHrP gene family has been implicated in many human cancers including 
breast cancer (24), prostate cancer (184) and osteosarcoma (OS) (25). In vitro 
studies have demonstrated that PTHrP in breast cancer cell lines increases 
proliferation and protects against apoptosis (185, 186).  
 
PTHrP has not only been implicated in primary tumour development but also 
metastasis. Neutralizing PTHrP produced by tumour cells has been shown to 
reduce progression and incidence of skeletal metastases in mouse models of 
lung squamous cell carcinoma (187) and breast cancer (165).  
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Importantly, just as PTHrP is important in differentiation in normal mammary 
development it plays a role in normal bone formation and maintenance (Figure 
1.2). Aberration of its normal function has been linked to defective osteogenic 
differentiation in the development of OS (188).  
 
 
Figure 1.2 Summary diagram of regulation of cartilage and bone including cell 
types which are affected by PTHrP (189). 
 
PTHrP is required for normal mammary gland development (133). It has also 
been demonstrated that PTHrP can be localised in up to 60% of primary breast 
cancers (24). The role of PTHrP within these breast cancers is contentious. Some 
reports suggest that it is associated with an improved prognosis (172, 190) whilst 
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other groups purport that its presence protects cancer cells from apoptosis 
facilitating tumour survival (185). 
 
In a prospective clinical study primary breast cancers which are positive for 
PTHrP were found to be  less likely to metastasise to any distant site (136). The 
loss of PTHrP expression by the tumour is associated with a poor outcome and 
prognosis (190). This result is contrary to its known ability to facilitate tumour cell 
growth in rodent bone using an intra-cardiac injection of a human breast cancer 
cell line. (191, 192). Consequently, it is probable that the mechanism in which 
PTHrP exerts a beneficial effect is more likely to be before malignant cells begin 
to disseminate into the lymphatics or vasculature. Once metastatic tumour cells 
have established themselves within the bone the PTHrP secreted by the tumour 
cells then has a negative effect on the surrounding tumour by facilitating its 
destruction (165, 193). This destruction may be accomplished by indirectly 
activating osteoclasts via the RANK/RANK ligand pathway in osteoblasts. 
RANKL is essential for osteoclast formation and function through the interaction 
with its receptor RANK (194). PTHrP gene family also has a role in osteosarcoma 
development. 
 
1.6.2.1 Osteosarcoma 
Osteosarcoma is a malignant bone tumour which has a bimodal distribution (195-
198).  Firstly, it is the most common non-haematological bone tumour in children.  
Secondly, it develops in older patients as a secondary tumour to conditions such 
as Paget’s disease (199). In its primary form OS usually develops at either the 
distal femur or proximal tibia, in approximately 75% of cases, and is most strongly 
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associated with the metaphysial plate (200). This location fits with its increased 
incidence in males, (3:2 ratio) at an age of rapid bone growth (200). 
 
It is a locally aggressive tumour and metastasises early in its development, up to 
25% of patients with OS present with clinically detectable metastatic lesions 
(201). The presence of undetectable micro-metastases is even higher. 
Approximately 80% of patients already having or will develop radiographically 
undetectable micro-metastases (188). Consequently, the five-year survival rate 
for patients with metastatic disease is less than 30% and has been steady at this 
level since the 1970’s (202). Due to early metastasis surgical resection alone has 
limited success whilst the current adjuvant chemotherapy regimens have reached 
their limit in improving the survival of paediatric OS patients (198). 
 
To improve survival rates of paediatric OS patients there has been significant 
effort into further elucidating its genetics and pathobiology to identify new 
potential therapeutic targets (196, 203, 204). Despite this, there has been limited 
translation into clinical improvements. Promising potential targets include 
Smoothened (SMO) (205), membrane tyrosine kinase receptors such as VEGF 
(196) which have been targeted by the multikinase inhibitor Sorafenib. Sorafenib 
has also shown promise in OS treatment in combination with Everolimus by 
targeting mammalian target of Rapamycin (mTOR) (206). The focus of part of the 
research in this thesis is on the presence and role of the PTHrP gene family in 
OS development and consequently it’s potential as therapeutic target. In 
particular, the morphological changes and the phenotype of OS’s which has 
reduced PTH/PTHrP functionality through the knockdown of the PTHR1 receptor.  
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1.6.2.2 Histopathology 
Histologically there are numerous subtypes of OS with many being clinically 
infrequent or rare, making up less than 5% of OS cases (195). There are three 
main subtypes of OS that are classified based on the predominant matrix 
surrounding the tumour cells; osteoblastic, chondroblastic and fibroblastic (200). 
Though histologically discrete, to date there is no difference in treatment and no 
successful differentiation in patient outcomes between subtypes has been 
effectively established (195, 207). 
 
1.6.2.3 Molecular basis of osteosarcoma 
OS has a complex genetic background. It is not characterised by specific genomic 
rearrangements like many types of sarcomas (200). Cancers such as breast 
cancer (31), diffuse large B-cell lymphoma (208) and specific types of ovarian 
cancer (209) have distinct, discrete molecular profiles that are significantly linked 
to patient outcome. Contemporary research also suggests that distinct molecular 
subtypes may also exist in other cancers such as bladder cancer (210) and 
glioblastoma (211).  In contrast to these cancers, the three subtypes of OS, 
osteoblastic, chondroblastic and fibroblastic OS are associated with complex and 
inconsistent genetic alterations rather than with distinguishing genetic features 
that allow for molecular stratification (212).  
 
A consistent genetic link is the increased incidence of OS in individuals with Li-
Fraumeni syndrome which involves a germline TP53 mutation. These mutations 
were originally identified by Malkin and colleagues in 1990 (213). A second 
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frequent association is the presence of mutations in the retinoblastoma 
susceptibility gene (Rb) in OS patients (197, 214, 215). Nearly 70% of OS 
demonstrate either loss of heterozygosity or deletion of the Rb1 locus and 
mutations have been detected in up to 35% of cases (212). Individuals with 
germline inactivation of Rb1 are 1000-times more likely to develop OS (188). 
Exploitation of these genes has facilitated the creation of mouse models of OS 
using a double-conditional knockout (216, 217). The tumours seen in these mice 
most closely resemble a fibroblastic/undifferentiated histopathological subtype 
(216).  
 
It is through these genetic changes that the differentiation of osteoblasts from 
mesenchymal stem cells (MSC) is interrupted; leading to OS being considered a 
differentiation disease (Figure 1.4) (218) (219). Using normal murine bone 
marrow stem cells, it has been shown that through long-term in vitro passaging 
these cells transform into tumourigenic multipotent stem cells still capable of 
differentiation into either osteoblasts, chondroblasts or adipocytes but they are 
also capable of inducing osteosarcoma tumour growth when injected into mice 
(220). OS induced in mice by inactivation of Rb and TP53 in osteoblast lineage 
cells have also been shown to demonstrate properties of mesenchymal stem cells 
including multipotency and the expression of stem cell markers, such as mouse 
stem cell surface antigen (Sca-1) (217).  
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Figure 1.3 Schematic of the commitment of MSC to the osteoblast lineage and 
the potential time point differentiation leading to OS development; where 
inactivation of p53 and Rb can promote induction (215). 
 
1.6.2.4  Wnt signalling in osteosarcoma 
During osteoblast differentiation from MSC Wingless (Wnt) canonical signalling 
increases and is considered a pro-differentiation factor (218). An important 
member of this signalling pathway is β-catenin. Removal of β-catenin function 
has been shown to result in a failure of osteoblasts reaching terminal 
differentiation (221).  
 
The Wnt family plays an important role in proliferation and differentiation of 
osteoblasts. This pathway’s main antagonists, the Dickkopf (Dkk) family 
members, are key modulators of its activity (222). The members bind to the Wnt 
receptor, LRP, and surface co-receptor Kremen-1/2. This results in the 
internalization of the receptor complex (222). Consequently, signalling of 
canonical Wnt/β-catenin is reduced but non-canonical pathways are unaffected 
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(223) Dkk-1 is regulated in part by β-catenin (216). Reduced nuclear β-catenin 
has been detected in up to 90% of OS cases but is still present in benign bone 
tumours (224) which is important as only nuclear localization of β-catenin should 
be interpreted as active Wnt signalling as cytoplasmic β-catenin is unable to alter 
target gene expression (225). Part of this reduced Wnt signalling in OS has been 
attributed to elevated levels of Dkk-1 expression (224). In a broader context, the 
inactivation of the Wnt pathway may also play a role in the formation of sarcomas 
in general. In particular, Dkk1 has been shown to block lineage commitment of 
MSCs and increase the malignant transformation of cells (226).  
 
In vitro studies have demonstrated that long-term exposure to high levels of Dkk1 
results in a loss of cell viability (227) possibly also in osteoblast stem cells, 
blocking proliferation (228). The secretion of Dkk-1 by tumours can result in 
significant damage to surrounding tissue (228). This is possibly due to increased 
osteoclastogenesis resulting from Dkk-1 by inhibiting bone morphogenetic 
protein 2 (BMP2) expression via Wnt3a suppression (229). OS cell lines have 
been shown to express high levels of Dkk-1 in culture and as a result exhibit a 
lag phase in growth. This phase can be prolonged by addition of antibodies to 
Dkk-1 to the cell culture (227). The addition of anti-Dkk-1 antisera to OS cell 
cultures inhibited necrosis of tumour cells (230). This is in addition to Dkk-1 being 
a requirement for MSCs to return to the cell cycle and as such may limit replication 
of cells based on concentration of Dkk-1 present (227). In culture, Dkk1 is 
maximally secreted by rapidly proliferating cells and becomes significantly 
reduced as proliferation slows (231). Higher levels of serum Dkk-1 have been 
found in paediatric OS patients compared to healthy controls (231). The 
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circulating Dkk-1 levels have been linked to the number of surviving cells, within 
the tumour, in in vivo studies (231). Dkk-1 is also known to enhance gene 
expression of other genes involved in bone formation and regulation such as 
BMP2, alkaline phosphatase and osterix, via BMP2, (229). 
 
1.6.2.5 PTHrP gene family in osteosarcoma 
This gene family involves two ligands parathyroid hormone (PTH) and PTHrP 
which bind to a common receptor, parathyroid hormone receptor 1 (PTHR1), and 
this results in the stimulation of a G-protein, adenylyl cyclase second messenger 
system (232). Amino acids 1-34 in both PTH and PTHrP activate this cell-surface 
receptor. This N-terminal region of both ligands is highly conserved in evolution 
(189). PTHR1 is mainly expressed in the kidney and bone (232). Activation of the 
receptor by PTH induces calcium release by acting indirectly on osteoclasts. PTH 
has a more confined action, circulating controlling circulating calcium levels 
whereas PTHrP has a much wider field of action as it is expressed in many normal 
tissues. In normal bone PTHrP increases proliferation of chondrocytes, 
suppressing their terminal differentiation and helps maintain an active state (189, 
233). In addition, both osteoblasts and osteocytes express PTHR1 (234). PTH 
can stimulate bone formation via osteoblast signalling as well as bone resorption 
mediated by osteoclasts (234). PTHrP shares many of the actions of PTH in 
osteoblasts through their common receptor (235).  
 
This gene family also plays a role in the development and progression of many 
tumours; though less is known about their role in OS. PTHR1 has been identified 
at a high frequency in prostate cancer, melanoma, ductal pancreatic 
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adenocarcinoma and in approximately 50% of OS (236). Higher levels of PTHR1 
mRNA have been detected in relapsed and metastatic OS samples compared to 
primary OS tumours (188). Furthermore, in OS, the over-expression of PTHR1 is 
linked a more aggressive phenotype (237).  
 
PTHrP has been shown to have multiple actions in OS. One action includes 
inhibiting apoptosis through both PTHR1-dependent and independent 
mechanisms (238). In this role, it inhibits the activation of caspases, blocks 
mitochondrial apoptosis signalling pathway and inhibits death receptor-mediated 
apoptosis (238). Endogenous PTHrP has been shown to down regulate PTHR1 
production even at very low concentrations (239). PTH has been shown to 
regulate OS cell migration (240, 241). Intermittent PTH resulted in up-regulation 
of a gene shown to enhance OS cell motility (240).  
 
1.6.2.6 Lymphangiogenesis in osteosarcoma 
The formation of new blood and lymphatic vessels within and around a tumour is 
an important factor in allowing the tumour to grow and spread. Through the 
stimulation of vascular endothelial growth factor (VEGF) endothelial cells of 
established capillaries migrate from these parental vessels and establish new 
micro-vessels (242).  VEGF has been demonstrated in over 70% of OS (242) and 
is linked with a more aggressive OS phenotype (243). Consequently, it has also 
been associated with poor patient outcome (242, 244-246). Blocking VEGF in 
mouse models of OS has been shown to reduce tumour growth (247). VEGF 
exists in multiple isoforms, VEGF-A to VEGF-E. VEGF-C and its receptor 
VEGFR3 are important factors in lymphangiogenesis. VEGF-C induces the 
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formation of new lymphatic vessels in and around tumours (248). In particular, 
VEGFR3 has been localized in tumour cells from non-small cell lung carcinoma 
(249), colon cancer (250) and breast cancer (251). The increased formation of 
lymphatic vessels provides additional avenues for cells to spread and therefore 
has been linked to enhanced cancer cell mobility and invasion, ultimately 
promoting cancer cell metastasis (251). To date, there is limited data on the 
expression and localization of VEGF-C and VEGFR3 in OS; which has been 
categorized as low (252). 
 
Similarly to VEGFR3, factor VIII, also known as Von Willebrand factor (vWF), is 
produced by endothelial cells with its major function relating to primary and 
secondary haemostasis (253). In vitro studies have demonstrated that reduced 
or absent VWF results in significantly increased endothelial cell proliferation and 
creates increased stability within capillary networks (254). In OS, vWF is usually 
localized in new microvessels. Interestingly, it has also been localized in tumour 
cells of over 40% of OS cases (255). In addition, it is more highly expressed in 
metastatic tumours compared to their matched primary tumour samples, 
suggesting a possible involvement in metastasis (255).  
 
Overall, OS is a complex disease with a heterogeneous genetic background. The 
role of Wnt signalling in OS is controversial though it is known that many OS have 
impaired Wnt signalling. Other factors which also play a role in OS development 
and progression include members of the PTHrP gene family and angiogenic 
factors such as VEGFR3 and vWF. Characterizing the changes in these factors 
as a result of PTHR1 knockdown may better outline pathways this gene family is 
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involved in. In addition, as OS most likely arises from multi-potent MSCs 
therapeutic targets which promote cell differentiation may potentially slow tumour 
growth and metastasis.  
 
1.6.3 GATA-3 
A key regulator of mammopoiesis, the formation of the mammary gland, is GATA-
3 (132). It belongs to the GATA transcription factors family. This family of 
transcription factors are ubiquitous throughout eukaryotes from fungi to 
invertebrates to vertebrates (256).  There are six known genes and they play a 
crucial role in the regulation of network pathways which govern the specification 
of the fate of multipotent stem cells (257). GATA-3 is essential for directing the 
differentiation of mammary stems cells into the luminal cell lineage outlined in 
Figure 1.4 (132). In the mature mammary gland, GATA-3 is expressed in the 
ductal epithelial cells and the lobuloalveolar units but not the underlying 
myoepithelial cells (132).   
 
More recently, this transcription factor has also been, through its association with 
ER, as a potentially important gene in breast cancer to help predict response to 
hormone therapy (258-260). GATA-3 has been shown to be strongly associated 
with the tumour grade, which the authors believe is important in predicting the 
malignant potential of a tumour (135), and as such been suggested as a 
prognostic marker (261). The loss of a GATA-3 positive phenotype has been 
shown to coincide with the initiation of metastasis in a mouse luminal breast 
cancer model. The restoration of this phenotype produced tumour differentiation 
and halted tumour dissemination (135). Further research has also suggested that 
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GATA-3 inhibits breast cancer metastasis through the reversal of EMT (262). Due 
to its relationship with the ER higher GATA-3 expression is associated with the 
luminal subtypes of breast cancer (260). To date, the expression or localisation 
of this protein has not been demonstrated in any canine tissue. The only member 
of the GATA family to have been demonstrated in canine tissues is GATA-4 (263). 
 
 
 
Figure 1.4 GATA-3 deficiency in the mammary glands prevents the 
differentiation of luminal progenitor cells into either ductal or alveolar epithelial 
cells (132). 
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  Aims and scope of this study 
This study aimed to establish Australia’s first comparative oncology biobank for 
canine mammary tumours. Using veterinarians from both metropolitan and rural 
areas to characterize the incidence, breed distribution and survival of dogs with 
mammary tumours. This would allow the comparison of demographic data to the 
incidence and survival of different molecular subtypes of CMT. This research 
aimed to demonstrate the utility of three biomarkers as potential prognostic 
markers for luminal A and basal-like subtyped CMTs. Additionally, it aimed to 
further investigate the marker PTHrP and compare it presence in CMTs to that 
seen in a mouse model of OS. These aims are underpinned by the hypotheses 
that canine mammary tumours can be subtyped similarly to human breast cancer; 
and that these subtypes have a similar prognosis to those seen in humans. This 
similarity may be related to genes known in humans to be associated with specific 
breast cancer subtypes.
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 Materials and methods 
 
A full animal ethics application was presented to the RMIT University Animal 
Ethics Committee. After review, it was decided that the project was not within 
the scope of the Committee and did not require Animal Ethics approval 
(Appendix 1). 
  Biobank design and pilot project 
Establishing the Australian Veterinary Cancer Biobank (AVCBB) was divided into 
two stages. Firstly, the required infrastructure, consumables and operating 
procedures for a comparative oncology biobank were determined. This was 
achieved through a review of current literature and consultation with the biobank 
manager of the St. John of God biobank VCBB member, Ms Katie-Lee Alexander. 
The result of this collaboration was the design of a remote collection biospecimen 
kit, called the DogMATIC kit.  
 
The second stage was to launch a pilot project to evaluate the remote biobank 
design created. The pilot project ran from September 2010 to September 2011. 
The pilot study was also used to determine if the quality of samples collected via 
the DogMATIC kit was high enough for downstream experiments including qPCR 
and microarray analysis. Finally, it also allowed estimation of a yearly sample 
collection size based on the collection rate calculated in the pilot project.   
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  Participant recruitment 
Veterinary clinics were progressively recruited across both metropolitan and rural 
Victoria over an initial period of 6 months. The project was advertised in the 
Australian Veterinary Association (AVA) Victorian Newsletter, The Vic Vet, across 
2010-2011 (Figure 2.1). The website www.yellowpages.com.au was used to 
search for veterinary clinics in rural areas. Clinics found during the search were 
cold-called to further increase participant recruitment. In addition, a copy of the 
AVA advertisement was mailed to veterinary clinics found through the online 
search.    
Chapter 2 – Materials and methods 
 
57 
 
 
Figure 2.1 Advertisement used to recruit veterinarians via the Vic Vet newsletter 
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After the initial recruitment period, new clinics were recruited by targeting specific 
catchment areas including the Central Highlands and Loddon districts (Figure 
2.2).  
 
Interested veterinary clinics were visited in person to outline the research project, 
what their participation entailed and how to use the DogMATIC sample collection 
kit. Three Victorian veterinary pathology services were also recruited and visited 
in person to outline the goals of the AVCBB and the requirements for their 
participation. The clinics that were progressively recruited are listed in Table 2.1. 
In addition, to further improve recruitment and retention of veterinary clinics a 
website and HTML newsletter were designed. 
Figure 2.2 Recruited veterinary clinic locations in each statistical division 
of Victoria, Australia. 
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The AVCBB developed a website, http://www.avcbb.org. It featured a design that 
divided information into three areas: one for pet owners, one for veterinarians and 
one for researchers. Within these areas was information on how to participate, 
frequently asked questions, current research projects, media releases and 
research output, and finally staff profiles and contact details of members of the 
biobank.  
 
Information for pet owners used language for a non-scientific audience; whilst 
information for veterinarians used scientific language and included either web 
links or complete files of all published data including peer-reviewed journals and 
conference papers. To assist users to find content the website also included a 
search box function.  
 
The website was designed in association with a web developer, Mr Matthew 
Taylor. The site was designed using WordPress, (WordPress, 
http://www.wordpress.com), using the NuBlu theme (Version 1.0) by Jai Nischal 
Verma (264). It uses a custom menu widget for the headings of Pet Owners, 
Veterinarians, Researchers, and Staff Profiles. 
 
Additionally, to maintain engagement with participating clinics the AVCBB also 
produced an electronic newsletter. This newsletter featured a summary of the 
biobank’s development along with a ‘sample target thermometer’, with the 
progressive sample total each newsletter. It also featured short articles on 
biobank members’ recent publications or conference attendance. Finally, it was 
also used to advertise new research projects being run through the biobank. For 
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continuity and creating a ‘brand’ the biobank website and HTML designs 
attempted to use the same colour scheme and fonts. The newsletter was 
automatically displayed within the recipients email without the user needing to 
click a link. Veterinary clinics which did not have a registered email address 
received a colour printed version via Australia Post. 
  
  Sample collection and registration 
The DogMATIC sample collection kit was provided to 56 participating veterinary 
clinics. They were most commonly distributed in pairs to provide each veterinary 
clinic with a spare kit.  This prevented fresh sample loss if the veterinary clinic 
had used a sample kit and another possible CMT case presented within a short 
timeframe. The kit included the following (Figure 2.3): 
1. Sample collection instruction sheets (Figure 2.4, Figure 2.5) 
2. Patient history sheet – dog’s first name, breed, age, reproductive history, CMT 
history, sample collection time, date, temperature (Figure 2.6) 
3. Two sterile single use 5mm punch biopsies (Vital Medical Supplies, Sydney, 
Australia) 
4. Two sterile forceps (Medilife, Sydney, Australia)  
5. One pre-labelled ‘tumour’ 3mL cryovial (Astral Scientific, Sydney, Australia) 
filled with 2.5mL RNAlater (Sigma Aldrich, Castle Hill, Australia). The vial was 
also colour coded with a blue cap and barcoded 
6. One pre-labelled ‘normal’ 3mL cryovial (Astral Scientific, Sydney, Australia) 
filled with 2.5mL RNAlater (Sigma Aldrich, Castle Hill, Australia). The vial was 
also colour coded with a yellow cap and barcoded 
Chapter 2 – Materials and methods 
 
61 
 
7. A permanent marker 
8. A barcoded specimen container containing 10% neutral buffered formalin 
(NBF) (Grale Scientific, Melbourne, Australia)   
9. Sheets of Fan Pad-GL (Grale Scientific, Melbourne, Australia) 
10. Two separate specimen bags (Grale Scientific, Melbourne, Australia) 
11. Reply-paid envelope
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Figure 2.3 The DogMATIC sample collection kit provided to veterinarians to 
collect CMT and normal mammary tissue samples. 
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Figure 2.4 Sample collection instructions provided in the DogMATIC kit.
Chapter 2 – Materials and methods 
 
64 
 
 
 
Figure 2.5 Illustrative instructions on how to sample the tumour provided in the DogMATIC kit  
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Figure 2.6 Patient history sheet included in the DogMATIC kit. 
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The sample collection sheet instructed veterinarians to sample towards the 
centre of the lesion, to avoid surgical margins, and any obvious necrotic areas. 
To improve sample collection a collection diagram (Figure 2.5) was also added 
to the kit in 2012. Basic data entry details including collection date, time and 
storage method (refrigerated or ambient temperature) prior to postage were 
recorded using the patient history sheet (Figure 2.6). This information sheet was 
also used to log the dog’s first name, age, breed, reproductive history and 
previous history of mammary tumours. It was pre-barcoded to match the barcode 
of the cryovials. Finally, veterinarians also logged their consent to be contacted 
by biobank in the future for follow-up information on the patient. The two sets of 
sterile forceps and punch biopsies were used to sample the tumour and any 
adjacent normal mammary tissue if available, respectively. These samples were 
stored in cryovials. The patients’ name, date and veterinary clinic were recorded 
on the cryovial using the permanent marker. The formalin-filled specimen 
container was added three months after the initial recruitment period started to 
maximise fixed tissue sample collection. To ensure the formalin did not leak 
during transit the Formalex-treated formalin neutralizing pads (Fan Pad) were 
wrapped around the formalin-filled sample pot. A second specimen bag was used 
to separate the cryovials, containing RNAlater, from the formalin sample. The 
samples and information sheet were submitted to the biobank using the reply-
paid envelope. 
 
Rural veterinarians utilized the postal return option whilst metropolitan veterinary 
clinics also had the option to contact the biobank directly and the samples were 
then collected in person.  
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After receipt of samples at the biobank, the number and type of samples was 
recorded. The date and time of collection and storage of these samples was also 
recorded in addition to all patient data. The RNAlater stabilised samples were 
stored in a -80oC freezer (Thermo Scientific, Scoresby, Australia).  
 
Formalin-fixed tissue of samples was collected either by the veterinarian following 
surgery or from a participating veterinary pathology service. In addition, the 
veterinary pathology services also submitted any suspected CMT’s that they 
received that were from veterinary clinics outside the AVCBB network. 
 
Registration of samples included the time and the date the cryovials were frozen. 
In addition, the number of cryovials and formalized specimens was also recorded. 
The formalin pot was given the same barcode as the cryovials and patient 
information sheet.  
 
All samples were sufficiently fixed before macroscopic dissection. The fixation 
times varied due to the nature of sample submission. This variable, given the 
structure of the biobank, is outside its control.   
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  Data entry and storage 
Samples received at the AVCBB were registered into a specially designed 
database.  The database was designed, using Microsoft Access (Version 
Windows 2010), and created to catalogue all clinical and experimental details of 
each dog and their CMT sample. It was designed with a main sample record form 
that used three tabs that segregated sample details into either clinical, tumour-
related or experimental results. This allowed clinical data to be correlated to 
experimental results while maintaining an interface that was clean and easy to 
navigate. This was deliberate to improve search capabilities for specific subsets 
of samples in the future easier.  The main screen contained a search box that 
allowed existing records to be identified and opened based on either the animal's 
name or its unique case ID. 
 
To minimize data entry errors, specifically key stroke error, where possible a 
drop-down or check-box selection was used (Chapter 3, Figure 3.3c). To further 
minimise data entry errors the case ID for each animal was used as the data 
forms’ unique identifier. Furthermore, the form was designed to allow data entry 
of only one case at a time. This prevented duplicate record entry of the same 
animal or duplicate case ID entry of two different animals. Specific data boxes in 
the form were linked to separate tables to minimise the key strokes needed by 
the user to completely enter all details for a new case ID record. For example, all 
Australian National Kennel Club (ANKC) recognised dog breeds were pre-
entered into a table (Chapter 3, Figure 3.4) that also assigned the AKC breed 
group number. This table was then linked to the registration form which then used 
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a drop-down box for selection (Chapter 3, Figure 3.3d). Similarly, all participating 
veterinary clinics were linked to the form using a separate table which then used 
a drop-down box for selection. An additional benefit was that all the veterinary 
clinic details including address, phone number, email, contact staff member 
details could all be added into the table without overwhelming the display of the 
registration form (Chapter 3, Figure 3.5). In addition, within this table, clinics were 
allocated either a rural or metropolitan designation which allowed subsequent 
analysis of the distribution of sample locations. 
 
To improve accuracy, calculated fields were used to automatically generate the 
age of the animal when the sample was taken, survival time and tissue fixation 
time rather than manual input by the user. Furthermore, to facilitate amending 
data within existing records for future users, the database search box identifies 
records based on either the animal’s name or case ID (Chapter, Figure 3.3b).  
 
Data entry of experimental results was clustered into pre-analytical quality control 
results and analytical method results. Pre-analytical results included RNA 
concentration, 260/280 ratio from a Nanodrop reading and gel electrophoresis 
band presence. Analytic methods were segmented into immunohistochemistry 
either for molecular subtyping or for genes of interest and in situ hybridisation. 
Genes of interest included GATA-3, Runx2, PTHrP, BMP-4, Sox9 and 
osteopontin (Chapter, Figure 3.6). The layout of this page in the registration form 
was to allow for the easy addition of new analytical method or gene of interest 
result fields in the future when the biobank began to disseminate collected 
samples. Similarly, to the clinical data tab, the experimental results tab also used 
Chapter 2 – Materials and methods 
 
70 
 
drop-down fields linked to different table to minimise key stroke entry for users as 
well as increase data accuracy. 
 
  Sample processing 
Before macroscopic dissection, where possible, all fixed tissue samples had a 
macroscopic photo taken (Figure 2.7). Macroscopic dissection of a sample 
depended on how it was received at the AVCBB. Firstly, intact samples submitted 
via the DogMATIC kit were, in general, not submitted to a veterinary pathology 
service by the referring veterinarian. Consequently, the samples were treated as 
either incisional or excisional biopsies depending on the macroscopic features 
and clinical notes of the sample submitted.  Whereas, samples received from 
pathology services had previously been dissected. In these cases, an aggregate 
sample size and description was recorded with representative samples being 
placed into cassettes for processing.  
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Figure 2.7 A representative macroscopic image taken during macroscopic 
dissection of CMT samples. 
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2.5.1 Macroscopic description and dissection 
Each barcoded fixed tissue specimen was also given a unique identifier that 
followed the form of 10P1, 10P2, 10P3 etc. This identifier was then used as the 
case ID identifier within the Microsoft Access database. The macroscopic 
description and dissection of samples followed guidelines from Susan Lester’s 
Manual of Surgical Pathology (265).  
  
Figure 2.8 Unique identifier system used for CMT samples. 
The macroscopic description of each fixed tissue specimen included: 
• The number of specimen containers submitted 
• The labelling of the specimen container including the date, site, age, breed 
of dog if written  
• The dimensions of the tissue 
• The dimensions and appearance of any visible lesion, including size, 
colour and consistency. 
• Presence and location of any nipples 
After dissection, the following details were also recorded: 
• For multiple lesions:  a range up to the largest dimension was used 
• The number and type of slices made i.e. 4 transverse sections 
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• The location of the slices was recorded on the macroscopic photo or in a 
diagram 
• The number of slices sampled 
• Whether the tissue was all submitted or if only representative sections 
were processed. 
The punch biopsy samples from DogMATIC kit were either bisected or processed 
whole. Small excisional lesions, defined by ability to sample all tissue provided in 
six tissue cassettes or less, had all tissue processed. In the case of larger tissue 
samples, such as mammary chains, a minimum of six representative blocks were 
processed. In most cases, in excess of ten cassettes were submitted for 
processing; where possible perpendicular sections of the closest margin were 
also submitted for processing. The deep resection margin was not inked.  
 
Samples from pathology services were received not intact. Consequently, only 
representative sections of the tissue were taken using the same guidelines as 
DogMATIC specimens.  
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2.5.2 Fixed tissue specimen processing 
All tissue samples were processed in a Leica ASP200 (Leica, Mt. Waverley, 
Australia) using a specifically designed 14.5-hour processing schedule (Table 
2.2). Tissues were embedded in paraffin wax and sectioned at 4 µm.  A 
regressive H&E stain of each block was made as a reference using the Leica 
ST5010 autostainer (Leica, Mt. Waverley, Australia) and coverslipper (Leica, Mt. 
Waverley, Australia) at St. John of God Pathology, Geelong, Australia (Table 2.3). 
Slides remained in the final xylene change until they staining rack was collected 
by the automated coverslipper.   
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Table 2.1 Tissue processing schedule used for CMT samples. RT = room 
temperature, V = vacuum, P = pressure. 
Reagent 
Duration 
(min) 
Temperature 
(oC) 
Pressure
/Vacuum 
Drain (sec) 
Neutral buffered 
formalin (Grale Scientific, 
Ringwood, Australia) 
20:00 RT V 140:00 
Ethanol 70% 45:00 RT V 80:00 
Ethanol 90% 45:00 RT V 80:00 
Ethanol absolute 
(Grale Scientific, Ringwood, 
Australia) 
60:00 RT V 80:00 
Ethanol absolute 60:00 RT V 80:00 
Ethanol absolute 60:00 RT V 140:00 
Ethanol/Xylene (50/50) 60:00 RT V 80:00 
Xylene 
(Grale Scientific, Ringwood, 
Australia) 
60:00 37 V 80:00 
Xylene 60:00 37 V 80:00 
Xylene 80:00 37 V 140:00 
Paraffin wax 
(Grale Scientific, Ringwood, 
Australia) 
90:00 62 P/V 140:00 
Paraffin wax 90:00 62 P/V 140:00 
Paraffin wax 140:00 62 P/V 140:00 
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Table 2.2 Regressive H&E stain method 
 
 
Step Solution Time (min) 
1. Oven, 65 oC 8:00 
2. Xylene 3:00 
3. Xylene 2:00 
4. Ethanol absolute 1:00 
5. Ethanol absolute 1:00 
6. Ethanol 50% 1:00 
7. Wash, tap water 1:00 
8. Harris Haematoxylin 3:45 
9. Wash, tap water 1:00 
10. Acid alcohol 0:15 
11. Wash, tap water 1:00 
12. Scott’s tap water 1:30 
13. Wash, tap water 1:00 
14. Ethanol absolute 1:00 
15. Eosin-Phloxine 1:15 
16. Ethanol absolute 1:15 
17. Ethanol absolute 0:45 
18. Ethanol absolute 0:45 
19. Xylene 1:00 
20. Xylene 1:00 
21. Xylene - 
 Total 32:30 
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  DogMATIC specimen 
histopathological diagnosis 
A copy of the macroscopic photo and description were provided with the 
haematoxylin and eosin (H&E) stained sections of the tumour to veterinary 
pathologist’s Dr Judith Nimmo at ASAP laboratories or Dr Barbara Bacci at The 
University of Melbourne, Veterinary School. The World Health Organisation 
(WHO) classification system for canine mammary tumours was used for 
diagnosis (96).  
2.6.1 Other specimen histopathological diagnosis 
Specimens collected from veterinary pathology services were submitted to the 
AVCBB with a histopathology report from the consulting veterinary pathologist. A 
hard copy of the macroscopic and microscopic descriptions was added to the 
patient history for each sample.   
 
  Evaluating sample collection 
feasibility and sustainability of the 
AVCBB  
Following the pilot study period, the success of establishing the AVCBB was 
investigated and whether it was sustainable for the future. The following areas 
were reviewed/determined: 
• The created infrastructure and materials were defined 
• The DogMATIC kit was validated 
• The overall fixed tissue collection rate 
Chapter 2 – Materials and methods 
 
78 
 
• The rate on non-CMT submission 
• The projected and final sample size were compared 
• The structure and fixed and variable operating costs of the biobank were 
outlined and compared to published biobanking models 
• Survey results from participating veterinary clinics  
• Clinical data loss  
Cumulatively these factors were used to determine how successful establishing 
the biobank was and if it was sustainable in the future. 
2.7.1 DogMATIC kit validation 
To establish DogMATIC kit success the following aspects were investigated: 
• Kit usage 
• DogMATIC kit collection rate 
• DogMATIC kit non-CMT submission 
• Survey results of participating veterinary clinics 
• The RNA quality – gel electrophoresis, spectrometry 
• RNA quantity – spectrometry 
• The transit time of samples 
• Potential effect of transit time on RNA quality 
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2.7.2 DogMATIC kit success – The view of biobank 
network clinics 
To gauge the success and viability the biobank, every veterinary clinic that 
submitted a sample was asked to participate in a brief telephone questionnaire. 
The questionnaire contained eight questions: 
1. Were the kit instructions easy to understand? 
2. Was the kit easy to use? 
3. Would the clinic be willing to fix samples as part of the tissue banking kit? 
4. What percentage of all histology/tissue samples in general were sent 
histological for diagnosis?  
5. Over what time frame would the clinic be willing to continue to participate in 
sample collection? 
6. If the AVCBB also offered a histological diagnostic service, would that 
increase the likelihood of participating in future research projects? 
7. What form of communication between the AVCBB and clinic is preferable? 
8. Did the interviewee have any other comments or suggestions regarding the 
sample collection kit? 
Questions 1, 2, 3 and 6 were Yes/No response questions. Responses to the 
questions were recorded on a hard copy.  
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2.7.3 Sample collection rate 
The total number of DogMATIC kit samples was divided by the number of months 
in the pilot study. The total number of non-CMT DogMATIC kit samples was 
divided by the total number of DogMATIC kit samples.  
2.7.4 Transit time 
The transit time of each DogMATIC kit was determined by calculating the number 
of hours from sample collection, written by veterinary clinic staff on sample 
information sheet, to the sample being placed in the -80oC freezer.  
2.7.5 Testing RNA quality and quantity of DogMATIC 
samples 
Total RNA was isolated from cryovial samples per the manufacturer’s instructions 
(RNeasy kit, Qiagen, Chadstone, Australia). Isolated RNA and RNA loading dye 
(New England BioLabs, Arundel, Australia) were separated in a 1% denaturing 
agarose gel with Gel Red and TAE buffer pH 8. 28s and 18s ribosomal bands 
were visualised under UV light.  
 
In addition to determining the RNA integrity, the purity and RNA concentration of 
the final sample were also determined using the NanoDrop spectrophotometer 
(Thermo Scientific, Scoresby, Australia) by evaluating the ratio of the absorbance 
of the sample at both 260 and 280 nm. The concentration of the RNA sample was 
used to calculate the total RNA yield. Samples that did not produce visible 28s 
and 18s rRNA bands were excluded from future research use. The concentration 
of the RNA sample was used to calculate the total RNA yield based on final 
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volume of 50µL. Samples that did not produce visible 28s and 18s ribosomal 
bands were excluded from future research use. The difference in RNA 
concentration between tumour and normal samples was compared using an 
unpaired t test using GraphPad Prism version 6.00 for Windows (GraphPad 
Software, La Jolla, California, USA). 
 
2.7.6 Effect of transit time on RNA quality 
The correlation between transit time and the concentration of RNA isolated from 
the tissue was determined by establishing the coefficient of determination (R2) 
(GraphPad Software, La Jolla, California, USA). 
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2.7.7 Follow-up data collection 
Follow-up data on all canine mammary tumours from participating veterinarians was 
collected via phone, facsimile or email. The data collected included, where 
available: 
• Breed 
• Date of birth 
• Spay status 
• Date/age of spay 
• History of litters 
• Location of mammary tumour 
• Any additional treatment provided 
• Recurrence of the mammary tumour 
• History of CMT prior to sample removal 
• Survival 
• Cause of death or if euthanized 
 
All follow-up data was maintained in both hard copy and the AVCBB laboratory 
information management system (LIMS). The follow-up data collected was for a 
minimum of 1 year up to 4 years maximum.  
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  Tissue microarray construction 
The design of the tissue microarray (TMA) was based on the 8x10 microarray 
template provided by the VCB and published data using canine tissues in TMAs 
(266). Before the construction of the tissue microarray every test tissue had an 
H&E stain performed on the first section cut to ensure there was sufficient tumour 
in each test section. TMAs of malignant CMTs were constructed using four 0.6mm 
core biopsies of tumour and two 0.6mm core biopsies of normal mammary tissue, 
if present, from each animal. This was based on the work of Keller and colleagues 
who investigated the diameter and number of cores needed when constructing 
TMAs of canine lymphoma tissue for IHC (266). When no normal mammary tissue 
was present the corresponding core in the recipient block was left empty. Each of 
the cores from a donor block were added to the recipient block on a new row and 
column (Figure 2.9) (266). The blocks were created in duplicate and if possible 
produced in triplicate using a manual tissue array maker (Beecher Instruments, 
Wisconsin, USA). Once all donor cores had been added to the recipient block a 
glass slide was used to even the level of all the cores. A thin layer of molten 
paraffin was smoothed over the surface of the TMA using a flat edge knife. The 
TMA was then flipped over and the new smooth paraffin surface was placed on a 
slide and incubated at 46oC overnight to allow the cores from the donor blocks to 
anneal with the wax of the recipient block. Finished TMA blocks were stored at 
4oC. The layout of each TMA was recorded in an empty template (Figure 2.9) any 
changes to the block were also recorded on the template.  
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Figure 2.9 Layout of sample cores in an 8 column by 10 row tissue microarray. Where S= sample, N=normal and the number is 
the number of the core sampled from the donor block.
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  Immunohistochemistry  
2.9.1 Subtyping malignant CMTs 
Prior to sectioning the TMA’s were chilled on an ice block for at least 1 hour. Serial 
sections were cut on a microtome at 6µm and placed on to Superfrost Plus slides 
(Grale Scientific, Ringwood, Australia). Only three to five sections were cut before 
the TMA was placed back on the ice for another hour. Sections were then dried in 
an oven at 60oC for 30-45 minutes. Sections were dewaxed during antigen retrieval, 
(PT-link, Agilent, Botany, Australia). The antigen retrieval conditions and the 
antibodies used including their source, manufacturer and dilution are summarised 
in Table 2.4. After antigen retrieval (see Table 2.4 for conditions), sections were 
stained using an automated IHC staining machine (model LV1, Agilent, Botany)  
Briefly, sections were washed with 1% Triton-X (Sigma Aldrich, Castle Hill, 
Australia) for 30 minutes. Endogenous peroxidase was quenched using 10% 
hydrogen peroxide (Priceline Pharmacy, Bundoora, Australia) for 10 minutes. Non-
specific antibody binding was minimized by applying 0.5% casein (Instant Skim 
Long Life Milk Powder, Woolworths, Homebrand, Melbourne, Australis) for 30 
minutes prior to applying the primary antibody. Depending on the section a linking 
antibody was then applied to amplify the number of binding sites for the secondary 
antibody. The secondary antibody was applied for 30 minutes. Following this the 
reaction was visualized using DAB for 10 minutes.
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Table 2.3 Immunohistochemistry methods steps performed on the Dako 
Autostainer, where N/A = not applicable 
Step No. Reagent Time (min) 
1. Wash buffer Rinse 
2. 1% Triton-X 30:00 
3. Wash buffer Rinse 
4. 10% hydrogen peroxide 10:00 
5. Wash buffer Rinse 
6. 0.5% casein block 30:00 
7. Air blow N/A 
8. Primary antibody 30:00-45:00 
9. Wash buffer Rinse 
10. Linking antibody 20:00 
11. Wash buffer Rinse 
12. Labelled polymer 30:00 
13. Wash buffer Rinse 
14. DAB 10:00 
15. Wash buffer Rinse 
16. Deionized water Rinse 
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Tumour sample sections were incubated with primary monoclonal antibodies 
against ER, PR, HER2, p63, CK5 and vimentin (Table 2.4). A multi-tissue block 
containing a human HER2+ breast cancer, normal human breast, normal canine 
mammary tissue, normal canine skin and a canine soft tissue sarcoma were used 
as positive and negative control tissues. In addition, two negative method controls 
were run on each TMA by substituting the primary antibody for normal rabbit serum 
(Agilent, Botany, Australia) or normal mouse serum (Agilent, Botany, Australia) and 
when available a mouse isotype antibody solution (Agilent, Botany, Australia). 
Sections were then stained using the same protocol as test sections (Table 2.4). 
The conditions and dilutions of each antibody is summarised below in Table 2.5.  
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Table 2.4 The optimised antibody retrieval, dilution and incubation time for IHC. 
Antibody Source Clone Manufacturer Retrieval Dilution Incubation 
Estrogen receptor Rabbit EP1  Agilent, Botany, Australia pH 9, 20’ 
(Dako Flex Target Retrieval High pH, 
Agilent, Botany Australia) 
1:50 45’ 
Progesterone 
receptor (C-19) 
Rabbit - Santa Cruz 
(Metagene, Redcliffe, Australia) 
pH 9, 20’ 1:100 30’ 
HER2 Rabbit -  Agilent, Botany, Australia pH 9, 40’ Ready-
to-use 
30’ 
p63 Mouse 7JUL Novocastra, Mt. Waverley, 
Australia 
pH 9, 20’ 1:25 45’ 
CK5 Mouse XM26 Novocastra, Mt. Waverley, 
Australia 
None 1:100 30’ 
Vimentin Mouse V9  Agilent, Botany, Australia pH 9, 20’ Ready-
to-use 
30’ 
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2.9.2 Prognostic marker study 
In addition to being subtyped by IHC CMTs were also stained to demonstrate the 
presence of GATA-3, PTHrP and Runx-2. These markers were selected following 
a literature search of potential markers used in human breast cancer and CMTs. 
The presence of each marker was compared between normal, benign and 
malignant canine mammary tissue. In addition, where possible, the positivity of 
each marker in malignant CMTs was compared to the tumour subtype. Finally, to 
determine the prognostic value of each marker the association between survival 
and tumour positivity was determined.  
 
2.9.2.1 Prognostic marker IHC 
Staining conditions were optimized by testing the reagent variables including 
antigen retrieval, primary antibody concentration, adding/removing protein 
blocking steps, adding/removing a linking secondary antibody. Every assay 
contained a positive and negative tissue control, negative primary antibody 
control and was done on duplicate sections. Each IHC assay was repeated at 
least once and if there was no concordance between the results on each 
section in the separate experiments then the test section was restained. The 
final conditions for each marker are summarised in Table 2.6. All TMA sections 
were cut and stained using the same method used to subtype CMTs. A linking 
antibody was only used for GATA-3. In addition, TMA sections were run with the 
same multi-tissue control block used to subtype the CMTs.  
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Table 2.5 The optimised antibody retrieval, dilution and incubation time for IHC. 
Antibody 
(amino acids) 
Source Clone Manufacturer 
Retrieval 
(pH, 
min) 
Dilutio
n 
Incubation 
(min) 
GATA-3 (167-214) Rabbit Polyclonal 
Santa Cruz 
(Metagene, 
Redcliffe, Australia) 
9, 20:00 1:100 45:00 
PTHrP (1-14) Rabbit Polyclonal 
Danks et al. 
(267)- 
9, 20:00 1:2500 30:00 
Runx2 (251-351) Rabbit Polyclonal 
Abcam 
(Brisbane, 
Australia) 
9, 20:00 1:600 45:00 
 
 
  Mouse osteosarcoma study 
Six paired mouse OS samples were provided fixed in 10% NBF by Dr Carl Walkley 
and Professor Jack Martin from St. Vincent’s Research Institute (Fitzroy, Australia). 
All samples were obtained from experiments approved by the Animal Ethics 
committee at St. Vincent’s Hospital, Melbourne. Osteosarcomas were generated 
with a cell specific deletion of p53 and Rb in osteoblasts, using a Cre:lox based 
deletion in Osx1.fl/fl mice (216). In addition, PTHR1 was knocked-down using short 
hairpin RNA (shRNA) (268). Cell lines of this knockdown (PTHR1.358) and a control 
cell line (Ren.1309) were injected into the back flanks of Balb/c nu/nu mice; tumours 
were established over four weeks prior to collection.  
 
The fixed undecalcified PTHR1.358 and Ren.1309 tumour samples were 
processed, sectioned and stained at RMIT University. The tissues were processed 
Chapter 2 – Materials and methods 
 
91 
 
using a routine 14-hour protocol (Table 2.3). They were then paraffin embedded 
and sections cut at 4 µm and stained with an H&E stain in addition to a Von Kossa 
stain (269).  
Table 2.6 Schedule used to process mouse tissues. 
Reagent 
Duration 
(min) 
Temperature 
(oC) 
Pressure/
Vacuum 
Drain (sec) 
Neutral buffered formalin 45:00 RT V 140:00 
Ethanol 70% 45:00 RT V 120:00 
Ethanol 90% 45:00 RT V 120:00 
Ethanol absolute 45:00 RT V 120:00 
Ethanol absolute 45:00 RT V 120:00 
Ethanol absolute 45:00 RT V 120:00 
Xylene 45:00 RT V 120:00 
Xylene 45:00 RT V 120:00 
Xylene 45:00 RT V 140:00 
Paraffin wax 45:00 62 P/V 140:00 
Paraffin wax 45:00 62 P/V 140:00 
Paraffin wax 45:00 62 P/V 140:00 
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2.10.1 Mouse OS IHC 
Serial sections were cut at 4µm and underwent antigen retrieval (Table 2.7). 
Following retrieval, sections were incubated for 30 minutes in 1% Triton-X, 
followed by 30 minutes each in 1% BSA (A7906-100G, Sigma Aldrich, Scoresby, 
Australia), mouse Ig G blocking reagent (MKB-2213, Vector Labs, East Brisbane, 
Australia), if required, and primary antibody. The reaction was then visualised 
using either a biotinylated anti-rabbit antibody followed by ABC (PK6101, Vector 
Labs, East Brisbane, Australia) or HRP-conjugated polymer (K4061, Agilent, 
Botany, Australia) and DAB (Agilent, Botany, Australia). Sections were briefly 
counterstained in Mayer’s hematoxylin (Grale Scientific, Ringwood, Australia) 
before being dehydrated, cleared and mounted.  
 
A multi-tissue block of Balb/c nu/nu mouse liver, spleen, skin and kidney was 
used as a positive/negative tissue control whilst negative method test sections 
were generated using either a cocktail of mouse IgG and IgM antibodies (Agilent, 
Botany, Australia) or the immunoglobulin fraction of normal rabbit serum (Agilent, 
Botany, Australia). 
  
Chapter 2 – Materials and methods 
 
93 
 
Table 2.7 Primary antibodies and immunostaining protocols used for mouse OS 
samples. 
Antibody Clone Manufacturer Source Dilution 
Retrieval 
(pH) 
Detection 
Cyclin D1 
EP-12 
(M3642) 
Agilent, 
Botany, 
Australia 
mouse RTU* 9 
Envision 
polymer 
PTHrP 
(1-14) 
Polyclonal 
(R1904) 
Danks et al. 
(267) 
rabbit 1:500 none 
avidin-
biotin 
PTHR1 Polyclonal Ho (270) rabbit 1:200 9 
Envision 
polymer 
VEGFR3 
AFL4 
(1-4-5988-
82) 
Abcam, 
Brisbane, 
Australia  
rat 1:400 9 
Envision 
polymer 
DKK-1 H-120 
Santa Cruz 
Biotechnology 
(Metagene, 
Redcliffe, 
Australia) 
rabbit 1:25 none 
Envision 
polymer 
Ki-67 Polyclonal 
Abcam, 
Brisbane, 
Australia rabbit 
1:200 6 
Envision 
polymer 
Von 
Willebrand, 
Factor 
(VIII) 
Polyclonal 
Agilent, 
Botany, 
Australia 
rabbit RTU* 9 
Envision 
polymer 
*RTU – Ready to use 
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  Image scoring and analysis 
2.11.1 Scoring and image analysis 
All sections were digitally scanned (Aperio Technologies, Ashgrove, Australia) 
and analysed using ImageScope software (Aperio Technologies, Ashgrove, 
Australia). When scanning slides the scanning area was manually selected 
during white balancing. The magnification of each slide is based on the total 
scanning area. The magnification of each image is based on the total scanning 
area and consequently varies slightly between each TMA slide. 
 
2.11.1.1 CMT subtyping and image analysis 
Estrogen receptor and p63 were analysed using the ImageScope ‘IHC nuclear v 
9’ algorithm (Aperio Technologies, Ashgrove, Australia) (Table 2.8, 2.9). It was 
adjusted to include cytoplasmic rejection as the mode of segmentation, as some 
cores demonstrated non-specific cytoplasmic staining. Using cytoplasmic 
rejection analysis within the algorithm means that identification of nuclei is 
performed on the statistics of the positive staining channel assuming a bimodal 
distribution.  
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Table 2.8 The three algorithms used to analyse IHC sections used to subtype 
CMT. 
 
 
 
 
 
Consequently, the lighter mode, being the weaker cytoplasmic stain, is removed. 
In addition, the minimum and maximum nuclear sizes were changed to 20 and 
100 µm2 respectively. This range was narrow enough to eliminate contaminant or 
disrupted tissue areas being confused as cells and artificially altering the final 
scoring results during analysis. HER2 was analysed using the ImageScope ‘IHC 
membrane v1’ algorithm (Aperio Technologies, Ashgrove, Australia). No changes 
were made to its’ specifications as it has Federal Drug Administration (USA) 
approval for diagnostic use (Table 2.10). CK5 and vimentin were analysed using 
the ImageScope ‘IHC cytoplasmic v2’ algorithm (Aperio Technologies, Ashgrove, 
Australia) (Table 2.11).     
Algorithm Antibody 
IHC nuclear v1 ER, p63 
IHC membrane v1 HER2 
Cytoplasmic v2 CK5, Vimentin 
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Table 2.9 Algorithm inputs used to analyse CMT samples using the IHC nuclear 
v9 (Aperio technologies). 
Algorithm input type Input value 
Algorithm Nuclear v9 
Version 9.1 
View Width 1000 
View Height 1000 
Overlap Size 100 
Image Zoom 1. 
Classifier None 
Class List   
Classifier Neighborhood 0 
Pixel Size (µm) 0.2516 
Averaging Radius (µm) 1. 
Averaging Radius (Pixels) 4 
Curvature Threshold 2.5 
Segmentation Type 2 
Threshold Type 1 
Lower Intensity Threshold 0 
Upper Intensity Threshold 230 
Min Nuclear Size (µm^2) 20 
Max Nuclear Size (µm^2) 100 
Min Roundness 0.1 
Min Compactness 0. 
Min Elongation 0.1 
Remove Light Objects 0. 
Weak (1+) Threshold 210 
Moderate (2+) Threshold 188 
Strong (3+) Threshold 162 
Black Threshold 0 
Edge Trim Weighted 
Markup Image Type Analysis 
Nuclear Red OD 0.696858 
Nuclear Green OD 0.643073 
Nuclear Blue OD 0.317563 
Positive Red OD 0.244583 
Positive Green OD 0.509334 
Positive Blue OD 0.825081 
Color(3) Red OD 0. 
Color(3) Green OD 0. 
Color(3) Blue OD 0. 
Clear Area Intensity 240 
Use Mode Analysis/Tuning 
Classifier Type IHCNuclear 
Classifier Definition File IHCNuclearTraining 
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Table 2.10 Parameters of the IHC membrane v1 algorithm used to analyse HER2 
staining. 
Algorithm input type Input value 
Algorithm IHC Membrane v1 
Classifier Neighborhood 0 
Classifier 0- None 
Class list  
Averaging Radius (µm) 1 
Blue Curvature Threshold 2.5 
Threshold Type 0 – Edge Threshold Method 
Lower BlueThreshold 0 
Upper Blue Threshold 220 
Min Nuclear Size (µm^2) 10 
Max Nuclear Size (µm^2) 2000 
Min Nuclear Roundness 0.1 
Min Nuclear Compactness 0 
Min Elongation 0.1 
Cytoplasmic Correction 1 - Yes 
Cell/Nuclear Requirement 0 – All Cells 
Max Cell Radius (µm) 5 
Min Cell Size (µm^2) 30 
Max Cell Size (µm^2) 2000 
Min Cell Roundness 0.1 
Min Cell Compactness 0.1 
Min Cell Elongation 0.1 
Background Threshold 240 
Weaken(+1) Threshold 200 
Moderate(+2) Threshold 170 
Strong(+3) Threshold 105 
Completeness Threshold 50 
Use Mode 0 – Analysis/Tuning 
Mark-up Image Type 1 – Analysis 
Classifier Type 0 – IHCMembrane 
Classifier Definition File IHC_Membrane_Training 
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Table 2.11 Parameters of Cytoplasmic v2 algorithm used to assess vimentin and 
CK5 staining. 
Algorithm input type Input value 
Algorithm Cytoplasmic v2 
View Width 1250 
View Height 1250 
Overlap Size 100 
Image Zoom 1 
Markup Compression Threshold 1 – JPEG 
Compression Quality 70 
Classifier Neighborhood 25 
Classifier 0 -None 
Class List   
Analysis stage 6 – Report Results 
Averaging Radius (µm) 0.5 
Nuclear Segmentation 0 
Nuclear Threshold Type 0 – Adaptive 
Nuclear Threshold Value 210 
Min Nuclear Area (µm^2) 20 
Cytoplasmic Distance (µm) 6 
Number of Positive Threshold 3 
(1+) Threshold 210 
(2+) Threshold 180 
(3+) Threshold 150 
Nuclear Stain (Red) 0.709 
Nuclear Stain (Green) 0.624 
Nuclear Stain (Blue) 0.328 
Positive Stain (Red) 0.268 
Positive Stain (Green) 0.57 
Positive Stain (Blue) 0.776 
3rd Stain (Red) 0 
3rd Stain (Green) 0 
3rd Stain (Blue) 0 
Max Cell Dimension (µm) 25 
Clear Area Intensity 240 
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Nuclear subtyping antibodies, ER and PR, were considered positive when at least 
10% of cells demonstrated with a stain intensity of 1 or greater (271). For the 
cytoplasmic basal cell marker CK5 tumours were considered positive when 10% 
or greater of the tumour demonstrated cytoplasmic staining with an intensity of 1 
or greater (3) . For p63 tumours were considered positive when at least 10% of 
tumour cells demonstrated any specific staining (3). As vimentin is a 
mesenchymal cell marker in addition to the tumour staining positively most of the 
surrounding tissue stromal cells such as fibroblasts were also stained. This made 
it more difficult to quantify the results as the tumour cells were harder to isolate, 
in the automated analysis, from the stroma. To minimize the potential for false 
positive results the positivity threshold was set a lot higher than that of published 
data (45, 272). The threshold was determined by upper end of the range of results 
of cores in which the tumour demonstrated no vimentin staining. This was found 
to be 27% percentage which was rounded up to 30%. This threshold was then 
used as the mark for the sum of the number of cells with either 2+ (moderate) or 
3+ (strong) staining. To evaluate HER2 expression the Herceptest scoring 
system (273) was applied which is incorporated into the Aperio ImageScope 
analysis algorithm IHC membrane v1.  
 
For basal cell markers, CK5, p63 and vimentin, the specificy and sensitivity of 
each marker was determined. The percentage of false negative staining was 
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used to determine the specificity whislt the percentage of false positive was used 
to determine the sensitivity. 
 
Type equation here. 
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2.11.1.2 Prognostic markers 
GATA-3 and Runx-2 were analysed using the ‘IHC nuclear v 1’ algorithm (Table 
2.9) whilst PTHrP was analysed using the ‘positive pixel count’ algorithm (Table 
2.12). The output of this algorithm was used to estimate the percentage of the 
tumour area that was PTHrP positive by determining the pretence of positive 
pixels compared to the total number of pixels within the tumour margins. The area 
positive was scored on a 0-3+ scale where 0 represents no positive cells, 1+ 
represents <10% of cells positive, 2+ represents 10-50% of cells positive and 3+ 
represents >50% of cells positive for PTHrP.  
 
GATA-3 and Runx-2 stained samples that demonstrated nuclear staining in at 
least 10% of tumour cells staining were considered positive. Samples were 
considered positive for PTHrP when the same threshold was met but the staining 
localisation was cytoplasmic.  
 
The intensity value generated from the analysis using the Aperio algorithm was 
used to further stratify Runx2 stained malignant tumours. The intensity value is 
created using the following formula: 
 
𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 𝑣𝑎𝑙𝑢𝑒
= (
𝑤𝑒𝑎𝑘 𝑝𝑜𝑠 𝑐𝑒𝑙𝑙𝑠
100
× 1) + (
𝑚𝑜𝑑 𝑝𝑜𝑠 𝑐𝑒𝑙𝑙𝑠
100
× 2)
+ (
𝑠𝑡𝑟𝑜𝑛𝑔 𝑝𝑜𝑠 𝑐𝑒𝑙𝑙𝑠
100
× 3) 
NB. Cells showing a negative result have a multiplication factor of zero and therefore do 
not affect the calculated intensity value. 
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An average intensity value was calculated for normal samples. This was then 
used as the threshold to stratify malignant CMTs. Those with an intensity value 
equal to or less than that of the normal intensity value were categorised as low 
intensity tumours. Samples with values greater than the average of the normal 
intensity were categorised as high intensity tumours.  
 
Table 2.12 Input values to algorithm Positive Pixel Count v9 (Aperio 
Technologies, Ashgrove, Australia) to analyse PTHrP in CMTs and mouse OS 
samples and PTHr1 positivty in mouse OS samples only  
 
  
Algorithm input type Input value 
Algorithm Positive Pixel Count v9 
View Width 1000 
View Height 1000 
Overlap Size 300 
Image Zoom 1. 
Markup Compression Type 0 – Same as processed image 
Compression Quality 30 
Classifier Neighborhood 0 
Classifier 0 – None 
Class list  
Hue Value 0.1 
Hue Width 0.5 
Colour Saturation Threshold 0.04 
Iwp(High) 220 
Iwp(Low)= Ip (High) 175 
Ip(Low) = Isp(High) 100 
Isp (Low) 0 
Inp(High) -1 
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2.11.1.3 Mouse osteosarcoma samples 
The images of staining for Cyclin D1, Ki-67, DKK1 were analysed using a trained 
nuclear staining algorithm (Aperio Technologies, Ashgrove, Australia) (Table 
2.13).  Microvessel formation was analysed using the microvessel algorithm 
(Aperio Technologies, Ashgrove, Australia), for VEGFR3 (Table 2.14). Both 
incomplete and complete microvessels within the tumour area were analysed. 
The percentage of tumour area stained by either PTHrP or PTHR1 was quantified 
using the same positive pixel count algorithm v9 used to quantify PTHrP staining 
in CMTs (Table 2.12). An optimized version of the positive pixel count v9 
algorithm was created to assess the Von Kossa stain (Table 2.15).   
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Table 2.13 Algorithm inputs to analyse mouse OS samples for Cyclin D1, Ki-67 
and Dkk1.  
Algorithm input type 
Input value 
Algorithm Nuclear v9 
View Width 1000 
View Height 1000 
Overlap Size 100 
Image Zoom 1. 
Markup Compression Type 0 – Same as processed image 
Compression Quality 30 
Classifier Neighborhood 0 
Classifier 0 – None 
Class list  
Averaging Radius (µm) 1. 
Radius (microns) for noise reduction 1 
Curvature Threshold 2.5 
Segmentation Type 2 – cytoplasmic rejection 
Threshold Type 1 – edge threshold method 
Edge trimming 1 - weighted 
Lower Threshold 0 
Upper Threshold 230 
Min Nuclear Size (µm^2) 10 
Max Nuclear Size (µm^2) 150 
Min Roundness 0.1 
Min Compactness 0. 
Min Elongation 0.1 
Remove Light Objects 0.1 
Clear Area Intensity 240 
Nuclear Stain (Red) 0.696858 
Nuclear Stain (Green) 0.643073 
Nuclear Stain (Blue) 0.317563 
Positive Stain (Red) 0.244583 
Positive Stain (Green) 0.509334 
Positive Stain (Blue) 0.825081 
3rd Stain (Red) 0 
3rd Stain (Green) 0 
3rd Stain (Blue) 0 
Cytoplasmic Intensity Threshold 230 
Weak (1+) Threshold 210 
Moderate (2+) Threshold 188 
Strong (3+) Threshold 162 
Black Threshold 0 
Use Mode 0 –Analysis/Tuning 
Mark-up Image Type 1 –Analysis 
Classifier Type 1- IHCNuclear 
Classifier Definition File IHCNuclearTraining 
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Table 2.14 Inputs to algorithm Microvessl Analysis v1 (Aperio) to analyse 
microvessel formation, area, wall thickness and lumen area in mouse OS 
samples. 
 
Algorithm input type Input value 
Algorithm Microvessel Analysis v1 
View Width 1000 
View Height 1000 
Overlap Size 0 
Image Zoom 1. 
Markup Compression Type 0 – Same as processed image 
Compression Quality 30 
Classifier Neighborhood 0 
Classifier 0 – None 
Class list  
Mark-up Image Type 2 – Analysis – Vessels 
Mode  
1 – Include incomplete 
vessels and other stained 
regions 
Filtering/Smoothing Level 2 
Dark Staining Threshold 160 
Light Staining Threshold 210 
Region Joining Parameter 6 
Vessels Completion Parameter  7 
Minimum Vessel Area Threshold 15 
Maximum Vessel Area Threshold 20000 
Maximum Vessel Wall Thickness 
(µm) 4 
Output histogram 1 – Vessel area 
Output histogram 2 3 – Lumen area  
Output histogram 3 5 – Vessel wall thickness 
Histogram Start Value 0 
Histogram End Value -1 
Number of Bins  20 
Endothelial Stain – Red 0.268 
Endothelial Stain – Green 0.57 
Endothelial Stain – Blue 0.776 
Background Stain 1 – Red 0.68 
Background Stain 1 – Green 0.57 
Background Stain 1 – Blue 0.44 
Background Stain 2 – Red 0 
Background Stain 2 – Green 0 
Background Stain 2 – Blue 0 
Clear Area Intensity 240 
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Table 2.15 Positive pixel count v9 parameters used to quantify Von Kossa 
staining in mouse OS. 
 
  
Algorithm input type Input value 
Algorithm Positive Pixel Count v9 
View Width 1000 
View Height 1000 
Overlap Size 300 
Image Zoom 1. 
Markup Compression Type 0 – Same as processed image 
Compression Quality 30 
Classifier Neighborhood 0 
Classifier 0 – None 
Class list  
Hue Value 0.1 
Hue Width 0.24 
Colour Saturation Threshold 0.04 
Iwp(High) 255 
Iwp(Low)= Ip (High) 255 
Ip(Low) = Isp(High) 0 
Isp (Low) 0 
Inp(High) -1 
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 Statistical analysis 
2.12.1 Animal demographics and survival 
Descriptive statistics are presented on the number of samples collected, the 
number of animals represented, histopathological classification, ANKC breed 
group, individual breed, type of breed, spay status and age of spay. 
Each histopathological classification within a sample was considered separately 
for the frequency of histological types; as any subsequent experiments could 
sample each tumour type separately.  
 
Samples with multiple tumour types were separated by manual manipulation of 
the follow-up data if they had been reported together. The expected number of 
CMT cases was determined by using the animal registration numbers for each 
breed group in 2013 (274) and the formula: 
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑛𝑢𝑚𝑏𝑒𝑟 =
𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 ×  𝑟𝑒𝑔𝑖𝑠𝑡𝑒𝑟𝑒𝑑 𝑝𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒
100
 
 
A Fisher’s t-test (275) was used to evaluate the distribution of ANKC breeding 
categories between rural and metropolitan collection sites, benign and malignant 
tumours the expected number and observed CMTs. The threshold for 
significance was when p was less than 0.05.  
 
All animals with follow-up information, regardless of diagnosis, including those 
not considered a mammary tumour, were used to compare overall survival 
between dogs’ metropolitan and rural locations. In addition, the survival of only 
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malignant CMTs was compared between animals in metropolitan and rural 
locations.  
 
The representation of breeding groups and specific breeds in the sample set was 
determined by establishing the expected frequency of CMTs based on the 
population of the ANKC national animal registration database from 2013 using a 
Chi squared test where statistical significance was set at p<0.05.  
 
All statistical analyses were performed using GraphPad Prism version 6.00 for 
Windows (GraphPad Software, La Jolla, California, USA). 
 
The difference between categorical variables including age, ovariohysterectomy 
status, histological type, subtype, breed, geographic location, basal cell marker 
positivity was determined using a chi-square test.  
 
Survival curves were calculated using the Kaplan-Meier (276) method and the 
log-rank (Mantel-Cox) (277) test was used to evaluate the significance of any 
difference between the defined groups within each graph. Animals were censored 
when they died for causes unrelated to CMTs or were lost to follow-up. The 
significance level was set at p<0.05.  
 
2.12.2 IHC analysis 
To analyse the staining results of PHTrP, GATA-3 and Runx2, the total number 
of positive and negative samples for normal tissue, benign and malignant tumours 
was compared using a Chi-square test. The percentage of positive cells for each 
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sample type was then compared using a one-way analysis of variance (ANOVA) 
(278) and a Bonferroni’s multiple comparisons test to correct for multiple 
comparisons (279). A two-way ANOVA (275) was also used to compare the 
staining intensity. The association between GATA-3 positivity and CMT subtype 
was determined using a two-tailed Fisher’s t test.  
 
In the mouse OS study results for each marker were compared between the 
Ren.1309 and the PTHR1.358 samples using an unpaired two-tailed Student’s t-
test (280) and one way ANOVA. All markers were analysed assuming 
homogeneity of variance except for the Von Kossa stain which was analysed 
using unequal variance.  All replicate experiments were analysed. As there was 
no difference between the results only a representative data set is presented. 
 
The effect size and post hoc power calculation were obtained using G*Power 
(University of Dusseldorf) (Version 3.1.9.2) (281, 282). The software was used to 
determine the achieved power of the ANOVA analyses for GATA-3 and Runx2 
by using a power calculation where 0.05 was used as the α error probability. The 
effect size variable in the power calculation was determined using the group 
means and standard deviations for each marker.
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 Establishing a canine mammary tumour 
biobank for comparative oncology 
research 
  Introduction 
Biobanks are valuable tools for research. The word “biobank” is the most widely 
accepted encompassing term for the infrastructure, governing policies and 
procedures that dictate best practice for collecting, processing, storing and 
disseminating biological specimens for research (142). Though biobanks have 
existed in varying forms for decades; research involving genomics and 
personalized medicine (155) have recently become increasingly more reliant on 
biobank samples (283).   This is due in part to the better link between annotated 
samples and complete clinical histories as well as more rigorous quality control 
and quality assurance of samples. Structured, well annotated patient information 
that contains a minimum data set helps to provide sample cohorts for specimen 
sharing, data mining and long term research aims. Policies and methods in place 
for collecting and maintaining patient data helps minimise sample loss due to 
insufficient primary, secondary or follow-up data. These sample sets can be used 
in many different fields but they are of particular use in oncology (11, 12). 
 
Breast cancer is the third most commonly diagnosed cancer and the fourth 
highest cause of cancer death in Australia (1). Between 2006 and 2011 over $1 
billion in research funding was used to assist more than 3000 cancer research 
projects/programs in Australia. In particular, Victoria is a hub of cancer research 
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with it receiving 41% of allocated funds (284). Despite this, it is difficult to the 
amount of comparative studies, using companion animals, in Australia. The 
Common Scientific Outline (CSO) classification system, used by the NHMRC is 
specific to cancer research and is used to group funded projects/programs in 
Australia (284). This system is based on the outcomes and area of research 
rather than the methods involved in the study. Consequently, it is difficult to 
isolate funded research that has used companion animals for comparative 
studies.  
 
Australia’s first comparative oncology program was only first funded in 2014 by 
the Australian Cancer Research Fund (285). This program focuses on drug 
research and medical imaging using Positron Emission Tomography-Computed 
Tomography (PET-CT) scanning rather than basic biology and pathogenesis and 
was established four years after the Australian Veterinary Cancer Biobank 
(AVCBB).  
 
Australia has one of the highest pet ownership rates in the world (286). Australia 
has a higher pet ownership rate than the UK and is comparative to that seen in 
the USA (287). Nearly 40% of Australian households own a dog, totalling more 
than 4.1 million dogs (286).  CMTs are a valuable comparative oncology model 
and our high pet ownership rate provides a substantial foundation for using these 
animals and their tumours as models for cancer research. As such, the aim of 
this research project was to establish a sustainable biobank, the AVCBB, of 
CMTs for breast cancer research. The structure of the AVCBB, was designed to 
capitalize on this large potential donor pool.   
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There are many significant considerations in designing the protocols and 
procedures for a biobank that ensure the samples and associated data is of the 
highest quality. These variables occur both prior and after sample collection. They 
also include the processing, storage and management of samples in the long 
term (142).  
 
The quality of biospecimens collected by biobanks is paramount for producing 
reproducible, accurate experimental results (142, 288-291). Consequently, when 
establishing new sample collection methods, it is important to determine the 
viability and validity of the method in addition to establishing the quality of 
samples that were collected. In addition, in order to establish the long-term 
sustainability of a biobank operating costs, attitudes (towards biobanking of 
samples) of participants and users should be investigated.  
 
The establishment of the AVCBB and analysis of its structure, operation and 
output can provide important insight into the issues surrounding establishing 
comparative oncology resources in Australia. This type of basic operational 
review is frequently overlooked in clinical research settings (142). Overall, 
establishing the AVCBB not only created policies and practices to remotely 
collect biospecimens but also provide samples to facilitate comparative 
breast cancer research using CMTs; the outcome of which has created a 
long-term resource for basic breast cancer research in Australia. 
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  Results - AVCBB pilot study  
3.2.1 Biobank network 
Over the recruitment period, September 2010 to September 2011, 56 veterinary 
clinics and three veterinary pathology services were recruited (Table 3.1). 
Table 3.1 List of all veterinary clinics and pathology services recruited to 
participate. 
No. Veterinary Clinic No. Veterinary Clinic 
1 Aberdeen St. Veterinary Clinic 31 Moama Veterinary Clinic 
2 ACE laboratory services 32 Monash Veterinary Clinic 
3 ASAP laboratory Services 33 Montmorency Veterinary Clinic 
4 Bellarine Veterinary Practice 34 Murray St. Veterinary Clinic 
5 Benalla Veterinary Clinic 35 North Geelong Veterinary Clinic 
6 Box Hill Veterinary Clinic 36 Northcote Plaza Vet Clinic 
7 Bundoora Veterinary Clinic 37 
Northern Veterinary Group (Kilmore + 
Wallan) 
8 Castlemaine Veterinary clinic 38 Oakleigh Veterinary Clinic 
9 
Central Highlands Veterinary Group 
(Broadford + Wadong) 
39 Pye St. Veterinary Clinic 
10 Colac Veterinary Clinic 40 Rochester Veterinary Practice 
11 Corio Veterinary Clinic 41 Rose City Veterinary Hospital 
12 Daylesford Veterinary Clinic 42 Rose's Veterinary Practice 
13 Deniliquin Veterinary Clinic 43 Rowville Veterinary Clinic 
14 Echuca Veterinary Clinic 44 Seymour Central Vets 
15 Eltham Central Veterinary Hospital 45 Seymour Veterinary Surgery 
16 Eltham Veterinary Practice 46 Shepparton Veterinary Clinic 
17 Eureka Veterinary Clinic 47 South Paws 
18 Euroa Vet Clinic 48 Strathbogie Veterinary Clinic 
19 Fawkner Vet Clinic 49 Swan Hill Veterinary Clinic 
20 Geelong Veterinary Hospital 50 Tatura Vet Clinic 
21 
Greensborough Vet Hospital 
(+Rosanna) 
51 
The Vet Practice (Whittlesea + South 
Morang) 
22 Grovedale Veterinary Clinic 52 Tony's Practice 
23 Hepburn Veterinary Clinic 53 Torquay Animal House 
24 Highton Veterinary Clinic 54 Traralgon Veterinary Centre 
25 IDEXX Veterinary Pathology 55 Vets All Natural 
26 Kangaroo Flat Veterinary Clinic 56 Warby Street Veterinary Hospital 
27 Leopold Pet Hospital 57 Western Districts Veterinary Services 
28 Maffra Veterinary Clinic 58 Eaglehawk Rd. Veterinary Clinic 
29 Main Street Vet Clinic 59 Rosanna Vet clinic 
30 
Melbourne University, Veterinary 
Pathology Lab 
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3.2.2 Infrastructure and materials created 
Three long term biobank software materials were created.  These being:  the 
AVCBB website (Figure 3.1), newsletter (Figure 3.2) and Access database 
(Figure 3.3) (Appendix 2. The website and newsletter were created to provide an 
additional biobank-participant contact point. It was hoped that continued contact 
with veterinary clinics would serve as a reminder to collect samples as well as 
making clinics feel involved in the biobank, engendering a sense of being part of 
the research community.  
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Figure 3.1  The AVCBB website contained information for the three main 
stakeholder groups involved with the biobank – scientific community, 
veterinarians, and the general public. 
Tabs for veterinarians 
Staff contact 
information 
Tabs for researcher 
Search 
Home page 
Tab to contact biobank 
Tabs for general public 
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Figure 3.2 The AVCBB HTML newsletter was designed to keep participating 
veterinary clinics informed and promote the biobank for further sample 
collection. 
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The layout of the AVCBB database is summarised in Figures 3.3 - 3.6. For data 
export and analysis, the content of all, some or one of the sample records were 
exported through the specifically written queries. A general query for the export 
of all data related to all records currently exists. Specific queries can be added in 
the future and written to incorporate inclusion/exclusion criteria based on the 
needs of specific project to identify samples which meet the needs of the 
researcher. 
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Figure 3.3 Design features of the AVCBB database which included a) three 
main tabs, b) search function, c) check boxes and d) drop-down boxes. 
 
a) 
b) d) 
c) 
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Figure 3.4 The linked table of breeds, that automatically assigned the Australian National Kennel Council (ANKC) breed category 
and was joined to the breed drop-down box in the data entry form.
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Figure 3.5 The complete participating veterinary clinic table which included the clinic name, postal address, phone number, 
email, contact staff member and metropolitan or rural location.
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Figure 3.6 The third tab of the data entry form included quality control results as well as experimental results. 
Analytic method results 
Pre-analytic quality results 
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3.2.3 The DogMATIC kit produces a moderate sample 
size 
In 2010, the AVCBB began with 47 veterinary clinics and two veterinary pathology 
services spread over 200,000km2 in Victoria, Australia. During the first 12 months 
17 veterinary clinics submitted at least one CMT case; a response rate of 36%. 
Six veterinary clinics submitted two or more suspected mammary tumour cases; 
with the number of cases submitted over the year from these clinics ranging 
between two and six. In total, 30 CMT cases (Table 3.2) were submitted using 
the DogMATIC kit in the first 12 months, a collection rate of 2.5 fresh sample 
cases per month. Sixteen cases were not submitted with a fixed sample either to 
the AVCBB or participating veterinary pathology service. This number was 
despite the addition of the formalin specimen container to the collection kit 
allowing vets to submit fixed tissue to both the AVCBB and a non-participating 
veterinary pathology service for diagnosis. Consequently, these samples do not 
have a histological diagnosis. Of the 14 remaining seven were benign CMTs, four 
were malignant CMTs, two were malignant tumours of a different histological 
origin and one contained no tumour. The rate of non-CMT submission was 
21.4%.  
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Table 3.2 The transit time, when unknown is listed as unavailable, total RNA yield and 
purity of each DogMATIC case sample submitted to the AVCBB during the pilot period 
(September 2010 to September 2011) . T= tumour, N= normal 
 
Case no. 
Histopathological 
classification 
Transit time 
(hours) 
Total RNA yield 
(g) 
260/280nm 
ratio 
1T Mammary adenoma 5.5 6.61 2.04 
2T 
Unavailable 
23.0 25.71 1.83 
2N 23.0 8.21 2.03 
3T Unavailable 24.0 29.89 2.11 
4T 
Unavailable 
25.0 3.04 1.98 
4N 25.0 18.68 2.06 
5T Mast cell tumour 29.0 25.14 2.05 
6T Tubular carcinoma 29.0 7.83 2.09 
7T 
Unavailable 
40.0 21.03 2.06 
7N 40.0 13.56 2.10 
8T Complex adenoma 45.0 2.72 1.94 
9T 
Unavailable 
47.0 22.05 2.07 
9N 47.0 9.06 2.05 
10T 
Unavailable 
48.0 2.08 1.86 
10N 48.0 12.93 2.06 
11T 
Unavailable 
48.0 9.60 2.05 
11N 48.0 0.71 2.04 
12T 
Unavailable 
67.0 8.18 2.02 
12N 67.0 5.27 2.02 
13T 
Mammary carcinoma 
70.0 1.72 1.90 
13N 70.0 10.02 2.06 
14T 
Unavailable 
70.0 27.75 2.02 
14N 70.0 8.85 2.06 
15T 
Unavailable 
72.0 7.15 2.02 
15N 72.0 25.77 2.04 
16T Unavailable 72.0 7.54 2.00 
17T 
Mammary adenoma 
74.0 6.02 1.99 
17N 74.0 6.11 2.04 
18T 
Unavailable 
91.0 4.19 1.97 
18N 91.0 16.40 2.08 
19T 
Benign mixed tumour 
93.0 0.38 1.68 
19N 93.0 14.28 2.08 
20T 
Unavailable 
93.5 unavailable unavailable 
20N 93.5 10.39 2.07 
21T Soft tissue sarcoma 94.0 7.75 2.03 
22T Mammary 
adenocarcinoma 
96.0 43.54 2.11 
22N 96.0 15.70 2.03 
23T 
Unavailable 
144.0 0.01 0.64 
23N 144.0 19.19 2.09 
24T 
Unavailable 
189.0 5.21 1.99 
24N 189.0 14.17 2.04 
25T 
Unavailable 
240.0 10.99 2.02 
25N 240.0 0.19 1.91 
26T Mammary papillary 
adenoma 
unavailable 21.43 2.02 
26N unavailable 32.12 2.06 
27T 
Benign mixed tumour 
unavailable 14.06 2.08 
27N unavailable 32.69 2.06 
28T Basaloid ductular 
carcinoma 
unavailable 33.91 2.06 
28N unavailable 0.12 1.84 
29T 
Benign mixed tumour 
unavailable 4.51 1.90 
29N unavailable 6.82 1.86 
30T Mammary lobular 
hyperplasia 
unavailable 26.58 2.07 
30N unavailable 16.43 2.08 
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3.2.4 DogMATIC kit survey analysis 
Sixteen veterinary clinics were able to be contacted for the feedback survey. All 
participants found the kit easy to use and the instructions easy to understand 
(Figure 3.7 a, b). Veterinary clinics were also willing to collect fixed tissue samples 
in addition to the fresh samples for research (Figure 3.7c).  It was found that 
veterinary clinics often do not send samples for histopathological diagnosis 
(Figure 3.7e) but that if the biobank provided a histopathological diagnosis it 
would likely increase their participation (Figure 3.7d). They were also happy to 
continue their involvement in the biobank in the long term (Figure 3.7f). Finally, 
veterinary clinics preferred electronic communication in particular an e-newsletter 
(Figure 3.7 g).  
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Figure 3.7 Survey results from 15 participating veterinary clinics. The responses of vets to a) were the kit instructions easy to 
understand b) was the kit easy to use c) they were also willing to send a fixed tissue sample to the biobank d) providing a 
histological diagnosis would be more likely to increase their participation e) what percentage of all fixed tissue samples did the clinic 
send for histological diagnosis f) how long were they willing to collect samples for the biobank and g) how did they prefer to be 
contacted with updates about the biobank or their samples results. 
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3.2.5 DogMATIC kit provides intact, quality total RNA 
Using the DogMATIC kit, in total 51 tissue samples were received (30 tumour and 
21 matched normal mammary tissue samples) from 30 CMT cases. Forty-three 
of the 51 samples available for analysis demonstrated intact 28s and 18s bands 
using gel electrophoresis (Figures 3.8 and 3.9).  Forty-six samples produced a 
260/280nm ratio of greater than 1.90 indicating pure RNA (Table 3.1). A 
representative absorption curve of intact and degraded RNA is demonstrated in 
Figure 3.10. The concentration range of samples was 2.4-870.7ng/L (Table 3.1). 
Overall, intact RNA was isolated from greater than 80% of samples. 
Consequently, the final total RNA yield ranged from 0.71-43.54g. The average 
total RNA yield was 14.49g. These results clearly demonstrate that the 
DogMATIC kit is suitable and sufficiently robust for the timely collection of 
samples for RNA extraction. Resulting RNA is of sufficient quality and yield for 
use in applications such as qPCR, gene microarrays and other molecular 
analyses.  
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Figure 3.8 Denaturing agarose gel electrophoresis of DogMATIC samples 1-10. (T=tumour, N=normal) demonstrating intact 
rRNA 18s and 28s bands. Samples 2T, 4T and 5T lack distinct bands. No sample added to lane 2, very weak bands detected for 
sample 10T. 
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Figure 3.9 Denaturing agarose gel electrophoresis of DogMATIC samples 10-30 (T=tumour, N=normal) 
demonstrating intact rRNA 18s and 28s bands. No rRNA bands detected for samples 19T, 23T, 25N, 28N. 
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Figure 3.10 a) A representative graph of intact RNA which demonstrates a peak 
at 260nm. b) Degraded RNA isolated from a DogMATIC sample which has an 
oblique slope at 260nm. 
b) 
a) 
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3.2.6 DogMATIC transit time 
The transit time from the participating clinic to the biobank varied, from 5.5 hours 
to 240 hours (Table 3.1). The average transit time for samples from time of 
collection until storage at -80oC was 76 hours (3.2 days). Two tumour samples 
(24, 25) took longer than the recommended storage time in RNA later to reach 
the biobank.  The transit time was unable to be determined for five samples. 
 
3.2.7 Potential effect of transit on RNA concentration 
 The transit time was not correlated to the concentration of RNA isolated from 
samples (Figure 3.11) (R2= 0.026). 
 
Figure 3.11 Scatterplot of RNA concentration compared to the transit time. There 
was no correlation between transit time and RNA yield  (R2 = 0.026). 
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3.2.8 Summary of pilot study collection 
During the pilot study the biobank also received formalin fixed CMT samples that 
were not submitted as part of the DogMATIC kit. During the pilot study an 
additional 111 suspected mammary tumours (just over 9 samples per month) 
were submitted this way (histopathological classification (Table 3.3). Of these, 
34.2% of these fixed samples were malignant CMTs; whilst 49.5% were benign 
CMTs.  
 
At the end of the pilot study the total number of samples collected was 141. Based 
on the histopathological classification of tissues the biobank was able to collect 
104 CMTs in a year. Consequently, the projected sample was 314 CMTs by the 
end of October 2013, the end of the available timeline for this project.   
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Table 3.3 Histological classification of fixed samples submitted to the AVCBB in 
the pilot study. 
Sample type No. of cases 
Malignant Mammary Neoplasms 38 
Simple Carcinoma 4 
Solid Carcinoma 5 
Complex Carcinoma 5 
Adenocarcinoma 20 
Malignant mixed mammary tumour 4 
Benign Mammary Neoplasms 55 
Simple Adenoma 17 
Intraductal papillary adenoma 4 
Ductal adenoma 2 
Fibroadenoma 5 
Complex adenoma 6 
Benign mixed mammary tumour 21 
Hyperplasia/Dysplasia 1 
Ductal ectasia, lobular hyperplasia 1 
Inflammatory 1 
Panniculitis 1 
Non-mammary origin neoplasm 10 
Haemangiosarcoma 1 
Mast cell tumour 2 
Osteosarcoma 1 
Plasmacytoma 1 
Sebaceous tumour 1 
Soft tissue sarcoma 4 
Different species 2 
Feline mammary adenocarcinoma 2 
No pathology present 4 
Total 111 
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3.2.9 Overall collection period- DogMATIC kits 
The total collection period of canine mammary tumour samples spanned from 
September 2010 to October 2013. During this time the biobank network was 
expanded to improve the sample collection rate. In total, 63 veterinary clinics were 
approached to participate. After the pilot project the network was expanded from 47 
to 56 veterinary clinics and three veterinary pathology services. (Table 3.1).  
 
Initially, 150 sample collection kits were distributed to participating veterinary clinics. 
Replacement kits were posted to each clinic that submitted a DogMATIC sample. 
Overall, 73 DogMATIC kits were submitted to the AVCBB during the collection 
period. The final collection rate was just under two cases per month via the 
DogMATIC kit. Of these, thirty cases were received without a fixed tissue sample.  
 
Overall, 13 malignant CMTs and 13 benign CMTs were collected using the 
DogMATIC kits. Paired normal samples were available for seven malignant samples 
and nine benign samples (Table 3.4). There was no difference in the concentration 
of RNA extracted between the tumour (?̅? = 433.6 ng/L) and normal (?̅?= 408.3 
ng/L) tissue samples (p=0.75) (Figure 3.12). There was also no significant 
difference between the weight of tumour (?̅? = 228.5mg) and normal (?̅? = 177.6mg) 
samples (p=0.24). Using a sample weight of 30 mg for each sample RNA isolation 
and a total volume of 50L the average 5mm tumour punch biopsy would yield a 
total of 165.11g.    
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Table 3.4 The histopathological diagnosis and total RNA yield of DogMATIC 
samples submitted to the AVCBB between 2010 and 2013. 
No. Case Diagnosis 
Yield 
g 
No. Case Diagnosis 
Yield 
g 
1 10P82 
Tubular 
carcinoma 
7.83 22 10P62 Adenoma 6.02 
2 10P82 Normal 19.19 23 10P62 Normal 6.11 
3 10P105 
Basaloid ductular 
mammary 
carcinoma 
33.91 24 10P81 
Papillary 
adenoma (pot 2) 
21.43 
4 10P113 
Mammary 
carcinoma 
43.54 25 10P81 Normal 32.12 
5 10P113 Normal 15.7 26 10P83 
Complex 
adenoma 
2.72 
6 10P146 Adenocarcinoma 37.94 27 10P84 
Benign Mixed 
Tumour 
14.06 
7 10P146 Normal 27.63 28 10P84 Normal 32.69 
8 10P147 
Malignant mixed 
tumour 
30.53 29 10P149 
Mammary 
adenoma 
19.93 
9 10P147 Normal 10.68 30 10P149 Normal 9.92 
10 10P162 Solid carcinoma 37.92 31 10P186 Mixed adenoma 7.18 
11 10P177 Adenocarcinoma 38.27 32 10P186 Normal 38.72 
12 10P177 Normal 5.09 33 10P195 Adenoma 22.23 
13 10P187 
Tubular 
carcinoma 
16.60 34 10P195 Normal 31.52 
14 10P228 
Tubular 
carcinoma 
25.53 35 10P196 
Mammary cyst 
adenoma 
30.28 
15 10P228 Normal 3.12 36 10P196 Normal 43.03 
16 10P229 
Solid carcinoma 
?origin 
12.61 37 10P227 Mixed adenoma 15.79 
17 10P234 
Mammary 
adenocarcinoma 
29.31 38 10P227 Normal 0.95 
18 10P242 
Cystic papillary 
Carcinoma 
20.25 39 10P243 
Intraductal 
papillary 
adenoma, 
hyperplasia 
N/A 
19 10P242 Normal 32.02 40 10P253 
Complex 
adenoma 
18.39 
20 10P252 
Mammary 
carcinoma 
16.79 41 10P260 
Mammary 
adenoma 
26.35 
21 10P60 Adenoma 6.61 42 10P260 Normal 18.17 
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Figure 3.12 Comparison of the total RNA concentration isolated from tumour and 
normal mammary tissue DogMATIC samples. 
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3.2.10 Summary overall collection period, fixed 
samples 
The AVCBB collected a total of 308 tissue samples, including samples collected 
using the DogMATIC kit, from 288 dogs (Table 3.5). Importantly, of these 234 
samples (76%) were CMTs. There were 91 malignant tumours and 143 benign 
tumours. These 234 samples came from 217 different dogs. Ten dogs had greater 
than one histopathological classification present within the same sample. Of these, 
eight samples contained both benign and malignant mammary tumours. Finally, 
there was no residual tumour after diagnosis in two samples.    
 
Overall, the incidence of malignant CMTs was 39.6% and the specificity of collection 
was 76%.     
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Table 3.5 Histological classification of fixed samples submitted to the AVCBB 
either using the DogMATIC kit or through a veterinary pathology service. 
Sample type No. of samples 
Malignant Mammary Neoplasms 91 
Simple carcinoma   
               Simple carcinoma 60 
               Tubulopapillary carcinoma 6 
               Solid carcinoma 7 
               Anaplastic carcinoma 1 
Complex carcinoma 10 
Special type of carcinoma   
               Squamous cell carcinoma 1 
Carcinosarcoma 5 
Sarcoma   
               Osteosarcoma 1 
Benign Mammary Neoplasms 143 
Adenoma   
               Simple adenoma 73 
               Complex adenoma 26 
Fibroadenoma 6 
Benign mixed tumour 38 
Mammary hyperplasia, dysplasia 9 
Non-mammary origin neoplasm 21 
No pathology present 4 
Other 9 
Different species 4 
Diagnosis unavailable 27 
Total 308 
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3.2.11 Animal follow-up, data loss 
All animals with a CMT were monitored until their death, 46 animals were lost to 
follow-up. These samples came from 12 different veterinary clinics. Additionally, 39 
of the animals lost to follow-up had CMTs (Table 3.6). Overall, there were 171 
animals available for follow-up data collection. Information that was collected 
included: breed, age at diagnosis, age at de-sexing, number of litters, previous 
history of a mammary tumour, recurrence of the mammary tumour, date of death, 
cause of death and any relevant treatment. Obtaining the reproductive history of the 
animals was the most difficult variable to obtain with this being unknown in over 
83% of dogs. In addition, the age the animal was de-sexed at was not available for 
21% of dogs. Finally, the age, breed and if the animal was de-sexed was not 
available in 8.2, 3.5 and 2.3% of animals respectively (Table 3.7). Interestingly, 
there were eight (4.2%) dogs that were not seen again after surgery to remove the 
mammary tumour. 
  
Table 3.6 Samples from dogs that were lost to follow-up. 
Diagnosis Number 
Malignant CMT 15 
Benign CMT 24 
Other 1 
Unavailable 6 
Total 46 
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Table 3.7 Total data loss of the five main categorical data fields included in the 
patient information sheets (n=171). 
Field Data loss n (%) 
Breed 6 (3.5) 
Age/date of birth 14 (8.2) 
De-sexed (spay) 4 (2.3) 
Age of de-sexing 36 (21.1) 
Number of litters 143 (83.6) 
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  Discussion  
3.3.1 Designing a sustainable biobank 
The aim of establishing the AVCBB was to create a long-term comparative cancer 
research platform in Australia. In particular, the aim was to design the collection 
method, storage infrastructure, materials and processes to house CMT 
biospecimens for research. 
 
These materials would allow a well-characterized sample cohort of normal tissue 
and benign and malignant CMTs for breast cancer research. These samples 
would allow further investigation into the distribution of the molecular subtypes in 
CMTs compared to humans, as well as their relative survival.   
 
Biobank samples are “essential to translating the observed pathophysiology of 
patients into new pharmaceutical agents” (283). Establishing the AVCBB has 
provided researchers with samples that can allow investigation into novel 
prognostic and potential therapeutic targets such as Runx2, GATA-3 and PTHrP.  
 
The outcome of developing this biobank was the creation of permanent 
infrastructure and policies that support the remote collection, processing, storage 
and dissemination of high quality animal tissue samples. This was achieved by: 
• designing a sustainable remote biobanking model 
• creating multi-platform media marketing material 
• establishing a network of participating veterinary clinics 
• developing collection, processing and storage protocols 
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• creating an electronic database for sample information and results 
• determining baseline quality data of samples collected 
• determining a collection rate and potential growth rate 
This infrastructure has now supported two PhD students to continue collection of 
samples and further grow the biobank. 
3.3.1.1 Biobank sustainability 
The concept of sustainability was key to creating the AVCBB and ensuring its 
ability to continue in the future. The establishment and continuation had to be 
achieved with a small operating budget of under AUD$5000 per year. The 
biobank design model, sample collection, processing, storage, maintenance and 
staffing all needed to be financially sustainable. An important step in designing 
the remote biobanking model was to investigate the structure and operations of 
existing biobanks. In this respect, there is limited peer-reviewed information on 
developing and maintaining a biobank (138). There is also very little published 
material available to assist in establishing a biobank from a financial perspective 
(292). There is only one specialised peer-reviewed journal, Biopreservation and 
Biobanking, for research focusing on best practice as well as the legal and ethical 
issues of biobanking. This publication also provides profiles on prominent 
biobanks.  
 
The main constraints when determining how to structure the biobank were: 
funding, staffing, and most importantly the paradigm difference between 
diagnosis and treatment of breast cancer in women and dogs; where dogs are 
diagnosed, treated and managed by a single health professional. The model used 
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to create and maintain biobank needed to have a low establishment and 
operation cost. It also needed to have procedures that were able to be followed 
by research students rather than a permanent biobank scientist. Finally, these 
procedures needed to allow sample collection and banking from a patient group 
that was diverse, with different diagnosis and treatment methods, and was spread 
over a large area.  
 
Most frequently, a biobank uses a structure that either focuses on a single (155, 
293, 294) or small network of sites (11, 295, 296) that have their own facilities to 
collect and store biospecimens. Historically, these networks were initially well 
established stand-alone biobanks that through large funding grants have 
consolidated to provide a wide-scale standardised biospecimen collection 
resource for research (296). The AVCBB deviates from these models. This main 
structure has two important distinctions from the AVCBB. Firstly, these facilities 
have both patients and materials required for all stages of biobanking on site.  
Secondly, they function on large start-up and operating budgets frequently more 
than AUD$1,000,000 (296, 297).  
 
It has been suggested that following the original grant funding biobanks find it 
difficult to  secure sustainable financing after the initial establishment period of 4-
5 years (298). This is believed to be partly due to the lack of long-term funding 
sources for biobanks and biobanking research (292). It could also partly be due 
to the failure of cost-recovery financing methods used by many biobanks and the 
sluggish uptake of samples (138). Both causes will be discussed in more detail 
later in this chapter. These issues have been highlighted in Australia by the Royal 
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College of Pathologists (RCPA) that suggest that not only is biobanking a costly 
activity but that it is not ‘self-sustaining’ (299). The exception to this view seems 
to be the Nottingham Health Science Biobank which was able to achieve financial 
and operational sustainability within its first three years of operation (295). It was 
able to achieve this by commissioning a financial report, identifying and 
establishing contracts with both non-commercial and commercial partners all 
before establishing the biobank. This allowed both a more accurate determination 
of operation costs and revenue which directly impacted on the structure and cost-
recovery schedule used by the biobank. The AVCBB would similarly benefit from 
adopting this strategy to better define operating costs and potential income 
streams.  
 
3.3.1.2 Biobanking models and sustainability 
There are currently three main business models used by biobanks (298). These 
being institute-funded, donations-based and price-based models. The AVCBB 
was established as an institute-funded biobank.  It is dependent on the financial 
support from its housing institution of RMIT University. This forces the biobank to 
be dependent on both the research budget of the university and the volume of 
incoming internal projects that may involve comparative oncology. In this respect 
the AVCBB is similar to most US biobanks.  Nearly 70% of North American 
biobanks are part of or are funded by an academic institution (138).  
 
 In order for the biobank to continue operating and grow it needs more funds. Two 
ways of facilitating longer term financial support is to either integrate either one 
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or both other business models into the AVCBB’s current operational structure. 
This would diversify the financial revenue platform the biobank is based on. It 
would provide a more robust income source that may allow it to withstand future 
funding challenges (298).  
 
Securing long-term financial security is important as the actual costs of 
biobanking an ‘average’ sample could cost 5-10 times more than publicly 
estimated (298). For human samples, the ongoing costs per sample/case is over 
AUD$800 per annum (297). Many human biobanks, for example the VCB in 
Australia, have adopted the price-based funding model. This is commonly 
referred to as ‘cost recovery’ (297). A biobank charges a researcher for each 
sample they request for a project. This cost is designed to allow the biobank to 
cover all the costs associated with collecting, processing, storing and 
disseminating the samples and their associated clinical data. Unfortunately, this 
model is also not ideal. It has been demonstrated that the total program costs of 
maintaining a biobank are not fully met by cost recovery and that self-
sustainability through cost recovery alone is not achievable (297).  
 
In terms of trying to develop cost recovery schedules the collection and utilization 
rate of samples is important as this affects the cost per case – through economies 
of scale (297). The pilot project demonstrated that the AVCBB had an RNAlater 
stabilised tissue collection rate of 2.5 samples per month whist the fixed tissue 
collection rate was nine samples per month. In the future, these rates can be 
used to help determine the cost recovery potential of the AVCBB. In addition, 
when the biobank begins to disseminate samples deliberately lowering the 
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predicted utilization rate of samples could be beneficial. It has been shown with 
human biobanks that the utilization over time was significantly lower than the 
initial prediction (297).  A sliding scale of cost recovery based on actual utilization 
rate in human biobanks which approximate the AVCBB collection size and 
resources ranged sample utilization could be created. This would allow more 
accurate financial predictions to be made which would support biobank 
sustainability even if the utilization of samples is significantly lower than expected.  
 
Part of designing a sustainable canine mammary tumour biobank with a small 
operating cost was to determine a cost-effective method of collecting patient 
samples. Traditionally repositories use their existing surgery and pathology 
facilities to collect their samples and store them on-site. A fresh sample can be 
sent directly from the operating theatre to pathology where a trained pathologist 
or pathology registrar can determine how much sample can be banked and what 
is needed for diagnosis. In contrast, canine patients with a suspected mammary 
tumour receive treatment/surgical resection at a local veterinary clinic. That 
comparison is close to having a woman undergo a mastectomy at her General 
Practitioner’s office. This highlights that veterinarians routinely fulfil a range of 
roles that includes being a primary care physician, surgeon and oncologist.  
 
Initial dialogue with veterinarians during recruitment and the survey revealed two 
important factors that influenced the collection of CMT for biobanking. Firstly, vets 
considered them as a low frequency tumour at their veterinary clinics. Their 
anecdotal evidence aligns with published evidence. In particular, that in 
developed countries the frequency of CMTs is significantly lower than that seen 
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in developing countries where early or mandatory desexing of animals is not 
present or enforced (12, 13, 16, 122).  In developed countries similar to Australia, 
the incidence is estimated between 2 per 1000 animals (15) whereas in 
developing nations such as Brazil the incidence is over five times higher with 11 
in every 1000 likely to be affected (122). Secondly, veterinarians indicated that 
they only refer a small percentage of cases to either speciality or tertiary 
veterinary clinics (Figure 3.7e) and in some of those cases it has been at the 
owner’s request. The results of the pilot study survey also revealed that the use 
of Anatomical Pathology services varied between clinics and overall there was 
significantly less use than is seen in humans. This is supported by the fact that 
the first fifteen DogMATIC kits returned to the biobank were not sent for 
histopathological diagnosis so all remaining excised tissue was lost to the 
biobank. These factors, lower frequency and reduced diagnosis, indicated that 
biobanking CMTs may be more difficult than collecting human samples. As such, 
there needed to be mechanisms embedded within the biobank operations to 
counter these disadvantages. 
 
3.3.1.3 Biobank design and promotion 
Consequently, rather than trying to follow successful established biobank 
structures (11, 292, 295, 296) by using a single large tertiary site such as the 
veterinary hospital at The University of Melbourne, recruitment focused 
networking many smaller veterinary clinics together. Increasing the number of 
clinics could potentially help overcome the limited number of CMTs seen 
clinically. The clinics that were recruited sites had surgery facilities but may or 
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may not have used pathology services routinely for CMT diagnosis. For this 
reason, veterinary pathology services were also approached. Using this structure 
enhanced the sample catchment area increasing the likelihood of obtaining 
samples. In addition, in some cases it bypassed the need to pay for pathology 
services, reducing costs.  
 
The National Center for Biotechnology Information (NCBI) best practice 
recommends storing fresh tissues either in vapour phase liquid nitrogen or at -
80oC (143).  At the VCB, fresh samples are initially frozen using liquid nitrogen 
and then stored in a -80oC freezer. This method would have been too costly and 
difficult to control for the AVCBB due to the number and geographic spread of 
participating veterinary clinics. It was for this reason the DogMATIC kit included 
the RNAlater cryovials to store and transport samples.  
 
Another reason why CMT is a low frequency tumour is the proportion of spayed 
animals. The incidence of canine mammary tumours is thought to be lower in 
urban areas where anecdotally a higher proportion of female dogs are spayed at 
a young age. This was identified during discussions with participating veterinary 
pathologists and consequently was why clinics were initially recruited from rural 
areas. An unforeseen benefit of recruiting the veterinary pathology services, was 
that based on the samples biobanked these services interacted with 
proportionately more urban veterinary clinics. This helped to balance the number 
of urban and rural participating clinics.  
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Both these urban and rural clinics were targeted using multi-platform marketing. 
Veterinary clinics were targeted through a postal, peer-newsletter and phone 
campaign. Of these methods, the phone campaign was the most successful. The 
peer-journal advertisement resulted in only one veterinary clinic contacting the 
biobank. The postal campaign delivered no results. All the clinics were recruited 
using the phone campaign. Consequently, when establishing a new biobank 
personal contact is the most successful recruitment method but not the most time 
efficient.  
 
Following on from the initial recruitment the AVCBB newsletter was used not only 
to keep participating clinics informed but to also a subtle reminder to continue 
collecting CMTs. In addition, in human biobanking updating participants on the 
use and outcomes of research using their samples is seen as a way of showing 
respect and gratitude to participants (300). The most desirable form of 
communication for biobank participants was a paper newsletter or an emailed 
newsletter (301). This was in line with the pilot study survey results where 
veterinarians suggested an electronic newsletter as the best way to disseminate 
updates to participating clinics. Research also suggests that participants prefer 
to be updated only once a year (301). This timeline was used during sample 
collection.  
 
The website was used as alternative platform for communication and advertising. 
The content was designed to inform the public as well as veterinarians. In 
addition, it was used to disseminate any research stemming from the biobank. 
During the pilot study and collection period the website was not analysed for 
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usage. Moving forward, linking the website to Google Analytics would allow the 
biobank to quantify website visits, visitor locations and its most popular pages. 
Furthermore, the AVCBB newsletter could be hosted by the website and the 
newsletter email could contain a link to the website. This would allow each 
newsletter to be a Google searchable item improving our visibility within online 
search engines.  
 
During the collection period the number of participating clinics was increased to 
increase the biobank catchment area and to improve the collection rate. To 
improve this further, it would be beneficial for the biobank to review which 
veterinary clinics were most frequently represented in samples collected from the 
veterinary pathology services. This would allow the biobank to recruit clinics that 
not only see CMT more frequently but ones that also routinely send suspected 
CMTs for histopathological diagnosis. Furthermore, the biobank could identify 
recruited clinics that were poor performers. This would allow the biobank to either 
target these clinics directly to improve their submission rate or remove them from 
the network to focus resources on clinics that are actively participating. 
 
The DogMATIC kit was deliberately designed to avoid exposure to owners’ 
personal details. This was an advantage as owner consent was not required. The 
sample was removed as part of the normal treatment protocol for the animal. The 
consent was given by the veterinarian through collecting and sending the sample 
to the biobank. This deviates from human biobanking which requires consent 
from the patient (143).  
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3.3.1.4 Biobank consent 
Consent can be a difficult issue with human biobanking. Multiple studies have 
shown that potential participants do not understand what is being outlined in the 
consent documents (302-304). There are also concerns over which type of 
consent, broad or specific, should be used (305-307). The ethics of using broad 
consent for participants is particularly controversial as factors such as the goals 
of the research, research techniques and potential risks to the participant cannot 
be defined at the time of consent (308-310). The absence of these difficulties in 
establishing the AVCBB further demonstrates the benefit of using companion 
animals for oncology research.  
 
Using the AVCBB researchers, are able to obtain quality annotated samples 
without having the same restrictions on the types of research conducted or how 
the samples and clinical data can be used. The pressure on the AVCBB is also 
reduced as it does not have to maintain consent and withdrawal records. This in 
turn also made it easier to select an appropriate LIMS to store patient data as it 
did not have identifying features that could restrict how and where the data could 
be stored. The absence of owner data did present some challenges. For example, 
collecting follow-up data for some animals was difficult especially when not all 
identifying data on the animal was originally provided by the vet. Consequently, 
moving forward QC for data storage should be more stringent as the barcode 
number is the only primary key to link baseline and follow-up data.  
 
In contrast to the strictly regulated consent policies surrounding human research 
in Australia, the policies regarding companion animal research lack depth in 
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terms of owner consent. During the establishment of the AVCBB the governing 
policy for animal research was the 7th  edition of the Australian Code of Practice 
for the Care and Use of Animals for Scientific Purposes (2003) (311). This edition 
only contains a single reference to using companion animals. It outlines that when 
privately owned animals are used the details and duration of the responsibility of 
the research investigator should be set out in the ethics proposal. There is no 
description of owner consent or involvement apart from that they may retain day-
to-day responsibility for the treatment, care and welfare of their animal. During 
the course of setting up the biobank a revised edition of this code was released 
(312). This edition more thoroughly defines the responsibility of stakeholders. In 
particular, that people involved in the care and use of the animals must 
understand their responsibilities and be competent in terms of understanding the 
code. Most importantly owners now need to be given detailed written information 
of their responsibilities as well as then providing written acceptance of these 
responsibilities. Interestingly though, the language does not use the word 
‘consent’ in respect to owners for the use of their animals for scientific purposes.  
 
These revised guidelines will affect the biobank as it continues in to the future. It 
will now need to prepare information sheets for owners that include provision for 
their signature. This will also require stricter protocols for data management as 
personal information of owners such as their names will have to be stored by the 
biobank. To ensure current data storage and prepare for personal information 
storage the biobank could initiate an external review of its storage database and 
protocols. 
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In human medical research, there is a high level of consent, 70-90%, from human 
patients to allow their samples to be used for medical research (298). Despite 
this, the perception of the public towards medical research can sometimes be a 
barrier in the donation of human samples to biobanks (313). There is no data on 
owner consent and perception for the use of companion animals in research. 
There is however well documented data on the negative public perception 
towards using animals.  In particular, the reluctance by the public to support the 
use of larger animals such as dogs or monkeys (314-316). Whether this attitude 
and awareness extends to the use of companion animals has not been 
established and could be investigated by the biobank in the future.  
 
Participation in the AVCBB was only declined by three veterinary clinics. These 
clinics declined due to their current involvement in other research projects rather 
than any objections to the use of their animals. Consequently, in broad terms of 
consent, 95% of potential participants consented. As the AVCBB continues in the 
future, an interesting factor to investigate would be if consent levels changed 
when consent for sample collection and research participation is obtained 
through owners rather than veterinarians.  
 
3.3.1.5 A growing community 
Internationally, there is a growing trend for the use of companion animals in 
medical research (7, 66, 90). Presently, there is a proprietary commercial 
veterinary biobank for comparative studies in France (317). The Oncovet Clinical 
Research Pharma canine and feline biobank has over 2300 FFPE samples 
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available for use.  Institutional veterinary biobanks have been established at 
Uppsala University in Sweden (318), the University of Pennsylvania in the USA 
(319) and the University of Veterinary Medicine (320), Vienna. Despite the lack 
of published data it is clear that the AVCBB is part of a growing community of 
veterinary biobanks world-wide. Locally in Australia, there is now a DNA canine 
biobank at the University of Sydney (321) as well a Comparative Oncology 
Special Interest Group (CO-SIG). Unfortunately, this group does not involve a 
biobank but it is focused on recruiting companion animals for comparative studies 
(322).  
 
As the biobank was created for a specific sample type it uses a ‘directed 
screening’ style. To expand in the future the AVCBB could also use ‘non-directed’ 
collection strategies to further expand the repository. This method collects 
samples without a specific intended purpose. This allows samples to be available 
in the future without needing long collection periods to collect the required sample 
size. An obstacle to implementing this collection method is that sample storage 
costs are one the highest running costs for the biobank (323). Operational data 
from other biobanks has established that maintaining five freezers can cost more 
than $6000 per year. This data suggests that if the biobank were not supported 
by RMIT nearly 20% of its operational budget would be used for storing samples. 
This cost is minimal compared to using automated systems which can cost more 
than US$1 million (323). A significant benefit of these systems is that they can 
extract samples without subjecting other samples to fluctuations in temperature 
potentially affecting their quality in future research.  
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Using the remote collection and central storage structure as the AVCBB’s 
structure successfully allowed CMT collection within the biobank’s operating 
budget. Currently, there is only one published example of a human cancer 
biobank that has been established at an institution without an integrated 
pathology service (324) and none that exclusively use off-site collection. This 
highlights the distinctive structure of the AVCBB compared to other biobanks.  
 
3.3.2 The DogMATIC kit, the foundation for remote 
biobanking 
Two important sustainability issues in biobanking stem from the nature of the 
funding and the limited scale of collection (325). A benefit of the AVCBB’s method 
of biobanking was that its foundation is based on a large scale collection network; 
a ‘hub and spoke’ (326) model which addresses the limited scale of collection 
issue. Once the design of the biobank was established the best use of this model 
to collect samples needed to be determined. The resulting DogMATIC kit was 
loosely based on the kit developed by the National Bowel Cancer Screening 
Program in Australia (327). It was the foundation needed to be able to 
successfully remotely collect CMT specimens. As part of the International Society 
for Biological and Environmental Repositories (ISBER) best practice the 
DogMATIC kit was validated using the pilot study (141). The kit was low-cost with 
a unit price of under AUD$30. The long-term sustainability of the biobank was 
easier to maintain while it remained a small-scale operation. The low kit cost and 
long shelf-life, along with the processing and storage of samples being performed 
Chapter 3 – Establishing a CMT Biobank 
 
158 
 
by trained research students rather than paying for specialised staff allowed the 
bank to have lower operating costs. 
 
The kit was designed to conform to both ISBER (141) and NCI (143) best 
practice. For example, the patient information sheet included the sample 
collection date, time and temperature to allow accurate timing of specimen transit. 
Additionally, for biological material tracking, the specimen containers and patient 
information sheet were barcoded. Furthermore, the kit contained punch biopsy 
needles to try to standardise the fresh tissue sample size submitted by 
veterinarians. This was important as the volume of RNAlater was calculated 
based on a piece of tissue with the dimensions produced by the punch biopsy 
needle. This also reduces internal bias between the tumour and the normal 
sample as well as externally between samples from different animals.  
 
3.3.2.1  DogMATIC sample annotation and quality 
Appropriate sample annotation is important to ensure optimal quality for research 
(328). Especially, recording pre-analytical elements that involve the sample 
collection and storage can be vital to determining sample quality. A recent study 
identified over 170 potential pre-analytical variables that could affect quality. 
Obviously trying to annotate all 170 variables would be unreasonable for a 
biobank to accurately and consistently record. Of these variables 80 are 
considered essential. Importantly, though some of these variables are not 
applicable for veterinary samples, all but one relevant variable was recorded by 
the AVCBB either in the specimen collection information sheet or during the 
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collection of follow-up data. The cold ischemic time of the sample was the only 
required element that was not successfully annotated by the AVCBB. 
 
In retrospect, the absence of a guide on cold ischemic time in the sample 
collection instructions and the lack of a field to record it on the patient information 
sheet was an initial design flaw with the DogMATIC kit. This variable is 
considered a priority for data collection for biospecimens (328). Most biobanks 
can exploit on-site surgical and pathology facilities to minimise the cold ischemic 
time of samples. Recording this variable was not initially outlined during 
consultation with VCB staff.  
 
Increased cold ischemic time, the time from surgical removal to 
fixation/stabilization, reduces both the quality (288) and yield (288) of RNA as 
well as potentially inducing significant transcriptional changes of the RNA isolated 
from breast cancer samples (289). To minimise the effect of this pre-analytical 
variable on biospecimens the time should be kept below 1 hour according to 
American Society of Clinical Oncology guidelines (329, 330).  An extended cold-
ischemic time could be responsible for the degraded RNA seen in some collected 
samples (Table 3.2, Figure 3.8 and Figure 3.9). For human breast cancer 
specimens in particular collecting samples within 30 minutes of surgical removal 
is ideal (331).  
 
In the future, this time frame should be incorporated into the instructions and 
patient information sheet for veterinarians. Hopefully, this will further improve 
sample quality and adhere to stricter sample monitoring guided by ISBER (141) 
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and NCI (143). Using a specific cold ischemic time guideline and the standardised 
sample size will minimise any changes in gene expression and RNA integrity. It 
has been shown that medium tissue samples, 4x4x4mm, akin to the DogMATIC 
punch biopsies have significantly reduced RNA integrity numbers compared to 
larger samples sizes (332). 
 
Similarly, to cold ischemic time the post-preservation transport time is another 
common pre-analytical variable that can significantly affect the quality of 
biospecimens (328). Normally, a fresh specimen is collected and stored on-site 
at a biobank. It is uncommon for a sample to be collected at a secondary site. 
During transport best practice also recommends that samples are continuously 
monitored (299). This was not a viable option for the AVCBB. There is no 
published data on the effect of specimen transport in uncontrolled temperature 
conditions in RNAlater. According to manufacturer’s guidelines tissue should be 
stable for 7 days at room temperature, this timeline does not take into account 
the extreme temperatures that can be recorded in Australia during summer. As 
DogMATIC samples were posted to Melbourne from remote areas it was 
important to demonstrate that the quality of the biospecimen was not 
compromised by the transit time. The transportation of RNAlater stabilised 
specimens in unmonitored conditions for up to 10 days was not correlated to any 
reduction in the concentration of RNA yielded from the sample (Figure 3.11). In 
addition, the absence of any correlation between the transit time and the yield of 
the sample further supports this. Though temperature monitoring is 
recommended the use of RNAlater is a suitable lower cost alternative to 
Chapter 3 – Establishing a CMT Biobank 
 
161 
 
temperature monitoring that maintains sample quality during uncontrolled 
transportation.   
 
Overall, the protocols established to collect and store DogMATIC samples 
successfully captured the data elements needed for good sample annotation. To 
improve sample and data collection the AVCBB could work towards 
ISO9001:2008 accreditation. This would provide a minimum benchmark of quality 
and result in more synchronous operating procedures. Some Australian biobanks 
such as the biobank at the Cancer Council of New South Wales have already 
achieved this accreditation (333).  
 
3.3.3 Data storage and loss 
The initial sample annotation along with additional clinical, quality control (QC) 
and experimental data was stored using a specially designed database. There 
are many specialised software solutions for biobanks in the current marketplace. 
Some have the ability to live track samples in transit or integrate demographic 
and geographical data related to each specimen (334). These programs are 
capable of maintaining and tracking data collected at multiple institutions 
concurrently (334). In this respect the selection of how a biobank stores its clinical 
data is very important, as the amount of data collected and stored can in of itself 
be used for research separate to the physical specimens they are linked to.  
 
Unfortunately, the cost of many commercial software solutions is prohibitive for 
smaller biobanks.  Using Microsoft Access the biobank was able to create a free 
and simple version of a LIMS. The Access database created conforms to the data 
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management guidelines of ISBER (141) and the NHMRC guidelines (Figures 3.3-
3.6)  (145). 
 
Developing and using an appropriate laboratory information management system 
can reduce operating costs by minimizing the manpower needed to interact with 
laboratory data (335). Most commercially available LIMS have about 80% of their 
functionality in common (335).  
 
To further develop the biobank into a facility that more strongly resembles the 
refined, controlled, monitored larger biobanks the AVCBB still needs to further 
develop internal policies. These should include a process for periodic auditing 
both internal and external. More rigorous management of sample storage 
conditions should be instigated. This could include collecting and storing 
temperature monitoring charts from -80oC freezers, cataloguing quality 
assurance (QA) and QC measurements during RNA isolation. Importantly the 
current LIMS needs to be adapted to include functionality that allows integration 
of this data with sample data.  
 
In addition, there are other desirable features to the current LIMS that would 
improve functionality. For example, login features for individual users would be 
desirable. This would allow better tracking of changes to patient information and 
results. Another desirable feature would be the ability to insert and link QC 
images or experimental results to records within the LIMS. These images could 
include spectrophotometry absorption curves, qPCR melt curves, IHC results or 
in situ hybridisation (ISH) results. This would allow easier data collation for quality 
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assurance. These images could also be provided to researchers that have 
requested samples.  
 
Though the LIMS created currently meets the needs of the biobank it is likely to 
struggle in the future as the biobank begins to disseminate samples. 
Consequently, in the future working with an organisation such as BioGrid 
Australia (336) that specialises in managing biobank data may be more suitable. 
This would allow open access via login to a version of the AVCBB LIMS that is 
hosted on an intermediate server secured by BioGrid. It provides two directional 
talk for the biobank LIMS but only one way talk from an external source. This 
allows the intermediate server to update the version of the LIMS it houses. It 
would also provide protection to sensitive data within the original LIMS but 
provide better outside access for researchers. This would also provide data-
mining capabilities within the hosted LIMS by external parties without 
compromising or corrupting the virgin data hosted at the AVCBB. Finally, using 
BioGrid would allow researchers who have used biobank samples to upload data 
based on their results that could be linked back to the original samples. 
 
The baseline and follow-up data was stored in the biobank database. Analysis of 
the data missing from each animal’s history revealed that the age when the 
animal was de-sexed was unknown in over 20% of animals. Furthermore, the 
reproductive history was unknown in over 80% of animals. This highlights that in 
recording when a bitch delivers a litter is not often recorded in a veterinary clinic. 
The absence of this data meant that the relationship between the number of litters 
and the presence of a CMT could not be established. It also meant that it was 
Chapter 3 – Establishing a CMT Biobank 
 
164 
 
difficult to establish if the age of de-sexing was associated with the presence of 
a tumour in anyway (Chapter 3). The amount of missing data for breed, age and 
de-sexed is in line with other published canine research data (337, 338).  
 
To determine the success of remotely biobanking CMT samples along with the 
overall success of the biobank several factors were investigated. Firstly, the 
DogMATIC sample quality and quantity were defined. Following this the 
specificity of the sample collection and survey results were determined.  
 
The pilot study demonstrated that it is feasible to establish a comparative 
oncology biobank and collect moderate numbers of samples for research. Based 
on fresh and fixed collection rates the biobank is able to increase its repository 
by 150 cases each year. The next challenge of the AVCBB is being able to 
disseminate these samples whilst maintaining financial viability. An important part 
of a biobank’s financial stability is driven by its ability to meet the needs of its 
customers – medical researchers (292).  
 
As a prospective collection, not all samples were guaranteed to be a CMT.  Of 
the samples submitted during the pilot study only 17% were not CMTs (either 
benign or malignant). This result indicates a specificity of 83% which is very 
reasonable. The reported range of the incidence of malignant CMT is 26-73% 
(339), whilst the WHO guidelines suggest 41-53% (340). The results of this 
collection suggest that in Victoria the incidence of malignant CMTs sits at the 
lower end of the WHO range just outside at 40.7% for the pilot study and lower 
again for the overall collection at 38.8%.  
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These rates guide future projections of sample sizes and increases in the banked 
specimens. They can also be used to better approximate the timeframe needed 
for future prospective studies run by or through the AVCBB.  
 
The results from this pilot study demonstrated that over 80% of samples collected 
offsite in rural locations yielded intact RNA with an average sample yield of 
14.46g whilst the overall average sample yield was 21.48 g. Analysis of 
samples following the pilot study revealed an even higher sample yield of 
165.11g. This was due to improved adherence to the RNA isolation method and 
more accurate weighing of samples. There was no difference in the concentration 
of RNA yield between paired tumour and normal samples. This held true when 
comparing all tumour samples to the normal and when comparing only the 
malignant samples to the normal. This is in contrast to human data which shows 
a significantly lower yield from normal breast samples compared to tumour 
samples (341). Though the RNA concentration of DogMATIC tumour samples 
(540 ng/L) was comparable to that produced by Mee et al. using the same 
weight, RNA isolation kit and RNA concentration analyser (341). The average 
yield of 165.11g would allow for downstream experiments, for example, 
microarray experiments may require between 2-40g of total RNA, RNAseq uses 
around 0.5g and qPCR generally uses 2g of total RNA.  
 
The quality of these frozen samples is particularly important as 60% of 
researchers have been shown to question their results when using low-quality 
biospecimens (342). 
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The high yield of intact RNA combined with the survey results indicated that the 
DogMATIC kit was easy to use and produced good quality biospecimens.  In 
addition, participating veterinarians were prepared to participate in biobank 
collection long-term (Figure 3.7f). This would allow the biobank to increase the 
repository size in the future. These results were the foundation for expanding the 
veterinary network to 56 clinics by the completion of the project.  
 
An interesting result from the survey was the low uptake of Anatomical Pathology 
services. Two thirds of surveyed clinics sent less than 50% of all fixed tissue 
samples for histopathological diagnosis. Discussions with surveyed clinics 
indicated those samples not sent for diagnosis were either thrown away or kept 
in formalin for a period in case the owner changed their minds. The disposal of 
these tissues highlighted the current under-utilization and loss of CMTs as 
potential valuable resources in research be it in veterinary or comparative 
oncology. Part of this limited use may be due to the cost of using these services. 
Staff members interviewed during the survey felt the cost of Anatomical 
Pathology can be a strong deterrent for owners. A higher sample submission rate 
might be achieved by the AVCBB if it provided pathology services for samples. 
This would encourage veterinarians and owners that would not normally keep the 
CMT sample to donate it in return for a diagnosis.  Offering this service would 
increase the operating costs of the biobank by $77.27 per sample based on the 
current rates provided by ASAP Laboratories.  
 
Not offering a timely diagnosis for vets may have affected the submission rate of 
DogMATIC kits. In addition, participating clinics may not have had a CMT case 
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during the collection period of the pilot study. Consequently, the sample 
submission rate of 36% could be artificially low. Regardless, there is the potential 
to improve both the response rate and compliance of veterinarians. The addition 
to the kit of the formalin pot, rather than relying on collection from veterinary 
pathology services greatly improved the number of matched fresh and fixed 
samples returned. Following its introduction, the subsequent 15 samples 
submitted using the DogMATIC kit all contained paired RNAlater stabilized and 
formalin fixed samples. In addition, the feedback from the survey was that 
veterinarians were willing to collect more fresh samples for RNA isolation given 
the large size of tumours. Consequently, the DogMATIC kit was changed to 
include two tumour sample cryovials. Another improvement made based on the 
results of the survey was creating the AVCBB newsletter. Participating clinics 
indicated that an electronic newsletter was a preferred form of communication.  
 
3.3.4 Chapter Summary 
This project has developed infrastructure and policies that supports the remote 
collection, processing, storage and dissemination of high quality animal tissue 
samples.  The biobank structure, though novel, does conform as much as 
possible to ISBER and NCI best practices. The remote biobanking model created 
was low cost, sustainable and produced moderate collection rates. This was 
achieved by creating marketing materials that were used to establish a network 
of veterinary clinics. These clinics used specially designed kits to collect samples. 
Standard operating procedures for the collection, processing and storage of 
these samples were created. Data produced was stored in a custom built LIMS. 
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The network of participating veterinary clinics also provided a foundation for 
supporting comparative oncology trials in the future. 
 
The success of using domestic dogs for both disease research and comparative 
oncology trials is keenly illustrated by the success of the Comparative Oncology 
Trials Consortium (COTC), based in the United States. Since its inception in 2003 
this consortium has successfully completed nine clinical trials of which two agents 
have also Phase 1 human studies (27, 343). 
 
Ultimately, this research has not only established the infrastructure, policies and 
practices to remotely collect biospecimens for research but the samples collected 
also can be used to improve our understanding of breast cancer in both humans 
and dogs. The pilot study demonstrated that remote biobanking can 
produce good quantities of high quality RNA matched with corresponding 
formalin-fixed paraffin-embedded tissue and patient data. These samples 
are available for molecular, biomarker identification and survival analysis studies.  
Consequently, the establishment of the AVCBB has created a long-term source 
for comparative oncology research. It provides samples to help identify new 
cancer biomarkers and improve treatments for dogs with malignant mammary 
tumours.  
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 Profiles of canine mammary tumours in 
Australia 
  Introduction 
The officially recognized dog breeds have been in existence for less than 400 
years (344). Most were created in the Victorian era, 19th century, when dog 
breeding was popular throughout the UK and Europe (345). This intense 
development period gave rise to more than 400 modern breeds (346).  
 
Until 1992, Australia adopted The Kennel Club breed standards and groups from 
the UK. After this the ANKC developed, in conjunction with the Fèdèration 
Cynolgoique Internationale (FCI), the Australian Standard for Australian Breeds 
(347). The FCI is the umbrella organisation that is responsible for not only the 
ANKC but also the national kennel clubs of the UK, USA and South Africa (348).  
The ANKC classifies dog breeds into seven different groups based on their form 
and function. These groups are: Toy dogs, Terriers, Gundogs, Hounds, Working 
Dogs, Utility dogs and Non-Sporting dogs. In addition, there are several uniquely 
Australian breeds that have been specifically bred in Australia. In particular, the 
Jack Russell Terrier, Australian Terrier, Kelpie, Australian Cattle Dog (347). 
These breeds are all recognised by the American Kennel Club. The Kelpie is not 
a breed recognized by The Kennel Club UK and the Jack Russell Terrier was 
only officially recognised as a breed by the club in 2015 (349).  
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All dog breeds share their genetic structure based on three levels of evolutionary 
development. Firstly, within breeds each has a breed of origin due to limited 
number of founding dogs. Secondly, breeds classified into each breeding group 
based on form and function are mirrored at the genetic level where they share 
the genotypes of phenotypes that were deliberately selected and enhanced such 
as herding or hunting. There is a strong correspondence between a dog’s genetic 
haplotype and these breed groups (350, 351). Thirdly, dogs of different breeds 
that share a similar feature such as relative leg length are due to variation in a 
small group of shared genes with large phenotype effect (351). This can be 
applied to canine mammary tumours both certain breed groups and specific 
breeds where each may be at an increased risk of development. 
 
There have been two major population bottleneck events in dogs that has 
resulted in a loss of genetic diversity (345, 350). The first occurred during 
domestication and the second occurred as part selective breeding for specific 
traits. In addition, there are past and current practices which have further reduced 
genetic diversity. These include the overuse of certain breeding stock, such as 
popular sires (345), selective breeding for phenotypic traits and the breed barrier 
rule (344). The breed barrier rule is where some breeding clubs only allow an 
animal to be registered if both its parents were registered members. In addition, 
significant social events such as war and economic depression have also 
reduced the breeding pool of a number of breeds (345). For example, after both 
World Wars only 10 registered Sussex Spaniels remained. Italian Greyhounds 
were lost completely and were only recreated after significant long term cross 
breeding (352).  
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Cumulatively, this has led to reduced gene pools within breeds and breed groups. 
This amplifies the presence of undesirable alleles within a gene pool and all later 
descendants (345, 353). There are over 80 known disorders, most of which are 
not neoplastic, that are related to breed standards (345), for some of these 
disorders the mutation is known (350).  Consequently, many breeds are at 
increased risk for a range of diseases (354). 
  
In addition to CMTs, other cancers such as haemangiosarcoma, osteosarcoma, 
mast cell tumour and lymphoma are also known to have a heritable component 
(350, 355). Some breeds are at increased risk for multiple cancers, such as 
Boxers who are at an increased risk for haemangiosarcoma, mast cell tumour 
and lymphoma (345).  
 
Up to 30% of deaths in dogs is due to cancer (17). Nearly half of the tumours 
found in bitches are mammary tumours (356). This incidence rises to 71% when 
specifically looking at intact bitches (98).  The two most important known risk 
factors for developing mammary tumours in dogs are hormone exposure and age 
(119). First established in 1969 (120) exposure to endogenous sex hormones 
early in life is an important cause of mammary tumour development (95, 119, 
120). As such, the risk of a bitch developing a mammary tumour drops to 0.05% 
when spayed prior to their first oestrus (120, 121).  The prevalence of CMTs is 
lower/decreasing in countries which operate preventive sterilisation programs 
(95). This includes countries such as the USA and parts of Western Europe (12, 
13). Despite this, it is still an important disease in veterinary medicine (122, 123).  
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In Australia, the Royal Society for the Prevention of Cruelty to Animals (RSPCA) 
Australia recommends that dogs are desexed between 5.5-6 months of age 
(357). Overall, over 78% of owned dogs in Australia are desexed and this has 
been effectively achieved through voluntary desexing (358, 359).  
The second most important risk factor for CMTs is age (120, 121, 356). Malignant 
tumours are associated with increasing age, with a peak incidence between 9 
and 11 years old (356). Younger dogs are more likely to develop benign 
mammary tumours (360).  
 
There is a difference in the range of breeds at higher risk of developing a 
mammary tumour (12-15). In particular, the geographic location of studies 
appears to affect the association of risk to specific breeds. Overall data on the 
risk of CMT development in specific breeds varies by the study and location and 
is in some cases contrary. Commonly, miniature and toy breeds have frequently 
been over-represented in epidemiological studies of CMTs (125). Though there 
is some data to suggest that small dog breeds in fact have a lower CMT incidence 
and better survival (126).  Larger breeds such as the German shepherd (16, 127) 
and Boxer (128, 129) are also commonly over-represented.  The risk of 
developing a CMT in the Boxer breed is also contradictory. For example, North 
American (130) data suggest Boxers are under-represented whereas the 
converse is true in European studies (13, 17, 128).  Other breeds with increased 
risk include the English Springer Spaniel (12), Cocker Spaniel and Pointer (125).  
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This suggests that local populations should be used to determine at risk breeds 
as remote populations are unlikely to be representative. This is possibly due to 
intra-breed genetic variation depending on breeding standards within different 
countries and the available breeding pool, quarantine laws and local laws. In 
Australia and the UK, breeders focus on enhancing peripheral traits important for 
the breed standard at the expense of overall health of the breeding line (345, 
354). In 1998, greater than 10% of the registered breeds in the ANKC had fewer 
than 20 new animals registered for the year (354).  
 
Australia has a unique domestic canine population with some breeds significantly 
more popular compared to other countries. The Jack Russell Terrier and Kelpie 
(359) represent two of the top five most popular breeds (361). Based on the 
registration data from the ANKC the top five breeds are Labradors, Staffordshire 
Bull Terriers, German Shepherd, French Bulldogs and Border Collies (274). 
Gundogs are the most common breed group followed by Terriers and Working 
Dogs (274).  
 
There is no data on the survival of different breeds in Australia with 
mammary tumours. In addition, contemporary studies lack representation of 
popular Australian breeds such as Jack Russell Terriers, Australian Cattle Dogs 
and Kelpies (13, 15-17).  Therefore, the main aim of this study was to 
establish the breeds that develop CMTs, their survival in both rural and 
metropolitan areas and outline the breed distribution and demographic 
features of the affected population. 
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  Results 
4.2.1 Malignant canine mammary tumours occur in 
older dogs  
In total, there were 91 malignant and 143 benign CMTs sampled from 217 
different dogs. The samples were received from 98 different veterinary clinics. 
This included the 65 veterinary clinics that were recruited by the AVCBB but also 
clinics that submitted samples to either of the two participating veterinary 
pathology services. The clinic names were provided by the veterinary pathology 
services and agreed to provide follow-up information on animals.  
 
The frequency of malignant CMT was 39.6%. Over seven percent (16/217) of 
animals had a previous history of a suspected or confirmed CMT. More than one 
histopathological subtype of tumour was found in 11.1% (24/217) dogs. Of these, 
ten animals (4.6%) had at least one benign and at least one malignant mammary 
tumour present concurrently.  
 
After surgical treatment, 8.7% (19/217) of dogs also had a suspected recurrence. 
Of these animals seven had suspected tumours removed but with no subsequent 
pathology performed. Another seven had new lumps that were noted/monitored 
but not removed. Only three recurrent samples had histopathological diagnosis. 
Of these, two had the same histopathological classification as the original tumour, 
the third was originally an adenoma and the subsequent tumour was a benign 
mixed tumour.   
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Three animals received adjuvant treatment in addition to surgical excision 
(3/217). All three animals received adjuvant chemotherapy, two of these animals 
were in rural locations. 
Malignant tumours developed in older bitches (p=<0.0001). The median age at 
diagnosis for benign CMTs was 9.3 years whilst for malignant tumours it was 10.5 
years. The range was 1-15.6 years. (Figures 4.1 and 4.2). The incidence rate of 
both benign and malignant tumours was associated with increasing age with the 
sharpest increase appearing between 9 and 10 years for benign tumours and 10 
and 11 years for malignant tumours. 
 
 
 
Figure 4.1 Cumulative age-specific incidence curve of benign (109) and 
malignant (n=74) mammary tumours in female dogs. 
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Figure 4.2 The frequency of CMT (n=183) in bitches in relation to their age 
(183).  
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4.2.2 Demographics of ANKC breeding groups Canine 
Mammary Tumours 
Seventy percent of CMTs were from purebred dogs. There was no difference in 
the number of total purebred dogs between rural and metropolitan areas 
(p=0.27). Samples were provided evenly from rural and metropolitan veterinary 
clinics (Table 4.1). Though, CMTs from Working dogs were more likely to come 
from rural areas.  
 
None of the breed groups varied significantly compared the number of expected 
cases based on the registered population (Table 4.2). 
CMTs collected by the AVCBB came from 45 different pure breeds (Table 4.3).  
Jack Russell Terriers were the most common breed followed by Border Collies 
and Kelpies. 
 
Samples from Jack Russell Terriers were common from both rural and 
metropolitan areas. CMTs from working dogs, Kelpie and the Australian cattle 
dog, were more common from rural veterinary clinics. In comparison, CMTs from 
Cocker Spaniels and Golden Retrievers were the two most common metropolitan 
breeds (Table 4.4). 
 
Jack Russell Terriers were also the second most common mixed breed dog. 
Mixed Maltese dogs were most common. Greyhound, Bichon Frise, Papillon, 
Samoyed, Schnauzer and Staghound were not present in the pure breed samples 
but they were present in mixed breed CMT samples (Table 4.5).   
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The most popular mixed breeds for the metropolitan areas were, Maltese cross, 
Jack Russell terrier cross and an unspecified terrier cross. In rural areas, the top 
three mixed breeds were, Maltese cross, Border collie cross and Kelpie cross 
(Table 4.6). 
 
Compared to registered ownership CMTs from Jack Russell Terriers, Labradors, 
Pomeranians and Shih Tzus were present more than expected (Table 4.7). 
 
There was no difference in the distribution of benign and malignant tumours 
between ANKC breeding groups except for Gundogs, represented mainly by 
Labradors, Cocker Spaniels, German Pointers and Golden Retrievers, which 
were more likely to present with a benign CMT (Table 4.8 and Figure 4.3) 
 
Table 4.1 CMT breed distribution between rural and metropolitan areas where 
p<0.05 is statistically significant. 
 ANKC category Total Rural Metro p 
1. Toys 15 7 8 0.78 
2 Terriers 26 13 13 1 
3. Gundogs 29 13 16 0.43 
4. Hounds 8 7 1 0.07 
5. Working Dogs 26 20 6 0.01 
6. Utility 13 5 8 0.39 
7. Non-Sporting 17 7 10 0.45 
8. Mixed Breed 57 27 29 0.52 
9. Total 190 99 91 0.47 
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Table 4.2 Representation of ANKC breeding categories in the AVCBB sample 
set and whether it matches the expected representation based on the registered 
population. 
  
Observed 
cases 
Expected 
cases 
ANKC registered 
population 
p 
ANKC 
category 
No. % No. No. %  
Toys 15 11.2 18 9055 13.5 0.58 
Terriers 26 19.4 24 12012 18.0 0.88 
Gundogs 29 21.6 26 12969 19.4 0.43 
Hounds 8 6.0 9 4574 6.8 0.81 
Working 
Dogs 
26 19.4 23 11462 17.13 0.75 
Utility 13 9.7 18 9931 13.4 0.35 
Non-
Sporting 
17 12.7 16 7900 11.81 1.00 
Total 134 100 133 126,907 100  
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Table 4.3 Summary of all breeds represented in samples collected by the 
AVCBB. 
Ranking Breed 
ANKC 
Category 
Total 
No. 
% 
1 Jack Russell Terrier 2 12 9.0 
2 Border Collie 5 7 5.2 
3 Kelpie 5 7 5.2 
4 Labrador Retriever 3 6 4.5 
5 Pomeranian 1 6 4.5 
6 Shih Tzu 7 6 4.5 
7 Australian Cattle Dog 5 5 3.7 
8 Cocker Spaniel 3 5 3.7 
9 German Pointer 3 5 3.7 
10 Golden Retriever 3 5 3.7 
11 Boxer 6 4 3.0 
12 Fox Terrier Wiry 2 4 3.0 
13 German Shepherd 5 4 3.0 
14 Poodle 7 4 3.0 
15 Rottweiler 6 4 3.0 
16 Staffordshire Bull Terrier 2 4 3.0 
17 Curly Coated Retriever 3 3 2.2 
18 Doberman 6 3 2.2 
19 Maltese 1 3 2.2 
20 Rhodesian Ridgeback 4 3 2.2 
21 American Staffordshire Terrier 2 2 1.5 
22 Beagle 4 2 1.5 
23 British Bulldog 7 2 1.5 
24 Bull Terrier 2 2 1.5 
25 Cavalier King Charles Spaniel 1 2 1.5 
26 Chihuahua 1 2 1.5 
27 Dalmatian 7 2 1.5 
28 Miniature Poodle 7 2 1.5 
29 Whippet 4 2 1.5 
30 Airedale Terrier 2 1 0.7 
31 Australian Shepherd 5 1 0.7 
32 Australian Silky Terrier 1 1 0.7 
33 Australian Terrier 2 1 0.7 
34 Dachshund 4 1 0.7 
35 Field Spaniel 3 1 0.7 
36 Gordon Setter 3 1 0.7 
37 Hungarian Vizsla 3 1 0.7 
38 Huntaway 5 1 0.7 
39 Irish Red and White Setter 3 1 0.7 
40 Keeshond 7 1 0.7 
41 Schnauzer 6 1 0.7 
42 Mastiff 6 1 0.7 
43 Tibetan Spaniel 1 1 0.7 
44 Weimaraner 3 1 0.7 
45 Welsh Corgi 5 1 0.7 
    Total 134 100 
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Table 4.4 The most common pure breeds in rural and metropolitan areas 
collected by the AVCBB. 
Rank Rural  No. Metropolitan No. 
1 Kelpie 7 Jack Russell Terrier 7 
2 Jack Russell Terrier 5 Cocker Spaniel 4 
3 Australian Cattle Dog 4 Golden Retriever 4 
 
Table 4.5 The distribution of mixed breeds that had a CMT submitted to the 
AVCBB. 
Breed  
Total 
No. 
Maltese X 8 
Jack Russell Terrier X 5 
Maltese Shih Tzu X 5 
Border Collie X 4 
Kelpie X 3 
Labrador X 3 
Staffordshire Bull Terrier X 3 
Terrier X 3 
Bull Arab 2 
Chihuahua X 2 
Fox Terrier X 2 
Pomeranian X 2 
Australian Cattle Dog X 1 
Australian Terrier X 1 
Beagle X 1 
Boxer X 1 
Cocker Spaniel X 1 
Greyhound X 1 
Huntaway X 1 
Maltese Bichon X 1 
Papillon X 1 
Rottweiler X 1 
Samoyed Husky X 1 
Schnauzer X 1 
Staghound X 1 
Unspecified X 1 
Total 56 
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Table 4.6 Most common mixed breeds in rural and metropolitan areas. 
Rank Rural  No. Metropolitan  No. 
1 Maltese 5 Maltese 9 
2 Border Collie 3 Jack Russell Terrier 3 
3 Kelpie 3 Terrier 3 
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Table 4.7 Analysis of the top 20 CMT pure breeds compared to the ANKC registered population (n=100). 
Rank Breed Location Observed cases ANKC group 
Expected 
cases 
ANKC registered 
population 
p 
  M R Total %  No. No. %  
1 Jack Russell Terrier 7 5 12 9.0 Terrier 1 848 0.7 0.001 
2 Border Collie 3 4 7 5.3 Working dog 3 2837 2.2 0.33 
3 Kelpie 0 7 7 5.3 Gun dog 0 235 0.2 0.014 
4 Labrador retriever 3 3 6 4.5 Working dog 5 4881 3.8 1.00 
5 Pomeranian 3 3 6 4.5 Toy 0 410 0.3 0.030 
6 Shih Tzu 2 4 6 4.5 Non-Sporting 0 445 0.4 0.030 
7 Australian Cattle dog 0 5 5 3.8 Working 1 1119 0.9 0.21 
8 Cocker Spaniel 4 1 5 3.8 Terrier 1 1364 1.1 0.21 
9 German Pointer 2 3 5 3.8 Gun dog 1 831 0.7 0.0.21 
10 Golden Retriever 4 1 5 3.8 Gun dog 3 2837 2.2 0.72 
11 Boxer 2 2 4 3.0 Utility 1 1182 0.9 0.37 
12 Fox Terrier 0 4 4 3.0 Terrier 3 3226 2.5 1.00 
13 German Shepherd 2 2 4 3.0 Working dog 0 364 0.3 0.12 
14 Poodle 3 1 4 3.0 Non-Sporting 2 1724 1.4 0.68 
15 Rottweiler 3 1 4 3.0 Utility 2 1500 1.2 0.68 
16 
Staffordshire Bull 
Terrier 
2 2 4 3.0 Terrier 5 4539 3.6 1.00 
17 
Curly Coated 
Retriever 
1 2 3 2.3 Gun dog 0 89 0.1 0.24 
18 Doberman 2 1 3 2.3 Utility 1 603 0.5 0.62 
19 Maltese 1 2 3 2.3 Toy 0 296 0.2 0.25 
20 
Rhodesian 
Ridgeback 
1 2 3 2.3 Hound 1 904 0.7 0.62 
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Table 4.8 Frequency of each breeding group presenting with a CMT (n=190). 
ANKC 
group 
Benign Malignant p 
Toys 8 7 0.71 
Terriers 16 10 0.17 
Gundogs 20 9 0.008 
Hounds 6 2 0.13 
Working 
Dogs 
13 13 1 
Utility 9 4 0.12 
Non-
Sporting 
10 7 0.49 
Mixed 32 24 0.19 
Total 114 76  
 
 
 
Figure 4.3 Distribution of benign and malignant tumours amongst ANKC 
breeding groups **p=0.0081. 
0
5
10
15
20
25
30
35
Toys Terriers Gundogs Hounds Working
Dogs
Utility Non
Sporting
Mixed
Benign
Malignant
** 
Chapter 4 – Profiles of CMTs in Australia 
 
187 
 
4.2.3 Victorian dogs with CMTs are not desexed 
Less than one percent of the dogs were spayed under two years old with 38.4% 
not being spayed at all. 16.3% were spayed but at an unknown age and the 
remaining 44.8% were spayed at older than two years or at the time of the 
mammary lump removal. Overall, 117 animals had been spayed, 61 from 
metropolitan areas and 56 from rural areas (Table 4.9). There was no difference 
in the spay rate in dogs with CMTs between metropolitan and rural clinics p=0.14.  
 
Table 4.4 Age animals were neutered between rural and metropolitan locations. 
Animals that were spayed at the time of tumour removal were included in 
animals spayed at older than 36 months. 
 Total (%) Rural Metropolitan  
Not spayed 73 (38.4) 43 (58.9) 30 (41.1) 
Spayed age unknown 31 (16.3) 13 (41.9%) 18 (58.1) 
Spayed <12 months 1 (0.5) 1 (100) 0 (0) 
Spayed <24 months 0 (0) 0 (0) 0 (0) 
Spayed <36 months 3 (1.6) 0 (0) 3 (100) 
Spayed >36 months 82 (43.2) 42 (51.2) 40 (48.8) 
Total 190 (100)   
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4.2.4 Malignant tumours have a significantly worse 
prognosis 
Follow-up data on survival was obtained for 76 animals with malignant CMTs. 30 
animals were euthanized, of which six euthanised due to suspected metastases, 
and six died at home. The reason for each animal’s death is summarised in Table 
4.10. Tissues noted as suspected sites of metastasis were the lung, liver, lymph 
nodes and spleen. 
 
There was no difference in the survival of animals that died due to their mammary 
tumour or its metastasis compared to animals that died or were euthanised for other 
or unknown reasons (Figure 4.4).  
 
One-year and two-year survival rates for malignant CMTs were 70.6% and 39.3% 
(Table 4.6).  
 
The median survival of animals was 1458 days (Figure 4.5). The one-year and two-
year survival rates are summarised in Figures 4.11-4.14. The survival of animals 
with malignant tumours, was 699 days, which was significantly poorer than that of 
benign CMTs (Figure 4.5) p=<.0001. Greater than 50% of animals with benign 
tumours were still alive at the longest survival point. The hazard ratio (Mantel-
Haenszel) of a malignant tumour was 9.5. 
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Table 4.5 Reasons animals with CMTs were euthanised or died following 
mammary tumour removal. 
Reason for death/euthanasia n (%) 
Mammary tumour/metastasis 17 (47.2) 
Other 5 (13.9) 
Old age 2 (5.6) 
Unknown 12 (33.3) 
Total 36 
 
 
Figure 4.4 Comparison of survival between animals that died from their CMT or 
from other causes (p=0.14). 
 
Table 4.6 One year survival of animals with a malignant CMT, only including 
animals where the cause of death was related to the tumour. 
Outcome  1 year (n (%)) 2 year (n (%)) 
Alive 24 (70.6) 11 (39.3) 
Dead 9 (34.6) 17 (60.7) 
Unknown 12 29 
Total 57 57 
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Figure 4.5 Kaplan-Meier overall survival compared to survival of benign and 
malignant CMTs. 
 
4.2.5 Survival is not affected by geographic location 
There was no difference in the survival of dogs, regardless of diagnosis, between 
rural and metropolitan locations (Figure 4.6a). There was also no difference in the 
survival of dogs with malignant CMTs in rural areas compared to those in Melbourne 
(Figure 4.6b).  
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Figure 4.6 Survival of animals based on location with any type of CMT p=0.54 (a) 
and only those with malignant p=0.64 (b). 
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4.2.6 Survival is not affected by breed group, 
histopathological subtype, if mixed breed or age 
The ANKC breed group (Figure 4.7) and WHO histopathological classification 
(Figure 4.8) of the tumour did not affect the animals’ survival.  
 
The survival of animals was also determined based on the modification of the WHO 
classification proposed by Goldschmidt (97). Tubular, papillary and papillary-cystic 
adenocarcinomas were all grouped together under the category of 
adenocarcinoma. This included both simple and complex sub-categories. Whereas, 
using the WHO classifications simple carcinomas, tubulopapillary and complex 
carcinomas were each a separate category. Solid, spindle cell, anaplastic, SCC and 
mucinous carcinomas were each their own category. Only the survival of 
adenocarcinomas solid carcinomas and carcinosarcomas were calculated. There 
was no difference in survival of animals with either of these histopathological 
subtypes (Figure 4.9). 
 
The survival of the popular Australian breeds, Jack Russell Terriers and Australian 
cattle dogs were not different to the overall survival of animals with malignant CMTs 
(Figures 4.10 and 4.11). There was also no difference in survival between purebred 
and mixed breed dogs (Figure 4.12). 
 
The survival of animals based on their age was determined using categories defined 
by Philibert (362) the difference in survival was approaching significance but not 
significant (Figure 4.13).  
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Figure 4.7 Kaplan-Meier survival of animals based on their breed group p=0.35. 
 
Figure 4.8 Kaplan-Meier survival of animals based on the WHO histopathological 
type of their tumour p=0.87. 
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Figure 4.9 Kaplan-Meier survival curve of animals with malignant CMTs based on 
the Goldschmidt classification. 
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Figure 4.10 Kaplan-Meier survival of Jack Russell Terriers (n=6) with malignant 
CMTs, p=0.24. 
 
Figure 4.11 Comparison of survival of Australian cattle dogs (n=2) compared to 
the overall survival of animals with CMTs, p=0.54. 
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Figure 4.12 Comparison of survival between pure bred (n=41) and mixed breed 
(n=16) dogs with malignant CMTs (p=0.35). 
 
 
Figure 4.13 Comparison of survival based on age of diagnosis in animals that died 
of CMTs or their metastases, (n=57) (p=0.07). 
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  Discussion 
4.3.1 Prevalence of malignant canine mammary 
tumours 
This data represents the first analysis of the presence and survival of canine 
mammary tumours in Australia. The frequency of malignant CMTs in other 
countries ranges from 41-53% (16, 123). This present study sits just below the 
lower end of this range at 39.6%. The incidence of malignant tumours has been 
reported as low as 24% (363). There is some suggestion that there may be a bias 
in submitting samples with certain features and characteristics to pathology which 
could artificially lower the benign percentage (364). This bias could be present in 
the sampling by Australian veterinarians as the majority of samples provided were 
through veterinary pathology services rather than through the DogMATIC kits. 
This means that there was no control over which samples were received, as there 
was no communication between the biobank and the veterinarian prior to tissue 
sampling. 
 
The age of mammary tumour development in these Australian dogs reinforces 
that younger animals are more likely to develop benign tumours and that the risk 
of developing a malignant tumour increases with age (120, 121, 123, 124, 339, 
360).  
 
It is not uncommon for multiple mammary tumours with different histopathological 
classifications to develop simultaneously in dogs (360). European data suggests 
67% of dogs with a malignant tumour have a concurrent benign tumour (124). A 
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lower percentage was found in this study. Anecdotal evidence suggests that 
some veterinarians do not submit all excised lesions for pathology. This could 
reduce the number of samples with multiple histopathological classifications 
reported in this study.  
 
After surgical excision, there is still the chance of tumour recurrence. Recurrence 
in bitches up to one year following surgery is 58% (365). The percentage in this 
study was significantly lower even after animals with a history of CMTs were 
combined with those that had a recurrence during the follow-up period. This lower 
percentage may be due to treatment type. Published data only covers recurrence 
following a regional mastectomy whilst animals in this study were not only treated 
using regional mastectomies but also unilateral, bilateral and radical 
mastectomies.  Additionally, follow-up data was difficult to obtain for many dogs, 
especially since some animals were not seen by their treating veterinarian again. 
A limitation of the study design was that it was not possible to determine if animals 
had moved to a different veterinary clinic. Difficult follow-up is a common barrier 
to investigating survival in dogs. A loss of animals to follow-up can be greater 
than 40% (3, 366, 367). The level seen in human studies is frequently significantly 
less (368-370). This is because humans are assigned unique identification 
numbers which can be tracked across different institutions.  
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4.3.2 Different breeds are over-represented in Australian 
dogs with CMTs 
In addition to establishing the frequency of malignant mammary tumours it also 
would have been beneficial to establish the incidence of CMTs in the whole 
population. Unfortunately, calculating the incidence of CMTs in Australia is very 
difficult. Each state has different laws regarding animal registration. Registration 
is often at the local council level with no centralised information storage or access. 
As tumour samples were submitted from 98 different veterinary clinics it was not 
feasible to determine the total number of female dogs registered at each clinic 
needed to determine the incidence within the population. The large number of 
clinics spread over a large area that covers both metropolitan and rural areas did 
help maximise the representation of breeds in the study. It allowed for differences 
in the popularity of breeds between metropolitan areas, which tend to select 
smaller breeds, and rural areas where working dogs are more common. 
 
There have been very few studies which have attempted to determine the 
incidence of CMTs in the total population. These studies have either used pet 
insurance databases (12, 15), surveys to veterinarians (356), or web-based 
interfaces for veterinarians to record animal information (17, 371). Studies using 
insurance databases have the added limitation that the histopathological 
diagnosis cannot be verified to ensure the most accurate tumour diagnosis for 
the sample set (372). Additionally, pet insurance companies often restrict 
eligibility for cover based on age reducing the population of covered older dogs 
as well as the length of follow-up information available after diagnosis (14). 
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The animal ownership registration data from the ANKC provided an opportunity 
to investigate CMT breed representation in this study. There are limitations to 
using this data, the registration numbers of ANKC are a snapshot of dog 
ownership rather than a comprehensive list as membership is not mandatory. 
Using ANKC groupings compared to other breed standards was important as 
some breeds are differently classified. For example, in Australia Shih Tzus are 
classified as Non-Sporting dogs but in the USA, they are classified as Toys. 
Despite its limitations, this data can be used to provide a benchmark for the over 
or under-representation of breeds in Australian dogs with CMTs. 
 
The majority of CMTs were from purebred dogs, with 30% of samples coming 
from mixed breed dogs. This amount is similar to a study from the Slovak 
Republic which found that over a 10-year period 24.7% of CMTs were from mixed 
breed dogs, which suggested there was an increased incidence (16). The 
regulation of mixed breeds is less stringent than that of pure breeds in Australia. 
As such, there is no registration data on mixed breed dogs. This prevented 
determining whether mixed breed dogs were over-represented or not.  
 
Limited data suggest the frequency of mixed breed dogs in the Australian 
population is between 34-43% (359, 373). In Australia, mixed breed dogs have 
shown to be at an increased risk of developing soft tissue sarcomas (374). The 
amount of mixed breed animals in this sample set was close to the lower end of 
the reported range. Consequently, this suggests they are not at an increased risk 
of developing CMTs. Mixed breed dogs may actually be at a lower risk of 
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developing CMTs as purebred dogs have frequently been shown to be more 
affected (123, 356, 375).  
 
Australia has a unique population profile of breed ownership compared to other 
countries. The popularity of different dog breeds varies around the world. 
Australia has similar popular breeds to those seen in Sweden and the USA, such 
as, German Shepherds, Golden retrievers and Labrador retrievers (12, 376). 
Other popular breeds vary depending on source. Based on registration and 
popular media in Australia Staffordshire Bull Terriers and Cavalier King Charles 
Terriers are also part of the top five breeds (274, 377). Whilst, a study from 2003 
into dog ownership in suburban Australia, specifically Melbourne, found that 
Maltese cross, Jack Russell Terriers and Jack Russell Terrier crosses were the 
three most common breeds (361). Over time smaller breeds have become more 
popular in Australia (378).  
 
Overall data on the risk of CMT develop in specific breeds varies by the study 
and location and is in some cases contrary. In addition, studies performed span 
many decades and the shifts in breed popularity and the shift in owners’ attitudes 
towards increasing veterinary care of their animals may influence the outcomes 
between studies (12). In Europe and the USA, smaller dog breeds are more 
frequently affected by CMTs (119, 123, 375). Whereas in Japan small dog breeds 
have a lower CMT incidence and better survival (366, 379). Two small dog breeds 
were over-represented in this study, Pomeranian and Shih Tzu. Overall there was 
no increased association between small dogs and CMTs. The Toy breed group 
was not over-represented and only four of the top 10 breeds were small dog 
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breeds.  Smaller breeds were more frequently sampled in metropolitan areas 
whereas larger working dog’s breeds were more common in rural areas.  
 
The Utility dog breed, the Boxer, is at higher risk of CMTs in the UK (128) and 
Denmark (13) but not in the USA (380) or Sweden (12). This present study mirrors 
the results of Priester (380)  and Egenvall (12) as Boxers were not over-
represented. Similarly, to Boxers, German Shepherds are at higher risk of 
developing CMTs in European populations such as the UK, Norway and the 
Slovak Republic (12, 13, 17, 128).  German Shepherd dogs were not over-
represented in our data. Though as they are classed as Gun dogs our data 
suggests that they are more likely to develop a benign CMT.  Other breeds at 
increased CMT risk include the English Springer Spaniel (12), Cocker Spaniel 
and Pointers (125), Dachshund (12, 366) and Poodles (16) none of which were 
over-represented in the our Australian samples.  
 
Two important aspects of this study are that it includes Australian breeds such as 
the Australian cattle dog, Kelpie and Bull Arab, which previous studies on CMT 
incidence or survival lack (12, 13, 123, 127, 372, 380, 381), and that it has 
captured a wide range of breeds. Some papers only investigate mammary 
tumours in a single breed (121, 360, 372) or less than five breeds (13). One of 
the largest studies of over 80,000 animals covered 38 pure breeds (12), whilst 
this study contained 45 pure bred breeds. Though this is still significantly less 
than the 174 breeds registered with the ANKC; only a quarter of this number were 
found in this present study.   
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In addition, the sample population also includes popular breeds in Australia such 
as the Jack Russell terrier which is not featured in most international studies (14, 
16, 127, 130, 366, 380). Scottish data from 2001 identified that Jack Russell 
terriers have higher odds ratios for a neoplastic diagnosis in the reproductive 
system and mammary gland biopsies (128). Australian dogs with mammary 
tumours were similarly more likely to be Jack Russell terriers.  
 
This research has demonstrated that Australian breeds - the Australian cattle 
dog, Kelpie and Bull Arab also develop mammary tumours. The Kelpie breed 
originated in the 1870’s from three pairs of ‘Working Collies’ that were imported 
from Scotland (382). It was first registered as breed in 1902 and is one of the 
earliest registered breeds in Australia. Kelpies are alert, eager, highly intelligent 
dogs that have an aptitude for the working of sheep. Despite being a well-known 
breed Kelpies do not feature in the top 20 breeds in the ANKC. Interestingly, 
compared to other breeds Kelpies are bred for temperament, intelligence, health 
and conformation. This is unlike other breeds where they need to conform to the 
written ANKC standard sometimes to the detriment of the overall health of the 
breed (382, 383). Overall, the breed is robust and has limited known disease 
associations (383). The main risk is in developing cerebellar abiotrophy (384). 
These present results also suggest that Kelpies may be at increased risk of 
developing mammary tumours.  
 
Similarly, to Kelpies, Australian cattle dogs were developed during early 
Australian settlement. There are no original breeding records. The dogs were 
bred for endurance and their herding abilities. They are strong, compact animal 
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but can be prone to aggressiveness (385). Their main and only significant health 
problem is hereditary deafness (386). Unlike Kelpies, Australian cattle dogs were 
not over-represented in mammary tumour samples. While they appear not to be 
at an increased risk of mammary tumours they are known to be at an increased 
risk of developing mast cell tumours (374). 
 
Jack Russell terriers are not a breed developed in Australia. They originated from 
Devon in England during the 1800’s. Similarly, to Australian cattle dogs and 
Kelpies they are a robust breed with few known health problems. In the UK, the 
breed has been shown to have similar levels of heterozygosity found in mixed 
breed dogs (348). Jack Russell terriers were the most common breed with 
tumours and were the most over-represented in this sample set. The only 
published data to specifically compare the incidence and risk of Jack Russell 
terriers found that they were at a higher relative risk compared to other breeds in 
particular compared to mixed breed dogs (128). Overall, the breed had a 
significantly lower odds of neoplasia (128). Despite being over-represented there 
was no difference in the survival of Jack Russell Terriers with malignant tumours 
compared to the overall survival.  
 
Additionally, the survival rate of Australian cattle dogs, does not significantly differ 
from the overall survival of dogs with malignant CMTs; though this is using a very 
small sample set and needs to be confirmed with a larger cohort. Unfortunately, 
the survival curve of Kelpies was not able to be established.  
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The over-representation of different breeds is important as it provides insight into 
the possible inheritance of breast cancer susceptibility genes. This has 
implications for both research and breeding.  It could be used to influence the 
selection of breeds when investigating genes involved in breast cancer initiation, 
progression and for prognosis. Secondly, owners selecting a new pet can be 
advised of this health potential health risk along with other well established breed 
disease predispositions.  The difference in the over-representation of breeds in 
the Australian population compared to those in Europe and the USA also 
potentially highlights the effect of the availability, overuse of breeding stock and 
practices that affect genetic diversity. The effect of this reproductive isolation has 
been demonstrated in Finnish and North American dog populations (348). It is 
likely that the geographic isolation, breeding practices and gene pools in breeds 
in Australia compared to those overseas are responsible for the difference in the 
representation of specific breeds in this present study. 
 
4.3.3 CMTs develop in intact bitches and is associated 
with ageing 
The incidence of CMTs is decreasing in certain regions, such as the United States 
and some countries in Western Europe, because of the common practice of 
performing ovariohysterectomy at an early age, varying from 8 weeks to 7–12 
months of age (12, 13). Australia has voluntary desexing, but is taken up by a 
significant percentage of pet owners. In contrast, in regions such as Scandinavia 
and Spain, the incidence of CMTs is much higher as preventive neutering is not 
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routinely performed (12, 13, 339). Despite this, CMTs are still an important 
disease in veterinary medicine (123).  
 
This present study mirrors data from Norway (13), Japan (387), Sweden (12), 
and the USA (356) as it supports that mammary tumours occur in intact bitches 
(Figure 2.7), and is a disease associated with increasing age (120, 121, 356) 
(Figure 3.2). In particular that malignant CMTs are present in older dogs 
compared to benign tumours (124, 360) (Figure 3.2). The peak onset of malignant 
tumours at 10 years is also similar to that found in the Slovak republic (16), the 
USA (360) and Mexico (123).  
 
The average onset and range was similar to that suggested by Withrow, 
MacEwen and Philibert where average age of onset was 11 years with a range 
of 5-15 (362, 375). In this study, average onset was just over one year younger 
at 9.8 years and had a broader range of 1-15.6 years. Peak onset in animals in 
the USA is between nine and 11 years (356) which were privately owned animals 
as in this present study. Whilst in Sweden the average onset was younger, at 7.3 
years, and only ranged from three to ten years, as the study only included animals 
up to ten years of age (12). Most studies report an average age range of eight to 
11 years (124). Only 1.5% of CMT arise below 4.8 years of age (5) which is similar 
to the results of this data in addition all of the earlier onset CMTs were benign. 
Follow-up data did not request history on animal’s treatment with exogenous 
hormones such as progestins but their treatment could account for the mammary 
tumours seen in young dogs in this study (5, 119, 121).  
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Overall, 83% of dogs were intact when they developed a mammary tumour. 
Nearly 40% of dogs in this study were not spayed and a further 43% were spayed 
at the time of tumour removal. This is despite there being no benefit of concurrent 
ovariohysterectomy with mammary tumour removal in dogs (120, 367, 388). The 
most recent data included the first randomised control trial to determine the effect 
of ovariohysterectomy at time of tumour removal. There was no significant 
reduction in the risk of relapse in animals that were de-sexed at the time of tumour 
excision (389). Though, a subset of animals with ER positive tumours are likely 
to benefit (124).  This is likely to be of benefit as dogs spayed closest to the time 
of tumour removal are more likely to contain hormonal receptors and be 
dependent on hormonal signals for their growth (390). Given that less than 20% 
of tumours subtyped in this study were hormone receptor positive this is likely to 
benefit only a small subset of Australian animals. Despite this, 43% of dogs in 
this study were spayed at time of tumour removal. The influence of 
ovariohysterectomy was not established in this study due to the low number of 
spayed dogs as well as the sizeable number where the age at spay was unknown.  
 
4.3.4 Histopathological classification as a prognostic 
marker in CMTs 
Being able to accurately determine the prognosis an animal with a malignant CMT 
continues to be difficult (362). The first classification system of CMTs was 
released in 1974 by the WHO (340). The main categories used were carcinoma, 
carcinosarcoma, which includes the malignant mixed mammary tumour, and 
benign tumours. The categories of carcinomas were separated based on whether 
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they were simple adenocarcinoma, solid carcinoma or a spindle cell carcinoma. 
A revised version of this system, released in 1999, focused more on simple or 
complex and special morphological features (340). A more refined version 
proposed recently in 2010 separates the broader categories used previously into 
more specific categories which include new histological subtypes not previously 
recognized (97). In this study, neither the traditional WHO classification nor the 
modification proposed by Goldschmidt produced any significant link between 
histopathological type and survival, though larger sample sizes are needed to 
adequately confirm this.  
 
Studies which have found a link between histopathological type and poor 
prognosis have used different classification systems similar, to or modified from, 
existing human systems (97, 99, 362, 366). Pooling different histopathological 
diagnoses into modified categories rather than using individual classifications for 
survival analysis has also been used (366, 379). This makes comparison 
between these studies and the current data more difficult. The sample sizes used 
for these analyses varies from 85-175 animals (99, 366). This current study is 
comparable to these studies in terms of sample size.  
 
Adenocarcinomas, including tubulopapillary carcinomas, have the longest overall 
survival (95, 362). Solid and anaplastic tumours are associated with poorer 
prognosis and survival (339, 362). Philibert used a small sample size of only five 
anaplastic tumours to demonstrate their worse survival (362). There were not 
enough anaplastic tumours submitted to the AVCBB with follow-up data to 
demonstrate a similar association.  
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Differences in survival using Goldschmidt’s classifications were also not 
demonstrated in this study. This may have been due to a smaller sample size 
overall and limited follow-up within each classification strata, in particular with 
anaplastic carcinomas and SCC as there were only two animals for each tumour 
type together with follow-up and no death events.  
Dogs with mammary tumours often have multiple lesions. Lesions do not 
necessarily have the same histopathological classification. Bitches can also have 
benign and malignant lesions concurrently. Around 7.6% of bitches have a benign 
and malignant tumour present at the same time (122) in this study less bitches 
presented with both less frequently (4.6%).  
 
In addition to histopathological classification the grade of the tumour is also a 
strong prognostic indicator (99, 100, 119). Unfortunately, the reporting format 
provided to the AVCBB for histopathological diagnosis did not include tumour 
grade. Consequently, to make a more robust association between 
histopathological diagnosis and tumour grade, survival would need to be further 
analysed within a larger sample set.  
Regardless, these results demonstrate the histolopathological heterogeneity and 
the variable and tenuous link between histopathological diagnosis and prognosis. 
This further illustrates the importance of validating other methods such as 
molecular classification of CMTs as an alternative more robust predictor of patient 
outcome.    
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4.3.5 Australian veterinarian treat CMTs with surgical 
excision alone 
In Australia, surgical excision alone remains the treatment of choice for CMTs 
(98, 391). This is highlighted as all but three animals were treated with surgical 
excision only in this present study. The only published Australian study 
investigating the effect of adjuvant chemotherapy for treating CMTs found no 
difference between animals that received surgery only to those that also received 
adjuvant chemotherapy (391). The results of this study also suggest that after 
initial surgical removal Victorian veterinarians chose to monitor, rather than 
excise, any new lumps that develop. 
 
4.3.6 Considerations for collecting follow-up data in 
veterinary studies 
Recent survey data conducted by La Trobe University for the Victorian 
Department of Primary Industry indicates that many Victorian dogs no not receive 
regular veterinary checks.  45% of animals had not seen a vet for at least the six 
months (392). This could explain the difficulty in obtaining complete follow-up 
data. Obtaining data about the reproductive history of animals was difficult with 
over three quarters of the sample set was unknown for the number of litters 
delivered.  
 
In this study, nearly a quarter of the animals were lost to follow-up. This figure is 
significantly higher than that published by other groups (393). The amount of 
unknown data recorded during follow-up is not unexpected as earlier Australian 
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data for the follow-up on age, breed, and desexing demonstrated similar levels 
(337). The age of desexing or the number of litters was not covered within the 
authors’ research though.  
 
The percentage of dogs lost to follow-up directly after surgery is lower than that 
seen in Australian data that found almost 10% of dogs were not seen following 
surgery (391). This data also indicated that time of neutering could not be 
established for just under 16% of dogs a similar amount found in this present 
study. The level of adjuvant chemotherapy used in these dogs, 2.6%, is 
significantly lower than the 38.3% found in CMT patients in New South Wales 
(391). This low level is surprising given that 60% of dog owners consider their pet 
as a member of their family and 83% agree or strongly agree that taking care of 
their pet is one of their highest priorities (392). 
 
Unlike humans who are allocated unique identifying numbers or Unit Record (UR) 
numbers at birth which links their medical records in the Australian health system 
the same system is not present in veterinary medicine. The benefit of using UR 
numbers is that it allows longer tracking of patient data across the country and in 
many cases, overseas. Unfortunately, as most the veterinary services industry is 
privately owned there is no continuity and tracking animals across multiple clinics 
is difficult. This was an important part of the lower follow-up data success in this 
study. In addition, as animals in this study were consented by their treating 
veterinarians there was no impetus on owners to present their animal at regular 
intervals after CMT treatment. This also created a significant obstacle in collecting 
follow-up clinical data, most importantly survival times. This should be an 
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important consideration for the biobank to continue follow-up data collection even 
when the patient has moved to a veterinary clinic that is not part of the biobank 
network.  
 
4.3.7 Factors affecting survival of dogs with malignant 
CMTs 
In this present study both the one and two-year survival rates along with the 
overall survival, the time from surgery to death, have been calculated. Most 
studies present survival data in one of these three forms or as disease-free 
survival (95). Disease-free survival is the time from surgery to occurrence of 
metastases or primary recurrence (95).  
 
Overall survival was chosen over a disease-free survival. This was because 
during follow-up information collection from veterinarians the limited visitations of 
animals following treatment meant that determining an accurate disease-free 
time was unreliable. An overall survival time was selected instead. This allowed 
all animals with follow-up to be used for analysis. Similarly, to disease-free 
intervals, the use of survival time as an endpoint also has barriers to its accuracy. 
These have been argued against its use as an endpoint (100). Factors include 
the differences in the type of therapy provided, deaths due to unrelated causes 
and euthanasia. In this present study, only three animals received adjuvant 
therapy so there was very little effect on survival due to variation in treatment 
type. As the goal was to broadly determine survival not survival based on 
treatment type, the selection of which excision type was not important. 
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Particularly as veterinarians follow guidelines based on tumour size and 
involvement to select how much tissue to remove. Additionally, animals 
euthanised due to mammary tumours were in the terminal stage of their 
diagnosis.  
 
Considering nearly 15% of animals in this study died or were euthanised for 
reasons other than a mammary tumour highlights the impact other comorbidities 
have on the survival of dogs. Of those animals that died or were euthanised due 
to metastases the lung was the most frequent site which is in line with published 
data (119, 363). This is different from women with breast cancer as the most 
common site of metastasis is bone.  
 
The survival of Australian dogs was significantly lower that published studies. In 
this study the 2-year survival rate of animals when excluding animals that died of 
other causes was 39.3%. Both Karayannopoulou et al. and Yamagami et al. 
excluded animals that died from other causes, they found 54.1% and 84-93% of 
study animals were alive at the same time point respectively (99, 367).  
 
Similarly, there is a wide variation in the published median survival of dogs. The 
median survival time for malignant CMTs in this study was 699 days or 23 
months. In the USA, Schneider et al. and Philibert et al. found a median survival 
of 14 months in privately owned dogs (120, 362). Whilst Betz et al., based in 
Germany, found a median survival of nearly 37 months (363). This study 
considered any death regardless of cause in survival analyses. The data from 
Schneider et al. was published in 1969. The significantly improved survival time 
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in this present study and that by Betz et al. could be due to greater veterinarian 
and client awareness resulting in earlier diagnosis and surgical treatment of 
animals increasing their chances of survival. 
 
The outcomes of analyses show that nearly half of the animals died due to their 
mammary tumour and/or its distant metastases; though there was no difference 
in survival times between animals that died from their mammary tumour 
compared to those that died for other reasons. Philibert et al. demonstrated a 
substantially longer survival in animals that died for reasons other than the 
mammary tumour (362). Other studies have excluded animals from survival 
analyses when they die for reasons other than those related to a mammary 
tumour (99, 366). In the context of this study, as a prospective study, it was 
important to review all causes of death to provide an insight into the factors 
influencing the death of dogs with CMTs in the Australian population.  
 
Mortality of animals at both one and two-years was from the mammary tumour or 
its metastasis rather than another cause. During the first year 75% of deaths were 
related to the tumour and nearly 90% of deaths between one and two years were 
due to the tumour. This highlights that in Australian dogs’ mortality due to a 
mammary tumour is spread across the first two years after diagnosis when other 
studies suggest it is more concentrated to the first year following diagnosis (120). 
This includes both natural deaths and those from euthanasia and demonstrates 
that persistent and recurrent cancer shorten a dog’s life.  
 
The length of survival in animals that died from their mammary tumour was not 
affected by their age at diagnosis. This is a known risk factor in women with breast 
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cancer. The limitation of combining all breeds when calculating the effect of age 
on survival is that it does not consider the differences in the life expectancy of 
each breed. The age categories used were those developed by Philibert et al. 
(362) where the author also did not find any difference in survival based on 
chronological age. The authors also compared survival based on physiological 
age at diagnosis to better compare survival to humans. The formula used by the 
authors to calculate the physiological age of the dogs, required breed-specific 
median ages at death and the chronological age of the dog. The original formula 
developed by Patronek et al. only calculated the mean at age death for the top 
30 breeds in the USA up until 1990 (394). Only five of the top 10 breeds in this 
present study were represented in these calculations. These 30 breeds did not 
include Jack Russell Terriers, Kelpies, Pomeranians, Australian Cattle Dogs or 
Pointers. Consequently, the physiological age was not compared in univariate 
analysis in this study. Unfortunately, this meant that a standardised comparison 
between the onset and survival of Australian dogs and women with breast cancer 
could not be made. The formula provides standardisation in the difference in life-
span between dog breeds and weights.  
 
In this study breed was also investigated as a potential prognostic factor in the 
survival of dogs with malignant mammary tumours. There was no association 
between survival and whether a dog was a pure or mixed breed. This lack of 
association has also been found animals from the USA (362).  
 
The geographic location, rural or metropolitan, has been shown to not only affect 
how many animals receive veterinary care but also how frequently (14). This 
influence was not present in this study with no difference in survival between rural 
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and metropolitan dogs. This suggests that the availability of veterinary care is just 
as accessible in rural areas, despite the less dense population, as it is in 
metropolitan areas. It may also suggest that owners in rural and metropolitan 
areas are equally inclined to seek veterinary care for their animals.  
 
To date this study is one of only two (363) prospective CMT survival studies in 
privately owned dogs, all other published data was retrospectively collected (12, 
14, 99, 120, 122, 362, 366, 379, 393).  
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4.3.8 Chapter Summary 
This is the first demonstration of the survival of animals with CMTs in Australia. 
This study highlights that nearly 40% of CMTs in Australian dogs are malignant 
and occur in intact bitches. Jack Russell Terriers, Kelpies, Pomeranians and Shih 
Tzus may be at higher risk of developing CMTs, whilst Gun dogs are more likely 
to develop a benign tumour.  CMTs can develop at any age but are significantly 
more common in older dogs with peak onset at 10.5 years. Surgery alone is still 
the treatment of choice with adjuvant chemotherapy not yet common practice 
amongst Victorian veterinarians. Following surgery, recurrence occurs in nearly 
10% of animals. Malignant mammary tumours significantly impact animal survival 
with most likely to die from their tumour or its metastasis than other causes. The 
lung was the most common site of metastasis for CMTs in this study. Finally, the 
survival of animals is not affected by whether they are pure breed or mixed breed, 
their geographical location or their breed group.   
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 Molecular subtypes of canine mammary 
tumours 
  Introduction 
CMTs are the most commonly occurring tumour in the female dog. An important 
feature of these tumours is their heterogeneity both morphologically and in their 
biological behaviour.  
Clinically breast cancer in women is also a heterogeneous disease where tumours 
with the same histopathological classification and/or staging can diverge greatly in 
their outcomes for patients (18-22). In trying to find a better classification method 
for breast cancer Perou and co-workers demonstrated firstly in cells (39) and then 
in solid tumours (31) that breast cancer has four different and distinct molecular 
subtypes. These subtypes are luminal A, luminal B, basal-like and HER2 over-
expressing. These four subtypes are fundamentally divided by their expression of 
ER (Figure 5.1).  
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Figure 5.1 The subtyping of breast cancer based on the reactivity to a panel of 
immunohistochemical markers. 
These subtypes have been more strongly linked to prognosis than the traditional 
histological classification (51, 395). They were based on the differential expression 
of over 1000 genes that were refined to an ‘intrinsic’ set of 534 that differentiates 
the subtypes (31). These subtypes allow for more targeted treatments and may 
provide the potential for the development of new targeted therapies (18, 43, 51).  
 
In women, luminal A tumours have the best survival rates (43) whilst basal-like and 
HER2 positive tumours have significantly worse survival rate (43, 51).  
 
These subtypes can also be identified using immunohistochemistry (43, 45, 50, 51, 
61). Though the panel of markers used varies depending on the research group, all 
panels need to use markers for estrogen receptor and HER2 (43-45, 47, 48, 50, 53-
56, 61). It is the choice of markers to identify luminal and basal cells that varies. 
Basal cell marker CK5 has been shown to be more sensitive than CK5/6 in 
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identifying basal-like tumour cells (45, 53). Similarly, vimentin has also been shown 
to be more sensitive than other basal cell markers (45). 
 
To date, two studies have attempted to demonstrate the same breast cancer 
subtypes in dogs using IHC (3, 23), the results of which had conflicting associations 
with survival. Both papers used relatively small sample sizes. Sassi et al. used 45 
tumours of which seven were in situ carcinomas (23) and Gama et al. was a 
retrospective study of 102 tumours of which only 69 had follow-up data to allow 
survival analysis (3). 
 
The aim of this study was to prospectively subtype CMT from Australian 
companion dogs collected by the AVCCB using a specially selected panel of 
antibodies (ER, HER2, p63, CK5 and vimentin) and secondly, to establish any 
association between tumour subtype and survival. 
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  Results 
5.2.1 Patient characteristics 
The mean age of dogs at the surgical removal of the tumour was 10.4±1.4 years 
(range 5.9-14.9 years). From the available follow-up information 50% of animals 
with CMTs were un-spayed. Over a quarter (25.9%) of the animals were spayed 
prior to CMT development with a further 12% were spayed at the time of tumour 
removal. Histological evaluation of the tumours revealed 40 (71.4%) simple 
carcinomas, 4 (7.1%) tubulopapillary carcinomas, 4 (7.1%) solid carcinomas, 5 
(8.9%) complex carcinomas and 3 (5.4%) carcinosarcomas. There was no 
association between tumour subtype and age (p=0.59) or purebred or mixed breed 
(p=0.59); though the basal-like subtype had the earliest onset at 5.9 years old. 
(Table 5.1). There was no significance overall between the breed of the dog and 
tumour subtype but when comparing basal tumours only animals were significantly 
more likely to be purebred (p=0.008).  
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Table 5.1 Association between tumour subtypes and clinicopathological variables. 
 
Luminal A  
[n (%)] 
Luminal 
B [n (%)] 
HER2 
over-
expressing   
[n (%)] 
Basal-like            
[n (%)] 
p* 
Age           
Average (range) 
11.8 (9.2-
14.9) 10 (10) 
10.5 (7.5-
12) 
11.3 (5.9-
14.9) 0.59 
Spayed       
No 7 (24) 1 (3) 2 (7) 19 (66) 
 
Yes, prior to CMT 
development 1 (7) 0 (0) 2 (13) 12 (80) 
Yes, performed with 
tumour removal 1 (14) 0 (0) 1 (14) 5 (71) 
Unknown age at 
spay 1 (14) 0 (0) 0 (0) 6 (86) 
Breed       
Purebred 8 (80) 0 (0) 4 (80) 27 (66) 
0.59 
Mixed breed 2 (20) 1 (100) 1 (20) 14 (34) 
Histological type       
Simple carcinoma 7 (18) 1 (3) 4 (10) 28 (70) 
 
Tubulopapillary 
carcinoma 
0  (0) 0 (0) 1 (25) 3 (75) 
Solid carcinoma 1 (25) 0 (0) 0 (0) 3 (75) 
Complex carcinoma 2 (40) 0 (0) 0 (0) 3 (60) 
Carcinosarcoma 0 (0) 0 (0) 0 (0) 3 (100) 
* Chi-square calculations are only valid when all expected values are greater than 
1.0 and at least 20% of the expected values are greater than 5.  These conditions 
were not met for if the dog had been spayed or the distribution of the histological 
types.  
 
 
5.2.2 Immunohistochemistry profiles of CMTs 
Seventy malignant CMTs were stained and 61 tumours producing results allowing 
their allocation to a specific subtype (Table 5.2, Figure 5.2). The remaining nine 
samples repeatedly floated off the slides during immunohistochemistry staining. 
Overall, 64.5% of tissue micro array (TMA) cores were present in stained sections. 
The first TMA created has the poorest staining result with only 45.1% of tissue cores 
present on the completed slides. The percentage of cores present increased with 
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each successive TMA constructed with the final two TMA’s demonstrating 83.0% 
and 76.4% of cores present on sections during subtyping. 
 
The first two TMA’s constructed were also stained for PR. Sixteen tumours were 
analysed and produced a 100% concordance to the ER stain result. The quality of 
the PR results was less than that of the ER stain making automated analysis more 
difficult. There was significantly more cytoplasmic localisation seen with the PR 
staining (Figures 5.2 and 5.3). PR was not used to subtype the remaining tumours 
due to the difficulty interpreting the stain result.   
 
Table 5.2 Frequencies of IHC defined subtypes of malignant CMTs (n=61). 
Subtype ER HER2 
p63 and/or CK5 
and or vimentin 
Frequency 
[n (%] 
Luminal A Positive Negative Positive/negative 11 (18.03) 
Luminal B Positive Positive Positive/negative 1 (1.64) 
HER2 over-
expressing 
Negative Positive Positive/negative 5 (8.20) 
Basal Negative Negative Positive 43 (68.85) 
Negative/null 
phenotype 
Negative Negative Negative 1 (1.64) 
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Figure 5.2 Immunohistochemical localisation of the five proteins used to 
subtype CMTs. Each row represents a different subtype first row - luminal A, 
second row - luminal B, thrid row - HER2 over-expressing and bottom row - 
basal-like subtype. Each column represents a different antibody; ER (A,F,K,P), 
HER2 (B,F,L,Q), p63 (C,H,M,R), CK5 (D,I,N,S) and vimentin (E,J,O,T).Scale 
bar is 600 m and is applicable to all panel images.
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Figure 5.3 Comparison of ER and PR staining in CMTs; an ER (A) and PR (C) 
positive luminal A tumour and an ER (B) negative and PR (D) negative basal 
tumour. PR stained sections clearly demonstrate both nuclear (C) and cytoplasmic 
staining (C,D). Image E is a higher magnification of C whilst image F is a higher 
magnification of image D. Whole TMA scale bar is 600 m. Higher magnification 
scare bar is 50 m and applicable for both images. 
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Overall, the basal-like subtype was the most common, representing 68.85% of 
samples. This was followed by the luminal A group which represented nearly 20% 
of the samples. The third most common subtype was the HER2-overexpressing 
group with 5 (8.20%) testing positive for HER2. There was only one sample that 
was both ER and HER2 positive making luminal B the least common subtype. 
One sample demonstrated a negative or null phenotype as it did not stain 
positively for any of the five markers used. ER and p63 positive cases showed 
the characteristic nuclear staining, whereas CK5 and vimentin positive tumours 
cells demonstrated a cytoplasmic localisation. HER2 positive tumours showed a 
positive cell membrane staining as predicted.  
 
5.2.3 Basal cell marker reactivity 
Positive basal cell marker, CK5 and/or p63 and/or vimentin, staining was seen in 
nine (75%) non-basal-like subtype tumours. CK5 was the most common basal 
marker present in six (66.6%) cases. Nearly 75% of basal tumours were positive 
or two or more of the basal cell markers (Tables 5.3 and 5.4).  
 
P63 was the weakest basal marker selected. It produced the weakest stain with 
none of the samples having a strong nuclear stain. Four tumours demonstrated 
strong CK5 staining whilst vimentin was the strongest intensity marker with 16 
tumours demonstrating 3+ staining (Figure 5.4 F). In addition, all tumours 
demonstrated either 2 or 3+ intensity for vimentin (Figure 5.4 H and I).    
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Table 5.3 Reactivity of basal cell markers in each CMT subtype. 
 Marker [n (%)] 
Subtype p63 CK5 Vimentin 
Luminal A (n=8)    
   Negative 6 (75) 4 (50) 6 (75) 
   Positive 2 (35) 4 (50) 2 (25) 
Luminal B (n=1)    
   Negative 0 (0) 0 (0) 0 (0) 
   Positive 1 (100) 1 (100) 1 (100) 
HER2 over-expressing (n=3)    
   Negative 1 (33.3) 2 (66.6) 2 (66.6) 
   Positive 2 (66.6) 1 (33.3) 1 (33.3) 
Basal (n=38)    
   Negative 6 (16) 25 (65.8) 5 (13.1) 
   Positive 32 (84) 13 (34.2) 33 (86.8) 
 
 
Table 5.4 Combination of reactivity of basal cell markers, p63, CK5 and 
vimentin, in CMT subtypes. 
 
Subtype [n (%)] 
Basal 
markers 
Luminal A Luminal B 
HER2 over-
expressing 
Basal 
All negative 3 (37.5) 0 (0) 0 (0) 0 (0) 
One positive 3 (37.5) 0 (0) 2 (66.6) 10 (26.3) 
Two positive 1 (12.5) 0 (0) 1 (33.3) 19 (50.0) 
All positive 1 (12.5) 1 (100) 0 (0) 9 (23.7) 
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Figure 5.4 Staining intensity, 1+ to 3+ left to right, of each basal cell marker A-C) p63, D-F) CK5 and G-I) vimentin, where no CMT 
demonstrated 1+ stain intensity (G). 
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Overall, vimentin was the most sensitive and the most specific marker used with 
a sensitivity of 86.8% and a specificity of 66.6%. This was followed by p63 with a 
sensitivity of 84.2% and a specificity of 58.3%. CK5 was the least sensitive and 
specific marker with 34.2% sensitivity and 50% specificity. 
 
5.2.4 Animal survival by subtype 
There was a significant difference in the survival of animals with luminal A 
tumours compared to HER2 over-expressing and basal-like subtype tumours. 
Luminal A tumours had the best survival with 75% of animals still being alive at 
the longest time point, over 1200 days. HER2 over-expressing and basal tumours 
had similar median survival of 452 and 409 days respectively. Only 33.3% of 
animals with HER2 over-expressing tumours and 23.7% with basal tumours were 
alive at the longest time point (Figure 5.5).  
 
 
Figure 5.5 Kaplan–Meier Survival of each molecular subtype for 43 animals with 
available follow-up information compared to survival of all animals with 
malignant CMTs with follow-up. 
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 Discussion 
5.3.1 CMT subtype is not related to age, de-sexing or 
histological type 
In this study the average age of onset, age range and the proportion of intact 
bitches is similar to earlier published data (3, 16, 23). Even though there was no 
association between animal age and subtype, the basal tumours did have the 
earliest onset of 5.9 years. Women with breast cancer demonstrate a significant 
association between their age and the subtype of their cancer. In particular, 
luminal A tumours are more often identified in older patients whilst basal and 
HER2 over-expressing tumours are associated with an earlier onset (48, 59, 396-
398). However, some studies have found no significant link between age and 
tumour subtype (399, 400). The results of this study have now formed the 
foundation of additional research expanding the demonstration of CMT subtype 
using additional molecular techniques including quantitative PCR and western 
blots. 
 
A limitation of this study and a possible reason for the lack of association between 
age and tumour subtype in dogs in this study is that the time from tumour 
development to diagnosis and surgery may have been varied. Clinically lumps 
found in bitches may be monitored over-time and removed at a later date at the 
owner’s request or veterinarian’s insistence (98). This information may not have 
been available or provided during the follow-up period. Consequently, a subset 
of animals may have had an artificially elevated age if the animals were monitored 
until surgery was needed, which in turn affected the age range seen. Unlike 
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breast cancer treatment in humans, there are fewer established standards of care 
for pets with cancer (92, 98). 
 
The proportion of animals un-spayed in this study (50%) is significantly lower than 
that seen in other CMT studies from Portugal (69.7%) (3) and South Korea 
(73.8%) (401).  Additional CMT investigations from similar geographical regions 
also show higher levels of un-spayed animals, some above 80% (162, 402, 403). 
The significantly lower levels of un-spayed animals in this study is in line with 
Australia having one of the highest spay rates in the world (404). The lower 
frequency of luminal and HER2-overexpressing tumours prevented comparison 
of tumour subtypes with ovariohysterectomy status. Two additional studies have 
also failed to demonstrate any association between if a dog has been spayed and 
the molecular subtype of the CMT that develops (3, 401). Only seven of the 
animals in this current study were spayed at the time of CMT removal. Common 
practice is to also perform an ovariohysterectomy to reduce the chance of disease 
relapse. A randomised control trial published in 2016 suggests 
ovariohysterectomy at the time of CMT removal does not significantly alter the 
risk of relapse or death (389).  
 
The most common histological type seen were simple carcinomas accounting for 
71.4% of subtyped samples. This frequency is substantially higher than that seen 
with Gama et al. (3), Sassi (23) et al. and Kim et al. (405) despite all studies using 
the same histological classification system (96). An association between the 
tumour subtype and histological type of the tumour could not be established in 
this study due to the low frequencies of the luminal B and HER2 over-expressing 
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subtypes similar to the study by Sassi et al. (23). Whereas, other investigations 
have shown that simple carcinomas and carcinosarcomas are more likely to be 
basal or HER2 over-expressing tumour subtypes (3). To increase the sample 
sizes for analysis other studies have condensed the histopathological diagnoses 
into broader categories. Such as simple, mixed/complex or ‘other’ for statistical 
analysis (23). The increased proportion of simple carcinomas seen in this study 
is similar to other published data (13, 99, 122, 366, 387, 406, 407); though other 
studies have found solid carcinomas (162, 393) or complex carcinomas (3, 23, 
405) to be the most prevalent histological type; including these three papers to 
investigate the molecular subtypes of CMT using IHC.  
 
In this study, other histopathological features such as the presence of necrosis 
or lymphatic invasion and grade were not investigated. This was due to the format 
of pathology reports provided by the participating veterinary pathology services. 
Lower grade tumours have been associated with the luminal A subtype whilst 
higher grade tumours are more often classified as luminal B (23) or Her2 over-
expressing (401). The link between tumour invasion and subtype is contentious 
with the work by Sassi et al. (23) not finding any association whilst the work from 
Im et al. (401) who clearly demonstrated that the presence lymphatic invasion is 
associated with basal-like subtype tumours and its absence associated with 
luminal A tumours. Further investigation of the association between 
histopathology features and the CMT subtype could be important in better 
characterising tumour subtypes in dogs compared to women. These features, 
such as tumour size, grade, necrosis, vascular or lymphatic invasion, are 
associated with poor prognosis and their positive presence in basal or HER2-
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overexpressing tumours would be in line with their more aggressive behaviour 
and poorer outcomes. 
  
5.3.2 Basal-like subtype tumours are the most common 
in Australian dogs 
Other studies have found that luminal A (44.8%, 44.0%) (3, 401) or luminal B 
(49%) (23) tumours are the most common subtype. In this study basal tumours 
were the most common subtype. Only one of the studies used PR as a secondary 
luminal subtype marker (23).  
 
In normal canine mammary tissue during pregnancy progesterone levels rise and 
is help stimulate the branching of mammary ducts as well as stimulating lobulo-
alveolar units (119, 408). PR was initially used for subtyping samples (16/61) from 
the AVCBB but the quality of the stain was poorer than that seen with the ER 
(Figure 5.2). In addition, as ER is the main marker used for subtyping limited 
additional value was provided by the PR. Consequently, it was more efficient to 
only run ER in the subtyping panel. There was significantly more cytoplasmic 
staining using the PR polyclonal antibody. Cytoplasmic PR staining has been 
demonstrated in spindle and stellate cells of complex and mixed CMTs (402). The 
PR antisera used by Sassi et al. was a monoclonal antibody which is designed to 
recognize both human PR-A and PR-B structures. Consequently, both antibodies 
are designed against human immunogens which may have reduced affinity for 
their canine equivalents. Cytoplasmic PR staining has also been reported by 
multiple groups investigating CMTs (23, 402, 409). Based on PR staining in work 
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by Sassi et al. (23) the antibody used in my study appears to produce crisper 
nuclear staining. In the future, PR staining could be used in subtyping cases 
where ER staining is equivalent or difficult to interpret.  
 
5.3.3 Basal-like tumours are more likely to be found in 
pure bred dogs 
Breed is an important risk factor in CMT (95, 119). The significant variation in 
breed popularity across geographical regions affects the incidence in CMT seen 
within that area (12, 13, 366, 379, 403). Consequently, it is important to try to 
characterise breed as a risk factor in an Australian context. This is the first study 
to compare the breed (pure or mixed) to the molecular subtype of the tumour. 
There was no significant association found between the subtypes but basal 
tumours were significantly more likely to be from a purebred dog.  The link 
between breed and CMT incidence as opposed to tumour subtype is discussed 
more in Chapter 4.  
 
5.3.4 Subtyping CMTs using TMAs is efficient but has 
limitations 
TMAs have been suggested as a cost and time-effective method for 
immunohistochemical and molecular studies (410) and have been validated as a 
tool in breast cancer research (411). Using a TMA was an obvious choice to 
produce cost-effective results in a moderate sample size using many antibodies. 
TMAs produce higher efficiency than whole tissue sections and yield a much 
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higher comparability between the different samples than whole sections in 
separate experiments (412). In this study staining tumours individually required 
at least 14 sections per tumour. Whereas, each TMA stained 12 different tumours 
and used the equivalent amount of slides and reagents as a single tumour stained 
using whole tissue sections.  
 
One of the greatest limitations of TMAs is ensuring the tumour is accurately 
represented in the block both by sampling appropriate areas within the tumour 
and using enough cores within the TMA (266, 411). In this study four 0.6mm 
tumour cores were sampled and where available an additional two cores of 
normal mammary tissue as a tissue control. The number of cores was selected 
based data using TMAs for canine tissue (266). In this study, the optimised 
sampling of tissue for diagnosis was either four or more 0.6mm or two 1.2mm 
cores. Four cores were selected over two to provide additional redundancy within 
the TMA to account for cores being at different levels, being cut through or floating 
off the slide whilst performing IHC. This number is more robust than published 
studies which have only used a single 1mm core (413). Given the variable 
percentage of cores present for subtyping within each TMA sampling greater than 
four cores might be advisable in the future if being implemented in to pathology 
service processes. This would ensure additional repeats of antibodies do not 
need to be performed saving precious TMA sections. Using 0.6mm cores is the 
standard diameter in many TMA protocols (414) but is difficult to determine which 
diameter is preferred from published literature where both 0.6mm and 1.2mm 
diameter cores are used (266, 410, 411, 415-418).  
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The lowest percentage of cores was found in the first TMA constructed with less 
than half of the cores present during experiments. This could be for a variety of 
reasons; though the most likely is inexperience. This is indicated as the 
percentage of cores present increased with each new TMA constructed. This 
increase in usable cores with successive TMA construction has also been found 
in other studies (411). The final TMAs had just under 80% of cores present for 
analysis. This percentage is closer to published studies in breast cancer which 
have produced greater than 95% of TMA cores on each slide for analysis (411, 
418).  
 
5.3.5 Validating the most appropriate basal cell markers 
The panel of markers used to subtype CMTs in this study were different to others 
used to subtype CMTs (3, 23) . This study used three basal cell markers of which 
p63 is in common with the study by Gama et al. who also used p-cadherin as a 
second basal cell marker (3). The current study demonstrated a superior 
sensitivity but reduced p63 specificity compared to that seen by Gama et al. (3).  
 
Luminal A, luminal B and HER2 overexpressing subtypes demonstrated varying 
levels of basal cell marker reactivity. HER2 overexpressing tumours were positive 
for at least one basal cell marker. Whilst, over a third of luminal A tumours were 
negative for basal cell markers. This level is substantially lower than that seen by 
Gama et al. (88). The co-expression of basal cell markers with hormone receptors 
or HER2 has been reported before so is not unexpected (419, 420). 
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There were no common markers between this current study and Sassi et al. (23) 
who used CK14 and CK5/6 as basal cell markers. Livasy and co-workers 
validated the specificity of commonly used basal cell markers for subtyping breast 
carcinomas in women using IHC (45). Vimentin which was substantially more 
specific than CK5/6. Vimentin was positive in 94% of basal-like subtype tumours 
whereas CK5/6 was only positive in 61% of basal-like tumours. P63 was the least 
specific basal marker only positive in 22% of basal-like cases but was also 
present in 12.5% of luminal subtype tumours (45). Consequently, vimentin and 
CK5 were selected as basal cell markers. CK5 was selected over CK5/6 because 
of its increased sensitivity. The same CK5 clone used in this study has been 
shown to have improved stain intensity and percentage of positive cells compared 
to CK5/6 in characterising the basal-like subtype in women (53). Overall, this was 
not replicated in this current study, despite producing a crisp intense stain CK5 
was the poorest performing marker of the three used in terms of sensitivity and 
specificity. 
 
Not only was vimentin positive in a high number of CMTs it is also positive in 
normal fibroblasts, fibrocytes, vascular smooth muscle cells and endothelial cells. 
This positivity in many of the normal stromal cells surrounding the tumour made 
it more difficult during analysis to identify and isolate tumour cells only. By 
including tumour stroma, which is negative for all the other markers, artificially 
elevates the result by increasing the likelihood of false positive results. This was 
successfully mitigated by determining the threshold for vimentin positivity based 
on the staining in the CMTs themselves rather than relying on published data.  An 
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additional benefit of using vimentin as a subtyping marker is that it is itself in 
women with breast cancer a marker of poor prognosis (272). 
 
Published in 2013, data in women suggests that CK14 and CK5/6 are superior 
markers, in both sensitivity and specificity, to p63 in identifying basal-like subtype 
tumours (405). In addition, CK5/6 for subtyping may be more beneficial, 
compared to p63, when subtyping both primary and metastatic tumour samples 
(421). The research did not compare vimentin which in this current study 
demonstrated superior specificity and sensitivity to p63 and CK5. In CMTs, it is 
now suggested that CK14 is the most superior basal cell marker and that p63 has 
limited use (405). The main limitation of the study by Kim et al. was that though it 
used a large CMT cohort, over 200 samples, only 45 were basal-like subtype 
which is comparable to the number in this current study. A subsequent study by 
the same authors subtyped a smaller cohort with these two markers (403). 
Unfortunately, they did not present any data on p63 or CK14 positivity. 
Consequently, there is still no large cohort study in basal-like subtype CMT to 
validate the use of CK14, p63, CK5/6 or vimentin.  
 
Similarly to Livasy et al. (45), the CMTs subtyped in my study demonstrated an 
incomplete basal/myoepithelial cell phenotype. As normally these cells are 
positive for all three markers. In this current study, only 23.7% of samples were 
positive for all three markers whilst 73.7% were positive for two of the three. This 
highlights the importance of using at least two markers to discern the basal-like 
subtype. Only 26.3% of samples demonstrated immunoreactivity for a single 
Chapter 5 – Molecular subtypes of CMTs 
 
242 
 
marker. An additional basal cell marker may be smooth muscle actin (SMA) which 
has an equal sensitivity but higher specificity than p63 (45).  
 
The results of this study suggest that of that p63 and CK5 are not as good at 
identifying basal-like subtype tumours as vimentin. Cumulatively, the data from 
my study and that published using CMTs suggests that vimentin and CK14 may 
be the best combination of basal cell markers. Regardless of how many or which 
markers it is clear that a panel of basal cell markers is important in accurately 
classifying CMT subtypes (3, 23, 401).  
 
5.3.6 CMT mammary tumour subtype is significantly 
associated with animal survival 
In women, molecular subtyping for diagnosis and prognosis provides significant 
value in all age groups, early (369), average (43, 44, 51, 422) and older (400), of 
breast cancer patients. These subtypes can predict patient outcome (43), are 
maintained across multiple ethnic groups (43, 51, 58, 423) and IHC has been 
validated as a method with specific markers as an accurate representation of their 
gene expression profile (43, 45, 50, 55, 58).  Similarly to breast cancer in women, 
CMT form a group of heterogeneous tumours that have different underlying 
development mechanisms (23). Consequently, the benefit of these subtypes lies 
in their potential to provide better classification to predict prognosis and response 
to treatment.  
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This present study is the first of its type in Australia to attempt to demonstrate 
distinct CMT subtypes and relate them to animal survival. The follow-up data 
revealed that the basal-like subtype was significantly associated with worse 
overall survival. The median survival of animals with basal tumours was only 409 
days. In addition, half of the animals with basal tumours were deceased by the 
end of the follow-up, more than 1200 days. This link between basal-like subtype 
and poorer outcome corroborates the results seen in a previous CMT study based 
in Portugal (3) and reflects what has already been established in the clinical 
behaviour and characteristics and survival of this subtype in women (18, 43-45, 
60). In addition, it mirrors earlier data in dogs that links individual features such 
as low ER expression is associated with a poorer prognosis (9, 401). Though 
HER2 overexpressing tumours have been significantly linked with poorer survival 
in this study there is currently still no consensus in the veterinary community on 
the prognostic value of HER2 (424). Previous studies have found that increased 
HER2 expression was associated with longer survival times in dogs (425) whilst 
other studies have found that HER2 positive CMTs are associated with negative 
prognostic factors such as lymphovascular invasion and higher proliferative rates 
similar to that seen in women (3, 45, 55).  
 
The survival rates for subtypes seen this this current data vary from the survival 
of a set of Italian dogs subtyped (23). This Italian study was not able to establish 
any variation in survival between subtypes. This was could be due to the small 
sample size used (n=39). In addition, Sarli et al. (23) found luminal B tumours 
were the most prevalent.  Interestingly, the authors also noted that basal tumours 
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resulted in a better outcome than the luminal subtypes; the opposite was found 
in this current study.  
 
In contrast to basal-like tumours, more than half of the animals with luminal A 
tumours were still alive at the end of the follow-up period, more than 1200 days, 
with a median survival greater than the average survival of 682 days. This result 
is not unexpected as hormone receptor positive tumours in women are 
associated with better survival and clinical outcomes (18, 43, 44, 51). Luminal A 
tumours in dogs have been associated with low grade and low levels of lymphatic 
invasion similar to levels seen in human breast cancer (401).  
 
Overall, this data supports the presence of cancer subtypes similar to those found 
in women with breast cancer. It is the first Australian study and second study 
world-wide to establish subtyped CMTs have similar survival profiles as the same 
subtype in human breast cancer. Importantly, it is the first and largest prospective 
study to establish these links between subtype and survival. No significant 
association between tumour subtype and age, de-sexing or the histological type 
of the tumour could be established. Overall, basal-like tumours were more likely 
to be found in pure breed dogs. The panel of five antibodies used in this study 
successfully stratified CMTs and provided prognostic information. 
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5.3.7 Chapter Summary 
This is the first study to subtype malignant CMTs in Australian dogs. It supports 
the use of subtyping CMTs as a tool for Australian veterinary pathologists to 
characterise and predict tumour behaviour to better inform treatment and 
prognosis. Importantly, the variability of basal cell marker reactivity in CMTs 
highlights the importance of validating and utilizing a panel of basal cell markers 
rather than a single marker to identify basal-like subtype tumours. Given the low 
frequency of luminal B tumours, a larger-scale study is needed to produce a 
sample size large enough to investigate the survival of animals with this tumour 
subtype. Finally, to further demonstrate the similarity of subtyped CMTs to human 
breast cancers the link between other known prognostic factors such as tumour 
size, grade, presence of necrosis and lymphatic or vascular invasion should also 
be validated.  
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 Evaluating potential prognostic markers in 
CMTs 
6.1 Introduction 
The developing field of CMT diagnosis and treatment over the past decade has 
been rapidly growing with owners prepared to financially support the cost of 
additional tests needed for more accurate diagnosis (26, 287, 404). This is leading 
to a more pivotal role for veterinary pathologists in the diagnosis of many canine 
cancers. In addition, this increasing role has led to the search for robust prognostic 
markers as veterinary pathologists are more frequently being asked to provide an 
opinion on the prognosis of cases (26). 
  
Many of the tumour markers investigated in CMTs come from well-established 
counterparts used in human breast cancer diagnosis. Two key examples are the 
identification of hormone receptor positivity, ER and PR, and the use of proliferative 
markers such as Ki-67 or PCNA. The diagnostic and prognostic value of ER and 
PR are well established in human breast cancer and are markers used for 
determining breast cancer subtypes (43, 50, 426). Similar value is also seen in 
CMTs (113, 402, 424, 427, 428). Proliferative markers, including Ki-67 and PCNA, 
are predictors of poor prognosis in both women (429, 430) and dogs (8, 111, 162).  
 
There are other well established prognostic markers in CMTs such as p53 and 
HER2 which hold similar prognostic value as that found in human breast cancer but 
are not used in routine diagnostic practice (431).  
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With the increasing suggestion of the utility of diagnosis using molecular subtypes 
for CMTs (3, 23) there is the potential to also identify specific prognostic markers 
associated with a single subtype. To this end, this study aimed to investigate 
emerging prognostic markers in human breast cancer, not yet investigated in dogs, 
and determine if there was association with each to a specific CMT molecular 
subtype.  
 
Two promising potential prognostic markers are GATA-3 (259-261, 432, 433) and 
Runx-2 (163, 169).  
 
GATA-3 is a transcription factor that is a key regulator of mammopoiesis and the 
differentiation of progenitor cells into luminal epithelial cells (132, 257). In breast 
cancer, higher GATA-3 mRNA levels are associated with ER positive tumours, 
however, this has not been found to be true with tumours that are ER and HER2 
positive (173, 174, 259, 434). Tumours with higher GATA-3 expression are also 
associated with a more favourable prognosis (261, 435). GATA-3 positive tumours 
are more likely to be a lower histological grade (434-436). The presence of GATA-
3 has not been demonstrated in CMTs and if present, we hypothesise it could have 
a similar association to ER positivity and improved survival. 
 
Similarly to GATA-3, Runx2 is a regulator of mammary epithelial cell fate (171). 
Changes in Runx2 expression and dysregulation have been associated with 
development of different cancers including osteosarcoma (437), prostate (438) and 
breast cancer (170, 438). Unlike GATA-3, Runx2 expression is inversely associated 
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with ER negative tumours and HER2 positive tumours (168, 170). In addition, 
increased staining of Runx2 is associated with a poorer prognosis (170). This 
suggests that if present in CMTs Runx2 positivity may also be more strongly 
associated with the HER2+ subtype and reduced survival.  
 
Runx2 also plays a role in human breast cancer metastasis (171). Up to 60% of 
breast cancers, cancer cells secrete PTHrP (24) which stimulates osteoblasts in the 
microenvironment surrounding skeletal metastases (439). This is regulated by 
Runx2 in metastatic breast carcinomas (440). Runx2 has also been shown to 
regulate the cell cycle of human primary breast carcinoma cells (440). 
Consequently, combined with the known, but contentious, association between 
PTHrP and survival in women with breast cancer, the presence of PTHrP in 
malignant CMTs may also be prognostic. In particular, the loss of PTHrP positivity 
may be associated with reduced survival as is found in women with breast cancer 
(190). The presence of PTHrP has been demonstrated, using 
immunohistochemistry, in normal, benign and malignant canine mammary tissues 
where the stain intensity of PTHrP was compared to histological subtype (441). 
There have been no studies on the association of PTHrP positivity and survival in 
dogs with malignant CMTs.  
 
Overall, this study was first to demonstrate GATA-3, PTHrP and Runx2 in 
normal benign and malignant CMTs. It aimed to determine if these markers 
have a similar prognostic potential to that seen in human breast cancer.  The 
aim of this study was to identify if any of these markers were significantly 
associated with a specific CMT subtype. 
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6.2 Results 
6.2.1 GATA-3 is present in canine mammary tissue and 
its positivity is progressively reduced in neoplastic 
canine mammary tissue 
Thirty-four malignant and 28 benign CMTs were analysed (Table 6.1). In addition, 
adjacent normal tissue was present and analysed, in 22 samples. Overall GATA-3 
positivity was progressively reduced from normal mammary tissue to malignant 
CMTs (Figure 6.1) 
 
 GATA-3 was localized in the nuclei of both the ductal epithelial cells (Figure 6.2A) 
and basal epithelial cells and myoepithelial cells (Figure 6.2B).  Stromal cells, such 
as fibroblasts or myofibroblasts, did not show any GATA-3 positivity. Diffuse weak 
cytoplasmic staining was also seen in some samples. The average percentage of 
epithelial cells staining positively in the normal mammary tissue adjacent to CMTs 
was 27.45%. Overall, 20 of the 22 (90.9%) normal samples were positive for GATA-
3 (Figure 6.1).  
 
The average percentage of tumour cells staining positively in benign CMTs was 
13.36%. In total, 14 benign CMTs were GATA-3 positive and 15 were GATA-3 
negative (Figure 6.1). GATA-3 positivity was least common in malignant CMTs. The 
average percentage of positive tumour cells was only 5.37%. Nearly 30% (10/34) of 
malignant tumours were GATA-3 positive (Figures 6.1, 6.3A).  
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There was a significant difference in the amount of staining for GATA-3 between all 
three types of canine mammary tissue; with the strongest variation seen between 
the normal mammary samples and the malignant tumours (Figure 6.4). 
 
The calculated effect size of the percentage of cells positive for GATA-3 between 
sample groups was 1.94. Using the smallest sample group size, normal samples, 
of 22 samples, the retrospective achieved power was 0.99.  
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Table 6.1 Distribution of the histopathological classification of CMTs stained for 
GATA-3. 
Tumour Type No. cases 
GATA-3 positivity 
n (%) 
Malignant 34 10 (29.4) 
Adenocarcinoma 14 3 (21.4) 
Simple carcinoma 13 4 (30.8) 
Complex carcinoma 5 3 (60.0) 
Malignant mixed tumour 2 0 (0) 
Benign 28 14 (50.0) 
Benign mixed tumour 15 6 (40.0) 
Simple adenoma 8 6 (75.0) 
Fibroadenoma 3 2 (66.6) 
Complex adenoma 1 0 (0) 
Intraductal papillary adenoma 1 0 (0) 
 
 
 
Figure 6.1 GATA-3 positivity in normal canine mammary tissue compared to 
benign and malignant CMTs.
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Figure 6.2 Localisation of GATA-3 in normal canine mammary tissue and benign 
CMTs. Normal branching alveolar duct demonstrating nuclear GATA-3 localisation 
(A), basal and myoepithelial staining (B), positive tumour cells in a simple 
adenoma (C) and in epithelial tumour cells of a complex adenoma (D). 
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Figure 6.3 Representative malignant CMTs stained for GATA-3, (A) an 
adenocarcinoma, with tumour cells positive for GATA-3 and (B) a solid carcinoma 
negative for GATA-3. 
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Figure 6.4 Comparison of the percentage of GATA-3 positive cells in each canine 
mammary tissue types *p ≤0.05, ***p≤0.001, ****p≤0.0001. 
 
Using a one-way ANOVA, the differences in the percentages of cells staining 
positive between normal, benign and malignant samples were statistically 
significant between the normal and malignant tumours where less than 6% of cells 
were positive.   
 
The tumour subtype was determined for 27 samples. In these subtyped tumours, 
GATA-3 positivity was associated with the Luminal A subtype compared to basal-
like subtype tumours (Table 6.2) (p=0.0042). Follow-up was available for 23 
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animals, seven with GATA-3 positive tumours. There was no difference in survival 
of animals with GATA-3 positive tumours compared to animals with GATA-3 
negative tumours (p=0.25) (Figure 6.5). The median survival for GATA-3 negative 
tumours was 1267 days whilst it was undefined for GATA-3 positive tumours.  
 
Table 6.2 Distribution of GATA-3 positivity between Luminal A and Basal CMT 
subtypes. 
Subtype GATA-3 negative GATA-3 positive Total 
Luminal A 4 6 10 
Basal 16 1 17 
 
 
 
Figure 6.5 Comparison of the survival of animals with either GATA-3 positive or 
GATA-3 negative tumours, Log-rank test p=0.25. 
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6.2.2 PTHrP positivity does not vary between normal 
mammary epithelial cells and neoplastic cells and is 
not related to survival 
Thirty-one benign and 21 malignant CMTs were stained for PTHrP using IHC (Table 
6.3). Adjacent normal mammary tissue was present in 17 samples. PTHrP was 
localised in the cytoplasm of epithelial cells within the acini of the lobules as well as 
the epithelial cells lining ducts. The positivity of PTHrP was similar in all samples 
(Figures 6.6).  
 
Table 6.3 Distribution of the histopathological classification of CMTs stained for 
PTHrP. 
Tumour Type No. cases 
PTHrP n (%) 
Malignant 21 21 (100.0) 
Adenocarcinoma 11 11 (100.0) 
Simple carcinoma 5 5 (100.0) 
Complex carcinoma 3 3 (100.0) 
Malignant mixed tumour 2 2 (100.0) 
Benign 31 31 (100.0) 
Benign mixed tumour 14 14 (100.0) 
Simple adenoma 13 13 (100.0) 
Complex adenoma 3 3 (100.0) 
Fibroadenoma 1 1 (100.0) 
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Figure 6.6 Rrepresentative normal, benign and malignant CMTs sample 
demonstrating strong PTHrP positivity. Normal mammary (A) and a mammary 
duct at higher magnification (B), benign samples, a complex adenoma (C), simple 
adenoma (D) and benign mixed mammary tumour (E), malignant samples, a 
complex carcinoma (F), and adenocarcinoma (G).
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One hundred percent of samples were positive for PTHrP. This included both 
equivalence in stain intensity and percentage of cells staining positively (Figure 6.7). 
There was no significant difference in the percentage of cells staining between 
normal, benign and malignant samples (p=0.095) and as all samples were positive 
no survival analysis was performed.  
 
 
Figure 6.7 Comparison of the percentage of cells positive for PTHrP in tissue 
samples. 
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6.2.3 Runx2 is present in mammary epithelial cells and the 
surrounding stroma and increased Runx2 stain 
intensity is associated with reduced survival  
 
Overall, 21 benign and 49 malignant CMTs were sampled and tested for Runx2 
positivity (Table 6.4). Normal adjacent mammary tissue was present in 37 samples. 
Over 90% (34/37) of normal samples were positive for Runx2. Over 80% (17/21) of 
benign CMTs were positive for Runx2 whilst 79.2% (38/48) of malignant CMTs were 
Runx2 positive (Figure 6.8). 
 
Similarly, to GATA-3, Runx2 demonstrated nuclear localisation and was present in 
the epithelial cells lining ducts and lobules (Figures 6.9). Runx2 was also present in 
basal and myoepithelial cells but were less frequently positive (Figure 6.10). Runx2 
was not only localised in epithelial cells it was also localised in surrounding stromal 
cells within tumour margins of mixed and complex CMT samples (Figure 6.11). 
 
In terms of overall positivity, normal mammary tissue had the highest percentage of 
Runx2 positive, 36.18%, cells. A similar amount of benign CMT epithelial cells were 
also Runx2 positive (34.68%). Malignant CMTs demonstrated the least Runx2 
positivity with 24.72% of nuclei staining positively and were significantly different 
from normal samples using a one-way ANOVA (Figure 6.12-15). 
 
Runx2 positivity was not restricted to a nuclear localisation. Most benign CMTs 
demonstrated predominately nuclear Runx2 localisation (Figure 6.13). Malignant 
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CMTs also had nuclear Runx2 localisation (Figure 6.14) but similarly to benign 
tumours some samples also contained cytoplasmic Runx2 (Figure 6.14 A, B, C). 
 
The intensity of the Runx2 stain between the adjacent normal tissue and the benign 
tumours was similar. In contrast, the Runx2 stain intensity between normal and 
malignant CMT’s was significantly different. Malignant tumours appeared to be 
composed of two distinct groups stratified by Runx2 stain intensity. Of the 51 
positive tumours, 32 demonstrated no staining or significantly weaker staining 
(Figures 6.14) than that of the normal mammary cells. The remaining 19 had 
significantly stronger stain intensity than the normal epithelial cells (Figure 6.16-
6.17). The greatest difference was between the normal and the weakly positive 
malignant tumour cells. Second to this was the difference in staining between 
benign and the weakly positive malignant tumours. Overall, the difference in the 
Runx2 stain intensity was significantly different in both malignant tumour groups 
compared to the normal cells (Figure 6.17).  
 
There was no difference in survival between Runx2 positive tumours and Runx2 
negative tumours based solely on the percentage of cells staining positively (Figure 
6.18a). Survival information was available for 42 animals. The median survival for 
Runx2 negative tumours was 724 days compared to 597 for animals with Runx2 
positive tumours. When the samples were stratified based on the staining intensity 
(Figure 6.17) animals with high intensity Runx2 positive tumours had a median 
survival of only 258 days compared to negative or low intensity tumours which was 
1258 days. The difference in survival between Runx2 weak stain intensity and 
Runx2 strong stain intensity was significant (Figure 6.18b).  
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Using G*Power, the calculated effect size of the percentage of cells positive for 
Runx2 between sample groups was 0.62. Comparing normal and malignant 
samples to each other, the retrospective achieved power was 0.88. The calculated 
effect size between the intensity of normal mammary tissue and samples over-
expressing Runx2 was 0.82.  Comparing these samples to each other in this present 
study achieved power of 0.96 
 
The subtype of malignant CMTs tested for Runx2 was available for 46 samples 
(Table 6.5). There was no association between subtype and Runx2 intensity found 
(p=0.08). 
.
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Table 6.4 Histopathological classification of CMTs tested for Runx2 positivity 
Tumour Type No. cases Runx2 n (%) 
Malignant 51 41 (80.4) 
Adenocarcinoma 26 21 (80.8) 
Basaloid ductal carcinoma 1 1 (100.0) 
Simple carcinoma 11 8 (72.7) 
Solid carcinoma 5 4 (80.0) 
Complex carcinoma 5 4 (80.0) 
Malignant mixed tumour 3 3 (100.0) 
Benign 21 17 (81.0) 
Benign mixed tumour 10 10 (100.0) 
Simple adenoma 7 4 (57.1) 
Complex adenoma 3 2 (66.7) 
Fibroadenoma 1 1 (100.0) 
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Figure 6.8 Distribution of Runx2 positive samples in normal, benign and malignant 
CMTs. 
 
 
Figure 6.9 Runx2 localisation in normal tissues. Normal canine mammary lobule  
and lobular ducts (A), a higher magnification of a branching alveolar duct with 
positive ductal cells (B), stroma surrounding lobules did not demonstrate Runx2 
reactivity (C), a higher magnification demonstrating Runx2 positivity in ductal cells 
whilst surrounding stromal nuclei are negative (D)..
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Figure 6.10 Runx2 positivity in basal and myoepithelial cells. In (A) basal cells 
(black arrows) and myoepithelial cells (purple arrows) are negative for Runx2. In 
(B)  myoepithelial cells (purple arrows) surrounding the ducts are positive for 
Runx2.
Chapter 6 – Evaluating prognostic markers 
 
268 
 
 
 
Figure 6.11 Runx2 staining in CMTs, benign (A) mixed mammary tumour and 
malignant (B) complex carcinoma where Runx2 is localised in the tumour epithelial 
cells as well as adjacent mesenchymal cells.
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Figure 6.12 Percentage of Runx2 positive cells in each canine mammary tissue 
sample type *p≤0.05.
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Figure 6.13 Weak cytoplasmic localisation of Runx2 within tumour cells (A) and a 
simple adenoma (B) with moderate nuclear localisation of Runx2 within tumour 
cells.
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Figure 6.14 Patterns of Runx2 staining in malignant CMTs. (A) mammary 
carcinoma with moderate cytoplasmic and weak nuclear Runx2 staining. (B) A 
basaloid ductal carcinoma with weak nuclear and cytoplasmic Runx2 staining. (C) 
A solid carcinoma with moderate nuclear and cytoplasmic staining. (D) A solid 
papillary carcinoma with moderate nuclear Runx2 staining..
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In some samples Runx2 staining was stronger at the growth front of the tumour 
(Figure 6.15). 
 
Figure 6.15 Positive Runx2 nuclear localisation in tumour cells at the periphery of 
a malignant mixed mammary tumour 
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Figure 6.16 Comparison of Runx2 staining intensity between low intensity 
malignant (A), normal mammary tissue (B), and high intensity malignant CMTs 
(C).   
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Figure 6.17 The variation in the staining intensity of Runx2 between normal, 
benign and the two subgroups of malignant CMTs, **p≤0.01, ***p≤0.001, 
****p≤0.0001. 
 
Table 6.5 Comparison of the frequency of low and high intensity Runx2 positive 
CMTs between subtypes. 
Subtype Low intensity High intensity Total 
Luminal A 6 2 8 
Luminal B 0 0 0 
HER2 + 1 4 5 
Basal-like 22 10 32 
Null 1 0 1 
Total 46 
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Figure 6.18 Kaplan-Meier overall survival analysis of animals a) based on Runx2 
percentage of cells positive, Log-rank test p=0.92 b) based on Runx2 stain 
intensity compared to normal samples, Log-rank test p=0.046.
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6.3  Discussion 
Identifying valuable prognostic markers for malignant CMTs is important as 
predicting the survival of affected dogs can be difficult due to the tumours 
heterogeneous pathological features and clinical behaviours (95, 339). Secondly, 
as many dogs are only treated with surgery, adjuvant treatments are still in their 
experimental phase in veterinary medicine, so it is important to predict patient 
outcome because often no other treatment is applied (95). IHC is a relatively 
inexpensive and robust method; consequently, identifying useful prognostic 
markers using IHC provides the potential for easy adoption into clinical veterinary 
pathology laboratories.  
 
6.3.1 GATA-3 as a potential prognostic marker 
GATA-3 belongs to a family of zinc-finger transcription factors. Overall, members of 
the GATA family are involved in embryogenesis and development (132, 174, 257). 
GATA-3 gene expression is essential for the differentiation of progenitor cells into 
mature luminal cells and their maintenance within in the breast (132, 257). Changes 
to GATA-3 expression and function have been reported in human cancers such as 
pancreatic (442), cervical (443) and most importantly breast cancer (132, 174, 259).  
 
This was the first study to immunohistochemically map the localisation of GATA-3 
in normal, benign and malignant canine mammary tissue. It is also only the second 
study to investigate the presence of any of the GATA family members in canine 
tissue (263). 
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6.3.2 GATA-3 protein is present in normal canine 
mammary tissue 
This study demonstrated the presence of GATA-3 in normal canine mammary 
tissue. Similarly, to the staining seen in humans, canine mammary tissue 
demonstrated diffuse nuclear staining in both ductal and lobular alveolar epithelial 
cells but not in myoepithelial cells (433, 444). The diffuse cytoplasmic staining seen 
in some samples has also been demonstrated in normal human mammary tissue 
(433). Cytoplasmic GATA-3 staining has also been identified in other tumour types 
(442).  
 
The percentage of normal tissues positive for GATA-3 in this study is significantly 
higher than that found in human studies (436). This current study has used a sample 
size twice of that published human data (436).  
 
6.3.3 GATA-3 is present in benign CMTs histological 
subtypes 
There is limited data on the localisation of GATA-3 in benign breast tumours in 
women. The only published study found 100% of fibroadenomas were positive for 
GATA-3 (436) with a small sample size of 10. In this present study one third of 
fibroadenomas were GATA-3 positive. This is the first study, comparative or 
otherwise, to demonstrate the presence of GATA-3 in other benign breast 
neoplasms, in particular, adenomas demonstrating the highest GATA-3 positivity 
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compared to benign mixed tumours; which are known as pleomorphic adenomas in 
the human breast.  
6.3.4 GATA-3 protein in CMTs shows a stronger 
association with luminal A tumours than in women 
but is not associated with survival 
In women, GATA-3 is a promising prognostic marker for breast cancer due to its 
association with ER (174, 259, 261, 433, 435).  Well-differentiated ductal 
carcinomas express significantly higher levels of GATA3 compared to ER-negative 
ones (173, 261, 445). Given this, GATA-3 should be a marker associated with 
luminal subtype tumours as has been shown in human breast cancer (446). A 
similar association between GATA-3 and luminal A tumours was found in this study.  
 
Despite the positive association between GATA-3 and the luminal A subtype overall, 
only 29% of tumours were GATA-3 positive. This was regardless of their ER 
positivity. This is significantly lower than that seen in human studies (444). The 
percentage of ER positive and GATA-3 positive breast cancer in women ranges 
from 70-92% (433, 435, 436, 444). Other studies have shown that 6.7-83% of ER 
negative breast cancers are GATA-3 positive (444, 447, 448) whereas, triple 
negative breast cancers (equivalent to the basal-like subtype) have demonstrated 
GATA-3 positivity between 43-73% (444, 449, 450). These studies used lower 
GATA-3 positivity thresholds. The only study using greater than 10% of cells as its 
threshold found 19.5% of ER negative tumours were GATA-3 positive (451). This is 
still significantly higher than the 5% of positive GATA-3 basal CMTs seen in this 
Chapter 6 – Evaluating prognostic markers 
 
279 
 
study. This suggests that GATA-3 may be more specific to ER positive tumours in 
dogs than in women.  
 
In this study, no relationship between GATA-3 positivity and survival was found and 
this is similar to a 10-year follow-up study of GATA-3 in human breast cancers (452) 
but contrary to findings in other studies (261, 433, 435).  
 
6.3.5 Study limitations and potential uses for GATA-3 
A limitation of this current study is the low number of GATA-3 positive tumours and 
the low number included in the survival analysis. As a prospective collection, there 
was no selection for tumours expressing genes of interest. In addition, accurate 
collection of follow-up information was difficult. Many veterinarians had not seen 
dogs with a mammary tumour removed again after the initial tumour resection.  
 
Differences in the positivity for GATA-3 between this study and published studies 
using human samples could be due to a number reasons. The two main variables 
are the type of antibody used and the thresholds used to define GATA-3 positivity. 
There can be a significant variation in the sensitivity of GATA-3 clones in detecting 
breast carcinomas (453). Studies in human tissues have used a variety of 
monoclonal antibodies (447). In this study, 10% of stained tumour cells was used 
as the threshold to determine GATA-3 positivity. Other scoring systems have 
included the percentage of staining cells only (453) or a combination of the 
percentage of stained cells and the stain intensity (260). In addition, the threshold 
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set for the number of positive cells also varied between studies from any positive 
cells (444, 450) to, 1% (453) to, 5%(436, 449) of total stained cells. 
 
To promote GATA-3 as a prognostic marker for malignant CMTs, a larger sample 
size needs to be used for survival analysis. In addition, it would also be important 
to test GATA-3 in a range of other malignant canine tumours. The most relevant 
tumours would be those from skin, soft tissue or urinary tract origins as they are the 
most common tumour sites in dogs (381). This would demonstrate if GATA-3 also 
has a restricted presence in tumours other than mammary and uroepithelial origin 
malignancies. 
  
Given its association with survival and ER positive tumours, GATA-3 could be used 
as a marker when testing fine needle aspirate samples of suspected malignant 
CMTs. Furthermore, it could be used when sampling possible tumour metastases. 
In women, GATA-3 positivity is retained in 56-96% of metastases (444, 449). 
Importantly, GATA-3 positivity was retained in metastases that had lost hormone 
receptor positivity compared to their primary counterpart. Unfortunately, this could 
not be tested in this study as no metastatic samples were collected by the AVCBB.  
 
GATA-3 also has the potential utility of GATA-3 as marker to help identify 
malignancies of unknown origin (436). This is given its restricted expression, where 
it is only significantly present in carcinomas of breast or urothelial origin (436). There 
is potential to further demonstrate the utility of GATA-3 not only as a prognostic 
marker but as a diagnostic marker in tumours of unknown origin. If GATA-3 
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demonstrates similarly restricted expression in other canine tissues, it could be 
helpful to identify tumours from a mammary origin.  
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6.3.6 GATA-3 conclusions 
This is the first study to immunohistochemically map the localisation of GATA-3 in 
normal, benign and malignant canine mammary tissue. GATA-3 positivity is limited 
to the epithelial and myoepithelial cells of mammary ducts and lobules. GATA-3 
localisation has an inverse association with the presence of malignant cells. This 
study has validated that, similarly to breast cancer in women, GATA-3 is associated 
with luminal A subtype tumours in dogs. With a greater sample size, an association 
between GATA-3 presence and survival might be established and have a similar 
link to improved survival as is seen in women (but was not confirmed in this present 
study). The absence of GATA-3 staining could be used as a marker to predict a 
basal-like subtype CMT which is associated with a significantly shorter overall 
survival time (Chapter 5).  
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6.3.7 PTHrP is present in normal, benign and malignant 
CMTs 
Murine models have shown PTHrP to be a critical regulator of morphogenesis in 
mammary gland development (167). It acts as a local autocrine/paracrine/intracrine 
growth factor not only in the mammary gland but also in other tissues such as bone 
and cartilage (166). In women, 60% of breast cancers express PTHrP (24). There 
is limited data on the expression of PTHrP in canine mammary tumours. There is 
some evidence to suggest that CMTs can also cause humoral hypercalcemia of 
malignancy which can be found in women with breast cancer (454). Eighty percent 
of humoral hypercalcemia of malignancy cases in women are mediated by the 
production of PTHrP (455).  
 
In humans, PTHrP has been shown to be secreted normally by epithelial cells (456). 
In this study, normal canine mammary epithelial cells were also positive for PTHrP. 
Canine tissue samples demonstrated a similar cytoplasmic localization in these 
ductal and alveolar epithelial cells as is seen in human tissue (457).  
 
All benign CMTs were PTHrP positive, including histological subtypes which had 
not been tested for PTHrP previously. These histological subtypes included simple 
and complex adenomas. In humans, only fibroadenomas (457, 458), had been 
tested for PTHrP expression; although only two samples were tested.  
 
The strong cytoplasmic localisation of PTHrP in the glandular components of benign 
and malignant mixed CMTs is in contrast to a study by Okada et al. which found 
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PTHrP positivity in the myxoid and stromal cells of tumours but not within the 
epithelial cells (441). 
 
This current study appears to have one of the largest samples sizes for 
demonstrating PTHrP in normal tissue and benign CMTs. In addition, it also appears 
to be the largest when including human subtyping studies as well. The antibody 
used in this study was developed by our collaborators, Prof Jack Martin and Dr Carl 
Walkley, and has been robustly validated in different tissue types (267).  
 
6.3.8 PTHrP conclusions 
 PTHrP was the only marker demonstrated in CMTs prior to this study (441) and 
was selected for its potential value when compared to mammary tumour subtype. 
In women with breast cancer, PTHrP has been associated with a better prognosis 
(136). Consequently, it potentially shared a similar outcome in dogs with malignant 
CMTs.  
 
Surprisingly, all the malignant CMTs tested were positive for PTHrP and as such it 
showed no discrimination between animals and survival regardless of subtype. This 
homogeneous PTHrP reactivity was similar to results outlined by Okada and co-
workers where all benign and malignant CMTs demonstrated PTHrP positivity.  
Furthermore, the authors found no difference in the stain intensity or distribution of 
PTHrP between benign and malignant samples (441). Overall, PTHrP has no 
prognostic value for discriminating between malignant CMTs with different 
outcomes.  
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6.3.9 Runx2 is present in normal and benign mammary 
tissues 
Runx2 acts with Core Binding Factor (CBF) complex bind DNA to either activate or 
repress gene transcription. It is a master regulator of osteoblast differentiation and 
for many years was mainly considered as a bone-specific transcription factor (175, 
176, 437, 459).  
 
There has been limited work on the presence of Runx2 protein in normal mammary 
tissues, particularly human tissue (169, 459, 460). Developmental studies in mice 
have shown that Runx2 in present in terminal end buds of mice (461). These 
structures are responsible for the branching of the developing gland. Runx2 is also 
present in the fully developed adult mouse mammary gland (459). 
 
Runx2 is also expressed in some breast cell lines, e.g. MDA-MB-231 and MCF-7 
(462). Runx2 expression regulates both osteopontin and β-Casein (164, 462). 
Similarly, to murine tissues Runx2 was demonstrated in adult ductal and alveolar 
epithelial cells of non-neoplastic canine mammary tissue in this present study. Its 
overall positivity was strongest in non-neoplastic samples compared to benign or 
malignant mammary tumours. Runx2 was predominately located within the nucleus 
of cells. Runx2 positivity has also been demonstrated in non-pathological ductal 
cells in human mammary samples (170). It has also been found in non-pathological 
myoepithelial cells (170) 
 
Detailed studies of murine mammary tissues identified Runx2 in basal and 
myoepithelial cells (164, 169, 176, 459). One of which used additional markers, 
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CD24 and Sca1, to identify the basal and myoepithelial cells (169). In my study 
Runx2 was present in both luminal, basal and myoepithelial cells.  
 
Myoepithelial cells rest parallel to the long axis of mammary ducts. This layer 
surrounds the luminal epithelial cells and separates them from the basement 
membrane and the stroma (463). In contrast to their formation in ducts myoepithelial 
cells in alveoli are discontinuous. This can allow some luminal epithelial cells to 
contact the basement membrane directly. Studies investigating basal and 
myoepithelial cell reactive group both cell types together (463, 464). Both cell types 
have similar immunoreactive profiles they are positive for CK5/6, CKAE1/AE3, 
CK14, p63 and vimentin (463). There are four morphological types of myoepithelial 
cells in canine mammary tissue (464). Runx2 staining was more predominant in 
luminal epithelial cells. There was staining in basal and myoepithelial cells but this 
was less common.  
 
Mixed mammary tumours represent between 40-50% of benign CMTs (465). These 
tumours are characterised by multiple cells types within the tumour margin. These 
cells are often benign proliferations of epithelial ductal, acinar or myoepithelial cells 
that are surrounded by mesenchymal tissue. The histogenesis of each of these cell 
types remains controversial (464). It is believed mixed mammary tumours occur 
through one of three mechanisms, metaplasia from either epithelial, stromal or basal 
cells (96, 466-468). These lesions can also be classified as malignant when the 
epithelial component transforms into invasive carcinoma cells (96). In this present 
study, mesenchymal stromal cells such as fibroblasts, fibrocytes and 
myofibroblasts, in non-neoplastic mammary tissues were not positive for Runx2. 
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Whereas stromal cells in proliferative and myxomatous areas within complex 
tumours both benign and malignant demonstrated Runx2 positivity (Figures 6.11). 
These spindle cells are possibly of myoepithelial origin (465). The retained Runx2 
positivity in these cells supports their development through metaplasia from either 
luminal, basal or myoepithelial cells. Overall Runx2 positivity was greater in 
mixed/complex benign tumours compared to simple tumours. This was not 
unexpected as the high frequency of CMTs which show myoepithelial or basal cell 
proliferation is an important and unique feature of canine mammary tumours 
compared to mammary tumours in other species (464).   
 
Another benign CMT subtype, simple adenoma, is composed of simple 
proliferations of well-differentiated cells. The Runx2 staining in these tumours was 
both nuclear and cytoplasmic. The labelling pattern in these tumours was less 
frequent but comparable to normal tissue except for the presence of cytoplasmic 
only staining.  
 
There was no difference in Runx2 staining between normal mammary tissue and 
benign CMTs suggesting Runx2 activity is preserved in benign tumour. In contrast, 
less malignant tumours were Runx2 positive this suggests the pathway involving 
Runx2 may be affected in malignant CMTs.   
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6.3.10 Runx2 localisation is variable in malignant 
CMTs 
Transcription factors with a role in mammary gland development such as GATA-3 
and Runx2 can also have pivotal roles in breast cancer (461, 469). Demonstrating 
these genes, involved in mammary epithelium cell-fate, may assist with better 
understanding of cancer processes and identify those that are associated with 
prognosis.  
 
An important finding of this study was the presence of two discrete subtypes in terms 
of Runx2 positivity. When compared to the staining intensity of normal mammary 
tissue, over 70% of malignant tumours demonstrated Runx2 weaker staining. 
Animals with weak Runx2 positivity had significantly better survival than those 
animals with tumours that had strong intensity Runx2. This suggested that in these 
CMTs Runx2 was up regulated. A similarly poor prognosis has also been found in 
humans (170).  
 
Runx2 can have both a negative or positive effect in cancer depending on the 
cellular context (470). The main known function of Runx2 in breast cancer is its 
antagonism of estrogen signalling (471). A similar mechanism is also believed to be 
responsible for Runx2 acting as a tumour suppressor in prostate cancer (472).  
 
In this study Runx2 positivity was more common in ER negative tumours suggesting 
its action was not in mediating hormone receptor transcription in cancer cells. Runx2 
positivity is more common in high grade ER negative breast cancers (473). Given 
the poor survival of strongly stained Runx2 tumours it is more likely that Runx2 was 
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acting in a fashion that promotes tumour development and or progression. It could 
be that the Runx2 over-expression resulted in increased proliferation and promoting 
abnormal acini formation; which has been demonstrated in a normal human 
mammary and an ER negative breast cancer cell line (460).  
 
Another possible action suggested by Runx2 positivity in tumour cells during earlier 
stages is assisting in inducing epithelial mesenchymal transition (EMT) (470) which 
is interesting as many Runx2 positive tumours were basal-like subtype and 
expressed the mesenchymal markers used for subtyping, vimentin and p63.  
 
Within the samples tested there were two tumours with different histopathological 
diagnoses that were removed from the same animal. Interestingly, both tumours 
demonstrated high intensity Runx2 positivity. This suggests that although the 
histopathological features were different, at least some of the underlying molecular 
changes were similar.  
 
Runx2 over-expression has also been correlated with the HER2 positive subtype 
and the presence of metastases (170). More samples are required to establish a 
similar link in this study. 
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6.3.11  Runx2 conclusions 
This is the first study to demonstrate Runx2 in canine mammary tissue. The pattern 
of Runx2 corresponded with the molecular subtype and clinical outcome for 
malignant CMTs. This study demonstrated variable localisation of Runx2; and 
27.8% of malignant mammary tumours which demonstrate likely Runx2 up-
regulation. These results are in concordance with studies in humans that suggest 
Runx2 is associated with ER negative breast cancer and with poorer patient 
outcomes.  
 
The clinical follow-up of animals with Runx2 over-expressing tumours suggested 
that Runx2 is associated with a more aggressive phenotype as its presence was 
significantly associated with reduced overall survival.  
 
6.3.12 Chapter Summary 
The findings of these studies demonstrated that of the potential prognostic markers, 
Runx2 has the most potential as a prognostic marker in CMTs. Furthermore, Runx2 
over-expressing tumours are associated with an aggressive phenotype. 
Consequently, Runx2 expression may be associated with poorer survival. Dogs with 
strong intensity Runx2 staining are at higher risk of tumour progression and a poor 
outcome. 
 
Of the three markers, GATA-3 has the most restricted expression being limited to 
epithelial and myoepithelial cells of the ducts and lobules. Both Runx-2 and PTHrP 
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have a more widespread distribution also being localised in mesenchymal stromal 
cells of benign and malignant CMTs.  
 
Although GATA-3 was not associated with survival, GATA-3 positive tumours were 
more likely to be the luminal subtype. Consequently, GATA-3’s use as a prognostic 
marker is more valuable in the absence of its staining, suggesting a basal 
phenotype.  
 
These studies provided solid evidence for a role for both GATA-3 and Runx2 in 
CMTs. Further studies are needed to elucidate their mechanisms of action and to 
demonstrate parity in function with their human orthologues.  
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 Effect of PTHR1 knockdown in OS tumour 
cells 
  Introduction 
Osteosarcoma is a complex disease with a strongly heterogenic molecular 
background. The three most common histological subtypes, chondroblastic, 
osteoblastic and fibroblastic, have been unable to be characterized by distinct 
genetic profiles. OS is believed to be derived from MSCs and is considered a 
differentiation disease (218, 219). Stages of this differentiation have been 
successfully demonstrated using mice models. For example, genetically induced 
Cre:Lox models of OS have successfully produced a reliable model for 
fibroblastic OS whilst models using shRNA inactivation of the same genes have 
produces a more differentiated osteoblastic subtype (268). To date, there is little 
data on the changes to OS biology in this shRNA model.  
 
Importantly, the PTHrP gene family may play significant role in the development 
and progression of OS (25). OS which over-express PTHR1, the common 
receptor for both PTH and PTHrP, are associated with a more aggressive 
phenotype (237). Consequently, the focus of this chapter is establishing the 
effect of the knockdown of PTHR1, in a shRNA induced mouse model of 
OS. To investigate the role of PTHrP in a primary bone cancer compared to 
CMTs. Investigating the result of minimising PTHrP’s effect on cell 
functions including  proliferation, apoptosis, lymphangiogenesis and Wnt 
signalling.  
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  Results 
7.2.1 Knockdown of PTHR1 produces a more 
differentiated histological phenotype 
Ren.1309 tumours (Figure 7.1A) demonstrated fibroblastic morphology with 
densely packed tumour cells and sparse areas of osteoid interspersed 
throughout. These were tumour cells in which the shRNA targeted a 
nonmammalian renilla luciferase gene. In contrast, PTHR1.358 tumours (Figure 
7.1B) demonstrated a more osteoblastic OS subtype with less densely packed 
tumour cells and widespread areas of mineralized osteoid formation.   
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Figure 7.1 Demonstration of variation in histological presentation of Ren.1309 
and PTHR1.358 tumours. 
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7.2.2 Knockdown of PTHR1 increases formation of 
mineralized bone  
The amount of mineralized bone in PTHR1.358 tumours was significantly higher 
than in the Ren.1309 tumours (Figure 7.2). Overall, PTHR1.358 tumours 
contained at least twice the mineralized osteoid area compared to Ren.1309. On 
average, only 2.8% of the Ren.1309 tumour area was positive compared to over 
7.8% in PTHR1.358 tumours. 
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Figure 7.2 Ren.1309 tumours (A) contained significantly less mineralized 
osteoid, black area of Von Kossa stain (C), compared to PTHR1.358 (B) 
tumours. This is also visible in the wide distribution of the percentage of tumour 
area containing mineralized osteoid 
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7.2.3 The knockdown of PTHR1 has no effect on PTHrP 
localization 
PTHrP and PTHR1 were localized in all tissue samples of both Ren.1309 and 
PTHR1.358. PTHrP was predominately localized in the cytoplasm of tumour cells 
(Figure 7.3A) and to a lesser extent demonstrated nuclear localization (Figure. 
7.3B). In contrast PTHR1 was solely localized in the cytoplasm of the tumour cells 
(Figure 7.4). Statistically, there was no difference in the amount of PTHrP staining 
between the two tumour lines (Figure 7.5).   
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Figure 7.3 Moderate cytoplasmic staining of Ren.1309 tumour cells with PTHrP 
(A). Nuclear PTHrP staining was also seen in PTHR1.358 cells (B). 
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Figure 7.4 Weak cytoplasmic staining of Ren.1309 (A) and PTHR1.358 (B) for 
PTHR1. 
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Figure 7.5 Similar levels of PTHrP positivity (C) were found in the Ren.1309 (A) 
and the PTHR1.358 samples (B).  
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7.2.4 Knockdown of PTHR1 significantly reduces cell 
proliferation 
To determine if the knockdown of PTHR1 had any effect on the proliferation of 
tumour cells the presence of cyclin D1 was localized using IHC. Positivity was 
significantly lower in PTHR1.358 tumour samples indicating that reducing PTHR1 
expression results in reduced proliferation of tumour cells. Overall, 44% of nuclei 
were positive in Ren.1309 tumours compared to 26% in PTHR1.358 tumour 
nuclei (Figure 7.6).  
 
While not as distinct as the cyclin D1 results, Ki-67, another proliferation marker, 
demonstrated a similar reduction in positivity in PTHR1.358 cells with successive 
runs approaching significance, (Figure 7.7).  
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Figure 7.6 Increased nuclear positivity of cyclin D1 was seen in Ren.1309 cells 
(A) compared to PTHR1.358 cells (B). The reduced positivity in PTHR1.358 
cells was statistically significant (C). 
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Figure 7.7 Renilla.1309 cells demonstrated increased Ki-67 activity compared to 
PTHR1.358 cells (A,B); though not statistically significant (C). 
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7.2.5 Knockdown of PTHR1 results in increased Wnt 
signalling antagonist localization 
DKK-1 was localized in the nuclei of both the Ren.1309 and PTHR1.358 tumours 
(Figure 7.8). DKK-1 was significantly higher in the PTHR1.358 samples with 26% 
of nuclei demonstrating positivity compared to only 7% positivity seen in 
Ren.1358. In addition, DKK-1 was more frequently localized in the periphery of 
the tumour in the Ren.1309 tumours; whilst in PTHR1.358 it was maximally 
localized both at the tumour periphery and in cells surrounding osteoid.  
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Figure 7.8 DKK-1 was not as strongly expressed in Ren.1309 cells (A) 
compared to PTHR1.358 cells (B). This variation is clearly visible in the DKK-1 
scatterplot (C). 
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7.2.6 Microvessel density is unaffected by PTHR1 
knockdown 
Factor VIII factor was localized in blood vessels surrounding both Ren.1309 and 
PTHR1.358 tumours (Figure 7.9 A,B). There was no factor VIII positivity was 
present within the tumour mass itself for either cell line (Figure 7.9 C, D); though 
mature blood vessels in both the surrounding tissue (Figure 7.9 A) and control 
tissue demonstrated positivity (Figure 7.9 B).  
 
Disparately, VEGFR3 (Figure 7.10) was successfully localized in new blood 
vessels within the tumour margins though there was no difference in the density 
of new blood vessel formation within the tumour (Figure 7.11, Figure 7.12). In 
addition, there was no variation in the microvessel wall thickness, lumen size or 
vascular area of the tumour (Figure 7.11 C-E).    
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Figure 7.9 Both control tissues (A) and internal positive controls (B) 
demonstrated positivity for factor VIII staining vascular endothelial cells. In 
contrast, both OS cell lines demonstrated little or no factor VIII positivity (C,D). 
 
 
Figure 7.10 Microvessels formed within the Ren.1309 tumour, with red blood 
cells present in the lumen, which are positive for VEGFR3
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Figure 7.11 Similar levels of angiogenesis were visible between the knockdown 
and control tumour cells (A,B). There was no statistical significance in the size (C), 
thickness (D) or lumen (E) of the new vessels formed. 
 
 
Figure 7.12 The amount of angiogenesis was not affected by the knockdown of 
PTHR1. 
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7.3 Discussion 
Utilizing IHC the changes that result from the knockdown of PTHR1 have been 
established. Firstly, an important change is the increased level of differentiation of 
the tumour cells in vivo (Figure 7.1). The PTHR1.358 cells demonstrated a less 
fibroblastic morphological appearance and produced significantly more mineralized 
osteoid (Figure 7.2). This degree of mineralization is similar to the stand-alone 
shRNA OS model produced through knockdown of p53 and Rb (268). In addition, 
this shRNA OS model from which this PTHR1 knockdown model stems 
demonstrates a PTH responsiveness similar to that of a mature osteoblast 
phenotype. Further research has also demonstrated that the shRNA knockdown of 
PTHR1 reduces the invasiveness of cells in vitro (270).  
 
In vitro studies of human OS cells transfected with PTHR1 resulted in lower 
mineralized bone formation and a delay in differentiation (188). These results are in 
line with the increased mineralized osteoid formation and increased differentiation 
in vivo through the knockdown of PTHR1. This more differentiated phenotype is 
important as OS over-expressing PTHR1 are associated with a more aggressive 
phenotype (237) and are correlated with relapse and metastasis in clinical OS 
samples (474). The more differentiated phenotype produced through knockdown of 
PTHR1 was also associated with reduced cell proliferation (Figure 7.6, Figure 7.7). 
As PTHrP/PTHR1 signalling results in proliferation of OS cells (475) the reduction 
in cell proliferation seen in PTHR1.358 is expected. It demonstrates the importance 
of PTHrP/PTHR1 signalling in maintaining both a less differentiated state and 
increased proliferation of tumour cells in vivo (Figure 7.7).   
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There is no significant difference in angiogenesis related gene expression, including 
VEGF, between normal human foetal osteoblasts and OS cells (230). Though it has 
been shown in breast cancer that PTHrP stimulates VEGF expression enhancing 
cell proliferation and migration of endothelial cells (476). Consequently, reduced 
PTHrP/PTHR1 signalling could potentially have resulted in reduced angiogenesis 
and microvessel formation. The knockdown of PTHR1 did not elicit this effect in OS 
cells as there was no difference in angiogenesis between the two tumour models. 
In addition, reduced PTHR1 had no effect on the physical attributes of the new 
vessels that formed such as their overall size, wall thickness or lumen size (Figure 
7.7 c-e).  
 
In contrast to published data for OS neither factor VIII (255) or VEGFR3 (252) was 
localized within tumour cells. This is interesting as nearly half of OS tested by Park 
et al. (252) were positive for VEGFR-3 regardless of histological subtype. In both 
Ren.1309 and PTHR1.358 tumours VEGFR3 was restricted to either tumour 
microvessels or established host blood vessels outside the tumour periphery and 
demonstrated crisp moderate immunoreactivity. In addition to OS, VEGFR3 
expression has also been localized in mesothelioma (477), lung andenocarcinoma 
(478) and vascular tumour cells (479).  
 
Both VEGFR3 and factor VIII antisera stain endothelial cells which line both 
lymphatic and blood vessels respectively. VEGFR3 is activated by VEGF-C and 
VEGF-D and this activation has been shown to induce proliferation of lymphatic 
endothelial cells. VEGF-C is the only ligand with potential as a lymphoangiogenic 
factor from the VEGF family (248, 251, 479). In normal foetal and adult tissues, it 
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has been localized lymphatic endothelia in discontinuous capillary endothelia with 
only weak positivity demonstrated in vascular endothelia (480). In contrast, factor 
VIII should be negative or only weakly positive in lymphatic endothelium. It should 
demonstrate moderate to strong immunoreactivity in vascular endothelia (481). 
Given this, the tumour endothelial cells factor VIII negativity and VEGFR3 positivity 
suggest they are more likely new lymphatic vessels; though some of the vessels 
contain red blood cells (Figure 7.10). Factor VIII demonstrates increased 
immunoreactivity in larger blood vessels than capillaries (481) which could be a 
reason for it not being reactive in the microvessels within the tumour.  
 
As factor VIII is a negative regulator of angiogenesis (253, 254) its absence within 
both tumour models creates a supportive environment for tumour angiogenesis; 
which is not affected by the knockdown of PTHR1. Angiogenesis could be further 
evaluated in these samples by using a marker such as CD31 or CD34 which 
demonstrate stronger immunoreactivity in smaller blood vessels such as capillaries 
compared to factor VIII (481). 
 
The reduction of PTHR1 was also associated with an increase in amount of the Wnt 
antagonist DKK-1. Both in vitro models and clinical samples of OS have been shown 
to express higher levels of DKK-1 (204, 227, 231). OS cells do not leave their lag 
phase to re-enter the cell cycle until they have synthesized sufficient levels of the 
DKK-1 protein (227) 
 
DKK-1 inhibits canonical Wnt signalling. As signalling in this pathway results in 
increased cell proliferation through the activation of cyclin D1 (482) it is possible the 
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increased DKK-1 resulted in reduced Wnt signalling that in turn reduced the 
activation of cyclin D1 seen in the PTHR1.358 cells (Figure 7.7). This mechanism 
would contribute to the overall reduced tumour size seen in the PTHR1.358 tumours 
also proposed by Tian and co-workers in multiple myeloma (228). The up-regulation 
of DKK-1 seen is in line with other published OS studies including those that 
demonstrate differential up-regulation of DKK-1 in osteoblastic OS compared to the 
fibroblastic subtype (204). Increased DKK-1 with reduced cell proliferation contrasts 
with the results of Gregory et al. (227) who found that the addition of a DKK-1 
antibody inhibiting DKK-1 activity delayed cell growth in normal bone marrow MSCs. 
Furthermore, other research suggests that in fact Wnt signalling may be impaired 
or inactive in 90% of OS potentially indicating a different mechanism for reduced 
tumour cell proliferation (224). To could be confirmed using the OS models in this 
study by demonstrating absent nuclear staining of -catenin.  
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7.3.1 Chapter Summary 
Collectively, these results demonstrate that the loss of PTHR1 in OS cells produces 
a more differentiated phenotype leading to increased mineralized osteoid within the 
tumour.  In addition, there is a significantly diminished proliferation rate that could 
be mediated through reduced cyclin D1 activation via the inhibition of canonical Wnt 
signalling due to increased levels of the Wnt antagonist DKK-1. The loss of PTHR1 
does not appear to affect lymphangiogenesis but these results could be confirmed 
through more appropriate endothelial cell marker analysis  
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 Discussion  
8.1 Remote collection of CMTs in Australia is 
feasible, provides a long-term resource, and is 
needed as geography affects CMT risk and 
genetic diversity 
This biobank was developed to collect CMTs to provide a long-term resource for 
comparative oncology research in Australia. The establishment of the AVCBB, 
which is one of the first its kind in the world, provides a facility that allows 
researchers access to CMTs, which are an under-valued resource for oncology 
studies. The AVCBB model is different from many other biobanks as the most 
common structures focus on single or small networks of collection sites (11, 295, 
296) and are established with large funding grants (296). The pilot study 
demonstrated that CMTs can be successfully collected and banked using the 
remote collection and centralised storage model developed by the AVCBB. 95% of 
veterinary clinics consented to participate in this study. Additionally, the successful 
engagement with veterinary pathology services was pivotal to the success of 
biobanking greater numbers of CMT samples. The existing relationship with a high 
number of veterinary clinics greatly improved the biobank’s ability to collect follow-
up information.  
 
By combining the remote DogMATIC collection with formalin-fixed tissue samples 
from veterinary pathology services, there was a moderate collection rate. The 
feasibility and acceptability of this model was demonstrated through in the pilot 
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project by the number and quality of tissue samples. The pilot survey demonstrated 
that the kit was easy to use and that veterinary clinics were willing to participate in 
a network like this long-term. Additionally, the low rate of submission to pathology 
services revealed in the survey, further demonstrated the need to use a remote 
collection kit with a formalin specimen container. An alternative would have been to 
investigate ways the biobank could have provided free pathology as an incentive to 
participate in the biobank.  
 
This project has developed infrastructure and policies that support the remote 
collection, processing, storage and dissemination of high quality animal tissue 
samples.  The biobank structure, though novel, does conform to ISBER and NCI 
best practices. The remote biobanking model created was designed to be low cost, 
sustainable and produced moderate collection rates. This was achieved by creating 
marketing materials that were used to establish a network of veterinary clinics. 
These clinics used specially designed kits to collect samples. Standard operating 
procedures for the collection, processing and storage of these samples were 
created. Data produced was stored in a custom built LIMS. The network of 
participating veterinary clinics also provided a foundation for supporting 
comparative oncology trials in the future. 
 
Isolation of RNA from samples collected through DogMATIC kits produced a good 
yield of intact RNA, with discrete ribosomal subunit gel electrophoresis bands and 
clean absorbance curves, for downstream experiments. The collection of samples 
from many different breeds also provided genetic diversity delivering a higher cross-
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sectional value than that offered by laboratory animals; and it in some respects 
replicates the genetic diversity seen in human studies (92).  
 
In order for the biobank to continue operating and grow it needs to secure additional 
funding. Two ways of facilitating longer term financial support is to either integrate 
charitable funding or begin cost-recovery pricing for CMT samples.  This would 
diversify the biobanks revenue platforms providing a more robust income source 
that may allow it to withstand future funding problems (298). This is particularly 
crucial as the actual costs of biobanking an ‘average’ human sample could cost 5-
10 times more than publicly estimated (298) and this increased cost could also occur 
when biobanking veterinary samples. 
 
8.2  Improving biobank awareness 
Community engagement and awareness is an essential component of biobanking 
and biobanking governance. Moving forward, the AVCBB could consider linking its 
website to Google Analytics which would allow the biobank to quantify website visits, 
visitor locations and its most popular pages. Furthermore, the AVCBB newsletter 
could be hosted by the website and the newsletter email could contain a link to the 
website. This would allow each newsletter to be a Google searchable item improving 
our visibility within online search engines.  
 
During the collection period, the number of participating clinics was increased to 
grow the biobank catchment area and to improve the collection rate. Many 
veterinary clinics were happy to participate but admitted they often forgot about the 
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study. Based on their suggestions it would be beneficial for the biobank to produce 
promotional materials that clinics can put up in their surgeries as a reminder to 
collect samples.  
 
To further improve sample collection, it would be beneficial for the biobank to review 
which veterinary clinics were most frequently represented in samples collected from 
the veterinary pathology services. This would allow the biobank to recruit clinics that 
not only see CMTs more frequently but ones that also routinely send suspected 
CMTs for histopathological diagnosis. Furthermore, the biobank could identify 
recruited clinics that were poor performers. This would allow the biobank to either 
target these clinics directly to improve their submission rate or remove them from 
the network to focus resources on clinics that are actively participating. 
 
The need for both a novel biobanking kit and an Australian-specific biobank due to 
the known variability in risk for CMT development between the same breed from 
different geographic regions; as well as the large sample collection network created. 
The wide variation in risk suggested that international results could not be applied 
to a local canine population. This is supported by the fact that none of the higher 
risk breeds internationally, including the Boxer, German shepherd, English springer 
spaniel, Dachshund and Poodle, were over-represented in the sample set collected 
by the AVCBB. Additionally, the Jack Russell terrier, not shown to be at risk 
overseas, may be at a higher risk of CMT development given its significant over-
representation in this study.  
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These differences suggest that the genetic diversity of Australian dogs is likely to 
be different from published international populations. This may be due to the effect 
of the original number of breed founding dogs, breeding animal availability, overuse 
of breeding stock and breeding practices that effect genetic diversity. The effect of 
this reproductive isolation has been demonstrated in Finnish and North American 
dog populations (348). This genetic diversity would affect the frequency of known 
germ-line mutations in breast cancer risk susceptibility genes and may affect the 
frequency of tumour subtypes seen.  
 
8.3  The importance of dogs as a comparative 
breast cancer model 
This study is the first Australian study to investigate the suitability of CMTs as a 
model for the molecular subtypes of human breast cancer. This hypothesis was built 
on a strong foundation of evidence about the similarity of CMTs to human breast 
cancer. 
 
This similarity stems from the presence, function and conservation of key genes 
involved in breast cancer such as BRCA1 (2, 483, 484), p53 (103), ER (113) and 
HER-2 (9) and extends to risk factors, aetiology and the pathogenesis of malignant 
lesions (4, 7, 485). Two examples of this is the orthologous homology of the BRCA1 
and p53 both greater than 80% (5, 6, 27). Germ-line mutations in both BRCA1 and 
BRCA2 in dogs are associated with significantly increased risk of breast cancer, of 
up to a 4-fold increase (102) and occur in highly conserved domains in similar areas 
to humans (2). Similarly, to humans, BRCA1 expression is significantly reduced in 
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malignant CMT samples (406).  Tumour markers such as p53, Ki-67, MUC1, HER-
2 and ER demonstrate similar functional roles to what has been shown in humans 
(2, 8, 9, 105, 115, 402). 
 
CMTs are an important model for comparative oncology. Some non-clinical 
research questions can be more easily answered using a dog model compared to 
both mice and humans (66). Investigating tumours in pets where they have grown 
naturally with an intact immune system allows the complex immune interactions 
between the tumour and its surrounding tissue to develop and progress naturally. A 
benefit of which is that these tumours are susceptible to selective pressure and 
results in tumour heterogeneity and genetic instability similar to that seen in human 
cancers (80). As there currently are no gold standard drug treatments for CMTs 
testing new therapies not only provides expedited results in less heavily pre-treated 
populations for humans but also provides a treatment option not currently available 
to veterinarians (80, 92). The agents commonly used with invasive breast cancer in 
women are not routinely used for dogs (391).  
 
Using CMTs provides other practical advantages for both basic and translational 
research. Firstly, CMTs are often larger than tumours from their human 
counterparts. CMTs may be monitored over time rather than being excised shortly 
after diagnosis. This provides a wealth of tissue that can be banked for future 
research without compromising the surgical margins for diagnosis.  Secondly, there 
are reduced costs when using companion animals. The animals are housed and 
cared for outside an animal housing facility and the burden of care is shouldered by 
animals’ owners.  
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8.4  CMTs subtypes demonstrate similar clinical 
outcomes and potential prognostic markers to 
human breast cancer 
The molecular subtype of breast subtypes has been more strongly linked to 
prognosis than the traditional histological classification (51, 395). These subtypes 
determined through microarray analysis are not yet routinely used in clinical 
decision making due to the high cost and technical expertise needed for high-
throughput next generation sequencing (51). These subtypes are more cost-
efficiently demonstrated using IHC. In women, luminal A tumours have the best 
survival rates (43) whilst basal-like and HER2 positive tumours have significantly 
worse survival rate (43, 51). Basal-like tumours are also associated with poor 
relapse-free time (43, 50). If a similar link between prognosis, survival and subtype 
exists in dogs with malignant CMTs not only would this provide another option for 
veterinary pathologists during diagnosis but it would also further support the use of 
these tumours for comparative studies.  
 
Only two studies have previously attempt to establish the presence of the molecular 
subtypes of human breast cancer in CMTs. These studies also attempted to 
establish the prognostic significance of these subtypes in a canine population.  
These studies produced conflicting results with Gama et al. demonstrating similar 
survival based on subtype as seen in humans  (3). Whilst Sassi et al. was unable 
to demonstrate any link between tumour subtype and survival (23). This present 
study departed from Gama et al. in terms of the most common tumour subtype 
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luminal A versus basal-like. That study presented a luminal A frequency equivalent 
to what is seen in most human studies (51). The frequency of HER2 positive 
tumours between all studies was similar with most human studies consistently 
finding less than 10% of their cohort to be HER2 subtype tumours (43, 51). The 
basal-like subtype was the most common subtype in Australian samples.  
 
A potential cause of lower luminal A tumours could have been the sensitivity of ER 
to prolonged fixation but this would have resulted in more null phenotype tumours 
rather than increasing the number of basal-like tumours. Importantly, the subtypes 
demonstrated in this study had a similar association between survival and subtype. 
The frequency of basal-like CMTs was significantly higher than found in human 
breast cancer which is closer to 15% (45, 50, 486). The similar clinical behaviour 
and poorer outcome for dogs in this study supports CMTs similarity to the basal, 
triple negative, subtype seen in women with breast cancer.  
  
Using three basal cell markers helped more accurately assign subtypes. The 
reactivity of the tumour to these markers was also similar to others in dogs and 
humans in that the HER2 subtype tumours expressed at least one basal marker (3, 
55) and that basal-like tumours rarely expressed just one basal marker. They more 
frequently expressed two, or all three of the basal markers suggesting a more 
undifferentiated tumour profile (3, 45).  
 
This study (similarly to other published work) also demonstrated that tumours of the 
same subtype often have different morphological presentations (3, 43, 45) 
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highlighting the value in using immunohistochemical subtyping of CMTs and human 
breast cancers.  
 
If future Australian studies confirm the higher frequency of basal-like CMTs it would 
make collecting samples for a larger cohort study easier. It also provides a good 
model to investigate epithelial mesenchymal transition (EMT).  
 
8.5  EMT: A developing story in CMTs 
This higher frequency of basal-like tumours is an interesting finding and brings into 
play the role of EMT in CMTs and human breast cancer. In women, EMT is an 
intrinsic characteristic of the basal-like subtype (487). This subtype exhibits both 
basal and mesenchymal features (488) and EMT is more likely to occur in basal-
like subtype tumours compared to other subtypes (489). There is evidence to 
suggest the establishment of distant metastasis in epithelial cancer, such as breast 
cancer, is due to this process (487, 490, 491). Four of the markers used in this study 
are also implicated in EMT: vimentin, GATA-3, Runx2 and PTHrP.  
 
Vimentin is not only valuable in helping to phenotype basal-like subtype tumours 
but is also an important marker of EMT. In epithelial cancer, such as breast cancer, 
epithelial cells can express vimentin (490). The expression of vimentin in this cell 
type is important as it is known to regulate cell migration which is why many 
aggressive breast cancer cell lines express vimentin (492). Vimentin regulates EMT 
by controlling expression of genes, Axl and Slug, involved in cell migration and 
motility (493). Additionally, the up-regulation of vimentin to induce EMT changes 
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caused by Slug and Ras (493). EMT in basal-like subtype CMTs is possible and 
demonstrated by the strong vimentin staining, a mesenchymal marker (494). It was 
strongly positive in nearly 90% basal-like subtype CMTs.  This high level of staining 
and less frequent p63 staining, a myoepithelial marker, is in line with human studies. 
This supports that vimentin expression is more likely from EMT as a result of de-
differentiation and origin of tumour cells from stem cells (45).  
 
The three prognostic markers investigated are also involved in EMT (Figure 8.1). 
Consequently, not only do GATA-3 and Runx2, provide value in predicting animal 
disease outcome they also suggest that EMT also plays a role in basal-like CMT. 
This in turn supports the use of CMTs as a model for human breast cancer.  
 
In murine models, GATA-3 inhibits EMT. Basal-like tumours that acquire GATA-3 
underwent an epithelial-like differentiation, reversing the EMT (262). The absence 
of GATA-3 in basal-like CMTs is also in line with EMT theory in human breast 
cancer. GATA-3 inhibits metastasis through the reversal of EMT (262). The low 
levels of GATA-3 in the CMTs supports that many of these tumours are in fact basal-
like tumours which have undergone EMT.  
 
Runx2 not only stimulates EMT but also most likely plays a role in metastasis (168). 
Though nearly 80% of malignant CMTs were Runx2 positive, only 37% of these 
demonstrated significantly stronger positivity that was related to poor survival. The 
effect of Runx2 in EMT is dependent on Wnt and Tgf-β signalling (471), SNAI2 as 
its target gene and is antagonised by estradiol (168, 471). The poor survival seen 
in strongly positive Runx2 tumours is mostly likely due to unopposed stimulation of 
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Runx2 target genes, including SNAI2, which has been suggested in in vitro studies 
(168, 470, 471).   
 
Many of these tumours have most likely been developing for a significant amount of 
time allowing EMT to occur. This is supported by data that shows that GATA-3 is 
significantly up-regulated in the early stages of breast cancer along with ER (495).  
Having data on when a mammary lump was first clinically noticed would help 
determine how rapidly the tumours grow. 
 
Runx2 has been implicated in thyroid cancers as a regulator of EMT (178). In breast 
cancer, it has been shown to stimulate EMT and invasion of breast cancer cell lines 
(168). Even though PTHrP provided no prognostic value in this study its presence 
does support EMT in basal-like CMTs. PTHrP has been implicated in EMT in both 
normal (496) and malignant tissues (497). In prostate cancer, PTHrP has been 
shown to promote EMT (497). A recent in vitro study, in a model of breast cancer 
progression, demonstrated that the ablation of PTHrP in PTHrP flox/flox;Cre+ knock 
out tumour cells, categorized as luminal progenitor cells, significantly reduces the 
number of cells which develop an EMT phenotype (498). The results suggested that 
PTHrP may play a role in shifting luminal progenitor tumour cells towards an EMT 
phenotype. Its presence in all CMT samples is interesting and warrants further 
investigation into the development differences between human and canine 
mammary tumours. Particularly around the role PTHrP has in the primary tumour 
and whether the PTHrP receptor PTHR1 is functional.  
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Figure 8.1 Summary of known epithelial mesenchymal transition actions of 
prognostic markers investigated in this study. 
 
This is the first study, human or otherwise, to characterise the presence of Runx2, 
GATA-3 or PTHrP in different mammary tumour subtypes.  
 
8.6  Runx2 shows the most promise as a prognostic 
marker for CMTs 
This first demonstration of GATA-3 and Runx2 in canine tissue has shown that their 
localisation within mammary epithelial cells is similar to that seen in human samples. 
For GATA-3 this was diffuse nuclear staining in both ductal and lobular alveolar cells 
(433, 444). Additionally, the diffuse cytoplasmic staining seen had also been 
reported in normal human mammary tissue (433).  The main contrast between 
canine tissue and reported human results is the percentage of positive normal 
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tissues in this study is significantly higher than that found in human samples (436). 
This current study has used a sample size twice of that published human data (436).  
 
GATA-3 protein in CMTs shows a stronger association with luminal A tumours than 
in women but is not associated with survival. In contrast, the clinical follow-up of 
dogs with Runx2 over-expressing tumours was significantly associated with 
reduced overall survival and suggests that it is associated with a more aggressive 
phenotype.  
 
Whilst a correlation between the HER2 positive subtype and Runx2 over-expression 
and the presence of metastases was not established in this study it did demonstrate 
that over a quarter malignant CMTs demonstrate likely Runx2 up-regulation which 
was associated with a poorer outcome. This is in concordance with human breast 
cancer where Runx2 is associated with ER negative tumours and with poorer patient 
outcomes.  
 
The findings of these studies demonstrated that Runx2 has the most potential as a 
prognostic marker. CMTs with strong Runx2 stain intensity are associated with an 
aggressive phenotype. Consequently, Runx2 stain intensity is associated with 
poorer survival. This group of dogs are at higher risk of tumour progression and a 
poor outcome. 
 
Of the three markers, GATA-3 has the most restricted localisation being limited to 
epithelial and myoepithelial cells of the ducts and lobules. Both Runx-2 and PTHrP 
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have a more widespread distribution also being present in mesenchymal stromal 
cells of benign and malignant CMTs.  
 
Though GATA-3 itself was not associated with survival it was negatively associated 
with the basal-like subtype. Consequently, GATA-3’s use as a prognostic marker is 
more valuable in the absence of its staining; GATA-3 negative tumours are more 
likely to be a basal-like subtype. 
 
While the differential staining of Runx2 and GATA-3 was distinct between normal, 
benign and malignant mammary samples PTHrP was universally positive. Only 60% 
of primary breast cancers in women are positive for PTHrP (24). The role of PTHrP 
within these breast cancers is contentious with both positive (172, 190) and negative 
(185) associations with survival being reported. In dogs, there was no loss of PTHrP 
localisation in tumour cells that was linked with a poor outcome and prognosis (190). 
It is likely that the mechanism in which PTHrP exerts a beneficial effect is likely to 
primary tumour cells  before malignant cells begin to disseminate into the lymphatics 
or vasculature. It is clear that once metastatic tumour cells have established 
themselves within the bone PTHrP is secreted by the tumour cells. This then has a 
negative effect on the surrounding tumour by facilitating its destruction. This 
destruction is accomplished by indirectly activating osteoclasts via the RANK/RANK 
ligand (RANKL) pathway in osteoblasts. RANKL is essential for osteoclast formation 
and function through the interaction with its receptor RANK (194).   
 
The uniformity of PTHrP staining in CMTs and the lack of metastatic CMT samples 
collected by the AVCBB meant it was not possible to investigate the presence of 
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PTHrP in metastatic CMTs. Ideally, matched metastatic samples would have been 
used to compare the localisation of PTHrP to the primary sample. In particular, 
investigating bone metastases would have been interesting as up to 40% of humans 
with breast cancer develop metastatic disease and is the most common secondary 
site (29). An alternative option was used, as we had access to a primary bone 
tumour cell line, osteosarcoma. PTHrP plays an important role in both normal 
mammary and bone development. Additionally, both breast cancer bone 
metastases and osteosarcoma produce osteolytic lesions where aberrant PTHrP 
expression produces defective osteogenic differentiation during the development of 
OS (188). 
 
The knockdown of PTHR1, minimising the action of PTHrP, in OS cells produced a 
more differentiated phenotype with increased mineralized osteoid within the tumour.  
The loss of PTHR1 did not affect lymphangiogenesis but did produce tumours with 
significantly reduced proliferation. PTHR1 has been shown to have a higher affinity 
for PTHrP compared to PTH in breast cancer cells compared to OS cells (499).  
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8.7  Study Limitations 
The low rates of pathology submission rates for CMT was a barrier encountered 
during the pilot study. Discussions with veterinary clinic staff and the results of the 
pilot study survey revealed that the choice to send suspected CMTs to pathology 
relied on owner willingness, cost and the recommendation of veterinarians. This 
project was not able to offer free pathology to participating veterinary clinics. 
 
It was also difficult to collect some important data from veterinary clinics. In 
particular, the location of where a CMT was excised from was not recorded and if 
recurrent tumours were noted in subsequent visits, these sites were not always 
recorded. Additionally, the high percentage of animals that did not see the 
veterinarian following surgery was not anticipated. It was assumed that all animals 
would return for a check-up and suture removal following surgery. 
 
The reporting format from participating veterinary pathology clinics also varied and 
made it difficult to extract some histopathological features for comparison between 
tumour types. Ideally, to improve data collection by the AVCBB site, the tumour site 
and number of palpable masses should be added to the original data collection 
sheet filled in by veterinary clinics.  
 
Another limitation of the study design was the collection of normal mammary tissue 
and follow-up for metastases. Firstly, the DogMATIC kit contained a container for a 
sample of adjacent normal tissue. Some researchers do not consider adjacent non-
malignant mammary tissue as normal. It was not feasible to collect tissue samples 
from unaffected glands as our ethics approval did not allow this. A proposed 
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improvement of the current kit is to include tissue inking pens to allow veterinarians 
to mark the space left after the punch biopsy in the fixed tissue specimens. This 
would at the very least allow tissue sections to be scanned for morphological 
features and those with clearly malignant tissue around the punch to be excluded 
as a ‘normal’ sample.  
 
Secondly, because of the lack of follow-up of recurrent tumours with clinical 
pathology, very few metastatic samples were collected by the biobank. The details 
provided by veterinarians were only of suspected metastases with little data around 
the timeline of development and symptoms seen. Additionally, many animals were 
euthanised because of metastasis without confirmation and it was not within the 
design of the study to be able to request samples from euthanised dogs as they 
were not being removed as part of standard care.  
 
8.8  Future Studies 
The higher frequency of basal-like tumours found in this study should be further 
investigated in the context of risk in dogs. The limitation of this study was the 
difficulty in obtaining a control population for comparison. A larger study where the 
total population of eligible females within each clinic is recorded would allow a breed 
risk determination for CMT develop and specific subtype development.  
 
Additionally, given the different distribution of subtypes in Australian dogs it would 
be beneficial to further study BRCA1 in subtypes. There is evidence in human 
studies that suggests a link between the BRCA1 pathway and basal-like tumours 
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(57, 500). Many of the tumours that develop from BRCA1 germ-line mutation 
carriers have a basal-like phenotype (500). Additionally, most basal-like tumours 
have mutated p53 (18, 501). This phenotype has been demonstrated by both IHC 
and gene microarrays (446, 502). In CMTs, Kim et al. showned significant breed 
related difference in BRCA1 expression (484). This should be coupled with further 
investigation of EMT in CMTs. Especially as intact BRCA1 supresses EMT in human 
breast cancer (503) and that Runx2 interacts with p53 (504). Only one study has 
investigated altered BRCA1 expression in CMTs in which it focused on four small 
breed dogs but was associated with the basal-like subtype (484). This could have 
implications for our population as over time smaller breeds have become more 
popular in Australia (378) with three small dog breeds, Jack Russell Terrier, 
Pomeranian and Shih Tzu, being over-represented in this present study.  
 
A study using 139 tumours has been used to investigate the association between 
subtype and BRCA1 positivity (484). A larger study using both IHC and qPCR to 
compare the expression levels of BRCA1, p53 and Runx2 would not only further 
demonstrate their similarity to human breast cancer but also tease out elements of 
the process of EMT in CMTs. Currently, there are only three studies of EMT in 
canine neoplasia, all of which are in vivo studies of CMT cell lines (505-507) and 
the other is in a CMT cell line xenograft model (505). This is clearly an area of 
research that will grow over the next five years.  
 
A comparative pathway and functional study between malignant CMT cell lines and 
human breast cancer cells lines would be interesting to compare PTHrP and PTHR1 
expression levels. It is clear from this study that PTHrP is localised in all malignant 
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CMTs. Investigating why PTHrP expression is not lost in some cases as it is in 
human breast cancer may help further elucidate the role PTHrP plays in 
tumourogeneis and progression and how these processes diverge between the two 
species.  
 
In this present study tumour subtypes were not correlated to pathological features. 
Moving forward it is important to demonstrate that the basal-like subtype in CMTs 
demonstrates the same histological features associated with basal-like tumours in 
women. In particular, to demonstrate that basal-like tumours in dogs are high grade 
and likely involve areas of central necrosis and pushing borders (45, 500).  
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8.9  Final Conclusions 
This study is the first to pilot developing an Australian biobank for CMTs to provide 
a resource for both veterinary and comparative oncology research. In Australia, 
Jack Russell terriers, Pomeranians and Shih Tzus were over-represented based on 
the registered population. Animals which develop CMTs are older and intact. Ten 
percent of these animals will develop a recurrence after surgery. Malignant 
mammary tumours significantly impact animal survival with the most likely to die 
from their tumour or its metastasis compared to other causes. The lung was the 
most common site of metastasis for CMTs in this study. Finally, the survival of 
animals is not affected by whether they are pure breed or mixed breed, their 
geographical location or their breed group. 
 
CMTs can be subtyped similarly to humans but with different frequencies previously 
reported in canine and human studies. Regardless, similar links between survival 
and subtype exist. For example, basal-like subtype tumours have poorer outcomes 
than luminal tumours. The importance of using subtypes as an alternative diagnostic 
and prognostic tool was demonstrated through the absence of a link between the 
histopathological subtype of a CMT and its’ prognosis. The heterogeneity in 
outcomes for dogs with a mammary tumour mean that finding and validating 
prognostic markers is important to help provide insight for veterinarians and owners.  
 
This study has investigated the utility of three potential prognostic markers – GATA-
3, PTHrP and Runx2. Of these markers Runx2 has the most potential for routine 
use in CMT diagnosis. Its over-expression is associated with poorer outcomes and 
a more aggressive phenotype. Though PTHrP does not appear to be linked to 
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survival in CMTs it was shown that limiting its action in osteosarcoma cells will 
produce a more differentiated, slow growing phenotype.  Not only do these results 
provide insight into new markers for veterinary pathology but they further support 
the similarity of CMTs to human breast cancer.  
 
Overall, this study has demonstrated that CMTs are similar to human breast cancer 
in terms of their suitability for routine subtyping using the molecular subtypes found 
in human breast cancer. These subtypes in dogs have similar outcomes and new 
prognostic markers in human breast cancer convey similar information in dogs with 
a mammary tumour. These tumours are valuable for comparative oncology 
research given their molecular similarity, the presence of the same risk factors for 
their development and the shortened timeline needed to complete survival studies 
in dogs. Further investigation is needed to establish why the frequency of basal-like 
tumours is significantly greater in Australia than that seen in European dogs.  
 
Furthermore, the pedigree breeding of dogs has resulted in specific risk gene 
amplification in specific breeds. This can be used to guide future research using 
breeds as a surrogate for human familial risk. To better demonstrate the suitability 
of Australian dogs more research is needed to demonstrate breed susceptibility to 
CMTs.  
 
A comparative oncology biobank should have bidirectional feedback. It should 
provide samples to help better discern the underlying basic biology behind the 
pathogenesis and progression of breast cancer in women. In addition, there should 
also be an opportunity to provide translation of findings in to veterinary clinical 
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practice. To this end establishing the AVCBB has not only provided a sustainable 
resource for comparative oncology but it has also established a panel of biomarkers 
to subtype CMTs and establish that Runx2 over-expression is a utile marker for poor 
prognosis. Finally, the samples collected and these results provide the foundation 
to further investigate prognostic markers and the role of EMT in CMTs. 
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Appendix 1 
Communication from Peter Burke, representative of the RMIT Animal Ethics 
Committee regarding the full animal ethics application submitted for this study.  
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Appendix 2 
The report format of the AVCBB Microsoft Access Database with the details of 
samples collected for this study.  
Export Details Friday, 29 December 2017
12:07:50 PM
Case ID Clinic Dog's name Date of birth
10P1 Milly 1/01/2000 10
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 18/08/2010
Sample processed 20/08/2010
Total fixation time 2
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.6
Diag
nosis
IsMalignant No. of litters
Age at spayWestern Districts Veterinary 
Huntaway X8 (Cross) Unknown
Unknown
Diagnosis
Unavailable
395
Case ID Clinic Dog's name Date of birth
10P10 Heidi 5/03/2001 8.75
Recurrent CMT after sample
Further details recurrence
Last known date alive 28/07/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
229
Sample taken 11/12/2009
Sample processed 5/09/2010
Total fixation time 268
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.8
Diag
nosis
IsMalignant No. of litters
Age at spayWestern Districts Veterinary 
Staghound X8 (Cross) Unknown
Unknown
Diagnosis
Benign Mixed Tumor
396
Case ID Clinic  Dog's name Date of birth
10P100 Bella -1
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/07/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
776
Sample taken 17/05/2011
Sample processed 18/07/2011
Total fixation time 62
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken
Diag
nosis
IsMalignant No. of litters
Age at spayChannel Hwy Animal Hospital
Labrador retriever3 Gundog Unknown
6
Diagnosis
Ductal adenoma
397
Case ID Clinic Dog's name Date of birth
10P101 Meg 1/01/1998 7
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/08/2011
Euthanized?
Reason for euthanasia
due to megaoesphagus
Date euthanasia/death 1/08/2011
Survival (days calculated)
109
Sample taken 14/04/2011
Sample processed 18/07/2011
Total fixation time 95
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.3
Diag
nosis
IsMalignant No. of litters
Age at spayBurwood Bird and Animal Ho
Golden Retriever3 Gundog 1
5
Diagnosis
Complex adenoma
398
Case ID Clinic  Dog's name Date of birth
10P102 Suzie 1/06/2003
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Suspected kidney failure
Date euthanasia/death 26/08/2011
Survival (days calculated)
Sample taken 29/04/2011
Sample processed 18/07/2011
Total fixation time 80
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.9
Diag
nosis
IsMalignant No. of litters
Age at spayBenalla Veterinary Clinic
Rottweiler6 Utility Unknown
9
Diagnosis
Fibroadenoma
399
Case ID Clinic  Dog's name Date of birth
10P104 Bella 1/01/2001 13
Recurrent CMT after sample
Further details recurrence
19/12/13 Mammary tumour removal no 
pathologyLast known date alive 4/01/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1017
Sample taken 24/03/2011
Sample processed 18/07/2011
Total fixation time 116
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.2
Diag
nosis
IsMalignant No. of litters
Age at spayMoonee Ponds Central Vet
Staffordshire Bull Te8 (Cross) 0
12
Diagnosis
Ductular Adenocarcinoma
400
Case ID Clinic Dog's name Date of birth
10P105 Gin Gin Austin 1/01/1997 10
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 11/05/2011
Sample processed 18/07/2011
Total fixation time 68
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 14.4
Diag
nosis
IsMalignant No. of litters
Age at spayWestern Districts Veterinary 
German Pointer3 Gundog 0
9
Diagnosis
Basaloid ductular mammar
401
Case ID Clinic Dog's name Date of birth
10P106 Phoebe 19/05/2001
Recurrent CMT after sample
Further details recurrence
11/8/11 mammary strip caudal 3 glands 
removed very wide excision, no extra 
tissue taken, Benign Mixed tumour
Last known date alive 28/08/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1162
Sample taken 23/06/2011
Sample processed 19/07/2011
Total fixation time 26
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.1
Diag
nosis
IsMalignant No. of litters
Age at spayHighton Veterinary Clinic
Curly Coated Retrie3 Gundog 0
0
Diagnosis
Adenoma
402
Case ID Clinic Dog's name Date of birth
10P107 Suzie 1/08/1999
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/07/2011
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
8
Sample taken 23/06/2011
Sample processed 19/07/2011
Total fixation time 26
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.9
Diag
nosis
IsMalignant No. of litters
Age at spayColac Veterinary Clinic
Jack Russell Terrier 8 (Cross) Unknown
14
Diagnosis
Sclerotic Adenocarcinoma
403
Case ID Clinic  Dog's name Date of birth
10P108 Mindi 1/07/1998
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 18/07/2011
Sample processed 19/07/2011
Total fixation time 1
RNA concentration 597.7
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio 2.11
AgeWhenSampleTaken 13.1
Diag
nosis
IsMalignant No. of litters
Age at spayBellarine Veterinary Practice
Labrador retriever3 Gundog 2
0
Diagnosis
Unavailable
404
Case ID Clinic Dog's name Date of birth
10P109 Nic 1/02/1998
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 6/05/2011
Euthanized?
Reason for euthanasia
Arthritis
Date euthanasia/death 1/05/2011
Survival (days calculated)
74
Sample taken 21/02/2011
Sample processed 23/02/2011
Total fixation time 2
RNA concentration 420.5
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio 2.06
AgeWhenSampleTaken 13.1
Diag
nosis
IsMalignant No. of litters
Age at spayColac Veterinary Clinic
Australian Cattle do5 Working Dogs 0
0
Diagnosis
Unavailable
405
Case ID Clinic  Dog's name Date of birth
10P11 QT 6/09/2000 10
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/12/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
131
Sample taken 23/07/2010
Sample processed 15/11/2010
Total fixation time 115
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.9
Diag
nosis
IsMalignant No. of litters
Age at spayMain Street Vet Clinic
Labrador X8 (Cross) Unknown
14
Diagnosis
No Tumor
406
Case ID Clinic  Dog's name Date of birth
10P110 Molly 2/09/2001
Recurrent CMT after sample
Further details recurrence
No recurrence
Last known date alive 1/12/2013
Euthanized?
Reason for euthanasia
Unknown
Date euthanasia/death 1/12/2013
Survival (days calculated)
979
Sample taken 28/03/2011
Sample processed 20/07/2011
Total fixation time 114
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.6
Diag
nosis
IsMalignant No. of litters
Age at spayYarrambat Veterinary Hospit
Golden Retriever3 Gundog Unknown
9
Diagnosis
Adenocarcinoma
407
Case ID Clinic  Dog's name Date of birth
10P113 Essy 1/08/1999 10.75
Recurrent CMT after sample
Further details recurrence
No extra details given
Last known date alive 15/10/2012
Euthanized?
Reason for euthanasia
due to mammary tumour
Date euthanasia/death 15/10/2012
Survival (days calculated)
452
Sample taken 21/07/2011
Sample processed 2/08/2011
Total fixation time 12
RNA concentration 870.7
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio 2.11
AgeWhenSampleTaken 12
Diag
nosis
IsMalignant No. of litters
Age at spayColac Veterinary Clinic
Australian Cattle do5 Working Dogs 1
6
Diagnosis
Adenocarcinoma
408
Case ID Clinic  Dog's name Date of birth
10P114 Melody 9/08/1998
Recurrent CMT after sample
Further details recurrence
Last known date alive 2/01/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
562
Sample taken 20/06/2011
Sample processed 22/08/2011
Total fixation time 63
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.9
Diag
nosis
IsMalignant No. of litters
Age at spayHobart Animal Hospital
Chihuahua1 Toy 2
6
Diagnosis
Adenoma
409
Case ID Clinic  Dog's name Date of birth
10P116 Angel 22/03/2002 7
Recurrent CMT after sample
Further details recurrence
Mets 3/8/11 Lung
Last known date alive 4/02/2012
Euthanized?
Reason for euthanasia
Chest X-ray 3/8/11 showed possible mets, 
enlarged LNs at least 3 large opaque 
masses around hilar region and other 
opaque areas strongly suggest mets
Struggling to breathe, had strange 
episode, euthanized
Date euthanasia/death 4/02/2012
Survival (days calculated)
212
Sample taken 7/07/2011
Sample processed 22/08/2011
Total fixation time 46
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.3
Diag
nosis
IsMalignant No. of litters
Age at spayHigh St. Vet Clinic Kew
American Staffords2 Terrier 2
8
Diagnosis
Simple Carcinoma
410
Case ID Clinic  Dog's name Date of birth
10P117 Ashka 14/10/1997 -1
Recurrent CMT after sample
Further details recurrence
September 2011 - 2 mammary lumps 
removed histopathology results were an 
Adenoma, Low Grade Adenocarcinoma 
not fully excised had low mitotic index. 
Owners decided not to further excise
Last known date alive 21/02/2013
Euthanized?
Reason for euthanasia
Passed away at home during the night
Date euthanasia/death 21/02/2013
Survival (days calculated)
597
Sample taken 5/07/2011
Sample processed 22/08/2011
Total fixation time 48
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.7
Diag
nosis
IsMalignant No. of litters
Age at spayGreencross Morwell
German Shepherd5 Working Dogs 1
3
Diagnosis
Adenocarcinoma
411
Case ID Clinic  Dog's name Date of birth
10P118 Skye 17/10/2002 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/05/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1031
Sample taken 5/07/2011
Sample processed 22/08/2011
Total fixation time 48
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.7
Diag
nosis
IsMalignant No. of litters
Age at spayEltham Central Veterinary Ho
Weimaraner3 Gundog Unknown
5
Diagnosis
Cyst adenoma
412
Case ID Clinic  Dog's name Date of birth
10P119 Rosie 1/01/2004 6
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/04/2012
Euthanized?
Reason for euthanasia
Due to mammary cancer. Had been on 
chemo and having seizures
Date euthanasia/death 1/04/2012
Survival (days calculated)
258
Sample taken 18/07/2011
Sample processed 22/08/2011
Total fixation time 35
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.5
Diag
nosis
IsMalignant No. of litters
Age at spayEltham Central Veterinary Ho
German Pointer3 Gundog 0
6
Diagnosis
Adenocarcinoma
413
Case ID Clinic  Dog's name Date of birth
10P12 Sadie 2/10/2001 8.75
Recurrent CMT after sample
Further details recurrence
15/10/11 - suspected new mammary 
lump or rightLast known date alive 12/11/2011
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
479
Sample taken 21/07/2010
Sample processed 13/10/2010
Total fixation time 84
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.8
Diag
nosis
IsMalignant No. of litters
Age at spayMain Street Vet Clinic
Border Collie5 Working Dogs 1
15
Diagnosis
Benign Mixed Tumor
414
Case ID Clinic  Dog's name Date of birth
10P120 Tia 1/01/2002 9
Recurrent CMT after sample
Further details recurrence
Last known date alive 4/10/2011
Euthanized?
Reason for euthanasia
Due to mammary tumour
Date euthanasia/death 4/10/2011
Survival (days calculated)
96
Sample taken 30/06/2011
Sample processed 23/08/2011
Total fixation time 54
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.5
Diag
nosis
IsMalignant No. of litters
Age at spayBayswater Veterinary Clinic
Chihuahua1 Toy 0
9
Diagnosis
Simple Carcinoma
415
Case ID Clinic  Dog's name Date of birth
10P121 Cougar
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/02/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
225
Sample taken 21/06/2011
Sample processed 23/08/2011
Total fixation time 63
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken
Diag
nosis
IsMalignant No. of litters
Age at spayBayswater Veterinary Clinic
Samoyed Husky X8 (Cross) Unknown
8
Diagnosis
Complex adenoma
416
Case ID Clinic  Dog's name Date of birth
10P122 Gypsy
Recurrent CMT after sample
Further details recurrence
Last known date alive 29/07/2011
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
29
Sample taken 30/06/2011
Sample processed 23/08/2011
Total fixation time 54
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken
Diag
nosis
IsMalignant No. of litters
Age at spayWandin Veterinary Hospital
Bull Arab8 (Cross) 0
9
Diagnosis
Ductal cyst Adenocarcinom
417
Case ID Clinic  Dog's name Date of birth
10P123 Milly 10/08/2005 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive 10/09/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1077
Sample taken 29/09/2011
Sample processed 25/10/2011
Total fixation time 26
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 6.1
Diag
nosis
IsMalignant No. of litters
Age at spayMain Ridge Veterinary Clinic
Staffordshire Bull Te2 Terrier Unknown
3
Diagnosis
Adenoma
418
Case ID Clinic  Dog's name Date of birth
10P125 Angel 1/01/2001 10
Recurrent CMT after sample
Further details recurrence
Last known date alive 31/08/2011
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
21
Sample taken 10/08/2011
Sample processed 25/10/2011
Total fixation time 76
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.6
Diag
nosis
IsMalignant No. of litters
Age at spayBannockburn Veterinary Clini
Fox Terrier X8 (Cross) Unknown
9
Diagnosis
Benign Mixed Tumor
419
Case ID Clinic  Dog's name Date of birth
10P126 Maddison 1/01/2007 2.5
Recurrent CMT after sample
Further details recurrence
Last known date alive 2/01/2014
Euthanized?
Reason for euthanasia
Attacked another dog/aggression
Date euthanasia/death 2/01/2014
Survival (days calculated)
885
Sample taken 1/08/2011
Sample processed 25/10/2011
Total fixation time 85
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 4.6
Diag
nosis
IsMalignant No. of litters
Age at spayFountain Gate Veterinary Cli
Staffordshire Bull Te2 Terrier Unknown
3
Diagnosis
Benign Mixed Tumor
420
Case ID Clinic  Dog's name Date of birth
10P128 Lucy 20/01/2006
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 1/09/2013
Euthanized?
Reason for euthanasia
No reason given
Date euthanasia/death 1/09/2013
Survival (days calculated)
754
Sample taken 9/08/2011
Sample processed 25/10/2011
Total fixation time 77
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 5.6
Diag
nosis
IsMalignant No. of litters
Age at spayTarwin Vet Group
Beagle4 Hounds 0
7
Diagnosis
Ductal adenoma
421
Case ID Clinic  Dog's name Date of birth
10P129 Zena 4/09/2002
Recurrent CMT after sample
Further details recurrence
17/10/11- new mass present
Note pathology of originial sample 
indicates lymphatic invasion and local 
lymph node metastsis
Last known date alive 17/10/2011
Euthanized?
Reason for euthanasia
Due to recurrence of mammary mass
Date euthanasia/death 17/10/2011
Survival (days calculated)
34
Sample taken 13/09/2011
Sample processed 25/10/2011
Total fixation time 42
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9
Diag
nosis
IsMalignant No. of litters
Age at spayBoronia Veterinary Clinic
Boxer6 Utility Unknown
8
Diagnosis
Adenocarcinoma
422
Case ID Clinic  Dog's name Date of birth
10P13 Heidi 1/01/1999 12
Recurrent CMT after sample
Further details recurrence
No but there were other lumps
We also have uterus and ovaries of this 
dog
Last known date alive 18/09/2014
Euthanized?
Reason for euthanasia
Old age
Date euthanasia/death 18/09/2014
Survival (days calculated)
1458
Sample taken 21/09/2010
Sample processed 23/09/2010
Total fixation time 2
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.7
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
German Pointer3 Gundog Unknown
0
Diagnosis
Adenoma
423
Case ID Clinic  Dog's name Date of birth
10P130 Chloe 1/01/2000
Recurrent CMT after sample
Further details recurrence
Note pathology report indicates 
metastases in lymphatics - poor prognosis.Last known date alive 28/11/2011
Euthanized?
Reason for euthanasia
Sudden deterioration so euthanaised
Date euthanasia/death 28/11/2011
Survival (days calculated)
87
Sample taken 2/09/2011
Sample processed 25/10/2011
Total fixation time 53
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.7
Diag
nosis
IsMalignant No. of litters
Age at spayEast St. Albans Veterinary Cli
Maltese Shih Tzu X8 (Cross) Unknown
6
Diagnosis
Adenocarcinoma
424
Case ID Clinic  Dog's name Date of birth
10P131 Lily 28/08/2000 10
Recurrent CMT after sample
Further details recurrence
Last known date alive 28/10/2011
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
31
Sample taken 27/09/2011
Sample processed 25/10/2011
Total fixation time 28
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.1
Diag
nosis
IsMalignant No. of litters
Age at spayMont Albert Veterinary Surg
Rhodesian rdigebac4 Hounds 0
9
Diagnosis
Adenocarcinoma
425
Case ID Clinic  Dog's name Date of birth
10P133 Daisy 3/12/1999 12
Recurrent CMT after sample
Further details recurrence
Last known date alive 23/06/2014
Euthanized?
Reason for euthanasia
Old age
Date euthanasia/death 23/06/2014
Survival (days calculated)
1056
Sample taken 2/08/2011
Sample processed 25/10/2011
Total fixation time 84
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.7
Diag
nosis
IsMalignant No. of litters
Age at spayBoronia Veterinary Clinic
Dalmatian7 Non-Sporting Unknown
6
Diagnosis
Adenoma
426
Case ID Clinic  Dog's name Date of birth
10P135 Irma 19/09/1998 7
Recurrent CMT after sample
Further details recurrence
Last known date alive 22/02/2012
Euthanized?
Reason for euthanasia
No further reason provided
Date euthanasia/death 22/02/2012
Survival (days calculated)
138
Sample taken 7/10/2011
Sample processed 9/11/2011
Total fixation time 33
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.1
Diag
nosis
IsMalignant No. of litters
Age at spayJohn the Vet
Rottweiler X8 (Cross) Unknown
9
Diagnosis
Adenocarcinoma
427
Case ID Clinic  Dog's name Date of birth
10P137 Dorrie 30/11/2001 10
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/03/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
884
Sample taken 29/09/2011
Sample processed 9/11/2011
Total fixation time 41
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.8
Diag
nosis
IsMalignant No. of litters
Age at spayGreencross Morwell
Maltese X8 (Cross) 0
6
Diagnosis
Benign Mixed Tumor
428
Case ID Clinic Dog's name Date of birth
10P14 Sanou 11/07/2003 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 12/08/2009
Sample processed 16/11/2010
Total fixation time 461
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 6.1
Diag
nosis
IsMalignant No. of litters
Age at spayKangaroo Flat Veterinary Clin
Rhodesian rdigebac4 Hounds Unknown
5
Diagnosis
Adenoma
429
Case ID Clinic  Dog's name Date of birth
10P144 Danni 1/06/1999
Recurrent CMT after sample
Further details recurrence
Last known date alive 28/05/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
179
Sample taken 1/12/2011
Sample processed 30/01/2012
Total fixation time 60
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.5
Diag
nosis
IsMalignant No. of litters
Age at spayBundoora Veterinary Clinic
Border Collie5 Working Dogs Unknown
2
Diagnosis
Complex adenoma
430
Case ID Clinic Dog's name Date of birth
10P146 Molly 13/11/2000 -1
Recurrent CMT after sample
Further details recurrence
27/6/2012 - Suspected mammary, new 
mass removed but no pathology doneLast known date alive 12/07/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
210
Sample taken 15/12/2011
Sample processed
Total fixation time
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.1
Diag
nosis
IsMalignant No. of litters
Age at spaySouth Paws
Schnauzer6 Utility Unknown
Unknown
Diagnosis
Adenocarcinoma
431
Case ID Clinic Dog's name Date of birth
10P147 Mina 1/02/1997 10
Recurrent CMT after sample
Further details recurrence
Mets shown on X-ray November 2013 not 
removed
Note: Chest X-rays were clear in 
December 2011 and November 2012 and 
normal blood results
Last known date alive 20/11/2013
Euthanized?
Reason for euthanasia
Due to metastasis, renal failure
Dog had multiple mets in lung shown on X-
ray
Date euthanasia/death
Survival (days calculated)
699
Sample taken 22/12/2011
Sample processed 30/01/2012
Total fixation time 39
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 14.9
Diag
nosis
IsMalignant No. of litters
Age at spayGreensborough Vet Hospital 
Jack Russell Terrier2 Terrier 0
8
Diagnosis
Malignant Mixed Mammar
432
Case ID Clinic Dog's name Date of birth
10P148 Charlotte 6/08/2000 6
Recurrent CMT after sample
Further details recurrence
Last known date alive 11/01/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
371
Sample taken 6/01/2012
Sample processed 10/01/2012
Total fixation time 4
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.4
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
Labrador X8 (Cross) Unknown
0
Diagnosis
Benign Mixed Tumor
433
Case ID Clinic  Dog's name Date of birth
10P149 Roxy 4/01/2004
Recurrent CMT after sample
Further details recurrence
No, not seen since surgery
Last known date alive 6/01/2011
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
0
Sample taken 6/01/2011
Sample processed 24/02/2011
Total fixation time 49
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7
Diag
nosis
IsMalignant No. of litters
Age at spayShepparton Veterinary Clinic
Curly Coated Retrie3 Gundog 0
6
Diagnosis
Adenoma
434
Case ID Clinic Dog's name Date of birth
10P150 Sasha 27/07/2003 6
Recurrent CMT after sample
Further details recurrence
Last known date alive 9/11/2011
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
2
Sample taken 7/11/2011
Sample processed 30/01/2012
Total fixation time 84
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.3
Diag
nosis
IsMalignant No. of litters
Age at spayWarby Street Veterinary Hos
Schnauzer X8 (Cross) Unknown
9
Diagnosis
Mixed adenoma
435
Case ID Clinic  Dog's name Date of birth
10P155 Coco 1/01/2002
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/01/2012
Euthanized?
Reason for euthanasia
Passed away from the mammary lump in 
2012 vet does not have any extra details
Date euthanasia/death 1/01/2012
Survival (days calculated)
409
Sample taken 18/11/2010
Sample processed 24/01/2011
Total fixation time 67
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.9
Diag
nosis
IsMalignant No. of litters
Age at spayFarrier Vet
Staffordshire Bull Te8 (Cross) Unknown
10
Diagnosis
Tubulopapillary adenocarci
436
Case ID Clinic  Dog's name Date of birth
10P156 Millie 9/08/1999 12.75
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 28/10/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
656
Sample taken 11/01/2012
Sample processed 24/01/2012
Total fixation time 13
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.4
Diag
nosis
IsMalignant No. of litters
Age at spayJohn the Vet
Chihuahua X8 (Cross) Unknown
7
Diagnosis
Complex adenoma
437
Case ID Clinic  Dog's name Date of birth
10P158 Mysti 1/01/1999 7
Recurrent CMT after sample
Further details recurrence
Last known date alive 21/01/2012
Euthanized?
Reason for euthanasia
Dog is known to have died but vets have 
no date for when this happened
Date euthanasia/death
Survival (days calculated)
46
Sample taken 6/12/2011
Sample processed 24/01/2012
Total fixation time 49
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.9
Diag
nosis
IsMalignant No. of litters
Age at spayEast Malvern Veterinary clini
Keeshond7 Non-Sporting 1
7
Diagnosis
Simple Carcinoma
438
Case ID Clinic  Dog's name Date of birth
10P159 Angel 17/11/2004
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 17/11/2011
Sample processed 24/01/2012
Total fixation time 68
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7
Diag
nosis
IsMalignant No. of litters
Age at spayKangaroo Flat Veterinary Clin
Pomeranian1 Toy Unknown
6
Diagnosis
Mixed adenoma
439
Case ID Clinic  Dog's name Date of birth
10P16 Mollie 1/01/1995
Recurrent CMT after sample
Further details recurrence
Last known date alive 7/06/2013
Euthanized?
Reason for euthanasia
Deceased - just old age
Date euthanasia/death 7/06/2013
Survival (days calculated)
1040
Sample taken 2/08/2010
Sample processed 17/10/2010
Total fixation time 76
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 15.6
Diag
nosis
IsMalignant No. of litters
Age at spayBrimbank Veterinary Clinic
Chihuahua X8 (Cross) 0
6
Diagnosis
Mixed adenoma
440
Case ID Clinic  Dog's name Date of birth
10P160 Roxy 1/05/2004 7
Recurrent CMT after sample
Further details recurrence
No mammary but has had melanocytoma 
17/7/14 and a splenic fibrohistiocytic 
mass grade 2 23/6/14
Last known date alive 26/08/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1026
Sample taken 4/11/2011
Sample processed 24/01/2012
Total fixation time 81
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.5
Diag
nosis
IsMalignant No. of litters
Age at spayTorquay Animal House
Maltese1 Toy Unknown
9
Diagnosis
Adenoma
441
Case ID Clinic  Dog's name Date of birth
10P161 Dixie 8/02/2004 7.6
Recurrent CMT after sample
Further details recurrence
Last known date alive 11/11/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1063
Sample taken 14/12/2011
Sample processed 24/01/2012
Total fixation time 41
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.9
Diag
nosis
IsMalignant No. of litters
Age at spaySeaford Veterinary Clinic
Maltese X8 (Cross) Unknown
4
Diagnosis
Complex adenoma
442
Case ID Clinic  Dog's name Date of birth
10P162 Tiny 1/01/2002 10
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/01/2014
Euthanized?
Reason for euthanasia
Passed away at home early 2014 no exact 
date vet contacted owners for me.
Date euthanasia/death
Survival (days calculated)
713
Sample taken 19/01/2012
Sample processed 30/01/2012
Total fixation time 11
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.1
Diag
nosis
IsMalignant No. of litters
Age at spayEaglehawk Rd. Veterinary Cli
Fox Terrier Wiry2 Terrier Unknown
5
Diagnosis
Solid Carcinoma
443
Case ID Clinic  Dog's name Date of birth
10P164 Honey 1/01/1999
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 16/11/2011
Sample processed 30/01/2012
Total fixation time 75
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.9
Diag
nosis
IsMalignant No. of litters
Age at spayACE laboratory services
Kelpie5 Working Dogs Unknown
9
Diagnosis
Complex Carcinoma
444
Case ID Clinic  Dog's name Date of birth
10P165 Meg 7/01/2000 11.4
Recurrent CMT after sample
Further details recurrence
30/9/2013 - Right caudal lobulated mass 
notices, monitored but not removedLast known date alive 3/05/2014
Euthanized?
Reason for euthanasia
Suspected heart failure
Date euthanasia/death 3/05/2014
Survival (days calculated)
906
Sample taken 9/11/2011
Sample processed 30/01/2012
Total fixation time 82
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.8
Diag
nosis
IsMalignant No. of litters
Age at spaySouth Cranbourne Veterinary
Labrador retriever3 Gundog Unknown
6
Diagnosis
Complex adenoma
445
Case ID Clinic  Dog's name Date of birth
10P166 Jasmine 24/12/2002 8.9
Recurrent CMT after sample
Further details recurrence
Last known date alive 24/01/2012
Euthanized?
Reason for euthanasia
in pain
Date euthanasia/death 24/01/2012
Survival (days calculated)
588
Sample taken 15/06/2010
Sample processed 31/01/2012
Total fixation time 595
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.5
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
Australian Cattle do5 Working Dogs Unknown
10
Diagnosis
Simple Carcinoma
446
Case ID Clinic  Dog's name Date of birth
10P167 Tigger 1/02/2003 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 2/12/2011
Sample processed 31/01/2012
Total fixation time 60
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.8
Diag
nosis
IsMalignant No. of litters
Age at spayEast Doncaster Veterinary Ho
Boxer X8 (Cross) Unknown
8
Diagnosis
Adenoma
447
Case ID Clinic  Dog's name Date of birth
10P169 Elle -1
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 7/04/2011
Sample processed 31/01/2012
Total fixation time 299
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken
Diag
nosis
IsMalignant No. of litters
Age at spayKangaroo Flat Veterinary Clin
Doberman6 Utility Unknown
6
Diagnosis
Ductal carcinoma
448
Case ID Clinic  Dog's name Date of birth
10P17 127982 1/06/2000 5
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/01/2014
Euthanized?
Reason for euthanasia
Old age
Date euthanasia/death 1/01/2014
Survival (days calculated)
1267
Sample taken 14/07/2010
Sample processed 15/11/2010
Total fixation time 124
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.1
Diag
nosis
IsMalignant No. of litters
Age at spayBoronia Veterinary Clinic
Bull Arab8 (Cross) 1
14
Diagnosis
Adenocarcinoma
449
Case ID Clinic  Dog's name Date of birth
10P171 Skye 1/01/2003
Recurrent CMT after sample
Further details recurrence
Last known date alive 20/01/2012
Euthanized?
Reason for euthanasia
No reason given
Date euthanasia/death 20/01/2012
Survival (days calculated)
0
Sample taken 20/01/2012
Sample processed 31/01/2012
Total fixation time 11
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.1
Diag
nosis
IsMalignant No. of litters
Age at spayAberdeen St. Veterinary Clini
Kelpie X8 (Cross) Unknown
0
Diagnosis
Unavailable
450
Case ID Clinic  Dog's name Date of birth
10P173 Kylie 2/02/2003 5
Recurrent CMT after sample
Further details recurrence
No - most recent visit (8/1/14) note 
mammary was okLast known date alive 8/01/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
706
Sample taken 2/02/2012
Sample processed 5/03/2012
Total fixation time 32
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9
Diag
nosis
IsMalignant No. of litters
Age at spayMontmorency Veterinary Cli
Jack Russell Terrier2 Terrier Unknown
5
Diagnosis
Adenoma
451
Case ID Clinic  Dog's name Date of birth
10P175 Amber 4/08/2004 6
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 15/10/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
693
Sample taken 22/11/2011
Sample processed 3/03/2012
Total fixation time 102
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.3
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
Shetland Sheepdog5 Working Dogs Unknown
8
Diagnosis
Unavailable
452
Case ID Clinic  Dog's name Date of birth
10P176 Zelda 29/07/2001
Recurrent CMT after sample
Further details recurrence
Last known date alive 14/01/2013
Euthanized?
Reason for euthanasia
no reason given
text hard to read in fax
Date euthanasia/death 14/01/2013
Survival (days calculated)
502
Sample taken 31/08/2011
Sample processed 5/03/2012
Total fixation time 187
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.1
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
Beagle4 Hounds Unknown
12
Diagnosis
Benign Mixed Tumor
453
Case ID Clinic  Dog's name Date of birth
10P177 Abbie 15/08/1998 9
Recurrent CMT after sample
Further details recurrence
Vet has lost contact with animal
Last known date alive 20/08/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
171
Sample taken 2/03/2012
Sample processed 13/03/2012
Total fixation time 11
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.6
Diag
nosis
IsMalignant No. of litters
Age at spaySeymour Veterinary Surgery
Jack Russell Terrier2 Terrier Unknown
4
Diagnosis
Adenocarcinoma
454
Case ID Clinic  Dog's name Date of birth
10P178 Candy 1/01/2004
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 5/08/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
882
Sample taken 6/03/2012
Sample processed 13/03/2012
Total fixation time 7
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.2
Diag
nosis
IsMalignant No. of litters
Age at spayThe Vet Practice (Whittlesea 
Pomeranian X8 (Cross) Unknown
2
Diagnosis
Intraductal adenoma
455
Case ID Clinic  Dog's name Date of birth
10P179 Cadbury
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 16/01/2012
Sample processed 13/03/2012
Total fixation time 57
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken
Diag
nosis
IsMalignant No. of litters
Age at spayFrankston Heights Veterinari
Curly Coated Retrie3 Gundog Unknown
7
Diagnosis
Complex adenoma
456
Case ID Clinic  Dog's name Date of birth
10P18 Lexi 17/01/2002
Recurrent CMT after sample
Further details recurrence
Last known date alive 16/07/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
0
Sample taken 16/07/2010
Sample processed 17/10/2010
Total fixation time 93
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.5
Diag
nosis
IsMalignant No. of litters
Age at spayEast Doncaster Veterinary Ho
Pomeranian1 Toy Unknown
4
Diagnosis
Adenoma
457
Case ID Clinic  Dog's name Date of birth
10P180 Shingy 24/12/1999 8
Recurrent CMT after sample
Further details recurrence
Last known date alive 31/08/2012
Euthanized?
Reason for euthanasia
Was on chemo, put down related to that
Date euthanasia/death 31/08/2012
Survival (days calculated)
232
Sample taken 12/01/2012
Sample processed 13/03/2012
Total fixation time 61
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.1
Diag
nosis
IsMalignant No. of litters
Age at spayPort Philip Animal Hospital
Jack Russell Terrier2 Terrier 1
9
Diagnosis
Adenocarcinoma
458
Case ID Clinic  Dog's name Date of birth
10P182 Tiny 14/01/2002 6
Recurrent CMT after sample
Further details recurrence
Last known date alive 9/05/2012
Euthanized?
Reason for euthanasia
No reason given in records
Date euthanasia/death 9/05/2012
Survival (days calculated)
149
Sample taken 12/12/2011
Sample processed 13/03/2012
Total fixation time 92
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.9
Diag
nosis
IsMalignant No. of litters
Age at spayWesternport Vet Group
Terrier X8 (Cross) 0
8
Diagnosis
Adenocarcinoma
459
Case ID Clinic  Dog's name Date of birth
10P183 Inca 1/08/2000
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 9/01/2012
Sample processed 13/03/2012
Total fixation time 64
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.4
Diag
nosis
IsMalignant No. of litters
Age at spayFrankston Heights Veterinari
Rottweiler6 Utility Unknown
6
Diagnosis
Complex adenoma
460
Case ID Clinic  Dog's name Date of birth
10P186 Lucy 12/04/2003
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 23/03/2013
Euthanized?
Reason for euthanasia
Euthanaised due to pyometra at Geelong 
emergency vet clinic
Date euthanasia/death 23/03/2013
Survival (days calculated)
345
Sample taken 12/04/2012
Sample processed 2/05/2012
Total fixation time 20
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9
Diag
nosis
IsMalignant No. of litters
Age at spayGrovedale Veterinary Clinic
Papillon X8 (Cross) Unknown
3
Diagnosis
Mixed adenoma
461
Case ID Clinic  Dog's name Date of birth
10P187 Beckie 4/08/2006 5
Recurrent CMT after sample
Further details recurrence
Last known date alive 20/06/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
784
Sample taken 27/04/2012
Sample processed 2/05/2012
Total fixation time 5
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 5.7
Diag
nosis
IsMalignant No. of litters
Age at spayGreensborough Vet Hospital 
Border Collie5 Working Dogs 1
2
Diagnosis
Tubular Carcinoma
462
Case ID Clinic  Dog's name Date of birth
10P188 Bessie 1/09/1998
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 2/03/2012
Sample processed 2/05/2012
Total fixation time 61
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.5
Diag
nosis
IsMalignant No. of litters
Age at spayFrankston Heights Veterinari
Shih Tzu7 Non-Sporting Unknown
1
Diagnosis
Simple Carcinoma
463
Case ID Clinic  Dog's name Date of birth
10P189 Jessie 26/10/2003 8.3
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 1/08/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
528
Sample taken 20/02/2012
Sample processed 2/05/2012
Total fixation time 72
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.3
Diag
nosis
IsMalignant No. of litters
Age at spayMont Albert Veterinary Surg
Airedale terrier2 Terrier 0
8
Diagnosis
Benign Mixed Tumor
464
Case ID Clinic  Dog's name Date of birth
10P19 Csoki 13/07/2000 11
Recurrent CMT after sample
Further details recurrence
Mammary lumps removed from right 
cranial margin 12/4/2011.
More lumps removed around 20/5/14 by 
another veterinary clinic
Last known date alive 20/05/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1398
Sample taken 22/07/2010
Sample processed 17/10/2010
Total fixation time 87
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10
Diag
nosis
IsMalignant No. of litters
Age at spayGlenhuntly rd Vet Clinic
Poodle7 Non-Sporting Unknown
3
Diagnosis
Complex Carcinoma
465
Case ID Clinic  Dog's name Date of birth
10P190 Lady 1/04/2001
Recurrent CMT after sample
Further details recurrence
17/3/14 mammary lumps removed 
Lranial mass near last excision hard 
approximately 5mm the 2nd was a 
possible lipoma. No pathology done
Last known date alive 31/03/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
766
Sample taken 24/02/2012
Sample processed 2/05/2012
Total fixation time 68
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.9
Diag
nosis
IsMalignant No. of litters
Age at spayHorsham Veterinary Hospital
Fox Terrier Smooth2 Terrier Unknown
4
Diagnosis
Cribriform ductular carcino
466
Case ID Clinic  Dog's name Date of birth
10P191 Sunshine 1/01/2008 5
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 30/05/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
89
Sample taken 2/03/2012
Sample processed 2/05/2012
Total fixation time 61
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 4.2
Diag
nosis
IsMalignant No. of litters
Age at spayYarra Ranges Animal Hospital
Australian Cattle do5 Working Dogs 1
8
Diagnosis
Papillary Cystadenoma
467
Case ID Clinic  Dog's name Date of birth
10P193 Shera 16/02/2005 7
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 23/12/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
656
Sample taken 7/03/2012
Sample processed 2/05/2012
Total fixation time 56
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.1
Diag
nosis
IsMalignant No. of litters
Age at spayDandenong Veterinary Hospi
Kelpie X8 (Cross) Unknown
4
Diagnosis
Low Grade Adenocarcinom
468
Case ID Clinic  Dog's name Date of birth
10P194 Zoe 9/10/1999 8
Recurrent CMT after sample
Further details recurrence
Last known date alive 12/04/2012
Euthanized?
Reason for euthanasia
Due to mammary tumour
Date euthanasia/death
Survival (days calculated)
43
Sample taken 29/02/2012
Sample processed 2/05/2012
Total fixation time 63
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.4
Diag
nosis
IsMalignant No. of litters
Age at spayVermont Value Vet
Cocker Spaniel3 Gundog Unknown
10
Diagnosis
Adenocarcinoma
469
Case ID Clinic  Dog's name Date of birth
10P195 Princess 23/01/2001
Recurrent CMT after sample
Further details recurrence
Last known date alive 4/05/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
17
Sample taken 17/04/2012
Sample processed 19/04/2012
Total fixation time 2
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.2
Diag
nosis
IsMalignant No. of litters
Age at spayBundoora Veterinary Clinic
Jack Russell Terrier2 Terrier Unknown
0
Diagnosis
Adenoma
470
Case ID Clinic  Dog's name Date of birth
10P196 Buffy 1/01/2001
Recurrent CMT after sample
Further details recurrence
Last known date alive 26/11/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
944
Sample taken 26/04/2012
Sample processed 2/05/2012
Total fixation time 6
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.3
Diag
nosis
IsMalignant No. of litters
Age at spayBundoora Veterinary Clinic
Pomeranian1 Toy Unknown
0
Diagnosis
Cyst adenoma
471
Case ID Clinic  Dog's name Date of birth
10P198 Missy 1/02/2000
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 21/02/2012
Sample processed 2/05/2012
Total fixation time 71
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.1
Diag
nosis
IsMalignant No. of litters
Age at spayRowville Veterinary Clinic
Cocker Spaniel3 Gundog 0
0
Diagnosis
Unavailable
472
Case ID Clinic  Dog's name Date of birth
10P2 Pepi Pain-Davis 1/01/1996
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Known to be deceased but when is 
unknown has not been seen by the clinic 
since the mammary tumour removal
Date euthanasia/death
Survival (days calculated)
Sample taken 27/07/2010
Sample processed 20/09/2010
Total fixation time 55
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 14.6
Diag
nosis
IsMalignant No. of litters
Age at spayNorthcote Plaza Vet Clinic
Terrier X8 (Cross) Unknown
14
Diagnosis
Benign Mixed Tumor
473
Case ID Clinic  Dog's name Date of birth
10P20 Yoki 1/01/2000
Recurrent CMT after sample
Further details recurrence
Last known date alive 3/02/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1278
Sample taken 5/08/2010
Sample processed 17/10/2010
Total fixation time 73
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.6
Diag
nosis
IsMalignant No. of litters
Age at spayMalvern Central Vet Centre
Maltese X8 (Cross) 0
1
Diagnosis
Adenocarcinoma
474
Case ID Clinic  Dog's name Date of birth
10P200 Sade 28/05/2007
Recurrent CMT after sample
Further details recurrence
Last known date alive 11/10/2012
Euthanized?
Reason for euthanasia
Respiratory problems, x-ray suggested 
mets euthanized (note our diagnosis is not 
a tumour thoughy)
Date euthanasia/death 11/10/2012
Survival (days calculated)
135
Sample taken 29/05/2012
Sample processed 5/06/2012
Total fixation time 7
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 5
Diag
nosis
IsMalignant No. of litters
Age at spayTraralgon Veterinary Centre
Field Spaniel3 Gundog Unknown
5
Diagnosis
No Tumor
475
Case ID Clinic  Dog's name Date of birth
10P201 Gigi 1/01/2004 -1
Recurrent CMT after sample
Further details recurrence
Note: no tumour in our blocks
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 11/04/2012
Sample processed 5/06/2012
Total fixation time 55
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.3
Diag
nosis
IsMalignant No. of litters
Age at spayCarnegie Veterinary Clinic
Poodle7 Non-Sporting Unknown
5
Diagnosis
Adenocarcinoma
476
Case ID Clinic  Dog's name Date of birth
10P202 Pixie 5/01/1999 -1
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 5/02/2014
Euthanized?
Reason for euthanasia
Passed away at home
Date euthanasia/death 5/02/2014
Survival (days calculated)
658
Sample taken 18/04/2012
Sample processed 5/06/2012
Total fixation time 48
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.3
Diag
nosis
IsMalignant No. of litters
Age at spayCorio Veterinary Clinic
Pomeranian1 Toy Unknown
5
Diagnosis
Complex adenoma
477
Case ID Clinic  Dog's name Date of birth
10P203 Pebbles 1/09/1998
Recurrent CMT after sample
Further details recurrence
Last known date alive 12/06/2012
Euthanized?
Reason for euthanasia
Unknown - put down at southern animal 
emergency centre.
Date euthanasia/death
Survival (days calculated)
41
Sample taken 2/05/2012
Sample processed 5/06/2012
Total fixation time 34
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.7
Diag
nosis
IsMalignant No. of litters
Age at spayCentral Veterinary Hospital
Tibetan spaniel1 Toy 0
6
Diagnosis
Scirrhous Carcinoma
478
Case ID Clinic  Dog's name Date of birth
10P204 123261 8/05/1997
Recurrent CMT after sample
Further details recurrence
Last known date alive 20/06/2012
Euthanized?
Reason for euthanasia
Respiratory disease.
Mets in chest not found but also were not 
ruled out by vet.
Date euthanasia/death 20/06/2012
Survival (days calculated)
68
Sample taken 13/04/2012
Sample processed 5/06/2012
Total fixation time 53
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 14.9
Diag
nosis
IsMalignant No. of litters
Age at spayBoronia Veterinary Clinic
Cocker Spaniel3 Gundog 0
8
Diagnosis
Simple Carcinoma
479
Case ID Clinic  Dog's name Date of birth
10P206 Zara 11/10/1998
Recurrent CMT after sample
Further details recurrence
Last known date alive 31/07/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
13
Sample taken 18/07/2012
Sample processed 18/07/2012
Total fixation time 0
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.8
Diag
nosis
IsMalignant No. of litters
Age at spayBundoora Veterinary Clinic
Pomeranian X8 (Cross) Unknown
0
Diagnosis
'Other tumour type'
480
Case ID Clinic  Dog's name Date of birth
10P207 Chloe 1/01/2002 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 21/06/2012
Sample processed 19/07/2012
Total fixation time 28
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.5
Diag
nosis
IsMalignant No. of litters
Age at spayRingwood Veterinary Clinic
Shih Tzu7 Non-Sporting Unknown
4
Diagnosis
Adenocarcinoma
481
Case ID Clinic  Dog's name Date of birth
10P208 Chloe 1/01/2000 12
Recurrent CMT after sample
Further details recurrence
Last known date alive 9/07/2013
Euthanized?
Reason for euthanasia
Vet indicated dog had poor prognosis so 
owner chose to put down.
Date euthanasia/death 9/07/2013
Survival (days calculated)
405
Sample taken 30/05/2012
Sample processed 19/07/2012
Total fixation time 50
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.4
Diag
nosis
IsMalignant No. of litters
Age at spayEast Malvern Veterinary clini
Staffordshire Bull Te2 Terrier 1
5
Diagnosis
Complex adenoma
482
Case ID Clinic  Dog's name Date of birth
10P209 Belle 17/05/2005 -1
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 14/03/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
666
Sample taken 17/05/2012
Sample processed 19/07/2012
Total fixation time 63
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7
Diag
nosis
IsMalignant No. of litters
Age at spayMoe Veterinary Centre
British Bulldog7 Non-Sporting 0
9
Diagnosis
Mixed adenoma
483
Case ID Clinic  Dog's name Date of birth
10P21 Cody 11/10/2000 -1
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 9/12/2011
Euthanized?
Reason for euthanasia
Clinic unsure if euthanised but showing 
deceased in their system
Date euthanasia/death
Survival (days calculated)
514
Sample taken 13/07/2010
Sample processed 17/10/2010
Total fixation time 96
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.8
Diag
nosis
IsMalignant No. of litters
Age at spayDandenong Veterinary Hospi
Bull terrier2 Terrier Unknown
5
Diagnosis
Adenoma
484
Case ID Clinic  Dog's name Date of birth
10P210 Cindy 1/01/2002 -1
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 23/12/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
931
Sample taken 5/06/2012
Sample processed 19/07/2012
Total fixation time 44
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.4
Diag
nosis
IsMalignant No. of litters
Age at spayEast St. Albans Veterinary Cli
German Shepherd5 Working Dogs Unknown
4
Diagnosis
Benign Mixed Tumor
485
Case ID Clinic  Dog's name Date of birth
10P211 Charli 11/08/2005 7
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 7/08/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
76
Sample taken 23/05/2012
Sample processed 19/07/2012
Total fixation time 57
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 6.8
Diag
nosis
IsMalignant No. of litters
Age at spayDandenong Veterinary Hospi
Labrador retriever3 Gundog Unknown
6
Diagnosis
Adenoma
486
Case ID Clinic  Dog's name Date of birth
10P212 Keeley 18/05/2006 6
Recurrent CMT after sample
Further details recurrence
Last known date alive 4/06/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
12
Sample taken 23/05/2012
Sample processed 19/07/2012
Total fixation time 57
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 6
Diag
nosis
IsMalignant No. of litters
Age at spaySouth Cranbourne Veterinary
Jack Russell Terrier 8 (Cross) Unknown
9
Diagnosis
Cyst adenoma
487
Case ID Clinic  Dog's name Date of birth
10P213 Emily 1/06/2004
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 19/06/2012
Sample processed 19/07/2012
Total fixation time 30
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.1
Diag
nosis
IsMalignant No. of litters
Age at spayStawell Veterinary Clinic
Fox Terrier Smooth2 Terrier Unknown
4
Diagnosis
Benign Mixed Tumor
488
Case ID Clinic  Dog's name Date of birth
10P214 Kelly 1/06/2003
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 6/06/2012
Sample processed 19/07/2012
Total fixation time 43
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9
Diag
nosis
IsMalignant No. of litters
Age at spayStawell Veterinary Clinic
Kelpie5 Working Dogs Unknown
7
Diagnosis
Adenoma
489
Case ID Clinic  Dog's name Date of birth
10P215 Boo 28/02/2003
Recurrent CMT after sample
Further details recurrence
11/4/2013 - suspect mammary went to 
ASAP for diagnosisLast known date alive 3/03/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
662
Sample taken 10/05/2012
Sample processed 19/07/2012
Total fixation time 70
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.2
Diag
nosis
IsMalignant No. of litters
Age at spayPet Emergency and Specialist
Cocker Spaniel3 Gundog 0
6
Diagnosis
Low Grade Adenocarcinom
490
Case ID Clinic  Dog's name Date of birth
10P216 Coco 1/12/2000
Recurrent CMT after sample
Further details recurrence
Possible lung mets
Last known date alive 1/05/2014
Euthanized?
Reason for euthanasia
euthanaised for lung tumours, possibly 
metastases
Date euthanasia/death 1/05/2014
Survival (days calculated)
682
Sample taken 18/06/2012
Sample processed 19/07/2012
Total fixation time 31
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.6
Diag
nosis
IsMalignant No. of litters
Age at spayEast St. Albans Veterinary Cli
Bull terrier2 Terrier 0
7
Diagnosis
Low Grade Carcinoma
491
Case ID Clinic  Dog's name Date of birth
10P218 Pippa 21/04/2000 12
Recurrent CMT after sample
Further details recurrence
Last known date alive 7/07/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
15
Sample taken 22/06/2012
Sample processed 19/11/2012
Total fixation time 150
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.2
Diag
nosis
IsMalignant No. of litters
Age at spayVermont Value Vet
Dalmatian7 Non-Sporting Unknown
6
Diagnosis
Ductal adenoma
492
Case ID Clinic  Dog's name Date of birth
10P219 Nina 1/07/2003 9
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 26/06/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
674
Sample taken 21/08/2012
Sample processed 19/11/2012
Total fixation time 90
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.1
Diag
nosis
IsMalignant No. of litters
Age at spayMont Albert Veterinary Surg
Golden Retriever3 Gundog 0
8
Diagnosis
Adenoma
493
Case ID Clinic  Dog's name Date of birth
10P22 Hayley 1/06/2004
Recurrent CMT after sample
Further details recurrence
Yes - no further details given
We have 2 sets of samples those take 
24/8/10 (10P22) Adenoma and those 
taken 16/10/12 (10P241) Complex 
Adenoma
Last known date alive 23/12/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1582
Sample taken 24/08/2010
Sample processed 17/10/2010
Total fixation time 54
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 6.2
Diag
nosis
IsMalignant No. of litters
Age at spayEast St. Albans Veterinary Cli
Doberman6 Utility 1
15
Diagnosis
Adenoma
494
Case ID Clinic  Dog's name Date of birth
10P220 Whoopee 20/08/2007
Recurrent CMT after sample
Further details recurrence
Last known date alive 8/10/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
11
Sample taken 27/09/2012
Sample processed 19/11/2012
Total fixation time 53
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 5.1
Diag
nosis
IsMalignant No. of litters
Age at spayPort Philip Animal Hospital
Labrador retriever3 Gundog Unknown
5
Diagnosis
Mixed Cystadenoma
495
Case ID Clinic  Dog's name Date of birth
10P221 Lexus 13/09/2002 5
Recurrent CMT after sample
Further details recurrence
Last known date alive 9/01/2014
Euthanized?
Reason for euthanasia
Upper airway disease
No mention of mammary tumours
Date euthanasia/death 9/01/2014
Survival (days calculated)
505
Sample taken 22/08/2012
Sample processed 19/11/2012
Total fixation time 89
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.9
Diag
nosis
IsMalignant No. of litters
Age at spayDandenong Ranges Veterinar
British Bulldog7 Non-Sporting Unknown
2
Diagnosis
Benign Mixed Tumor
496
Case ID Clinic  Dog's name Date of birth
10P222 Brandy 1/01/2001 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive 23/10/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
12
Sample taken 11/10/2012
Sample processed 19/11/2012
Total fixation time 39
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.8
Diag
nosis
IsMalignant No. of litters
Age at spayAvodale Heights Vet
Jack Russell Terrier2 Terrier Unknown
4
Diagnosis
Benign Mixed Tumor
497
Case ID Clinic  Dog's name Date of birth
10P224 Pepper 1/01/2001 12
Recurrent CMT after sample
Further details recurrence
No
Note this sample has 4 different benign 
histological mammary tumours present
Last known date alive 23/12/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
886
Sample taken 20/07/2012
Sample processed 19/11/2012
Total fixation time 122
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.6
Diag
nosis
IsMalignant No. of litters
Age at spayEast St. Albans Veterinary Cli
Cocker Spaniel3 Gundog 0
7
Diagnosis
Benign Mixed Tumor
498
Case ID Clinic  Dog's name Date of birth
10P225 Coffee 13/02/2007 -1
Recurrent CMT after sample
Further details recurrence
No
Note sample is an ossifying BMT
Last known date alive 9/10/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
376
Sample taken 28/09/2012
Sample processed 19/11/2012
Total fixation time 52
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 5.6
Diag
nosis
IsMalignant No. of litters
Age at spayHeidleberg Veterinary Clinic
Labrador retriever3 Gundog Unknown
6
Diagnosis
Benign Mixed Tumor
499
Case ID Clinic  Dog's name Date of birth
10P226 Tara 15/12/2000 11.5
Recurrent CMT after sample
Further details recurrence
Note pot 2 is the adenoma
Pot 3,4 is hyperplasia/ectasiaLast known date alive 1/01/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
161
Sample taken 24/07/2012
Sample processed 11/12/2012
Total fixation time 140
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.6
Diag
nosis
IsMalignant No. of litters
Age at spayFerntree Gully Veterinary Ho
American Staffords2 Terrier Unknown
6
Diagnosis
Adenoma
500
Case ID Clinic  Dog's name Date of birth
10P227 Pee 3/08/2005
Recurrent CMT after sample
Further details recurrence
Yes - no further details given
Last known date alive 28/11/2014
Euthanized?
Reason for euthanasia
Due to mammary lumps
Date euthanasia/death 28/11/2014
Survival (days calculated)
752
Sample taken 6/11/2012
Sample processed 11/12/2012
Total fixation time 35
RNA concentration not run yet
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.3
Diag
nosis
IsMalignant No. of litters
Age at spayColac Veterinary Clinic
Shih Tzu7 Non-Sporting 0
4
Diagnosis
Mixed adenoma
501
Case ID Clinic  Dog's name Date of birth
10P228 Twiggy 9/11/2002
Recurrent CMT after sample
Further details recurrence
Not seen since initial surgery
Last known date alive 13/09/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
0
Sample taken 13/09/2012
Sample processed 11/12/2012
Total fixation time 89
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.9
Diag
nosis
IsMalignant No. of litters
Age at spaySeymour Veterinary Surgery
Kelpie5 Working Dogs Unknown
6
Diagnosis
Tubular Carcinoma
502
Case ID Clinic  Dog's name Date of birth
10P229 Bonnie Blue 25/06/2000
Recurrent CMT after sample
Further details recurrence
Last known date alive 23/01/2014
Euthanized?
Reason for euthanasia
Fitting, mets present in abdomen
Date euthanasia/death 23/01/2014
Survival (days calculated)
468
Sample taken 12/10/2012
Sample processed 11/12/2012
Total fixation time 60
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.3
Diag
nosis
IsMalignant No. of litters
Age at spayBenalla Veterinary Clinic
Border Collie5 Working Dogs 0
2
Diagnosis
Solid Carcinoma
503
Case ID Clinic  Dog's name Date of birth
10P230 Sally 12/03/2003 9
Recurrent CMT after sample
Further details recurrence
Note the pathology report of this 2012 
sample indicates multiple benign 
mammary tumours
22/11/2013 Mammary lumps removed 
but no histo done
Last known date alive 6/12/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
420
Sample taken 12/10/2012
Sample processed 11/12/2012
Total fixation time 60
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.6
Diag
nosis
IsMalignant No. of litters
Age at spayEast West Veterinary Clinic
Dachshund4 Hounds Unknown
7
Diagnosis
Unavailable
504
Case ID Clinic  Dog's name Date of birth
10P231 Yidiz 1/03/2004 8.6
Recurrent CMT after sample
Further details recurrence
Last known date alive 26/10/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
351
Sample taken 9/11/2012
Sample processed 11/12/2012
Total fixation time 32
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.7
Diag
nosis
IsMalignant No. of litters
Age at spayBrimbank Veterinary Clinic
German Pointer3 Gundog 0
10
Diagnosis
Adenoma
505
Case ID Clinic  Dog's name Date of birth
10P232 Fendi 1/03/2001 11.5
Recurrent CMT after sample
Further details recurrence
Last known date alive 8/12/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
821
Sample taken 8/09/2012
Sample processed 11/12/2012
Total fixation time 94
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.5
Diag
nosis
IsMalignant No. of litters
Age at spayGreencross Vets Sandringha
Labrador retriever3 Gundog 0
6
Diagnosis
Benign Mixed Tumor
506
Case ID Clinic  Dog's name Date of birth
10P234 Tiffie 3/02/2003
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 1/08/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
349
Sample taken 17/08/2012
Sample processed 10/01/2013
Total fixation time 146
RNA concentration not yet run
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.5
Diag
nosis
IsMalignant No. of litters
Age at spayColac Veterinary Clinic
Kelpie X8 (Cross) Unknown
2
Diagnosis
Adenocarcinoma
507
Case ID Clinic  Dog's name Date of birth
10P237 Holly 28/05/2003 2
Recurrent CMT after sample
Further details recurrence
Last known date alive 12/12/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
198
Sample taken 28/05/2012
Sample processed 30/05/2012
Total fixation time 2
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
Australian Cattle do5 Working Dogs Unknown
0
Diagnosis
Unavailable
508
Case ID Clinic  Dog's name Date of birth
10P239 Catherine 19/02/1999
Recurrent CMT after sample
Further details recurrence
Dog had many tumours
Last known date alive 16/12/2013
Euthanized?
Reason for euthanasia
mammary tumours- had large ulcerated 
mass under right axilla (necrotic)
Date euthanasia/death 16/12/2013
Survival (days calculated)
425
Sample taken 17/10/2012
Sample processed 10/01/2013
Total fixation time 85
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.7
Diag
nosis
IsMalignant No. of litters
Age at spayBurke Rd. Veterinary Clinic
Poodle7 Non-Sporting 1
6
Diagnosis
Adenocarcinoma
509
Case ID Clinic  Dog's name Date of birth
10P24 Pepper 6/03/1997 4
Recurrent CMT after sample
Further details recurrence
Last known date alive 7/01/2012
Euthanized?
Reason for euthanasia
reason other than mammary tumour
Date euthanasia/death 7/01/2012
Survival (days calculated)
500
Sample taken 25/08/2010
Sample processed 17/10/2010
Total fixation time 53
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.5
Diag
nosis
IsMalignant No. of litters
Age at spayNewtown Veterinary Clinic
German Shepherd5 Working Dogs Unknown
6
Diagnosis
Scirrhous Adenocarcinoma
510
Case ID Clinic  Dog's name Date of birth
10P242 Sooty 1/01/2003
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 10/01/2013
Sample processed 17/01/2013
Total fixation time 7
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10
Diag
nosis
IsMalignant No. of litters
Age at spayWestern Districts Veterinary 
Kelpie X8 (Cross) 0
10
Diagnosis
Complex Carcinoma
511
Case ID Clinic  Dog's name Date of birth
10P243 Bailey 1/01/2004
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 11/01/2013
Sample processed 17/01/2013
Total fixation time 6
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9
Diag
nosis
IsMalignant No. of litters
Age at spayPye St. Veterinary Clinic
Boxer6 Utility Unknown
8
Diagnosis
Intraductal adenoma
512
Case ID Clinic  Dog's name Date of birth
10P244 Gypsy 1/01/1999 13
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 26/06/2012
Sample processed 17/01/2013
Total fixation time 205
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.5
Diag
nosis
IsMalignant No. of litters
Age at spayPye St. Veterinary Clinic
Staffordshire Bull Te2 Terrier Unknown
4
Diagnosis
Mixed adenoma
513
Case ID Clinic  Dog's name Date of birth
10P245 Jane 1/01/2003 10
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 10/01/2013
Sample processed 17/01/2013
Total fixation time 7
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10
Diag
nosis
IsMalignant No. of litters
Age at spayPye St. Veterinary Clinic
Kelpie5 Working Dogs Unknown
7
Diagnosis
Tubular Carcinoma
514
Case ID Clinic  Dog's name Date of birth
10P246 Ebony 17/03/2002 9
Recurrent CMT after sample
Further details recurrence
Note: SCC but needs IHC to prove 
mammary originLast known date alive 24/12/2012
Euthanized?
Reason for euthanasia
None given
Date euthanasia/death 24/12/2012
Survival (days calculated)
94
Sample taken 21/09/2012
Sample processed 17/01/2013
Total fixation time 118
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.5
Diag
nosis
IsMalignant No. of litters
Age at spayPye St. Veterinary Clinic
Cocker Spaniel3 Gundog Unknown
3
Diagnosis
Squamous Cell Carcinoma  
515
Case ID Clinic  Dog's name Date of birth
10P247 Bonnie 1/04/2002 10
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 16/10/2012
Sample processed 17/01/2013
Total fixation time 93
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.6
Diag
nosis
IsMalignant No. of litters
Age at spayPye St. Veterinary Clinic
Boxer6 Utility Unknown
6
Diagnosis
Complex adenoma
516
Case ID Clinic  Dog's name Date of birth
10P25 Ollie 16/09/1999
Recurrent CMT after sample
Further details recurrence
Last known date alive 20/05/2011
Euthanized?
Reason for euthanasia
Died at home - reason unkown
Date euthanasia/death 20/05/2011
Survival (days calculated)
290
Sample taken 3/08/2010
Sample processed 17/10/2010
Total fixation time 75
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.9
Diag
nosis
IsMalignant No. of litters
Age at spayHighton Veterinary Clinic
Whippet4 Hounds Unknown
4
Diagnosis
Adenocarcinoma
517
Case ID Clinic  Dog's name Date of birth
10P251 Puss 1/02/2005
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 18/02/2013
Sample processed 12/08/2013
Total fixation time 175
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.1
Diag
nosis
IsMalignant No. of litters
Age at spayWestern Districts Veterinary 
Border Collie5 Working Dogs 0
9
Diagnosis
No Tumor
518
Case ID Clinic  Dog's name Date of birth
10P252 Sally 24/01/2001
Recurrent CMT after sample
Further details recurrence
Early 2014 no specific date given
Note pathology report for original 
indicates multiple morph presentations 
including solid, cribriform and 
tubulopapillary carcinoma
Last known date alive 3/04/2014
Euthanized?
Reason for euthanasia
Large mammary tumour, secondary in 
liver, ascites
Date euthanasia/death
Survival (days calculated)
426
Sample taken 1/02/2013
Sample processed 12/08/2013
Total fixation time 192
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12
Diag
nosis
IsMalignant No. of litters
Age at spaySeymour Veterinary Surgery
Jack Russell Terrier2 Terrier Unknown
8
Diagnosis
Solid Carcinoma
519
Case ID Clinic  Dog's name Date of birth
10P253 Poodles 1/01/2002 11
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 1/03/2013
Sample processed 12/08/2013
Total fixation time 164
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.2
Diag
nosis
IsMalignant No. of litters
Age at spayPye St. Veterinary Clinic
Australian Terrier X8 (Cross) Unknown
17
Diagnosis
Complex adenoma
520
Case ID Clinic  Dog's name Date of birth
10P254 Lucy 1/01/2003
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 21/09/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
163
Sample taken 11/04/2013
Sample processed 12/08/2013
Total fixation time 123
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.3
Diag
nosis
IsMalignant No. of litters
Age at spayMalvern Central Vet Centre
Miniature Poodle7 Non-Sporting 0
3
Diagnosis
Adenoma
521
Case ID Clinic  Dog's name Date of birth
10P255 Lucy 1/10/2002 9
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 1/04/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
483
Sample taken 4/12/2012
Sample processed 12/08/2013
Total fixation time 251
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.2
Diag
nosis
IsMalignant No. of litters
Age at spayHeidleberg Veterinary Clinic
Jack Russell Terrier2 Terrier Unknown
2
Diagnosis
Benign Mixed Tumor
522
Case ID Clinic  Dog's name Date of birth
10P256 Ruby 1/01/2000 10
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 1/07/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
525
Sample taken 22/01/2013
Sample processed 12/08/2013
Total fixation time 202
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.1
Diag
nosis
IsMalignant No. of litters
Age at spayEltham Central Veterinary Ho
Cocker Spaniel X8 (Cross) 2
4
Diagnosis
Papillary Cystadenoma
523
Case ID Clinic  Dog's name Date of birth
10P257 Guiness 1/10/2002
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 5/04/2013
Sample processed 12/08/2013
Total fixation time 129
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.5
Diag
nosis
IsMalignant No. of litters
Age at spayBellarine Veterinary Practice
Maltese X8 (Cross) Unknown
4
Diagnosis
Adenocarcinoma
524
Case ID Clinic  Dog's name Date of birth
10P258 Mollie 24/01/2003 6
Recurrent CMT after sample
Further details recurrence
15/2/13 Mammary lumps return
Was then treated with chemo by the 
Victorian Animal Cancer Care
Last known date alive 8/04/2013
Euthanized?
Reason for euthanasia
Due to suspected metastatic spread of 
tumour to the lungs as Mollie had already 
had spread to abdominal organs and was 
not responding to any chemo drugs.
Date euthanasia/death
Survival (days calculated)
101
Sample taken 28/12/2012
Sample processed 12/08/2013
Total fixation time 227
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.9
Diag
nosis
IsMalignant No. of litters
Age at spayMoe Veterinary Centre
Shih Tzu7 Non-Sporting Unknown
10
Diagnosis
Adenocarcinoma
525
Case ID Clinic  Dog's name Date of birth
10P259 Pepper 1/01/2000 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive 3/07/2013
Euthanized?
Reason for euthanasia
Dog passed away at home
Date euthanasia/death
Survival (days calculated)
176
Sample taken 8/01/2013
Sample processed 12/08/2013
Total fixation time 216
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13
Diag
nosis
IsMalignant No. of litters
Age at spayDoncaster Veterinary Hospita
Border Collie X8 (Cross) 0
5
Diagnosis
Complex Carcinoma
526
Case ID Clinic  Dog's name Date of birth
10P26 Jess 25/01/2004 6
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/12/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1228
Sample taken 22/07/2010
Sample processed 17/10/2010
Total fixation time 87
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 6.5
Diag
nosis
IsMalignant No. of litters
Age at spayLilydale Veterinary Centre
Staffordshire Bull Te8 (Cross) 0
9
Diagnosis
Benign Mixed Tumor
527
Case ID Clinic  Dog's name Date of birth
10P260 Amy 1/08/2005 8
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 13/08/2013
Sample processed 20/08/2013
Total fixation time 7
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8
Diag
nosis
IsMalignant No. of litters
Age at spayWestern Districts Veterinary 
Kelpie5 Working Dogs Unknown
10
Diagnosis
Adenoma
528
Case ID Clinic  Dog's name Date of birth
10P261 Matilda 1/01/2001
Recurrent CMT after sample
Further details recurrence
Last known date alive 25/06/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
140
Sample taken 5/02/2013
Sample processed 20/08/2013
Total fixation time 196
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.1
Diag
nosis
IsMalignant No. of litters
Age at spayNorthcote Plaza Vet Clinic
Miniature Poodle7 Non-Sporting Unknown
10
Diagnosis
Simple Carcinoma
529
Case ID Clinic  Dog's name Date of birth
10P262 Moon Moon 31/10/2007
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 12/11/2013
Euthanized?
Reason for euthanasia
Pancreatic islet cell carcinoma and 
hypoglycaemic seizures
Date euthanasia/death 12/11/2013
Survival (days calculated)
337
Sample taken 10/12/2012
Sample processed 20/08/2013
Total fixation time 253
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 5.1
Diag
nosis
IsMalignant No. of litters
Age at spayPeace Avenue Vet Clinic
Maltese1 Toy 0
6
Diagnosis
Adenoma
530
Case ID Clinic  Dog's name Date of birth
10P263 Mia 1/01/2004 8
Recurrent CMT after sample
Further details recurrence
L ventral thorax along previous suture 
line no date givenLast known date alive 16/04/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
47
Sample taken 28/02/2013
Sample processed 20/08/2013
Total fixation time 173
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.2
Diag
nosis
IsMalignant No. of litters
Age at spayAustralian Animal Protection 
Gordon Setter3 Gundog Unknown
9
Diagnosis
Undifferentiated neoplasm
531
Case ID Clinic  Dog's name Date of birth
10P264 Sally 13/12/2000
Recurrent CMT after sample
Further details recurrence
Last known date alive 31/12/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
11
Sample taken 20/12/2012
Sample processed 20/08/2013
Total fixation time 243
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12
Diag
nosis
IsMalignant No. of litters
Age at spayTarwin Vet Group
Australian Cattle do5 Working Dogs Unknown
4
Diagnosis
Adenoma
532
Case ID Clinic  Dog's name Date of birth
10P268 Nicki 1/08/2002 10.5
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 6/02/2013
Sample processed 20/08/2013
Total fixation time 195
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.5
Diag
nosis
IsMalignant No. of litters
Age at spayRowville Veterinary Clinic
Maltese X8 (Cross) Unknown
6
Diagnosis
Ductal carcinoma
533
Case ID Clinic  Dog's name Date of birth
10P27 121944 1/09/2005 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive 6/07/2013
Euthanized?
Reason for euthanasia
Vet unsure of reason
Date euthanasia/death 6/07/2013
Survival (days calculated)
1062
Sample taken 9/08/2010
Sample processed 17/10/2010
Total fixation time 69
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 4.9
Diag
nosis
IsMalignant No. of litters
Age at spayBoronia Veterinary Clinic
Boxer6 Utility 3
10
Diagnosis
Adenoma
534
Case ID Clinic  Dog's name Date of birth
10P273 Meg 1/05/1998
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 14/08/2013
Sample processed 29/10/2013
Total fixation time 76
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 15.3
Diag
nosis
IsMalignant No. of litters
Age at spayWestern Districts Veterinary 
Kelpie X8 (Cross) Unknown
7
Diagnosis
Unavailable
535
Case ID Clinic  Dog's name Date of birth
10P274 Cindy Lou 19/09/2003
Recurrent CMT after sample
Further details recurrence
Mammary lumps reappeared October 
2013 surgery recommended but not 
performed
Last known date alive 1/10/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
6
Sample taken 25/09/2013
Sample processed 29/10/2013
Total fixation time 34
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10
Diag
nosis
IsMalignant No. of litters
Age at spayColac Veterinary Clinic
Maltese1 Toy Unknown
3
Diagnosis
Unavailable
536
Case ID Clinic  Dog's name Date of birth
10P275 Rosie 10/08/2003 -1
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 23/09/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
145
Sample taken 1/05/2013
Sample processed 29/10/2013
Total fixation time 181
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.7
Diag
nosis
IsMalignant No. of litters
Age at spayNorthcote Plaza Vet Clinic
Poodle7 Non-Sporting Unknown
4
Diagnosis
Adenoma
537
Case ID Clinic  Dog's name Date of birth
10P277 Maggie 1/01/2003 -1
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 23/12/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
504
Sample taken 6/08/2013
Sample processed 29/10/2013
Total fixation time 84
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.6
Diag
nosis
IsMalignant No. of litters
Age at spayEast St. Albans Veterinary Cli
Maltese X8 (Cross) Unknown
5
Diagnosis
Adenoma
538
Case ID Clinic  Dog's name Date of birth
10P278 Soxe 1/01/1999 -1
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 16/04/2014
Euthanized?
Reason for euthanasia
Passed away at home - suspected renal 
failure as cause of death USG (urine 
specific gravity) result: 1.007
Date euthanasia/death 16/04/2014
Survival (days calculated)
218
Sample taken 10/09/2013
Sample processed 29/10/2013
Total fixation time 49
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 14.7
Diag
nosis
IsMalignant No. of litters
Age at spayHallam Park Animal Hospital
Border Collie5 Working Dogs Unknown
6
Diagnosis
Simple Carcinoma
539
Case ID Clinic  Dog's name Date of birth
10P279 Zari 10/02/2005
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 8/12/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
516
Sample taken 10/07/2013
Sample processed 29/10/2013
Total fixation time 111
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.4
Diag
nosis
IsMalignant No. of litters
Age at spayCorio Veterinary Clinic
Rhodesian rdigebac4 Hounds Unknown
7
Diagnosis
Adenoma
540
Case ID Clinic  Dog's name Date of birth
10P280 Ali 29/05/2008
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 9/04/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
315
Sample taken 29/05/2013
Sample processed 29/10/2013
Total fixation time 153
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 5
Diag
nosis
IsMalignant No. of litters
Age at spayEast West Veterinary Clinic
Irish Red and White 3 Gundog 0
6
Diagnosis
Adenoma
541
Case ID Clinic  Dog's name Date of birth
10P281 Oprah 1/01/2005 8
Recurrent CMT after sample
Further details recurrence
Not seen since the tumour was removed 
on the 25/5/13Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 25/05/2013
Sample processed 29/10/2013
Total fixation time 157
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.4
Diag
nosis
IsMalignant No. of litters
Age at spayBrighton Veterinary Hospital
Jack Russell Terrier 8 (Cross) Unknown
6
Diagnosis
Adenoma
542
Case ID Clinic  Dog's name Date of birth
10P282 Lucky 15/05/2000 10
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 2/04/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
345
Sample taken 22/04/2013
Sample processed 29/10/2013
Total fixation time 190
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.9
Diag
nosis
IsMalignant No. of litters
Age at spayMoe Veterinary Centre
Jack Russell Terrier 8 (Cross) Unknown
6
Diagnosis
Cyst adenoma
543
Case ID Clinic  Dog's name Date of birth
10P283 Dew 1/06/2006 7
Recurrent CMT after sample
Further details recurrence
Last known date alive 11/04/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
256
Sample taken 29/07/2013
Sample processed 29/10/2013
Total fixation time 92
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.2
Diag
nosis
IsMalignant No. of litters
Age at spayBerwick Springs Vet Hospital
Jack Russell Terrier 8 (Cross) 0
12
Diagnosis
Complex Carcinoma
544
Case ID Clinic  Dog's name Date of birth
10P284 Casey 28/05/2002 10
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 26/07/2013
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
13
Sample taken 13/07/2013
Sample processed 29/10/2013
Total fixation time 108
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.1
Diag
nosis
IsMalignant No. of litters
Age at spaySeaford Veterinary Clinic
Beagle X8 (Cross) Unknown
7
Diagnosis
Simple Carcinoma
545
Case ID Clinic  Dog's name Date of birth
10P285 Ronnie 1/05/2005 8
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 1/05/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
352
Sample taken 14/05/2013
Sample processed 29/10/2013
Total fixation time 168
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8
Diag
nosis
IsMalignant No. of litters
Age at spayEltham Central Veterinary Ho
Doberman6 Utility 0
6
Diagnosis
Papillary Adenoma
546
Case ID Clinic  Dog's name Date of birth
10P29 Jacinta 1/01/1996
Recurrent CMT after sample
Further details recurrence
Yes 4/11/2010 mammary lumphs left 
hand side mammaryLast known date alive 5/11/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
78
Sample taken 19/08/2010
Sample processed 2/11/2010
Total fixation time 75
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 14.6
Diag
nosis
IsMalignant No. of litters
Age at spayEuroa Vet Clinic
Kelpie5 Working Dogs Unknown
3
Diagnosis
Complex Carcinoma
547
Case ID Clinic  Dog's name Date of birth
10P3 Lassie MacGugan 8/09/1998 10
Recurrent CMT after sample
Further details recurrence
Last known date alive 27/09/2010
Euthanized?
Reason for euthanasia
deceased - labored breathing
Date euthanasia/death 27/09/2010
Survival (days calculated)
12
Sample taken 15/09/2010
Sample processed 17/09/2010
Total fixation time 2
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12
Diag
nosis
IsMalignant No. of litters
Age at spayHamilton Vetcare
Border Collie X8 (Cross) Unknown
0
Diagnosis
Unavailable
548
Case ID Clinic  Dog's name Date of birth
10P32 Jedda
Recurrent CMT after sample
Further details recurrence
Last known date alive 18/08/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
736
Sample taken 13/08/2010
Sample processed 2/11/2010
Total fixation time 81
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken
Diag
nosis
IsMalignant No. of litters
Age at spayVets All Natural
Welsh Corgi5 Working Dogs Unknown
2
Diagnosis
Adenoma
549
Case ID Clinic  Dog's name Date of birth
10P33 Sally 10/12/2000
Recurrent CMT after sample
Further details recurrence
Yes, vet supspected chest/lung tumours 
6/4/2010
Note this tumour is an OS but possible 
arose from a malignant mixed tumour
Last known date alive 6/04/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
470
Sample taken 22/12/2008
Sample processed 2/11/2010
Total fixation time 680
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
Shih Tzu7 Non-Sporting Unknown
6
Diagnosis
'Other tumour type'
550
Case ID Clinic  Dog's name Date of birth
10P35 Monique 15/03/2002 5
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 30/08/2007
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
6
Sample taken 24/08/2007
Sample processed 2/11/2010
Total fixation time 1166
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 5.4
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
Poodle7 Non-Sporting Unknown
6
Diagnosis
Adenoma
551
Case ID Clinic  Dog's name Date of birth
10P37 Toya 29/10/1999
Recurrent CMT after sample
Further details recurrence
4/11/09 - we have this sample 10P38 also 
a cyst adenomaLast known date alive 23/09/2013
Euthanized?
Reason for euthanasia
Mast cell tumour of lip, muzzle and maxilla
Date euthanasia/death 23/09/2013
Survival (days calculated)
1630
Sample taken 7/04/2009
Sample processed 2/11/2010
Total fixation time 574
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.4
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
Hungarian Vizsla3 Gundog Unknown
9
Diagnosis
Cyst adenoma
552
Case ID Clinic  Dog's name Date of birth
10P4 Nipper Hodges 29/07/1998 10
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/05/2014
Euthanized?
Reason for euthanasia
Coughing, getting old, note male dog
Date euthanasia/death 1/05/2014
Survival (days calculated)
1350
Sample taken 20/08/2010
Sample processed 23/08/2010
Total fixation time 3
RNA concentration 143
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio 2.02
AgeWhenSampleTaken 12.1
Diag
nosis
IsMalignant No. of litters
Age at spayHamilton Vetcare
Jack Russell Terrier2 Terrier 0
0
Diagnosis
Unavailable
553
Case ID Clinic  Dog's name Date of birth
10P40 Dee 1/10/2001 7
Recurrent CMT after sample
Further details recurrence
Last known date alive 20/06/2008
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
4
Sample taken 16/06/2008
Sample processed 2/11/2010
Total fixation time 869
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 6.7
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
Jack Russell Terrier2 Terrier 0
16
Diagnosis
Solid Carcinoma
554
Case ID Clinic  Dog's name Date of birth
10P42 Jessie 2/08/2000 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive 3/08/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
0
Sample taken 3/08/2010
Sample processed 3/11/2010
Total fixation time 92
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
Australian silky terri1 Toy Unknown
13
Diagnosis
Solid Carcinoma
555
Case ID Clinic  Dog's name Date of birth
10P43 Maggie 6/07/1997
Recurrent CMT after sample
Further details recurrence
Sample pot 1) Solid carcinoma
Sample pot 2) BMT
Sample pot 3) MMT
Last known date alive 5/09/2010
Euthanized?
Reason for euthanasia
none given
Date euthanasia/death 5/09/2010
Survival (days calculated)
33
Sample taken 3/08/2010
Sample processed 9/11/2010
Total fixation time 98
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.1
Diag
nosis
IsMalignant No. of litters
Age at spayTatura Vet Clinic
Border Collie X8 (Cross) Unknown
12
Diagnosis
Solid Carcinoma
556
Case ID Clinic  Dog's name Date of birth
10P45 92850 12/05/2003 7
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 17/10/2010
Sample processed 15/11/2010
Total fixation time 29
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.4
Diag
nosis
IsMalignant No. of litters
Age at spayBoronia Veterinary Clinic
Jack Russell Terrier2 Terrier 0
10
Diagnosis
Benign Mixed Tumor
557
Case ID Clinic  Dog's name Date of birth
10P48 Sheba 1/01/2000
Recurrent CMT after sample
Further details recurrence
Last known date alive 8/11/2013
Euthanized?
Reason for euthanasia
Hit by car
Date euthanasia/death
Survival (days calculated)
1135
Sample taken 30/09/2010
Sample processed 9/11/2010
Total fixation time 40
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.8
Diag
nosis
IsMalignant No. of litters
Age at spayMontmorency Veterinary Cli
Maltese1 Toy Unknown
8
Diagnosis
Low Grade Adenocarcinom
558
Case ID Clinic  Dog's name Date of birth
10P49 Lady 1/09/1998 13
Recurrent CMT after sample
Further details recurrence
Yes, no further information given
Last known date alive 1/10/2012
Euthanized?
Reason for euthanasia
Died in October 2012 no reason given
Date euthanasia/death 1/10/2012
Survival (days calculated)
752
Sample taken 10/09/2010
Sample processed 9/11/2010
Total fixation time 60
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12
Diag
nosis
IsMalignant No. of litters
Age at spayEast St. Albans Veterinary Cli
Labrador X8 (Cross) Unknown
13
Diagnosis
Benign Mixed Tumor
559
Case ID Clinic  Dog's name Date of birth
10P5 Belle Moran 19/12/1999
Recurrent CMT after sample
Further details recurrence
No 
x/7/14 painful abdomen but chest x-ray 
clear
Last known date alive 30/07/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1422
Sample taken 7/09/2010
Sample processed 10/09/2010
Total fixation time 3
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.7
Diag
nosis
IsMalignant No. of litters
Age at spayTraralgon Veterinary Centre
Chihuahua1 Toy Unknown
0
Diagnosis
Unavailable
560
Case ID Clinic  Dog's name Date of birth
10P50 Gemma 1/01/1997 10
Recurrent CMT after sample
Further details recurrence
Last known date alive 31/08/2012
Euthanized?
Reason for euthanasia
Nurse believed died not long after 
31/8/2012 visit of old age
Date euthanasia/death
Survival (days calculated)
724
Sample taken 7/09/2010
Sample processed 9/11/2010
Total fixation time 63
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.7
Diag
nosis
IsMalignant No. of litters
Age at spayHampton Vet Hospital
Border Collie5 Working Dogs Unknown
2
Diagnosis
Adenocarcinoma
561
Case ID Clinic  Dog's name Date of birth
10P51 Sealy 10/01/1999 11
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/12/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
815
Sample taken 8/09/2010
Sample processed 9/11/2010
Total fixation time 62
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.7
Diag
nosis
IsMalignant No. of litters
Age at spayTarwin Vet Group
Maltese Shih Tzu X8 (Cross) 1
6
Diagnosis
Solid Carcinoma
562
Case ID Clinic  Dog's name Date of birth
10P52 Cate 1/09/2003
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 7/09/2010
Sample processed 9/11/2010
Total fixation time 63
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7
Diag
nosis
IsMalignant No. of litters
Age at spayStawell Veterinary Clinic
Jack Russell Terrier2 Terrier Unknown
10
Diagnosis
Complex adenoma
563
Case ID Clinic  Dog's name Date of birth
10P53 Cassie 1/06/1997
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 29/06/2010
Sample processed 15/11/2010
Total fixation time 139
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.1
Diag
nosis
IsMalignant No. of litters
Age at spayACE laboratory services
X8 (Cross) Unknown
5
Diagnosis
Complex Carcinoma
564
Case ID Clinic  Dog's name Date of birth
10P54 Misty 4/11/2000
Recurrent CMT after sample
Further details recurrence
Unknown, nothing in records
Last known date alive 21/02/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1205
Sample taken 4/11/2010
Sample processed 15/11/2010
Total fixation time 11
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10
Diag
nosis
IsMalignant No. of litters
Age at spayACE laboratory services
Pomeranian1 Toy 0
7
Diagnosis
Complex Carcinoma
565
Case ID Clinic  Dog's name Date of birth
10P55 Meg 1/01/2000
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 19/10/2010
Sample processed 16/11/2010
Total fixation time 28
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.8
Diag
nosis
IsMalignant No. of litters
Age at spayMc Ivor Rd. Vet Centr
Shih Tzu7 Non-Sporting Unknown
8
Diagnosis
Benign Mixed Tumor
566
Case ID Clinic  Dog's name Date of birth
10P58 Maggie 17/10/1994 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 19/03/2007
Sample processed 16/11/2010
Total fixation time 1338
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.4
Diag
nosis
IsMalignant No. of litters
Age at spayKangaroo Flat Veterinary Clin
Fox Terrier X8 (Cross) Unknown
4
Diagnosis
Intraductal adenoma
567
Case ID Clinic  Dog's name Date of birth
10P59 Tina 1/06/1999
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/09/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
6
Sample taken 26/08/2010
Sample processed 16/11/2010
Total fixation time 82
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.2
Diag
nosis
IsMalignant No. of litters
Age at spayColac Veterinary Clinic
Border Collie X8 (Cross) Unknown
17
Diagnosis
Adenoma
568
Case ID Clinic  Dog's name Date of birth
10P6 Uknown 1/01/1997 13
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 26/08/2010
Sample processed 2/09/2010
Total fixation time 7
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.7
Diag
nosis
IsMalignant No. of litters
Age at spayMaffra Veterinary Clinic
Kelpie5 Working Dogs 0
0
Diagnosis
Unavailable
569
Case ID Clinic  Dog's name Date of birth
10P60 Kelly 1/02/2001 9
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/02/2011
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
82
Sample taken 11/11/2010
Sample processed 16/11/2010
Total fixation time 5
RNA concentration 132.2
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio 2.04
AgeWhenSampleTaken 9.8
Diag
nosis
IsMalignant No. of litters
Age at spayColac Veterinary Clinic
Kelpie5 Working Dogs Unknown
3
Diagnosis
Adenoma
570
Case ID Clinic  Dog's name Date of birth
10P61 Pound dog (no 
name)
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death 17/11/2010
Survival (days calculated)
Sample taken 17/11/2010
Sample processed 18/11/2010
Total fixation time 1
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken
Diag
nosis
IsMalignant No. of litters
Age at spayBroadford Veterinary Clinic
Pomeranian1 Toy Unknown
0
Diagnosis
Unavailable
571
Case ID Clinic  Dog's name Date of birth
10P62 Jess 1/11/1999
Recurrent CMT after sample
Further details recurrence
Last known date alive 5/11/2011
Euthanized?
Reason for euthanasia
Oral cancer
Date euthanasia/death 5/11/2011
Survival (days calculated)
348
Sample taken 22/11/2010
Sample processed 25/11/2010
Total fixation time 3
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 11.1
Diag
nosis
IsMalignant No. of litters
Age at spayCastlemain Veterinary clinic
Whippet4 Hounds 1
8
Diagnosis
Adenoma
572
Case ID Clinic  Dog's name Date of birth
10P63 Molly 1/01/1998
Recurrent CMT after sample
Further details recurrence
Not seen since tumour removal
Last known date alive 30/11/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
0
Sample taken 30/11/2010
Sample processed 8/12/2010
Total fixation time 8
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 12.9
Diag
nosis
IsMalignant No. of litters
Age at spayTraralgon Veterinary Centre
Maltese X8 (Cross) Unknown
0
Diagnosis
Unavailable
573
Case ID Clinic  Dog's name Date of birth
10P64 Gemma 1/06/2001
Recurrent CMT after sample
Further details recurrence
Yes - no further information given
Last known date alive 23/12/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
783
Sample taken 1/11/2010
Sample processed 10/01/2011
Total fixation time 70
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.4
Diag
nosis
IsMalignant No. of litters
Age at spayEast St. Albans Veterinary Cli
Pomeranian1 Toy 0
2
Diagnosis
Low Grade Adenocarcinom
574
Case ID Clinic  Dog's name Date of birth
10P66 Dot 1/05/2001 9.5
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 26/03/2012
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
500
Sample taken 12/11/2010
Sample processed 10/01/2011
Total fixation time 59
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.5
Diag
nosis
IsMalignant No. of litters
Age at spayTorquay Animal House
Fox Terrier Smooth2 Terrier Unknown
6
Diagnosis
Benign Mixed Tumor
575
Case ID Clinic  Dog's name Date of birth
10P67 Elka 12/11/2000
Recurrent CMT after sample
Further details recurrence
Last known date alive 12/11/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
0
Sample taken 12/11/2010
Sample processed 10/01/2011
Total fixation time 59
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10
Diag
nosis
IsMalignant No. of litters
Age at spayMulgrave Vet Clinic
German Shepherd5 Working Dogs Unknown
7
Diagnosis
Adenocarcinoma
576
Case ID Clinic  Dog's name Date of birth
10P68 Abbey 1/11/2009
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 16/05/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1309
Sample taken 15/10/2010
Sample processed 10/11/2011
Total fixation time 391
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 1
Diag
nosis
IsMalignant No. of litters
Age at spayElsternwick Veterinary Clinic
Cavalier King Charle1 Toy 0
8
Diagnosis
Fibroadenoma
577
Case ID Clinic  Dog's name Date of birth
10P69 Bonnie 3/09/2000 10
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/11/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
0
Sample taken 1/11/2010
Sample processed 10/01/2011
Total fixation time 70
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.2
Diag
nosis
IsMalignant No. of litters
Age at spayTarwin Vet Group
Border Collie5 Working Dogs Unknown
4
Diagnosis
Adenoma
578
Case ID Clinic  Dog's name Date of birth
10P7 Annie 1/02/1996 14.6
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 31/08/2010
Sample processed 6/09/2010
Total fixation time 6
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 14.6
Diag
nosis
IsMalignant No. of litters
Age at spayWestern Districts Veterinary 
Jack Russell Terrier 8 (Cross) Unknown
Unknown
Diagnosis
Unavailable
579
Case ID Clinic  Dog's name Date of birth
10P70 Patch 1/01/2000
Recurrent CMT after sample
Further details recurrence
No further contact with dog since lump 
removal in 2010Last known date alive 5/10/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
0
Sample taken 5/10/2010
Sample processed 10/01/2011
Total fixation time 97
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.8
Diag
nosis
IsMalignant No. of litters
Age at spayEast St. Albans Veterinary Cli
Jack Russell Terrier2 Terrier Unknown
6
Diagnosis
Adenocarcinoma
580
Case ID Clinic  Dog's name Date of birth
10P72 171726 2/04/2008 2.5
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 19/10/2010
Sample processed 10/01/2011
Total fixation time 83
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 2.5
Diag
nosis
IsMalignant No. of litters
Age at spayBoronia Veterinary Clinic
Maltese Shih Tzu X8 (Cross) Unknown
9
Diagnosis
Fibroadenoma
581
Case ID Clinic  Dog's name Date of birth
10P73 Molly 1/01/2005
Recurrent CMT after sample
Further details recurrence
29/4/11 - new lump in abdomen found 
referred to a specialty centreLast known date alive 14/11/2011
Euthanized?
Reason for euthanasia
Metastasis to liver and spleen, fluid in 
thorax, pleural effusion
Date euthanasia/death
Survival (days calculated)
365
Sample taken 14/11/2010
Sample processed 10/01/2011
Total fixation time 57
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 5.9
Diag
nosis
IsMalignant No. of litters
Age at spayDandenong Ranges Veterinar
Mastiff6 Utility 0
10
Diagnosis
Adenocarcinoma
582
Case ID Clinic  Dog's name Date of birth
10P74 Lucky 25/11/1999 10
Recurrent CMT after sample
Further details recurrence
Yes, Mid 2012
Last known date alive 31/07/2012
Euthanized?
Reason for euthanasia
Large mammary tumour, ascites
Date euthanasia/death 31/07/2012
Survival (days calculated)
557
Sample taken 21/01/2011
Sample processed 24/01/2011
Total fixation time 3
RNA concentration 163.6
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio 2.02
AgeWhenSampleTaken 11.2
Diag
nosis
IsMalignant No. of litters
Age at spaySeymour Veterinary Surgery
Australian Cattle do5 Working Dogs Unknown
0
Diagnosis
Unavailable
583
Case ID Clinic  Dog's name Date of birth
10P75 Molly 11/10/1997 13
Recurrent CMT after sample
Further details recurrence
Yes 22/3/2011 - upper L mammary gland, 
no pathology doneLast known date alive 25/04/2011
Euthanized?
Reason for euthanasia
Due to arthritis type symptoms, suspect 
bone metastasis to humerus - no 
radiographs taken
Date euthanasia/death 25/04/2011
Survival (days calculated)
114
Sample taken 1/01/2011
Sample processed 3/02/2011
Total fixation time 33
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 13.2
Diag
nosis
IsMalignant No. of litters
Age at spayMoe Veterinary Centre
Maltese X8 (Cross) Unknown
6
Diagnosis
Malignant Mixed Mammar
584
Case ID Clinic  Dog's name Date of birth
10P76 Greg
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken
Sample processed 3/02/2011
Total fixation time
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken
Diag
nosis
IsMalignant No. of litters
Age at spayStawell Veterinary Clinic
Greyhound X8 (Cross) Unknown
7
Diagnosis
Benign Mixed Tumor
585
Case ID Clinic  Dog's name Date of birth
10P78 Daisy 1/01/2002
Recurrent CMT after sample
Further details recurrence
Last known date alive 1/06/2011
Euthanized?
Reason for euthanasia
Passed away cause of death unknown
Date euthanasia/death
Survival (days calculated)
182
Sample taken 1/12/2010
Sample processed 3/02/2011
Total fixation time 64
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.9
Diag
nosis
IsMalignant No. of litters
Age at spayNiddrie Veterinary Clinic
Cavalier King Charle1 Toy Unknown
7
Diagnosis
Adenocarcinoma
586
Case ID Clinic  Dog's name Date of birth
10P79 Chloe 1/12/2001 -1
Recurrent CMT after sample
Further details recurrence
Note: pathology reports indicate 
lymphatic invasionLast known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 3/12/2010
Sample processed 3/02/2011
Total fixation time 62
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9
Diag
nosis
IsMalignant No. of litters
Age at spayRingwood Veterinary Clinic
Maltese X8 (Cross) Unknown
7
Diagnosis
Adenocarcinoma
587
Case ID Clinic  Dog's name Date of birth
10P8 Victoria 1/04/1999 9.91
Recurrent CMT after sample
Further details recurrence
Last known date alive 27/07/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
504
Sample taken 10/03/2009
Sample processed 5/10/2010
Total fixation time 574
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.9
Diag
nosis
IsMalignant No. of litters
Age at spayWestern Districts Veterinary 
Australian Terrier2 Terrier Unknown
Unknown
Diagnosis
Benign Mixed Tumor
588
Case ID Clinic  Dog's name Date of birth
10P80 Indie 1/01/2004
Recurrent CMT after sample
Further details recurrence
Last known date alive 23/11/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
0
Sample taken 23/11/2010
Sample processed 3/02/2011
Total fixation time 72
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 6.9
Diag
nosis
IsMalignant No. of litters
Age at spayNiddrie Veterinary Clinic
Australian Cattle Do8 (Cross) Unknown
10
Diagnosis
Fibroadenoma
589
Case ID Clinic  Dog's name Date of birth
10P81 Inka 1/12/2004 3
Recurrent CMT after sample
Further details recurrence
Last known date alive 19/03/2011
Euthanized?
Reason for euthanasia
due to aggressive cancer (type not 
specified)
Date euthanasia/death 19/03/2011
Survival (days calculated)
45
Sample taken 2/02/2011
Sample processed 20/07/2011
Total fixation time 168
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 6.2
Diag
nosis
IsMalignant No. of litters
Age at spayRose City Veterinary Hosptial
German Pointer3 Gundog Unknown
2
Diagnosis
Adenoma
590
Case ID Clinic  Dog's name Date of birth
10P82 Zoe 28/09/2001 10
Recurrent CMT after sample
Further details recurrence
Last known date alive 16/02/2011
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
5
Sample taken 11/02/2011
Sample processed 16/03/2011
Total fixation time 33
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.4
Diag
nosis
IsMalignant No. of litters
Age at spayShepparton Veterinary Clinic
German Shepherd5 Working Dogs Unknown
6
Diagnosis
Tubular Carcinoma
591
Case ID Clinic  Dog's name Date of birth
10P83 Misty 20/12/2000
Recurrent CMT after sample
Further details recurrence
Last seen at the clinic 1/3/2011 but 
known to have passed away at some 
point in 2013 no specific date known
Last known date alive 1/01/2013
Euthanized?
Reason for euthanasia
01/01/2013 - died at some point in 2013
Date euthanasia/death
Survival (days calculated)
685
Sample taken 16/02/2011
Sample processed 24/02/2011
Total fixation time 8
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.2
Diag
nosis
IsMalignant No. of litters
Age at spayCorio Veterinary Clinic
Australian Shepherd5 Working Dogs 2
4
Diagnosis
Complex adenoma
592
Case ID Clinic  Dog's name Date of birth
10P84 Piper 1/06/2005
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 8/03/2011
Sample processed 4/04/2011
Total fixation time 27
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 5.8
Diag
nosis
IsMalignant No. of litters
Age at spayWestern Districts Veterinary 
Border Collie X8 (Cross) 0
7
Diagnosis
Benign Mixed Tumor
593
Case ID Clinic  Dog's name Date of birth
10P87 Gemma 29/06/2004 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 14/03/2011
Sample processed 16/03/2011
Total fixation time 2
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 6.7
Diag
nosis
IsMalignant No. of litters
Age at spayKangaroo Flat Veterinary Clin
Golden Retriever3 Gundog Unknown
5
Diagnosis
Malignant Mixed Mammar
594
Case ID Clinic  Dog's name Date of birth
10P88 Flossie 1/01/2001 0
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 24/02/2011
Sample processed 16/03/2011
Total fixation time 20
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.2
Diag
nosis
IsMalignant No. of litters
Age at spayPye St. Veterinary Clinic
Huntaway5 Working Dogs Unknown
4
Diagnosis
Benign Mixed Tumor
595
Case ID Clinic  Dog's name Date of birth
10P9 Missy 28/09/2000 9.3
Recurrent CMT after sample
Further details recurrence
Last known date alive 28/07/2010
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
180
Sample taken 29/01/2010
Sample processed 5/10/2010
Total fixation time 249
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.3
Diag
nosis
IsMalignant No. of litters
Age at spayWestern Districts Veterinary 
Dachshund4 Hounds Unknown
Unknown
Diagnosis
Benign Mixed Tumor
596
Case ID Clinic  Dog's name Date of birth
10P90 Melody 1/04/2001 8
Recurrent CMT after sample
Further details recurrence
Last known date alive 8/12/2012
Euthanized?
Reason for euthanasia
not given. But suspected lung cancer Dx by 
CT scan 5/12/12
Date euthanasia/death 8/12/2012
Survival (days calculated)
618
Sample taken 31/03/2011
Sample processed 31/03/2011
Total fixation time 0
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10
Diag
nosis
IsMalignant No. of litters
Age at spayTorquay Animal House
Australian Cattle do5 Working Dogs Unknown
0
Diagnosis
Benign Mixed Tumor
597
Case ID Clinic  Dog's name Date of birth
10P92 Ellie 18/04/2002 5
Recurrent CMT after sample
Further details recurrence
Last known date alive 15/08/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1277
Sample taken 15/02/2011
Sample processed 23/03/2011
Total fixation time 36
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.8
Diag
nosis
IsMalignant No. of litters
Age at spayHampton Vet Hospital
Rottweiler6 Utility 1
6
Diagnosis
Intraductal adenoma
598
Case ID Clinic  Dog's name Date of birth
10P94 Bruna 16/09/2006 2
Recurrent CMT after sample
Further details recurrence
Last known date alive 9/06/2011
Euthanized?
Reason for euthanasia
due to agression
Date euthanasia/death 9/06/2011
Survival (days calculated)
122
Sample taken 7/02/2011
Sample processed 5/04/2011
Total fixation time 57
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 4.4
Diag
nosis
IsMalignant No. of litters
Age at spayMont Albert Veterinary Surg
Rottweiler6 Utility 0
5
Diagnosis
Ductal adenoma
599
Case ID Clinic  Dog's name Date of birth
10P95 Pearl (61823) 8/09/2003 8
Recurrent CMT after sample
Further details recurrence
Last known date alive
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
Sample taken 5/04/2011
Sample processed 18/07/2011
Total fixation time 104
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.6
Diag
nosis
IsMalignant No. of litters
Age at spayBoronia Veterinary Clinic
Golden Retriever3 Gundog Unknown
7
Diagnosis
Benign Mixed Tumor
600
Case ID Clinic  Dog's name Date of birth
10P96 Dolly 1/12/2000
Recurrent CMT after sample
Further details recurrence
Yes - no further information given
Last known date alive 23/12/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1358
Sample taken 5/04/2011
Sample processed 18/07/2011
Total fixation time 104
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 10.3
Diag
nosis
IsMalignant No. of litters
Age at spayEast St. Albans Veterinary Cli
Maltese Shih Tzu X8 (Cross) 0
2
Diagnosis
Adenoma
601
Case ID Clinic  Dog's name Date of birth
10P97 Remy 1/09/2002
Recurrent CMT after sample
Further details recurrence
After initial removal kept growing rapidly 
and removed again, no date, no pathologyLast known date alive 1/07/2014
Euthanized?
Reason for euthanasia
Possible neurological condition, on 
cortisone
Date euthanasia/death
Survival (days calculated)
1203
Sample taken 16/03/2011
Sample processed 18/07/2011
Total fixation time 124
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 8.5
Diag
nosis
IsMalignant No. of litters
Age at spayDoncaster Veterinary Hospita
Maltese Bichon X8 (Cross) 0
8
Diagnosis
Low Grade Adenocarcinom
602
Case ID Clinic  Dog's name Date of birth
10P98 Penny 1/01/2002
Recurrent CMT after sample
Further details recurrence
Yes - no further information given
Last known date alive 23/12/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1334
Sample taken 29/04/2011
Sample processed 18/07/2011
Total fixation time 80
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.3
Diag
nosis
IsMalignant No. of litters
Age at spayEast St. Albans Veterinary Cli
Terrier X8 (Cross) 0
6
Diagnosis
Benign Mixed Tumor
603
Case ID Clinic  Dog's name Date of birth
10P99 Frania 1/01/2002 -1
Recurrent CMT after sample
Further details recurrence
Last known date alive 16/05/2011
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
0
Sample taken 16/05/2011
Sample processed 18/07/2011
Total fixation time 63
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.4
Diag
nosis
IsMalignant No. of litters
Age at spayMulgrave Vet Clinic
Maltese Shih Tzu X8 (Cross) Unknown
6
Diagnosis
Malignant Mixed Mammar
604
Case ID Clinic  Dog's name Date of birth
10P23 Lady 15/10/2000 9
Recurrent CMT after sample
Further details recurrence
No
Last known date alive 25/11/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1573
Sample taken 5/08/2010
Sample processed 17/10/2010
Total fixation time 73
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 9.8
Diag
nosis
IsMalignant No. of litters
Age at spayPound Rd. Veterinary Clinic
Cocker Spaniel X8 (Cross) Unknown
3
Diagnosis
Fibroadenoma
605
Case ID Clinic  Dog's name Date of birth
10P71 Chloe 14/08/2003 0.75
Recurrent CMT after sample
Further details recurrence
Last known date alive 18/08/2014
Euthanized?
Reason for euthanasia
Date euthanasia/death
Survival (days calculated)
1406
Sample taken 12/10/2010
Sample processed 10/01/2011
Total fixation time 90
RNA concentration
DogMATIC sample
FreshTissue
NumberOfFixedBlocks:
260/280 ratio
AgeWhenSampleTaken 7.2
Diag
nosis
IsMalignant No. of litters
Age at spayHigh St. Rd Animal Hospital
English Springer Spa3 Gundog 0
3
Diagnosis
Benign Mixed Tumor
212
606
